Issue 21: Volume 1b
GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (NIH)

(QUARTER: APRIL – JUNE, 2015)

A Compilation by the

Research Services Unit
Office of Research, Innovation and Development (ORID)

March 2015
## TABLE OF CONTENTS

### OPPORTUNITIES FOR APRIL 2015

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMINISTRATIVE SUPPLEMENTS FOR RESEARCH ON DIETARY SUPPLEMENTS (ADMIN SUPP)</td>
<td>20</td>
</tr>
<tr>
<td>Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.</td>
<td>20</td>
</tr>
<tr>
<td>EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R21/R33)</td>
<td>21</td>
</tr>
<tr>
<td>EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R33)</td>
<td>22</td>
</tr>
<tr>
<td>INTERNATIONAL PROGRAMME – AFRICA</td>
<td>23</td>
</tr>
<tr>
<td>INNOVATIVE RESEARCH IN CANCER NANOTECHNOLOGY (U01)</td>
<td>23</td>
</tr>
<tr>
<td>ADVANCED CLINICAL TRIALS TO TEST ARTIFICIAL PANCREAS DEVICE SYSTEMS IN TYPE 1 DIABETES (UC4)</td>
<td>24</td>
</tr>
<tr>
<td>DOCTORAL INTERNSHIPS</td>
<td>25</td>
</tr>
<tr>
<td>ADMINISTRATIVE SUPPLEMENTS FOR HUMAN ISLET RESEARCH (ADMIN SUPP)</td>
<td>26</td>
</tr>
<tr>
<td>NIDA TRANSLATIONAL AVANT-GARDE AWARD FOR DEVELOPMENT OF MEDICATION TO TREAT SUBSTANCE USE DISORDERS (UH2/UH3)</td>
<td>27</td>
</tr>
<tr>
<td>ADVANCING MEDICAL DEVICE POST-MARKET SURVEILLANCE INFRASTRUCTURE AND EPIDEMIOLOGIC METHODOLOGIES THROUGH MULTI-STAKEHOLDER PARTNERSHIP (U01)</td>
<td>28</td>
</tr>
<tr>
<td>SMALL GRANTS PROGRAMME FOR CANCER RESEARCH (R03): AIDS-RELATED</td>
<td>30</td>
</tr>
<tr>
<td>NCI EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (R21): AIDS-RELATED</td>
<td>31</td>
</tr>
<tr>
<td>RESEARCH ON ALCOHOL AND HIV/AIDS (R01)</td>
<td>32</td>
</tr>
<tr>
<td>DRUG ABUSE ASPECTS OF HIV/AIDS (R01)</td>
<td>33</td>
</tr>
<tr>
<td>HIV INFECTION OF THE CENTRAL NERVOUS SYSTEM (R01)</td>
<td>34</td>
</tr>
<tr>
<td>STRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R21)</td>
<td>35</td>
</tr>
<tr>
<td>RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/AIDS (R01)</td>
<td>35</td>
</tr>
<tr>
<td>HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R01): AIDS-RELATED</td>
<td>37</td>
</tr>
<tr>
<td>Grant Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Extended Deadline: International Research Collaboration on Drug Abuse and Addiction Research (R01): AIDS-Related</td>
<td>38</td>
</tr>
<tr>
<td>Dissemination and Implementation Research in Health (R21): AIDS-Related</td>
<td>39</td>
</tr>
<tr>
<td>Extended Deadline: Imaging - Science Track Award for Research Transition (R03): AIDS-Related</td>
<td>40</td>
</tr>
<tr>
<td>Health Disparities in NIDDK Diseases (R01): AIDS-Related</td>
<td>41</td>
</tr>
<tr>
<td>Small Research Grant Programme (Parent R03): AIDS-Related</td>
<td>41</td>
</tr>
<tr>
<td>Exploratory/Developmental Research Grant Programme (Parent R21): AIDS-Related</td>
<td>42</td>
</tr>
<tr>
<td>Drug Abuse Aspects of HIV/AIDS (R21)</td>
<td>43</td>
</tr>
<tr>
<td>Drug Abuse Aspects of HIV/AIDS (R03)</td>
<td>44</td>
</tr>
<tr>
<td>Research on Malignancies in the Context of HIV/AIDS (R21)</td>
<td>45</td>
</tr>
<tr>
<td>Biology of Manual Therapies (R21): AIDS-Related</td>
<td>46</td>
</tr>
<tr>
<td>NEI Research Grant for Secondary Data Analysis (R21): AIDS-Related</td>
<td>47</td>
</tr>
<tr>
<td>Prescription Drug Abuse (R21): AIDS-Related</td>
<td>48</td>
</tr>
<tr>
<td>Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol and Tobacco Abuse (R03): AIDS-Related</td>
<td>50</td>
</tr>
<tr>
<td>Women’s Mental Health During Pregnancy and the Postpartum Period (R01): AIDS-Related</td>
<td>51</td>
</tr>
<tr>
<td>Women’s Mental Health During Pregnancy and the Postpartum Period (R21): AIDS-Related</td>
<td>52</td>
</tr>
<tr>
<td>Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21): AIDS-Related</td>
<td>53</td>
</tr>
<tr>
<td>Exploratory/Developmental Bioengineering Research Grants (R21): AIDS-Related</td>
<td>54</td>
</tr>
<tr>
<td>Bioengineering Research Grants (R01): AIDS-Related</td>
<td>55</td>
</tr>
<tr>
<td>Behavioral and Integrative Treatment Development Programme (R01): AIDS-Related</td>
<td>56</td>
</tr>
<tr>
<td>Behavioral and Integrative Treatment Development Programme (R03): AIDS-Related</td>
<td>57</td>
</tr>
</tbody>
</table>
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21): AIDS-RELATED.................................................................58
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03): AIDS-RELATED.................................................................59
MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01): AIDS-RELATED.................................................................60
RESEARCH PROJECT GRANT (PARENT R01): AIDS-RELATED.................................61
RESEARCH ON ALCOHOL AND HIV/AIDS (R21)................................................62
RESEARCH ON ALCOHOL AND HIV/AIDS (R03)................................................63
MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01): AIDS-RELATED .................................................................64
PRESCRIPTION DRUG ABUSE (R01): AIDS-RELATED........................................65
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAS IN DRUG ADDICTION (R21): AIDS-RELATED .................................................................66
EXTENDED DEADLINE: INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R21): AIDS-RELATED.................................67
EXTENDED DEADLINE: INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED.................................68
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21) ........69
SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R03) ........70
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R01): AIDS-RELATED ..................71
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R21): AIDS-RELATED ..................72
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R03): AIDS-RELATED ..................73
DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01): AIDS-RELATED ..................74
DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21): AIDS-RELATED ..................................................75
BIOLGY OF MANUAL THERAPIES (R01): AIDS-RELATED ........................................76
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01): AIDS-RELATED .....77
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03): AIDS-RELATED .....78
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21): AIDS-RELATED .....79
RESEARCH ON THE HEALTH OF LGBTI POPULATIONS (R01): AIDS-RELATED ............80
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03): AIDS-RELATED ..................81
HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21): AIDS-RELATED

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01): AIDS-RELATED

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01): AIDS-RELATED

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21): AIDS-RELATED

INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01): AIDS-RELATED

ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R21): AIDS-RELATED

PROGRAMME FOR EXTRAMURAL/INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01): AIDS-RELATED

NLM EXPRESS RESEARCH GRANTS IN BIOMEDICAL INFORMATICS (R01): AIDS-RELATED

EPIDEMIOLOGY OF DRUG ABUSE (R01): AIDS-RELATED

EPIDEMIOLOGY OF DRUG ABUSE (R21): AIDS-RELATED

EPIDEMIOLOGY OF DRUG ABUSE (R03): AIDS-RELATED

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03): AIDS-RELATED

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01): AIDS-RELATED

BEHAVIORAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34): AIDS-RELATED

EXTENDED DEADLINE: MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME – ETIOLOGY, DIAGNOSIS, PATHOPHYSIOLOGY AND TREATMENT (R21): AIDS-RELATED

EXTENDED DEADLINE: RESEARCH TO ADVANCE VACCINE SAFETY (R21): AIDS-RELATED

EXTENDED DEADLINE: PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY OR UROLOGIC DISEASES (R21): AIDS-RELATED

SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21): AIDS-RELATED

PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG ABUSE PREVENTION TRIALS (R34): AIDS-RELATED
RENAL FUNCTION AND CHRONIC KIDNEY DISEASE IN AGEING (R01): AIDS-RELATED ................................................................. 100
RENAL FUNCTION AND CHRONIC KIDNEY DISEASE IN AGEING (R21): AIDS-RELATED ................................................................. 101
PAIN IN AGEING (R21): AIDS-RELATED ................................................................. 102
PAIN IN AGEING (R03): AIDS-RELATED ................................................................. 103
PAIN IN AGEING (R01): AIDS-RELATED ................................................................. 104
ANCILLARY STUDIES OF ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE ACCESSING INFORMATION FROM CLINICAL TRIALS, EPIDEMIOLOGICAL STUDIES AND DATABASES (R01): AIDS-RELATED ............................. 105
BIOMARKERS FOR EARLY DETECTION OF HAEMATOPOIETIC MALIGNANCIES (R01): AIDS-RELATED ................................................................. 106
IDENTIFYING NON-CODING RNA TARGETS FOR EARLY DETECTION OF CANCER (R01): AIDS-RELATED ................................................................. 107
NON-CODING RNA TARGETS FOR EARLY DETECTION OF CANCER (R21): AIDS-RELATED ................................................................. 108
FATIGABILITY, ACTIVITY LIMITATIONS AND BIOENERGETICS IN AGEING (R01): AIDS-RELATED ................................................................. 109
FATIGABILITY, ACTIVITY LIMITATIONS AND BIOENERGETICS IN AGEING (R21): AIDS-RELATED ................................................................. 110
FATIGABILITY, ACTIVITY LIMITATIONS AND BIOENERGETICS IN AGEING (R03): AIDS-RELATED ................................................................. 111
BIOMARKERS FOR EARLY DETECTION OF HAEMATOPOIETIC MALIGNANCIES (R21): AIDS-RELATED ................................................................. 112
SECONDARY ANALYSES OF EXISTING DATA SETS AND STORED BIOSPECIMENS TO ADDRESS CLINICAL AGEING RESEARCH QUESTIONS (R01): AIDS-RELATED .................... 113
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21): AIDS-RELATED ............................ 114
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01): AIDS-RELATED ............................ 115
BEHAVIORAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34): AIDS-RELATED ................................................................. 116
DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01): AIDS-RELATED ................................................................. 117
NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34): AIDS-RELATED ............................ 118
ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01): AIDS-RELATED ................................................................. 119
OBESITY POLICY EVALUATION RESEARCH (R01): AIDS-RELATED .............................................. 119
NIDCR SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03): AIDS-RELATED .............. 120
STIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (SHINE) (R01): AIDS-RELATED ...................................................................................................................... 121
STRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R01) ........... 122
CALCIUM OXALATE STONE DISEASES (R01): AIDS-RELATED ........................................ 123
TECHNOLOGY-BASED INTERVENTIONS TO PROMOTE ENGAGEMENT IN CARE AND TREATMENT ADHERENCE FOR SUBSTANCE ABUSING POPULATIONS WITH HIV (R01) .............................................................................................................................................................. 123
TECHNOLOGY-BASED INTERVENTIONS TO PROMOTE ENGAGEMENT IN CARE AND TREATMENT ADHERENCE FOR SUBSTANCE ABUSING POPULATIONS WITH HIV (R34) .................................................................................................................................................................. 124
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R01): AIDS-RELATED ........... 125
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R03): AIDS-RELATED .......... 126
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R21): AIDS-RELATED .......... 127
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R03): AIDS-RELATED .............................................................................................................. 128
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R01): AIDS-RELATED .............................................................................................................. 129
NINDS PHASE III INVESTIGATOR-INITIATED EFFICACY TRIALS (U01): AIDS-RELATED .................................................................................................................................................. 129
NINDS EXPLORATORY CLINICAL TRIALS (R01): AIDS-RELATED .................................. 130
COLLABORATIVE CLINICAL VISION RESEARCH PROJECT GRANT (U10): AIDS-RELATED .................................................................................................................................................. 131
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01): AIDS-RELATED ................................................................................................. 132
GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01): AIDS RELATED ............................................................................................................. 133
FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01): AIDS-RELATED .................................................................................................................................................. 134
PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIORAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01): AIDS-RELATED .... 135
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R01) AIDS-RELATED .................................................................................................................................................. 136
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21) AIDS-RELATED ................................................................. 137
SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R03) AIDS-RELATED ................................................................. 138
MECHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01): AIDS-RELATED ................................................................. 139
TARGETED BASIC BEHAVIORAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01) ................................................................. 139
TARGETED BASIC BEHAVIORAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21) ................................................................. 140
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIORAL AND SOCIAL SCIENCES (R01): AIDS-RELATED ................................................................. 141
SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIORAL AND SOCIAL SCIENCES (R21): AIDS-RELATED ................................................................. 142
BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED ................................................................. 143
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIORS IN CHILDREN AND ADOLESCENTS (R01): AIDS-RELATED ................................................................. 144
HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIORS IN CHILDREN AND ADOLESCENTS (R21): AIDS-RELATED ................................................................. 145
EFFECTS OF ADOLESCENT BINGE DRINKING ON BRAIN DEVELOPMENT (R21): AIDS-RELATED ................................................................. 147
HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01): AIDS-RELATED ................................................................. 148
BIOMECHANISMS OF PERIPHERAL NERVE DAMAGE BY ANTI-CANCER THERAPY (R01): AIDS-RELATED ................................................................. 149
BIOMECHANISMS OF PERIPHERAL NERVE DAMAGE BY ANTI-CANCER THERAPY (R21): AIDS-RELATED ................................................................. 150
RESEARCH ON THE HEALTH OF LGBTI POPULATIONS (R03): AIDS-RELATED ................................................................. 151
RESEARCH ON THE HEALTH OF LGBTI POPULATIONS (R21): AIDS-RELATED ................................................................. 152
NIDCR SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND STATISTICAL METHODOLOGY DEVELOPMENT (R03): AIDS-RELATED ................................................................. 153
PILOT HEALTH SERVICES AND ECONOMIC RESEARCH ON THE TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R34): AIDS-RELATED ................................................................. 153
TRANSLATIONAL RESEARCH AT THE AGEING/CANCER INTERFACE (R01): AIDS-RELATED .......................................................... 154
TRANSLATIONAL RESEARCH AT THE AGEING/CANCER INTERFACE (R21): AIDS-RELATED .......................................................... 155
ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01): AIDS-RELATED .......................................................... 156
ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R21): AIDS-RELATED .......................................................... 157
PILOT AND FEASIBILITY CLINICAL RESEARCH STUDIES IN DIGESTIVE DISEASES AND NUTRITION (R21): AIDS-RELATED .......................................................... 158
RESEARCH ON EMERGENCY MEDICAL SERVICES FOR CHILDREN (R01): AIDS-RELATED .......................................................... 159
RESEARCH ON EMERGENCY MEDICAL SERVICES FOR CHILDREN (R21): AIDS-RELATED .......................................................... 160
MECHANISMS OF ALCOHOL-ASSOCIATED CANCERS (R01): AIDS-RELATED .............. 161
MECHANISMS OF ALCOHOL-ASSOCIATED CANCERS (R21): AIDS-RELATED .............. 162
FUNCTIONS OF SKELETAL MUSCLE BEYOND CONTRACTION (R01): AIDS-RELATED .. 163
FUNCTIONS OF SKELETAL MUSCLE BEYOND CONTRACTION (R21): AIDS-RELATED .. 164
DEVELOPMENT AND TESTING OF NOVEL INTERVENTIONS TO IMPROVE HIV PREVENTION, CARE, AND PROGRAMME IMPLEMENTATION (R34).......................... 165
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01): AIDS-RELATED ........................................................................................................ 166
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21): AIDS-RELATED ........................................................................................................ 167
STEM CELLS AND ALCOHOL-INDUCED TISSUE INJURIES (R01): AIDS-RELATED ........ 168
STEM CELLS AND ALCOHOL-INDUCED TISSUE INJURIES (R21): AIDS-RELATED ........ 169
DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R21): AIDS-RELATED ........................................................................................................ 170
DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01): AIDS-RELATED ........................................................................................................ 171
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Funding Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE, URINARY, CARDIOVASCULAR AND PULMONARY SYSTEMS (R01): AIDS-RELATED</td>
<td>173</td>
</tr>
<tr>
<td>EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21): AIDS-RELATED</td>
<td>174</td>
</tr>
<tr>
<td>EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01): AIDS-RELATED</td>
<td>175</td>
</tr>
<tr>
<td>PILOT INTERVENTION AND SERVICES RESEARCH GRANTS (R34): AIDS-RELATED</td>
<td>176</td>
</tr>
<tr>
<td>EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R21): AIDS-RELATED</td>
<td>177</td>
</tr>
<tr>
<td>EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R01): AIDS-RELATED</td>
<td>178</td>
</tr>
<tr>
<td>EPIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R21): AIDS-RELATED</td>
<td>179</td>
</tr>
<tr>
<td>EPIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R01): AIDS-RELATED</td>
<td>180</td>
</tr>
<tr>
<td>SELECTED TOPICS IN TRANSFUSION MEDICINE (R21): AIDS-RELATED</td>
<td>181</td>
</tr>
<tr>
<td>SELECTED TOPICS IN TRANSFUSION MEDICINE (R01): AIDS-RELATED</td>
<td>182</td>
</tr>
<tr>
<td>ERYTHROPOIESIS: COMPONENTS AND MECHANISMS (R01): AIDS-RELATED</td>
<td>183</td>
</tr>
<tr>
<td>DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01): AIDS-RELATED</td>
<td>184</td>
</tr>
<tr>
<td>DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03): AIDS-RELATED</td>
<td>185</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIORS AND WEIGHT OUTCOMES (R21): AIDS-RELATED</td>
<td>186</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIORS AND WEIGHT OUTCOMES (R03): AIDS-RELATED</td>
<td>187</td>
</tr>
<tr>
<td>SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIORS AND WEIGHT OUTCOMES (R01): AIDS-RELATED</td>
<td>188</td>
</tr>
<tr>
<td>REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED</td>
<td>189</td>
</tr>
<tr>
<td>REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED</td>
<td>189</td>
</tr>
<tr>
<td>REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01): AIDS-RELATED</td>
<td>190</td>
</tr>
<tr>
<td>ACUTE KIDNEY INJURY IN OLDER ADULTS (R03) AIDS-RELATED</td>
<td>191</td>
</tr>
</tbody>
</table>
ACUTE KIDNEY INJURY IN OLDER ADULTS (R21) AIDS-RELATED ......................................................... 192
ACUTE KIDNEY INJURY IN OLDER ADULTS (R01) AIDS-RELATED ......................................................... 192
THE ROLE OF EXTRACELLULAR RNA IN MEDIATING THE HEALTH EFFECTS OF ALCOHOL (R21): AIDS-RELATED ........................................................................................................... 193
THE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01) AIDS-RELATED ...................................................................................................................... 194
RESEARCH GRANTS USING THE RESOURCES FROM THE OSTEOARTHRITIS INITIATIVE (R21): AIDS-RELATED .......................................................................................................................... 195
RESEARCH TO CHARACTERIZE AND REDUCE STIGMA TO IMPROVE HEALTH (R03): AIDS-RELATED .......................................................................................................................... 196
RESEARCH TO CHARACTERIZE AND REDUCE STIGMA TO IMPROVE HEALTH (R21): AIDS-RELATED .......................................................................................................................... 197
RESEARCH TO CHARACTERIZE AND REDUCE STIGMA TO IMPROVE HEALTH (R01): AIDS-RELATED .......................................................................................................................... 198
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21): AIDS-RELATED .......................................................................................................................... 199
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03): AIDS-RELATED .......................................................................................................................... 200
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIORS AND PREVENTION RESEARCH (R21): AIDS-RELATED ............... 200
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01): AIDS-RELATED .......................................................................................................................... 201
IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIORS AND PREVENTION RESEARCH (R01): AIDS-RELATED ............... 202
SYNERGISING OMIC AND SYMPTOM SCIENCE (R01): AIDS-RELATED ............................................ 202
SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01): AIDS-RELATED .......................................................................................................................... 203
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21): AIDS-RELATED .......................................................................................................................... 204
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R03): AIDS-RELATED .......................................................................................................................... 205
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33): AIDS-RELATED .......................................................................................................................... 206
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R01): AIDS-RELATED .......................................................................................................................... 207
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01): AIDS-RELATED ................................................................. 207

BEHAVIORAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R21): AIDS-RELATED ......................................................... 208

BEHAVIORAL AND SOCIAL SCIENCE RESEARCH ON UNDERSTANDING AND REDUCING HEALTH DISPARITIES (R01): AIDS-RELATED ......................................................... 209

GUT MICROBIOTA-DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK’S MISSION (R01): AIDS-RELATED .... 210

AUDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA – INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01): AIDS-RELATED ...... 211

STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01): AIDS-RELATED ................................................................. 212

MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R21): AIDS-RELATED ......................................................................................................................... 213

MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDICTION (R01): AIDS-RELATED ......................................................................................................................... 214

EXPLORATORY/DEVELOPMENTAL CLINICAL RESEARCH GRANTS IN OBESITY (R21): AIDS-RELATED ........................................................................................................ 214

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R03): AIDS-RELATED .................................................. 215

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R21): AIDS-RELATED .................................................. 216

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01): AIDS-RELATED .................................................. 217

EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION (R21/R33): AIDS-RELATED ........................................................................................................ 218

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03): AIDS-RELATED. 219

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21): AIDS-RELATED. 220

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01): AIDS-RELATED. 221

MODELING SOCIAL BEHAVIOR (R01): AIDS-RELATED .................................................................................................................. 222

NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01): AIDS-RELATED .................................................................................. 223
<table>
<thead>
<tr>
<th>Project Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01): AIDS-RELATED</td>
<td>224</td>
</tr>
<tr>
<td>PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01): AIDS-RELATED</td>
<td>225</td>
</tr>
<tr>
<td>NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED</td>
<td>226</td>
</tr>
<tr>
<td>NEUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R01): AIDS-RELATED</td>
<td>227</td>
</tr>
<tr>
<td>SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R01): AIDS-RELATED</td>
<td>228</td>
</tr>
<tr>
<td>ERADICATION OF HIV-1 FROM CENTRAL NERVOUS SYSTEM RESERVOIRS (R01)</td>
<td>229</td>
</tr>
<tr>
<td>CLINICAL VISION RESEARCH: RESOURCE CENTER GRANT (UG1): AIDS-RELATED</td>
<td>230</td>
</tr>
<tr>
<td>CLINICAL VISION RESEARCH: CHAIR’S GRANT (UG1): AIDS-RELATED</td>
<td>231</td>
</tr>
<tr>
<td>CLINICAL VISION RESEARCH: CLINICAL CENTER GRANT (UG1): AIDS-RELATED</td>
<td>232</td>
</tr>
<tr>
<td>CLINICAL VISION RESEARCH: COORDINATING CENTER GRANT (UG1): AIDS-RELATED</td>
<td>232</td>
</tr>
<tr>
<td>SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED</td>
<td>233</td>
</tr>
<tr>
<td>SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED</td>
<td>234</td>
</tr>
<tr>
<td>SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R01): AIDS-RELATED</td>
<td>235</td>
</tr>
<tr>
<td>FAMILY-CENTERED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R01): AIDS-RELATED</td>
<td>236</td>
</tr>
<tr>
<td>FAMILY-CENTERED SELF-MANAGEMENT OF CHRONIC CONDITIONS (R21): AIDS-RELATED</td>
<td>236</td>
</tr>
<tr>
<td>ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21): AIDS-RELATED</td>
<td>237</td>
</tr>
<tr>
<td>ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R21)</td>
<td>238</td>
</tr>
<tr>
<td>IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R21)</td>
<td>239</td>
</tr>
</tbody>
</table>
STRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R21) ............................................................ 240
ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R21) ................. 241
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01): AIDS-RELATED ........................................................................................................... 242
ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R01) ........................................................................................................... 243
IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R01) ..................... 244
STRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R01) ........................................................................................................... 245
ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R01) ................. 246
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R34): AIDS-RELATED ............................................................ 246
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED ........................................................................................................... 247
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS-RELATED ........................................................................................................... 248
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01): AIDS-RELATED ........................................................................................................... 249
NEUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01): AIDS-RELATED ........................................................................................................... 250
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21): AIDS-RELATED .......... 251
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01): AIDS-RELATED .......... 252
ESTABLISHING BEHAVIORAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY ...... 252
ESTABLISHING BEHAVIORAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY RESEARCH IN DENTAL, ORAL AND CRANIOFACIAL HEALTH (R01): AIDS-RELATED . 253
EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED ................................. 254
EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED ........................................................................................................... 255
TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED ....................... 256
<table>
<thead>
<tr>
<th>Grant Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01): AIDS-RELATED</td>
<td>257</td>
</tr>
<tr>
<td>EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21): AIDS-RELATED</td>
<td>258</td>
</tr>
<tr>
<td>EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED</td>
<td>259</td>
</tr>
<tr>
<td>EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01): AIDS-RELATED</td>
<td>260</td>
</tr>
<tr>
<td>CLINICAL TRIAL PLANNING GRANT FOR INTERVENTIONS AND SERVICES TO IMPROVE TREATMENT AND PREVENTION OF HIV/AIDS (R34)</td>
<td>260</td>
</tr>
<tr>
<td>MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21): AIDS-RELATED</td>
<td>262</td>
</tr>
<tr>
<td>MHEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) AIDS-RELATED</td>
<td>262</td>
</tr>
<tr>
<td>EXPLORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34) AIDS-RELATED</td>
<td>262</td>
</tr>
<tr>
<td>UNCONVENTIONAL ROLES OF ETHANOL METABOLIZING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01): AIDS-RELATED</td>
<td>264</td>
</tr>
<tr>
<td>B CELL HELP IMMUNOLOGY PROGRAMME FOR AIDS VACCINE STRATEGIES (R01)</td>
<td>265</td>
</tr>
<tr>
<td>NK CELLS TO INDUCE IMMUNOLOGICAL MEMORY TO PREVENT HIV INFECTION (R01)</td>
<td>266</td>
</tr>
<tr>
<td>FC RECEPTOR AND ANTIBODY EFFECTOR FUNCTION IN HIV VACCINE DISCOVERY (R01)</td>
<td>267</td>
</tr>
<tr>
<td>HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R21)</td>
<td>268</td>
</tr>
<tr>
<td>HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R01)</td>
<td>269</td>
</tr>
<tr>
<td>CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) AIDS-RELATED</td>
<td>270</td>
</tr>
<tr>
<td>ADVANCING RESEARCH IN VOICE DISORDERS (R21) AIDS-RELATED</td>
<td>271</td>
</tr>
<tr>
<td>ADVANCING RESEARCH IN VOICE DISORDERS (R01) AIDS-RELATED</td>
<td>271</td>
</tr>
<tr>
<td>BASIC RESEARCH ON HIV PERSISTENCE (R21): AIDS-RELATED</td>
<td>272</td>
</tr>
<tr>
<td>MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R21)</td>
<td>273</td>
</tr>
<tr>
<td>Grant Title</td>
<td>Page</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R01)</td>
<td>274</td>
</tr>
<tr>
<td>H2020-TWINN-2015 CALL FOR TWINNING</td>
<td>275</td>
</tr>
<tr>
<td>NINDS CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR</td>
<td>276</td>
</tr>
<tr>
<td>DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (U01): AIDS-</td>
<td></td>
</tr>
<tr>
<td>RELATED</td>
<td></td>
</tr>
<tr>
<td>NINDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE</td>
<td>277</td>
</tr>
<tr>
<td>CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3):</td>
<td></td>
</tr>
<tr>
<td>AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>BLUEPRINT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY</td>
<td>278</td>
</tr>
<tr>
<td>AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3): AIDS-</td>
<td></td>
</tr>
<tr>
<td>RELATED</td>
<td></td>
</tr>
<tr>
<td>ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01):</td>
<td>279</td>
</tr>
<tr>
<td>AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC</td>
<td>280</td>
</tr>
<tr>
<td>CARE (R03): AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC</td>
<td>281</td>
</tr>
<tr>
<td>CARE (R21): AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21):</td>
<td>282</td>
</tr>
<tr>
<td>AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>MOLECULAR AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R01):</td>
<td>283</td>
</tr>
<tr>
<td>AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC</td>
<td>284</td>
</tr>
<tr>
<td>CARE (R01): AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21): AIDS-</td>
<td>285</td>
</tr>
<tr>
<td>RELATED</td>
<td></td>
</tr>
<tr>
<td>SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21): AIDS-</td>
<td>286</td>
</tr>
<tr>
<td>NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING</td>
<td>287</td>
</tr>
<tr>
<td>GRANT (R34): AIDS-RELATED</td>
<td></td>
</tr>
<tr>
<td>SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01): AIDS-</td>
<td>288</td>
</tr>
<tr>
<td>STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21): AIDS-</td>
<td>289</td>
</tr>
<tr>
<td>STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03): AIDS-</td>
<td>290</td>
</tr>
<tr>
<td>STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R01): AIDS-</td>
<td>291</td>
</tr>
<tr>
<td>BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21):</td>
<td>292</td>
</tr>
</tbody>
</table>
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R01): AIDS-RELATED .......................................................................................................................................................................................... 293

BIOBEHAVIORAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21): AIDS-RELATED .......................................................................................................................................................................................... 294

BIOBEHAVIORAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01): AIDS-RELATED .......................................................................................................................................................................................... 295

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01): AIDS-RELATED .......................................................................................................................................................................................... 296

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R21): AIDS-RELATED .......................................................................................................................................................................................... 297

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03): AIDS-RELATED .......................................................................................................................................................................................................................................................... 298

DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01): AIDS-RELATED .......................................................................................................................................................................................................................................................... 299

UNDERACTIVE BLADDER IN AGEING (R03): AIDS-RELATED .......................................................................................................................................................................................................................................................... 300

UNDERACTIVE BLADDER IN AGEING (R21): AIDS-RELATED .......................................................................................................................................................................................................................................................... 301

UNCONVENTIONAL ROLES OF ETHANOL METABOLIZING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21): AIDS-RELATED .......................................................................................................................................................................................................................................................... 302

NIDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY COOPERATIVE AGREEMENT (U01): AIDS-RELATED .......................................................................................................................................................................................................................................................... 303

BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01): AIDS-RELATED .......................................................................................................................................................................................................................................................... 304

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERIZATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33): AIDS-RELATED .......................................................................................................................................................................................................................................................... 305

INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33): AIDS-RELATED .......................................................................................................................................................................................................................................................... 306

ACADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01): AIDS-RELATED .......................................................................................................................................................................................................................................................... 307

NIAID CLINICAL TRIAL PLANNING GRANTS (R34) .......................................................................................................................................................................................................................................................... 308

NEW INVESTIGATOR GRANT IN PHARMACEUTICS AND PHARMACEUTICAL TECHNOLOGIES .......................................................................................................................................................................................................................................................... Error! Bookmark not defined.
<table>
<thead>
<tr>
<th>Grant Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW INVESTIGATOR GRANT IN PHARMACOKINETICS, PHARMACODYNAMICS AND DRUG METABOLISM</td>
<td>18</td>
</tr>
<tr>
<td>NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01)</td>
<td>309</td>
</tr>
<tr>
<td>NIAID CLINICAL TRIAL IMPLEMENTATION GRANT (R01)</td>
<td>310</td>
</tr>
<tr>
<td>BIOENGINEERING RESEARCH PARTNERSHIPS (R01)</td>
<td>311</td>
</tr>
<tr>
<td>INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01)</td>
<td>312</td>
</tr>
<tr>
<td>NIDA RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25)</td>
<td>313</td>
</tr>
<tr>
<td>LONG-TERM OUTCOMES OF BARIATRIC SURGERY USING LARGE DATASETS (R01)</td>
<td>313</td>
</tr>
<tr>
<td>ALZHEIMER’S DISEASE SEQUENCING PROJECT REPLICATION PHASE ANALYSIS STUDIES (U01)</td>
<td>314</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01)</td>
<td>315</td>
</tr>
<tr>
<td>BUILDING EVIDENCE: EFFECTIVE PALLIATIVE/END OF LIFE CARE INTERVENTIONS (R01)</td>
<td>316</td>
</tr>
<tr>
<td>FUNDAMENTAL MECHANISMS OF AFFECTIVE AND DECISIONAL PROCESSES IN CANCER CONTROL (U01)</td>
<td>317</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R21)</td>
<td>318</td>
</tr>
<tr>
<td>DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03)</td>
<td>319</td>
</tr>
<tr>
<td>SMALL GRANTS FOR NEW INVESTIGATORS TO PROMOTE DIVERSITY IN HEALTH-RELATED RESEARCH (R03)</td>
<td>320</td>
</tr>
<tr>
<td>NIH: NATIONAL CANCER INSTITUTE</td>
<td>321</td>
</tr>
<tr>
<td>BRIDGING THE GAP BETWEEN CANCER MECHANISM AND POPULATION SCIENCE (U01)</td>
<td>322</td>
</tr>
<tr>
<td>BASIC CANCER RESEARCH IN CANCER HEALTH DISPARITIES (R01)</td>
<td>323</td>
</tr>
<tr>
<td>ADVANCED DEVELOPMENT OF INFORMATICS TECHNOLOGY (U24)</td>
<td>323</td>
</tr>
<tr>
<td>EARLY-STAGE DEVELOPMENT OF INFORMATICS TECHNOLOGY (U01)</td>
<td>324</td>
</tr>
<tr>
<td>COLLABORATIVE RESEARCH IN INTEGRATIVE CANCER BIOLOGY (U01)</td>
<td>325</td>
</tr>
<tr>
<td>IMAGE-GUIDED DRUG DELIVERY IN CANCER (R01)</td>
<td>326</td>
</tr>
<tr>
<td>EXPLORATORY GRANT AWARD TO PROMOTE WORKFORCE DIVERSITY IN BASIC CANCER RESEARCH (R21)</td>
<td>327</td>
</tr>
<tr>
<td>PHARMACOGENOMICS OF OROFACIAL PAIN MANAGEMENT (R01)</td>
<td>328</td>
</tr>
<tr>
<td>IDENTIFICATION OF GENE VARIANTS FOR ADDICTION-RELATED TRAITS BY NEXT-GEN SEQUENCING IN MODEL ORGANISMS SELECTIVELY BRED FOR ADDICTION TRAITS (UH2/UH3)</td>
<td>329</td>
</tr>
<tr>
<td>Research Area</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>TARGETING PERSISTENT HIV RESERVOIRS (R21/R33)</td>
<td>330</td>
</tr>
<tr>
<td>STUDIES OF HIV/AIDS AND AGEING (R21)</td>
<td>331</td>
</tr>
<tr>
<td>MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R01)</td>
<td>332</td>
</tr>
<tr>
<td>MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R03)</td>
<td>333</td>
</tr>
<tr>
<td>INTEGRATION OF INFECTIOUS DISEASES AND SUBSTANCE ABUSE INTERVENTION SERVICES FOR INDIVIDUALS LIVING WITH HIV (R01)</td>
<td>334</td>
</tr>
<tr>
<td>TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)</td>
<td>335</td>
</tr>
<tr>
<td>TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R01)</td>
<td>336</td>
</tr>
<tr>
<td>TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R21)</td>
<td>337</td>
</tr>
</tbody>
</table>
ADMINISTRATIVE SUPPLEMENTS FOR RESEARCH ON DIETARY SUPPLEMENTS (ADMIN SUPP)
NIH: National Institutes of Health

Description:
The Office of Dietary Supplements, in collaboration with several National Institutes of Health, invites applications for its administrative supplements for research on dietary supplements. This supplement announcement aims to support research in which the supplemental funding would investigate the role of dietary supplements or their ingredients in health maintenance and disease prevention.
Research interests of ODS are not limited to specific health conditions, organ systems or population groups. It supports all types of research, including preclinical, clinical, behavioral and epidemiological. However, primary consideration will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
Proposals may request up to US$100,000. The project and budget periods must be within the currently approved project period for the existing parent award.

Ref: PAR-14-201.
Closing date: 15 Apr 15

Deadline information: Applications due by 5pm local time of applicant organization. Deadlines on: 15 October 2014, 15 January 2015, 15 April 2015.
Posted date: 06 May 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Award budget total: $3,000,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-201.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Food Science, Primary Care, Nutrition & Dietetics, Allied Health Professions, Dietary Guidelines, Epidemiology, Clinical Medicine

Contact Details
----------------------------------------------
ODS
Building 6100, Room 3B01
6100 Executive Boulevard
Rockville MD 20852
Tel: 1 301 496 0168
Email: davisci@mail.nih.gov
EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R21/R33)
NIH: National Institute on Drug Abuse

Description:
A total of four institutes and offices of the NIH invite applications for their exploratory studies of smoking cessation interventions for people with schizophrenia (R21/R33) grants. The purpose of this R21 and R33 funding opportunity is to provide support for grant applications to generate and conduct preliminary tests of targeted smoking cessation treatments for individuals with schizophrenia. This funding opportunity announcement provides support for grant applications designed to generate novel treatments and improve existing treatments and conduct preliminary tests of novel and improved Behavioral, pharmacological, and combined smoking cessation treatments for individuals with schizophrenia by examining the mechanisms of nicotine addiction in individuals with schizophrenia as putative intervention targets. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. The NIH intends to fund an estimate of six to nine awards corresponding to a total of US$3,5 million for fiscal year 2015. The R21 phase may not exceed two years or US$275,000 in direct costs, with no more than US$150,000 in direct costs in any single year of the R21 phase. The R33 phase may not exceed three years or US$450,000 in direct costs, with no more than US$225,000 in direct costs in any single year of the R33 phase. The maximum period is five years.
Ref: PAR-14-230.

Closing date: 15 Apr 15
Deadline information: Applications due by 5pm local time of applicant organization on 15 August, 16 December 2014, 15 April, 17 August, December 15, 2015, 15 April, 16 August, 15 December, 2016, 17 April Until 8 September 2017.
Posted date: 20 May 14
Award type: Directed grants to institutions, research groups etc.
Award budget total: $3,500,000
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile

Country of applicant institution: Any

Disciplines
Mental Health, Schizophrenia & Other Psychotic Disorders, Psychology, Addiction, Drug & Substance Abuse, Economic & Social Environment, Medical Sociology, Primary Care, Mental Illness, Psychiatry, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Biomedical Engineering, Sociology, Smoking & Tobacco, Health Disparities, HIV/AIDS

Contact Details
NIH
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: 1 301 443 2235
Fax: 1 301 443 7397
Email: lisaonken@nih.gov
EXPLORATORY STUDIES OF SMOKING CESSATION INTERVENTIONS FOR PEOPLE WITH SCHIZOPHRENIA (R33)

NIH: National Institute on Drug Abuse

Description:
A total of four institutes and offices of the NIH invite applications for their exploratory studies of smoking cessation interventions for people with schizophrenia (R33) grants. The purpose of this R33 funding opportunity is to provide support for grant applications of two major types. Type I will conduct exploratory testing of novel, targeted treatments for smoking cessation for individuals with schizophrenia. Type II will conduct exploratory testing of targeted implementation strategies of existing efficacious treatments at the service-delivery system level. Ultimately, this R33 funding mechanism intends to speed the translation of emerging basic science findings of mechanisms and processes underlying treatments or implementation strategies into novel intervention approaches that can be efficiently tested for their promise to promote smoking cessation in individuals who have schizophrenia or promote the adoption of experimentally-supported smoking cessation interventions within organizations that provide services to smokers with schizophrenia.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. The NIH intends to fund an estimate of six to nine awards, corresponding to a total of US$3.5 million for fiscal year 2015. The budget may not exceed US$450,000 in direct costs over the three year project period, with no more than US$225,000 in direct costs in any single year. The maximum period is three years.

Ref: PAR-14-231.

Closing date: 15 Apr 15
Deadline information: Applications due by 5pm local time of applicant organization.

Posted date: 20 May 14
Award type: Directed grants to institutions, research groups etc.
Award budget total: $3,500,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-231.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse, Mental Illness, Psychiatry, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Biomedical Engineering, Mental Health, Schizophrenia & Other Psychotic Disorders, Psychology, Smoking & Tobacco, Sociology, Addiction, HIV/Aids, Health Disparities, Economic & Social Environment, Medical Sociology, Primary Care

Contact Details
NIH
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: 1 301 443 2235
Email: lisaonken@nih.gov
INTERNATIONAL PROGRAMME – AFRICA
Albert Baker Fund

Description:
The Albert Baker Fund invites applications for its Africa international programme. This supports individuals pursuing graduate or vocational education in Christian science, and who are citizens or permanent residents of Cameroon, Republic of Congo, Democratic Republic of Congo, Ghana, Kenya, Nigeria, Rwanda, Tanzania, Uganda and Zambia. Applicants must reapply for funding each new academic term and must be enrolled at an accredited educational institution in Benin, Burundi, Cameroon, Congo, DRC, Ghana, Kenya, Nigeria, Rwanda, Mwanza, Togo, Uganda or Zambia. Funding is provided for one academic year, semester or vocational course length and covers tuition, books, exams, housing and transport costs.

Closing date: 15 Apr 15
Posted date: 09 Jun 14
Award type: Financial aid for postgraduate students, Travel for research purposes, Directed grants to institutions, research groups etc. Directed grants for individual investigators, Equipment and materials
Website: http://africa.albertbakerfund.org/africa-college/
Application form: http://africa.albertbakerfund.org/application/

Eligibility profile
Country of applicant institution: Burundi, Benin, Congo, the Democratic Republic of the, Congo, Cameroon, Ghana, Kenya, Nigeria, Rwanda, Togo, Tanzania, United Republic of, Uganda, Zambia

Disciplines

Contact Details
Tel: +1 916 594 9602
Email: programs@albertbakerfund.org

INNOVATIVE RESEARCH IN CANCER NANOTECHNOLOGY (U01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its innovative research in cancer nanotechnology (U01) grants. The purpose of this U01 funding opportunity announcement is to enable multi-disciplinary research and transformative discoveries in cancer biology and oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology or oncology using nanotechnology and should emphasise fundamental understanding of nanomaterial interactions with biological
ADVANCED CLINICAL TRIALS TO TEST ARTIFICIAL PANCREAS DEVICE SYSTEMS IN TYPE 1 DIABETES (UC4)

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its advanced clinical trials to test artificial pancreas device systems in type 1 diabetes (UC4) grants. The purpose of this UC4 funding opportunity announcement is the conduct of advanced clinical trials designed to test the outpatient clinical safety
and efficacy of artificial pancreas device systems in type 1 diabetes, with the objective of improving glycemic control and reducing acute and chronic complications of the disease. Trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. NIDDK intends to commit up to US$20 million to fund one to three awards. The maximum project period is five years. Ref: RFA-DK-14-024

Closing date: 15 Apr 15
Deadline information: Applications are invited between 15 March and 5pm local time of applicant organization, 15 April 2015.
Posted date: 23 Jul 14
Award type: Directed grants to institutions, research groups etc. Clinical trials
Award budget total: $20,000,000
Website: http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-14-024.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Clinical Medicine, Chronic Care, Diabetes, Hormones & Endocrinology, Nephrology & Kidneys, Gastroenterology, Pathophysiology

Contact Details
NIH: National Institute of Diabetes and Digestive and Kidney Diseases
NIH
Building 31, Room 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
Tel: 1 301 594 4724
Email: arreazag@mail.nih.gov

DOCTORAL INTERNSHIPS
Hong Kong Institute for Monetary Research

Description:
The Hong Kong Institute for Monetary Research invites applications for its doctoral internships. These support visits to HKIMR, lasting typically three months. Applicants are encouraged to address the following topics:
• monetary and financial stability in Hong Kong and mainland China;
• capital account liberalization in mainland China, and its implications for Hong Kong;
• monetary and financial cooperation in Asia;
• renmimbi offshore market development in Hong Kong.
Each applicant must be enrolled in an economics, finance or related PhD programme. Preference is given to candidates in the final stages of writing their PhD dissertation, and who are conducting research on issues of important for the Asian region. HKIMR offers travel and accommodation allowances for interns from overseas, as well as a daily stipend.

Closing date: 15 Apr 15
Deadline information: This call is repeated once a year.
Posted date: 20 Oct 14
Award type: Directed grants for individual investigators, Travel for research purposes
Website: http://www.hkimr.org/content-id14

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------

Contact Details
----------------------------------------------
HKIMR
55/F, Two International Finance Center
8 Finance Street, Central
Tel: 852 2878 1978
Fax: 852 2878 7006
Email: hkimr@hkma.gov.hk

ADMINISTRATIVE SUPPLEMENTS FOR HUMAN ISLET RESEARCH (ADMIN SUPP)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its administrative supplements for human islet research. This supplement announcement aims to cover increased costs for human islets in order to facilitate scientific advances and accelerate human islet discovery research.

Applicants may be US or non-US based researchers with active NIDDK awards containing human islet focused aims. Applications may be submitted on paper via the P01 research programme projects grant mechanism, or submitted electronically via the following grant mechanisms:
- DP1 director’s pioneer award;
- DP2 Director’s New Innovator Awards;
- DP3 Type 1 Diabetes Targeted Research Award;
- DP4 Director’s Pathfinder Award – Multi-Year Funding;
- R01 Research Project Grant;
- R21 exploratory and Developmental Research Grant Award;
- R24 Resource-Related Research Projects;
- R37 Method to Extend Research in Time Award;
- U01 Research Project – Cooperative Agreements;
- UC4 High Impact Research and Research Infrastructure – Cooperative Agreement Programmes.

Funding is worth up to US$100,000 over the entire remaining project period.
Ref: PA-15-025.

Closing date: 15 Apr 15
Deadline information: Applications due by 5pm local time of application organization.
Posted date: 30 Oct 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://www.grants.gov/web/grants/applicant
IDA TRANSLATIONAL AVANT-GARDE AWARD FOR DEVELOPMENT OF MEDICATION TO TREAT SUBSTANCE USE DISORDERS (UH2/UH3)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its NIDA translational avant-garde award for development of medication to treat substance use disorders (UH2/UH3) funding opportunity announcement. This announcement encourages the translation of research discoveries into medications for the treatment of substance use disorders stemming from tobacco, cannabis, cocaine, methamphetamine, heroin or prescription opiate use. Applications may have the following focus:
- new chemical entities;
- already-marketed pharmacotherapies;
- biologics, for example immunotherapies such as vaccines and antibodies, enzymes, and gene therapies;
- combinations of medications;
- new delivery devices and technologies.

The UH2/UH3 phase innovation awards cooperative agreement involves two phases. The UH2 is to support a project with specific milestones to be accomplished at the end of the two-year period. The UH3 is to provide funding for three years to a project that successfully completed the milestones set in the UH2. UH2 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UH2 and UH3 phases.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. The total budget is US$3 million in fiscal year 2015 and will fund up to three grants. Application budgets are limited to US$1m in direct costs. The UH2 phase may request up to two years of support and the UH3 phase may request up to three years of support.

Ref: RFA-DA-15-017

Closing date: 15 Apr 15
Deadline information: Applications open on 15 March and are due by 5pm local time of applicant organization on 15 April 2015.

Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,000,000
Award budget total: $3,000,000
**Website:**

**Application form:**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

- Alcoholism, Drug Design, Drug & Substance Abuse, Smoking & Tobacco

**Contact Details**

- NSC BG Room 4131
- 6001 Executive Boulevard
- Rockville MD 20852
- Tel: 1 301 443 8639
- Email: imontoya@mail.nih.gov

---

**ADVANCED MEDICAL DEVICE POST-MARKET SURVEILLANCE INFRASTRUCTURE AND EPIDEMIOLOGIC METHODOLOGIES THROUGH MULTI-STAKEHOLDER PARTNERSHIP (U01)**

*Food and Drug Administration (FDA)*

**Description:**

The US Food and Drug Administration invites proposals for its grants for advancing medical device postmarket surveillance infrastructure and epidemiologic methodologies through multi-stakeholder partnership (U01). The purpose of this U01 funding opportunity announcement is to continue to facilitate development of the National Medical Device Postmarket Surveillance System, epidemiologic methodologies and scientific systems to facilitate a comprehensive understanding of medical device performance and clinical outcomes associated with medical device use. The specific aims are to:

- support implementation of the national medical device post-market surveillance system through sustainable multi-stakeholder partnership;
- develop new epidemiologic methodologies or to apply existing methodologies in new ways to provide a comprehensive understanding of medical device performance and clinical outcomes associated with device use in real-world use settings;
- develop new systems of data collection or analysis to permit prospective active medical device post-market risk identification, periodic systematic updates of comprehensive evidence syntheses, visual analytics and other efforts to broadly apply complex methodology to diverse data sources that facilitates post-market surveillance;
- develop methodological approaches or systems that facilitate the use of post-market information for regulatory decision-making throughout the entire device lifecycle;
- support the development of and access to high-quality data sources that can be used in comprehensive post-market evaluation of medical device performance and associated outcomes.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets should not exceed US$1.1 million per year, over a project period of one to five years. RFA-FD-13-232.
Closing date: 30 Apr 15
Deadline information: Applications due by 11:59pm Eastern time.
Posted date: 23 May 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $5,500,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Clinical Decision-making & Analysis, Quality Control & Management, Public Health,
Health Services & Primary Care, Medical Devices, Epidemiology, Political Risk Factors & Analysis, Business & Management Studies, Primary Care

Contact Details
----------------------------------------------
Division of Epidemiology
Center for Devices and Radiological Health
Office of In Vitro Diagnostics and Radiological Health
10903 New Hampshire Avenue
WO66-5521
Silver Spring, MD 20993-0002
Tel: 1 301 796 668
Email: danica.marinac-dabic@fda.hhs.gov
MALL GRANTS PROGRAMME FOR CANCER RESEARCH (R03): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its AIDS-related small grants programme for cancer research (R03). This AIDS-related R03 funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology and development of new research technology. This funding opportunity will use the small grant programme (R03) mechanism, and runs in parallel with an FOA of identical scientific scope, PAR-13-146, which solicits applications under the exploratory/developmental (R21) award mechanism. Applicants may request direct costs of up to US$50,000 per year over a two-year project period. Domestic and foreign for-profit or non-profit organizations and public or private institutions are eligible to apply. Ref: PAR-14-007 (replaces PAR-12-144).

Closing date: 05 May 15
Posted date: 22 Nov 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Website:
Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=P AR-14-007

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids, Molecularly Targeted Therapy, Physiology, Carcinogenesis, Diagnostic Sciences, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Breast Cancer, Oncology Nursing, Computer Science & Informatics, Brain Cancer, Project Management & Resource Allocation, Human Biological Sciences, Economics & Econometrics, Cancer Immunology, Nursing, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Ovarian & Cervical Cancers, Cancer Studies & Oncology, Leukaemia & Other Blood Cancers, Clinical Medicine, Lung Cancer, Non-cancerous Tumours, Data Analysis, Medical Research of Selected Fields

Contact Details
NCI
6120 Executive Boulevard
Bethesda, MD 20892-7150
Tel: 1 301 496 7800
NCI EXPLORATORY/DEVELOPMENTAL RESEARCH GRANT PROGRAMME (R21): AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites Aids-related applications for its exploratory/developmental research grant programme for cancer research (R21). This Aids-related R21 funding opportunity announcement supports the developmental of new research activities in all areas of cancer research. The mechanism is intended to encourage exploratory and developmental research projects by exploring support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models or applications that could have a major impact on a field of cancer research, either biomedical, behavioral or clinical. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 available in any year. PAR-13-146 (replaces PAR-12-145).

Closing date: 05 May 15
Deadline information: Proposals due by 5pm applicant’s local time on 5 September 2013; 5 January, 5 May and 5 September 2014; 5 January, 5 May and 4 September 2015.
Posted date: 20 Mar 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-13-146.html

Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cancer Studies & Oncology, Leukaemia & Other Blood Cancers, Nursing, Ovarian & Cervical Cancers, Oncology Nursing, Computer Science & Informatics, Brain Cancer, Economics & Econometrics, Diagnostic Sciences, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Breast Cancer, Data Analysis, Carcinogenesis, Medical Research of Selected Fields, Lung Cancer, Physiology, Non-cancerous Tumours, Clinical Medicine, HIV/Aids, Molecularly Targeted Therapy, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Project Management & Resource Allocation, Human Biological Sciences, Cancer Immunology

Contact Details
----------------------------------------------
National Cancer Institute
6116 Executive Boulevard
Suite 300
Bethesda MD 20892-8322
RESEARCH ON ALCOHOL AND HIV/AIDS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites R01 applications for its research on alcohol and HIV/AIDS programme.
This supports small research projects that aim to:

- characterize the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- Develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

This funding opportunity announcement will utilize the R01 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R03 and R21 mechanisms.

Application budgets are not limited but need to reflect the actual needs of the proposed project. Funding is available for up to five years.

Applications may be submitted by domestic and foreign for-profit and non-profit organizations and public or private institutions.

PA-13-121.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May, 7 September until 8 May 2016.

Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse, Pathogenesis, Sociology, Public Health, Health Disparities, HIV/Aids, Social Work & Social Policy, Psychology, Allied Health Professions, Alcoholism, Biomedical Engineering, Disadvantaged & Minority Groups, Epidemiology, Preventive Medicine, Diagnostic Sciences, Disease Control, Public Health, Health Services & Primary Care, Medical Sociology, Lesbian, Gay, Bisexual & Transgender Studies, Economic & Social Environment, Gender Roles & Sexuality, Women’s Health, Behavioral Medicine

Contact Details
Tel: 1 301 403 9289
Email: kbryant@mail.nih.gov
DRUG ABUSE ASPECTS OF HIV/AIDS (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse aspects of HIV/AIDS (R01) programme. This R01 funding opportunity announcement seeks to examine the drug abuse aspects of HIV/AIDS, including research on drug-related risk behaviors, addiction and HIV disease, and drug use and HIV-related co-morbidities and consequences. Applications are needed for the following areas:

- to identify and predict changes in the epidemiology of HIV/AIDS among the following groups among injection and non-injection drug users and among their sexual partners;
- to develop and test interventions for primary and secondary HIV prevention, including drug treatment interventions;
- to improve HIV testing, counseling and treatment services for those living with HIV/AIDS;
- To address basic mechanisms involved in HIV infection and Aids pathogenesis in the context of drug abuse and addiction.

This FOA will use the R01 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-294 that solicits applications under the R03 mechanism and PA-12-295 that solicits applications under the R21 mechanism. The maximum project period is five years. Application budgets are not limited, but must reflect the actual needs of the project. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-293 (replaces PA-10-129).

Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-12-293.html
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-293

Eligibility profile
-------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------
Drug & Substance Abuse, Neuroscience, Infectious Diseases, Virology, Venereology & Sexually Transmitted Diseases, Preventive Medicine, Diagnostic Sciences, Disease Control, Public Health, Health Services & Primary Care, Allied Health Professions, Biomedical Engineering, Pharmacy & Pharmacology, Neurology, Epidemiology, Social Behavior & Attitudes, Population Studies, Medical, Psychology, Physiology, Aetiology, Sociology, Clinical Medicine, Biochemical Markers, Addiction, Health Disparities, HIV/Aids, General Practice, Biological Markers & Sensor Mechanisms, Gender Roles & Sexuality, Behavioral Medicine, Economic & Social Environment, Medical Sociology, Infection Agents & Pathogens, Cognitive Processes

Contact Details
-------------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center, Room 4279
6001 Executive Boulevard

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Sep 12
IV INFECTION OF THE CENTRAL NERVOUS SYSTEM (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Allergy and Infectious Disease, the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke invite research applications for their HIV infection of the central nervous system (R01) grants. This R01 funding opportunity announcement focuses on defining the pathogenic mechanisms involved in human immunodeficiency virus-1 associated neurocognitive disorders and identifying therapeutic strategies to treat and prevent the neurobehavioral and neurological effects of HIV-1 on the CNS. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-094 (replaces PA-11-014).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 12 Feb 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
Award amount max: -

Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-094.html
Application form: http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true&oppNum=PA-14-094

Eligibility profile
 Country of applicant institution: Any

Disciplines
 Psychology, Clinical Medicine, Biological Sciences, Nucleus & Organelles, Neurology, Molecular Genetics, Virology, Neurobiology, Human Biological Sciences, Infection Agents & Pathogens, Neuroimaging, Infectious Diseases, Primary Care, Cellular Interactions, Pathogenesis, Central Nervous System, Proteomics & Molecular Interactions, Neuropsychology, Physiology, HIV/AIDS, General Practice, Public Health, Health Services & Primary Care, Medical & Diagnostic Tests, Diagnostic Sciences, Preventive Medicine

Contact Details
 NIMH
 6001 Executive Boulevard
 Bethesda, MD 20892
 Tel: 1 301 443 6100
 Email: jeymoha@mail.nih.gov
STRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites proposals for its structural interventions, alcohol use and risk of HIV/Aids (R21) programme. This R21 funding opportunity announcement solicits applications from institutions and organizations that propose to investigate the effectiveness of structural interventions that reduce the risk of HIV/Aids transmission by changing the environment of alcohol use. This FOA will use the research project grant R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-191, which solicits applications under the R01 research project grant mechanism. Applications budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-192 (replaces PA-10-243.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 20 May 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-192

Eligibility profile
Country of applicant institution: Any
Disciplines
Psychology, Alcoholism, Primary Care, Mental Illness, Health Systems Policy, Gender Roles & Sexuality, Behavioral Medicine, Education, HIV/Aids, Health Disparities, Social Work & Social Policy, Biomedical Engineering, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care

Contact Details
NIH
5635 Fishers Lane, Room 2073
Bethesda, MD 20892-9304
Tel: 1 301 443 8820
Email: rfreeman@mail.nih.gov

RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/AIDS (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Dental and Craniofacial Research invite applications for their research on malignancies in the context of HIV/Aids
The purpose of this R01 funding opportunity announcement is to advance understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immune deficiency syndrome. NCI and NIDCR seek to encourage research in areas such as the study of the aetiological factors, cofactors, immunopathogenesis, diagnosis, and consequences of both Aids-defining and non-Aids-defining malignancies in diverse populations in the context of an underlying HIV infection. This FOA invites research efforts that will: provide information on the clinical outcomes of such cancers in the HIV-infected population; and identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers.

This FOA will use the research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-378, which solicits applications under the R21 exploratory/developmental grant mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Ref: PA-13-377 (replaces PA-10-290).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 September 2016.
Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol and Tobacco Abuse (R01): AIDS-Related
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for AIDS-related health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R01). This AIDS-related R01 funding opportunity announcement encourages applications emphasizing any of the following subjects:

- clinical quality improvement;
- organization and delivery of services;
- implementation research;
- economic and cost studies;
- Development or improvement of research methodology, analytic approaches and measurement instrumentation used in the study of drug, alcohol and tobacco prevention, treatment and recovery services.

Research may focus on individual-level Behaviors as they affect access, engagement, adherence and retention in support services, or programme, organization or systems-level issue that affect the availability, accessibility, utilization, effectiveness, fidelity, cost and quality of support services. Investigators are strongly encouraged to integrate factors related to addressing the spread and prevention or treatment of infectious disease among substance users.

This FOA will use the NIH R01 research project grant award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-128, which solicits applications under the exploratory/developmental grant (R21) award mechanism, and PA-12-129, which solicits applications under the small research grant (R03) award mechanism. Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years. Applications will be accepted from domestic and foreign for-profit or not-for-profit organizations and public or private institutions. PA-12-127 (replaces PA-08-263)

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 20 Mar 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-127.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-127

Eligibility profile
Country of applicant institution: Any

Disciplines
Social Work & Social Policy, HIV/Aids, Sociology, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Medical Sociology, Primary Care, Quality of Care, Drug & Substance Abuse, Behavioral Medicine, Health Economics, Clinical Decision-making & Analysis, Economic & Social Environment, Psychology, Social Services Delivery, Addiction, Access to Health Care, Health Systems, Administration

Contact Details
Services Research Branch
Division of Epidemiology, Services & Prevention Research
National Institute on Drug Abuse
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 443 6504
Email: rchandle@nida.nih.gov
EXTENDED DEADLINE: INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse has extended the closing date for its Aids-related international research collaboration on drug abuse and addiction research (R01) grants. The previous expiration date of 8 January has now been extended to 8 May 2015, making the last application deadline 7 May 2015. All other call details remain the same.
This Aids-related R01 funding opportunity announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/AIDS and drug abuse, and prevention, initiation and treatment of nicotine and tobacco use.
Applications are welcome from domestic and foreign for-profit or non-profit organizations and public or private institutions. This FOA will use the NIH R01 research project grant award mechanism and runs in parallel with FOAs of identical scientific scope, PA-12-041 and PA-12-042, that solicit applications under the exploratory/developmental grant (R21) and small research grant (R03) award mechanisms, respectively. Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years.

Ref: PA-12-040 (replaces PA-09-020).

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2012 and are due by 5 pm local time of applicant organization every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 08 Jan 15
Award type: Directed grants to institutions, research groups etc., Networking/collaboration
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-040.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-040

Eligibility profile
Country of applicant institution: Any
Disciplines
Alcoholism, Smoking & Tobacco, HIV/AIDS, Drug & Substance Abuse

Contact Details
Office of the Director
National Institute on Drug Abuse
9000 Rockville Pike, Room 1B59
Bethesda, MD 20892-9581
Tel: 1 301 443 6480
Email: ipdirector@nida.nih.gov
DESCRIPTION AND IMPLEMENTATION RESEARCH IN HEALTH (R21): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
A total of 13 participating institutes and centers of the National Institutes of Health invite applications for their AIDS-related dissemination and implementation research in health (R21) grants. This AIDS-related R21 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behavior change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R21 exploratory/developmental award mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-055, which encourages applications under the R01 research project grant mechanism, and PAR-13-056, which encourages applications under the R03 small grant programme mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. PAR-13-054 (replaces PAR-10-040).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.

Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-054
Eligibility profile
Country of applicant institution: Any
Disciplines
Medical Sociology, Behavioral Medicine, Economic & Social Environment, Psychology, HIV/AIDS, General Practice, Public Health, Sociology, Public Health, Health Services & Primary Care, Preventive Medicine, Psychiatry, Medical & Diagnostic Tests, Biomedical Engineering, Mental Health, Health Systems, Administration, Health Systems, Mental Illness, Health Promotion
Contact Details
Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: 1 301 443 3747
Fax: 1 301 443 4045
Email: dchamber@mail.nih.gov
EXTENDED DEADLINE: IMAGING – SCIENCE TRACK AWARD FOR RESEARCH TRANSITION (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse has extended the expiration date for its Aids-related imaging – science track award for research transition. The expiration date has been extended from 8 January to 8 May 2015. All other aspects of the call remain the same.

***
This Aids-related R03 award facilitates the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programmes. The aim is to support small research projects that can be carried out in a short period of time with limited resources. The research may deal with any area of the clinical neurobiology of drug abuse and addiction, and may incorporate brain imaging.
US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply.
The award covers direct costs of up to US$150,000 over a one-year period.
Ref: PAR-12-066 (replaces PAR-09-073).
Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 05 Nov 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $150,000
Website: http://grants.nih.gov/grants/guide/par-files/PAR-12-066.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PAR-12-066

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Chronic Pain, Clinical Medicine, Addiction, Psychology, Mind-Body Dualism, Neurology, Biological Sciences, Neurobiology, Mental Illness, Primary Care, Neuroimaging, Central Nervous System, Drug & Substance Abuse, Behavioral Medicine, HIV/Aids, Radiology & Medical Imaging, Pain Management, Biomedical Engineering, Public Health, Health Services & Primary Care, Diagnostic Sciences

Contact Details
----------------------------------------------
Clinical Neuroscience Branch
DCNBR
NIDA
Room 3170
6001 Executive Blvd
Bethesda, MD 20892-9593
Tel: 1 301 443 4877
Fax: 1 301 443 6814
Email: sgrant@nida.nih.gov
HEALTH DISPARITIES IN NIDDK DISEASES (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites Aids-related applications for its health disparities in NIDDK diseases (R01) programme. This R01 funding opportunity announcement supports Aids-related research which aims to improve understanding of the causes of high priority diseases in the US, and to develop and test more effective interventions for reducing and eliminating health disparities. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. This funding opportunity announcement will utilize the R01 mechanism. Application budgets are not limited, but must reflect the actual needs of the proposed project. Funding is available for up to five years. PA-13-183 (replaces PA-09-262).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 May 2016.
Posted date: 28 Aug 13

Award type: Directed grants to institutions, research groups etc.
Application form: http://www.grants.gov

Eligibility profile
Country of applicant institution: Any

Disciplines
Diabetes, Chronic Care, Hepatology, Diagnostic Sciences, Allied Health Professions, HIV/Aids, Clinical Medicine, Hormones & Endocrinology, Nephrology & Kidneys, Nutrition & Dietetics, Obesity, Gastroenterology

Contact Details
Tel: 1 301 594 9652
Email: mcbrydekd@mail.nih.gov

SMALL RESEARCH GRANT PROGRAMME (PARENT R03): AIDS-RELATED
NIH: National Human Genome Research Institute

Description:
Participating institutes of the National Institutes of Health invite applications for its Aids-related small research grant programme (parent R03). This Aids-related R03 funding opportunity supports small research projects that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. Direct costs are limited to US$100,000 direct costs over the
R03 two year period, with no more than US$50,000 in direct costs allowed in a single year. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-13-304 (replaces PA-11-262)

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 06 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Applying for the grant will require a proposal that highlights the significance of the proposed research and its potential impact. The proposal should also outline the methodology and approach to be used, and the expected outcomes. Applicants may request direct costs of up to US$275,000 for a two-year period, with no more than US$200,000 in any year.

Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-13-303 (replaces PA-11-261).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 06 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

D RUG ABUSE ASPECTS OF HIV/AIDS (R21)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse aspects of HIV/AIDS (R21) programme. This R21 funding opportunity announcement seeks to examine the drug abuse aspects of HIV/AIDS, including research on drug-related risk behaviors, addiction and HIV disease, and drug use and HIV-related co-morbidities and consequences. Applications are needed for the following areas:

- to identify and predict changes in the epidemiology of HIV/AIDS among the following groups among injection and non-injection drug users and among their sexual partners;
- to develop and test interventions for primary and secondary HIV prevention, including drug treatment interventions;
- to improve HIV testing, counseling and treatment services for those living with HIV/AIDS;
- to address basic mechanisms involved in HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.

This FOA will use the R21 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-293 that solicits applications under the R01 mechanism and PA-12-294 that solicits applications under the R03 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-295 (replaces PA-10-130).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Sep 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-295

Eligibility profile
Country of applicant institution: Any
Disciplines
-------------------------------------------------
Behavioral Medicine, Gender Roles & Sexuality, Economic & Social Environment, Medical Sociology, Cognitive Processes, Infection Agents & Pathogens, Public Health, Health Services & Primary Care, Disease Control, Preventive Medicine, Diagnostic Sciences, Disadvantaged & Minority Groups, Epidemiology, Social Behavior & Attitudes, Tuberculosis, Pharmacy & Pharmacology, Neurology, Allied Health Professions, Biomedical Engineering, Psychology, Physiology, Population Studies, Medical, Immunization Programmes & Vaccination, General Practice, Biological Markers & Sensor Mechanisms, Health Disparities, HIV/Aids, Sociology, Clinical Medicine, Addiction, Biochemical Markers, Aetiology, Drug & Substance Abuse, Neuroscience, Drug Design, Venereology & Sexually Transmitted Diseases, Virology, Infectious Diseases

Contact Details
-------------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center, Room 4279
6001 Executive Boulevard
Bethesda, MD 20892-9555
Tel: 1 301 496 8804
Fax: 1 301 594 6043
Email: aavila@nida.nih.gov

D RUG ABUSE ASPECTS OF HIV/AIDS (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse aspects of HIV/AIDS (R03) programme. This R03 funding opportunity announcement seeks to examine the drug abuse aspects of HIV/AIDS, including research on drug-related risk behaviors, addiction and HIV disease, and drug use and HIV-related co-morbidities and consequences. Applications are needed for the following areas:

- to identify and predict changes in the epidemiology of HIV/AIDS among the following groups among injection and non-injection drug users and among their sexual partners;
- to develop and test interventions for primary and secondary HIV prevention, including drug treatment interventions;
- to improve HIV testing, counseling and treatment services for those living with HIV/AIDS;
- to address basic mechanisms involved in HIV infection and AIDS pathogenesis in the context of drug abuse and addiction.

This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-293 that solicits applications under the R01 mechanism and PA-12-295 that solicits applications under the R21 mechanism. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-294 (replaces PA-10-131).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Sep 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-294.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?option=PA-12-294

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Neuroscience, Drug & Substance Abuse, Virology, Venereology & Sexually Transmitted Diseases, Infectious Diseases, Drug Design, Neurology, Pharmacy & Pharmacology, Epidemiology, Social Behavior & Attitudes, Disadvantaged & Minority Groups, Biomedical Engineering, Allied Health Professions, Public Health, Health Services & Primary Care, Preventive Medicine, Diagnostic Sciences, Disease Control, HIV/AIDS, Health Disparities, Biological Markers & Sensor Mechanisms, General Practice, Aetiology, Biochemical Markers, Addiction, Clinical Medicine, Sociology, Population Studies, Medical, Physiology, Psychology, Economic & Social Environment, Gender Roles & Sexuality, Behavioral Medicine, Cognitive Processes, Infection Agents & Pathogens, Medical Sociology

Contact Details
----------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center, Room 4279
6001 Executive Boulevard
Bethesda, MD 20892-9555
Tel: 1 301 496 8804
Fax: 1 301 594 6043
Email: aavila@nida.nih.gov

RESEARCH ON MALIGNANCIES IN THE CONTEXT OF HIV/AIDS (R21)
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Dental and Craniofacial Research invite applications for their research on malignancies in the context of HIV/AIDS (R21) grants. The purpose of this R21 funding opportunity announcement is to advance understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency infection or acquired immune deficiency syndrome. NCI and NIDCR seek to encourage research in areas such as the study of the aetiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both Aids-defining and non-Aids defining malignancies in diverse populations in the context of an underlying HIV infection. This FOA invites research efforts that will: provide information on the clinical outcomes of such cancers in the HIV-infected population; and identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers.
This FOA will use the exploratory/developmental grant (R21) mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-377, which solicits applications under the research project R01 research project grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Ref: PA-13-378 (replaces PA-10-291).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 23 Oct 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile

BIOLOGY OF MANUAL THERAPIES (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Center for Complementary and Alternative Medicine invites Aids-related applications for its call on biology of manual therapies (R21). This Aids-related R21 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilization and massage therapy. This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-168, which solicits applications under the R01 mechanism.

Eligible institutions include domestic and foreign for-profit and non-profit organizations and public or private institutions.

Country of applicant institution: Any
Disciplines

Physiology, General Practice, Molecularly Targeted Therapy, HIV/AIDS, Diagnostic Sciences, Medical & Diagnostic Tests, Melanoma & Other Skin Cancers, Public Health, Health Services & Primary Care, Prostate & Testicular Cancers, Chemotherapy, Breast Cancer, Carcinogenesis, Nursing, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Ovarian & Cervical Cancers, Oncology Nursing, Primary Care, Human Biological Sciences, Brain Cancer, Immunopathology, Cancer Immunology, Health Systems, Risk Management, Cancer Studies & Oncology, Leukaemia & Other Blood Cancers, Lung Cancer, Non-cancerous Tumours, Clinical Medicine, Aetiology, Pathology

Contact Details

NCI
9609 Medical Center Drive
Rockville, MD 20850
Tel: 1 301 276 6226
Email: bconnole@mail.nih.gov
Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-14-167 (replaces PA-10-210).

Closing date: 07 May 15
Deadline information: Deadlines by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 31 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-167.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-167

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Electrophysiology, Therapy Evaluation, Clinical Medicine, Manufacturing & Industrial Engineering, Medical Research of Selected Fields, Folk, Complementary & Alternative Medicine, Cancer Cell Biology, Traumatology, Accidents & Injury, Biomechanics, Immunology, Mechanical Engineering, Human Biological Sciences, Central Nervous System, Hormones & Endocrinology, Aerospace Engineering & Avionics, Growth & Growth Factors, Endocrine & Neuroendocrine Cancers, Physiology, HIV/Aids, Diagnostic Sciences

Contact Details
----------------------------------------------
NCCAM
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Tel: 1 301 594 3462
Fax: 1 301 401 1587
Email: patrap.khalsa@nih.gov

NIH RESEARCH GRANT FOR SECONDARY DATA ANALYSIS (R21): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its research grant for its Aids-related secondary data analysis (R21) programme. The purpose of this Aids-related R21 funding opportunity announcement is to conduct secondary analyses using existing database resources. Applications may be related to, but must be distinct from, the specific aims of the original data collection. The NEI supports and extensive portfolio of clinical trials and large-scale epidemiologic research projects, wherein numerous data collection activities are required. Data are not limited to those collected under NEI support, but such data are of the highest programmatic interest. The R21 grant may be used to develop new statistical methodologies or to test hypotheses using existing data, but this FOA may not be used to support the collection of new data. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to submit applications. PAR-13-035 (replaces PAR-09-252).
Description:
The National Institute on Drug Abuse invites applications for its Aids-related prescription drug abuse research programme. The purpose of this Aids-related R21 funding opportunity announcement is to encourage a broad range of research strategies to address the problem of prescription drug abuse. Across proposed research strategies, there is an interest in stimulating the development and integration of novel technologies to observe and understand the aetiology and biological and Behavioral mechanisms associated with prescription drug abuse. The specific areas of interest include:

- basic preclinical and clinical research;
- epidemiology and prevention research;
- treatment and health systems research.

This FOA will use the NIH exploratory developmental (R21) award mechanism and runs in parallel an FOA of identical scientific scope, PA-13-015, which solicits applications under the research project grant (R01) mechanism. Application budgets are limited to US$275,000 over a two-year period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-016 (replaces PA-08-128).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 05 Nov 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Contact Details
Division of Extramural Research
NEI
5635 Fishers Lane, Suite 1300, MSC 9300
Bethesda, MD 20892-9300
Tel: 1 301 451 2020
Fax: 1 301 402 0528
Email: everettd@mail.nih.gov
Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, HIV/Aids, General Practice, Addiction, Psychology, Cognitive & Behavioral Therapies, Compulsive Behavior, Anxiety Disorders, Pharmacy & Pharmacology, Allied Health Professions, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Diagnostic Sciences, Psychiatry, Preventive Medicine, Primary Care, Economic & Social Environment

Contact Details

Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse, NIH.
DHHS
6001 Executive Boulevard, Room 5193
Bethesda, Maryland 20892
Tel: 1 301 594 4371
Email: deniscor@nida.nih.gov

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for Aids-related health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R21). This Aids-related R21 funding opportunity announcement encourages applications emphasizing any of the following subjects:

• clinical quality improvement;
• organization and delivery of services;
• implementation research;
• economic and cost studies;
• development or improvement of research methodology, analytic approaches and measurement instrumentation used in the study of drug, alcohol and tobacco prevention, treatment and recovery services.

Research may focus on individual-level Behaviors as they affect access, engagement, adherence and retention in support services, or programme, organization or systems-level issue that affect the availability, accessibility, utilization, effectiveness, fidelity, cost and quality of support services. Investigators are strongly encouraged to integrate factors related to addressing the spread and prevention or treatment of infectious disease among substance users.

This funding opportunity will use the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-127, which solicits applications under the research project grant (R01) award mechanism, and PA-12-129, which solicits applications under the small research grant (R03) award mechanism. Direct costs are limited to US$275,000 over an R21 two-year period. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-12-128 (replaces PA-08-264).

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 20 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-128

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Sociology, HIV/Aids, Social Work & Social Policy, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Primary Care, Medical Sociology, Clinical Decision-making & Analysis, Economic & Social Environment, Health Economics, Drug & Substance Abuse, Behavioral Medicine, Quality of Care, Addiction, Social Services Delivery, Psychology, Health Systems, Administration, Access to Health Care, Standards of Care

Contact Details
----------------------------------------------
Services Research Branch
Division of Epidemiology, Services & Prevention Research
National Institute on Drug Abuse
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 443 6504
Email: rchandle@nida.nih.gov

HEALTH SERVICES AND ECONOMIC RESEARCH ON THE PREVENTION AND TREATMENT OF DRUG, ALCOHOL AND TOBACCO ABUSE (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism invite proposals for Aids-related health services and economic research on the prevention and treatment of drug, alcohol and tobacco abuse (R03). This Aids-related R03 funding opportunity announcement encourages applications emphasizing any of the following subjects:
• clinical quality improvement;
• organization and delivery of services;
• implementation research;
• economic and cost studies;
• development or improvement of research methodology, analytic approaches and measurement instrumentation used in the study of drug, alcohol and tobacco prevention, treatment and recovery services.
Research may focus on individual-level Behaviors as they affect access, engagement, adherence and retention in support services, or programme, organization or systems-level issue that affect the availability, accessibility, utilization, effectiveness, fidelity, cost and quality of support services. Investigators are strongly encouraged to integrate factors related to addressing the spread and prevention or treatment of infectious disease among substance users.
This funding opportunity will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-127, which solicits applications under the research project grant (R01) award mechanism, and PA-12-
128, which solicits applications under the exploratory/developmental grant (R21) award mechanism. Direct costs are limited to a maximum of US$100,000 direct costs over a two-year project period. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-129 (replaces PA-08-265).

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 20 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-129.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-129

Eligibility profile
---------------------------------------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------------------------------------------------
Health Systems, Administration, Access to Health Care, Standards of Care, Addiction, Social Services Delivery, Psychology, Clinical Decision-making & Analysis, Economic & Social Environment, Health Economics, Drug & Substance Abuse, Behavioral Medicine, Quality of Care, Primary Care, Medical Sociology, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Sociology, HIV/AIDS, Social Work & Social Policy

Contact Details
---------------------------------------------------------------------------------------------------------------
Services Research Branch
Division of Epidemiology, Services & Prevention Research
National Institute on Drug Abuse
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 443 6504
Email: rchandle@nida.nih.gov

OMEN’S MENTAL HEALTH DURING PREGNANCY AND THE POSTPARTUM PERIOD (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute of Child Health and Human Development and the National Institute of Drug Abuse invite applications for their Aids-related women’s mental health during pregnancy and the postpartum period (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to outline priority areas for research related to women’s mental health during pregnancy and the postpartum period. Priority areas include basic and clinical neuroscience, studies of clinical course, epidemiological factors and risk factors, as well as interventions and services research. The goal is to support research that will increase scientific understanding of and treatments for mental disorders experienced by women during and following pregnancy, and result in improved health and wellbeing of new mothers, their children and their families. This funding opportunity will use the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-215, that encourages applications under the
exploratory/developmental (R21) award mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible organizations include domestic and foreign for-profit and non-profit organizations and public or private institutions. PA-12-216 (replaces PA-09-174).

Closing date: 07 May 15
Deadline information: Application deadlines every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 22 Jun 12
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-216

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Physiology, Health Disparities, HIV/Aids, General Practice, Public Health, Health Services & Primary Care, Psychiatry, Preventive Medicine, Pregnancy & Birth, Mental Illness, Maternal Health, Neurobiology, Primary Care, Women’s Health, Depression & Other Mood Disorders, Neuroscience, Psychology, Clinical Medicine, Biological Sciences, Schizophrenia & Other Psychotic Disorders, Epidemiology, Mental Health

Contact Details
----------------------------------------------
Office of Research on Disparities and Global Mental Health
National Institute of Mental Health
6001 Executive Boulevard, Room 8125, MSC 9659
Bethesda, MD 20892-9659
Tel: 1 301 443 3945
Email: olearyk@mail.nih.gov

WOMEN’S MENTAL HEALTH DURING PREGNANCY AND THE POSTPARTUM PERIOD (R21): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute of Child Health and Human Development and the National Institute of Drug Abuse invite applications for their Aids-related women's mental health during pregnancy and the postpartum period (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to outline priority areas for research related to women's mental health during pregnancy and the postpartum period. Priority areas include basic and clinical neuroscience, studies of clinical course, epidemiological factors and risk factors, as well as interventions and services research. The goal is to support research that will increase scientific understanding of and treatments for mental disorders experienced by women during and following pregnancy, and result in improved health and wellbeing of new mothers, their children and their families.

This funding opportunity will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-216, that encourages applications under the research project grant (R01) award mechanism. Direct costs are limited to US$275,000 over an R21
two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organizations include domestic and foreign for-profit and non-profit organizations and public or private institutions. PA-12-215 (replaces PA-09-175).

Closing date: 07 May 15
Deadline information: Application deadlines every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 22 Jun 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-215.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-215

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Pregnancy & Birth, Maternal Health, Mental Illness, Neuroscience, Physiology, General Practice, Health Disparities, HIV/Aids, Clinical Medicine, Public Health, Health Services & Primary Care, Biological Sciences, Psychiatry, Preventive Medicine, Epidemiology, Schizophrenia & Other Psychotic Disorders, Mental Health, Neurobiology, Primary Care, Depression & Other Mood Disorders, Women’s Health, Psychology

Contact Details
----------------------------------------------
Office of Research on Disparities and Global Mental Health
National Institute of Mental Health
6001 Executive Boulevard, Room 8125, MSC 9659
Bethesda, MD 20892-9659
Tel: 1 301 443 3945
Email: olearyk@mail.nih.gov

PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN DIABETES, ENDOCRINE AND METABOLIC DISEASES (R21): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for Aids-related pilot and feasibility clinical research grants in diabetes, and endocrine and metabolic diseases. This Aids-related R21 funding opportunity announcement encourage pilot and feasibility clinical research related to the prevention or treatment of diabetes and endocrine and genetic metabolic diseases. The programme is for exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to have high clinical impact. They can include testing a new prevention strategy, a new intervention, or unique combinations of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis.

This announcement uses the NIH exploratory/developmental grant (R21) award mechanism. Direct costs are limited to US$275,000 over the two years of the R21
Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/AIDS, Clinical Pharmacy & Pharmacology, Human Metabolism, Obesity, Genetic Diseases, Diabetes, Hormones & Endocrinology, Chronic Care, Clinical Medicine, Pharmacy & Pharmacology, Molecular Genetics

Contact Details

NIH
6707 Democracy Boulevard, Room 687
Bethesda, MD 20892
Tel: 1 301 594 7733
Email: marteylk@mail.nih.gov

AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
The National Institute of Biomedical Imaging and Bioengineering and 10 other participating institutes of the National Institutes of Health invite applications for their AIDS-related exploratory/developmental bioengineering research (R21) grants. The purpose of this AIDS-related R21 funding opportunity announcement is to establish the feasibility of technologies, techniques or methods that: explore a unique multidisciplinary approach to a biomedical challenge, are high-risk but have a considerable payoff, and develop data leading to significant future research. Applications may propose hypothesis-driven, developmental or design-directed research and is appropriate for evaluating unproven approaches for which there is minimal or no preliminary data.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organizations include domestic and foreign for-profit and non-profit organizations and public or private institutions. PA-12-284 (replaces PA-10-010).

Closing date: 07 May 15
Deadline information: Deadlines every 7 May, 7 September and 7 January until 8 January 2016.
Posted date: 12 Sep 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-284.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-284

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Clinical Medicine, Psychology, Bioengineering, Medical Research of Selected Fields, Assistive Technology, Behavioral Medicine, Medicine & Health, General Practice, HIV/Aids, Radiology & Medical Imaging, Biomedical Engineering, Medical & Diagnostic Tests, Preventive Medicine

Contact Details
----------------------------------------------
Division of Discovery Science and Technology NIBIB
6707 Democracy Boulevard, Suite 200
Bethesda, MD 20892-5477
Tel: 1 301 451 4778
Fax: 1 301 480 1614
Email: kelleyc@mail.nih.gov

BIOENGINEERING RESEARCH GRANTS (R01): AIDS-RELATED
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
Participating institutes and centers of the National Institutes of Health invite Aids-related applications for their R01 bioengineering research grants. Grants are provided for Aids-related basic and or applied multidisciplinary research that can increase understanding and solve problems in biological, clinical or translational science. This programme intends to support Aids-related participating institutes and centers of the National Institutes of Health invite applications for their R01 bioengineering research grants.

This FOA will use the NIH R01 research project grant (R01) award mechanism and runs in parallel with two FOAs of similar scientific scope, PA-12-284 that solicits applications under the R21 mechanism and R01 opportunity PAR-10-234. Proposed projects may not exceed five years. Applications are welcome from domestic and foreign for-profit and non-profit organizations and public or private institutions. PAR-13-137 (replaces PA-10-009)

Closing date: 07 May 15
Deadline information:
Posted date: 11 Mar 13
Award type: Directed grants to institutions, research groups etc.
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Dentistry, Medical Research of Selected Fields, Pharmacy & Pharmacology, Allied Health Professions, Bioengineering, Manufacturing & Industrial Engineering, Clinical Medicine, Assistive Technology, Aerospace Engineering & Avionics, Nursing, Human Biological Sciences, Mechanical Engineering, Blood Tests, Primary Care, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Preventive Medicine, Diagnostic Sciences, Medical & Diagnostic Tests, Biomedical Engineering,
**Behavioral and Integrative Treatment Development Programme (R01): AIDS-Related**

**NIH: National Institute on Drug Abuse**

**Description:**
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their AIDS-related Behavioral and integrative treatment development (R01) grants. The aim of this AIDS-related R01 programme is to develop and test Behavioral and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of Behavior change, determine dose-response, optimize combinations, or ascertain best sequencing of Behavioral, combined, sequential, or integrated Behavioral and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research. This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-079, which solicits applications under the R03 small grant programme mechanism, and PA-13-078, which solicits applications under the R34 clinical trial planning grant programme mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years. PA-13-077 (replaces PA-10-012).

**Closing date:** 07 May 15
**Deadline information:** Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
**Posted date:** 10 Jan 13
**Award type:** Directed grants to institutions, research groups etc.
**Award amount max:** -
**Award amount min:** -
**Award budget total:** -
Application form:  
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-077

Eligibility profile

Country of applicant institution: Any

Disciplines

Mental Illness, Neuroscience, Drug & Substance Abuse, HIV/AIDS, General Practice, Sociology, Population Studies, Medical, Physiology, Psychology, Cognitive & Behavioral Therapies, Molecular Genetics, Allied Health Professions, Public Health, Health Services & Primary Care, Biological Sciences, Counseling & Therapy, Diagnostic Sciences, Cognitive Processes, Neurobiology, Primary Care, Medical Sociology, Behavioral Medicine

Contact Details

Division of Clinical Neuroscience and Behavioral Research  
NIDA  
6001 Executive Boulevard, Room 3172, MSC 9593  
Bethesda, MD 20892-9593  
Tel: 1 301 443 2235  
Email: lisa_onken@nih.gov

Behavioral and Integrative Treatment Development Programme (R03): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their AIDS-related Behavioral and integrative treatment development (R03) grants. The aim of this AIDS-related R03 programme is to develop and test Behavioral and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, or ascertain best sequencing of Behavioral, combined, sequential, or integrated Behavioral and pharmacological treatments in the following circumstances:
• drug abuse treatment interventions in diverse settings;
• drug abuse treatment and adherence interventions for use in primary care;
• drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
• interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
• interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
• interventions to treat chronic pain.
Research of interest includes but is not limited to Stage II and Stage III efficacy research. This funding opportunity announcement will use the NIH small research grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-077, which solicits applications under the R01 research project grant mechanism, and PA-13-078, which solicits applications under the R34 clinical trial planning grant programme mechanism.
Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. PAR-13-079 (replaces PAR-10-011).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-079

Disciplines
----------------------------------------------
Allied Health Professions, Alcoholism, Molecular Genetics, Biological Sciences, Population Studies, Medical, Psychology, Neuroscience, Drug & Substance Abuse, Behavioral Medicine, Infection Agents & Pathogens, Infectious Diseases, Primary Care, Mental Illness, Cognitive Processes, Neurobiology, Medical Sociology, Counseling & Therapy, Diagnostic Sciences, Public Health, Health Services & Primary Care, Sociology, HIV/AIDS, General Practice, Cognitive & Behavioral Therapies, Physiology

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
Participating institutes and centers of the National Institutes of Health invite Aids-related applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centers at the NIH and to stimulate and foster a wide range of Aids-related basic, clinical, and translational R21 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of Behavioral and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; bio Behavioral pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.
This FOA will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that utilizes the R01 mechanism and PA-13-117, that utilizes the R03 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organizations include for-profit and non-profit organizations, and public or private institutions. PA-13-119 (replaces PA-10-007).

Closing date: 07 May 15
Deadline information: Applications due by 5pm applicant’s local time, every 7 May, 7 September and 7 January until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Behavioral Medicine, Muscle Diseases, Ethology, Gene Therapy, Osteoporosis & Other Bone Diseases, Traumatology, Accidents & Injury, Primary Care, Palliative Nursing, Medical & Diagnostic Tests, Chemotherapy, Public Health, Health Services & Primary Care, Biological Sciences, Cardiovascular Diseases, Allied Health Professions, Cell & Developmental Biology, Dermatology, Pharmacy & Pharmacology, Epidemiology, Molecular Genetics, Pain Management, Cognitive & Behavioral Therapies, Neuropharmacology, Clinical Medicine, HIV/Aids, Health Disparities, Chronic Pain, Geriatric Nursing, Nursing, Oncology Nursing, Diagnostic Sciences, Biochemistry & Molecular Biology

Contact Details
----------------------------------------------
National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: 1 301 496 9623
Email: mardens@mail.nih.gov

M ECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R03): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
Participating institutes and centers of the National Institutes of Health invite Aids-related applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centers at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R03 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of Behavioral and social sciences. Research may address: molecular and cellular mechanisms of pain; genetics of pain; bioBehavioral pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of
Eligibility profile

Country of applicant institution: Any

Disciplines

Dermatology, Cardiovascular Diseases, Public Health, Health Services & Primary Care, Chemotherapy, Diagnostic Sciences, Biochemistry & Molecular Biology, Medical & Diagnostic Tests, Health Disparities, HIV/Aids, Pain Management, Cognitive & Behavioral Therapies, Geriatric Nursing, Ethology, Muscle Diseases, Behavioral Medicine, Palliative Nursing, Oncology Nursing, Primary Care, Traumatology, Accidents & Injury, Osteoporosis & Other Bone Diseases, Gene Therapy, Nursing, Epidemiology, Molecular Genetics, Pharmacy & Pharmacology, Cell & Developmental Biology, Allied Health Professions, Biological Sciences, Chronic Pain, Clinical Medicine, Neuropharmacology

Contact Details

National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: 1 301 496 9623
Email: mardens@mail.nih.gov

MECHANISMS, MODELS, MEASUREMENT AND MANAGEMENT IN PAIN RESEARCH (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
Participating institutes and centers of the National Institutes of Health invite Aids-related R01 applications for research into the mechanisms, models, measurement and management in pain research. The purpose of this R01 funding opportunity announcement is to inform the scientific community of the pain research interests of the various institutes and centers at the NIH and to stimulate and foster a wide range of basic, clinical, and translational R01 studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of Behavioral and social sciences. Research may
address: molecular and cellular mechanisms of pain; genetics of pain; bioBehavioral pain; models of pain; diagnosis and assessment of pain; pain management; epidemiology of pain; health disparities; translational pain research. Research conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-119, that solicits applications under the R21 mechanism, and PA-13-117, that solicits applications under the R03 mechanism. Eligible organizations include for-profit and non-profit organizations, and public or private institutions. PA-13-118 (replaces PA-10-006).

Closing date: 07 May 15
Deadline information: Applications due by 5pm applicant’s local time, every 7 May, 7 September and 7 January until 8 May 2016.
Posted date: 18 Feb 13
Award type: Directed grants to institutions, research groups etc.
Website:

Eligibility profile
Email: mardens@mail.nih.gov

Country of applicant institution: Any

Disciplines
Neuropharmacology, Chronic Pain, Clinical Medicine, Biological Sciences, Epidemiology, Molecular Genetics, Pharmacy & Pharmacology, Cell & Developmental Biology, Allied Health Professions, Traumatology, Accidents & Injury, Osteoporosis & Other Bone Diseases, Gene Therapy, Nursing, Palliative Nursing, Oncology Nursing, Primary Care, Ethology, Muscle Diseases, Behavioral Medicine, Geriatric Nursing, Pain Management, Cognitive & Behavioral Therapies, HIV/AIDS, Health Disparities, Public Health, Health Services & Primary Care, Chemotherapy, Biochemistry & Molecular Biology, Diagnostic Sciences, Medical & Diagnostic Tests, Dermatology, Cardiovascular Diseases

Contact Details
Office of Extramural Activities
National Institute of Nursing Research, NIH
6701 Democracy Blvd., Suite 710
One Democracy Plaza
Bethesda, MD 20892-4870
Tel: 1 301 496 9623

RESEARCH PROJECT GRANT (PARENT R01): AIDS-RELATED
NIH: National Institutes of Health

Description:
Participating institutes and centers of the National Institutes of Health invite Aids-related applications for under the research project grant parent R01 funding opportunity announcement. The research project grant (R01) supports a discrete, specified, circumscribed project to be performed by the named investigators in areas representing the specific interests and competencies of the investigators. The proposed project must be related to the stated programme interests of one or more of the NIH institutes and centers
based on descriptions of their programmes. Research grant applications are assigned to an NIH institutes and centers based on receipt and referral guidelines and many applications are assigned to multiple ICs with related research interests. This FOA will use the NIH research project grant (R01) award mechanism. Application budgets are not limited, but should reflect the actual needs of the projects. A project duration of up to five years may be requested. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-13-302 (replaces PA-11-260)

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Aug 13

Awards type: Directed grants to institutions, research groups etc.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Clinical Medicine, Allied Health Professions, Pharmacy & Pharmacology, Biological Sciences, Dentistry, Primary Care, Human Biological Sciences, Nursing, Medicine & Health, HIV/Aids, Physiology, Diagnostic Sciences, Public Health, Health Services & Primary Care

Research on Alcohol and HIV/AIDS (R21)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites R21 applications for its research on alcohol and HIV/AIDS programme. This supports small research projects that aim to:

- characterize the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
- more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
- develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.

This funding opportunity announcement will utilize the R21 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R01 and R03 mechanisms.

Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.
Applications may be submitted by domestic and foreign for-profit and non-profit organizations and public or private institutions.
PA-13-122.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May, 7 September until 8 May 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-10-105.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Economic & Social Environment, Behavioral Medicine, Gender Roles & Sexuality, Women’s Health, Lesbian, Gay, Bisexual & Transgender Studies, Medical Sociology, Disadvantaged & Minority Groups, Epidemiology, Allied Health Professions, Alcoholism, Biomedical Engineering, Public Health, Health Services & Primary Care, Disease Control, Preventive Medicine, Diagnostic Sciences, HIV/AIDS, Health Disparities, Sociology, Public Health, Psychology, Social Work & Social Policy, Pathogenesis, Drug & Substance Abuse

Contact Details
----------------------------------------------
Tel: 1 301 403 9289
Email: kbryant@mail.nih.gov

Research on Alcohol and HIV/AIDS (R03)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites R03 applications for its research on alcohol and HIV/AIDS programme.
This supports small research projects that aim to:
• characterize the relative importance of reducing alcohol misuse in the prevention of acquisition and transmission of HIV, in order to identify and apply appropriate alcohol and HIV interventions as public health measures;
• more fully understand and prevent the progression of HIV in the presence of continued alcohol exposure;
• develop operational research frameworks for addressing the occurrence and persistence of infections in high-risk populations, such as minority women and gay men, and translate findings into effective, culturally appropriate preventive and treatment interventions for these targeted populations.
The R03 grant mechanism is intended to support small research projects that can be carried out in a short period of time with limited resources.
This funding opportunity announcement will utilize the R03 grant mechanism and runs in parallel with two funding opportunity announcements of identical scientific scope that solicit applications under the R01 and R21 mechanisms. Projects may request direct costs of US$50,000 over a maximum of two years.
Applications may be submitted by domestic and foreign for-profit and non-profit organizations and public or private institutions.
PA-13-120.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May, 7 September until 8 May 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $50,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-120.html

Eligibility profile
Country of applicant institution: Any

MOLECULAR GENETICS OF DRUG ADDICTION AND RELATED CO-MORBIDITIES (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for research into molecular genetics of drug addiction and related co-morbidities (R01) call. This Aids-related R01 funding opportunity announcement will support projects that identify or validate chromosomal loci and variations in genes that are associated with vulnerability to addiction and that inform the likelihood of responsiveness to treatment. Applications that propose to examine intermediate phenotypes or endophenotypes to assess the molecular genetics of drug addiction, addiction vulnerability or their associated co-morbidities and how they are related to drug addiction are especially encouraged. Also encouraged are genetic as well as computational and large-scale genomic approaches.

Application budgets are not limited, but must reflect the needs of the project. The maximum period is five years. Domestic and foreign for-profit and non-profit organizations and private or public institutions are eligible to apply.
Ref: PA-14-025 (replaces PA-11-026).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 12 Dec 13
Award type: Directed grants to institutions, research groups etc.
Prescription Drug Abuse (R01): AIDS-Related
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related prescription drug abuse research programme. The purpose of this Aids-related R01 funding opportunity announcement is to encourage a broad range of research strategies to address the problem of prescription drug abuse. Across proposed research strategies, there is an interest in stimulating the development and integration of novel technologies to observe and understand the aetiology and biological and behavioral mechanisms associated with prescription drug abuse. The specific areas of interest include:
- basic preclinical and clinical research;
- epidemiology and prevention research;
- treatment and health systems research.
This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-016, which solicits applications under the exploratory/developmental grant (R21) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-015 (replaces PA-08-127).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 05 Nov 12
Award type: Directed grants to institutions, research groups etc.
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Drug & Substance Abuse, Cognitive & Behavioral Therapies, Anxiety Disorders, Psychology, Addiction, HIV/Aids, General Practice, Preventive Medicine, Psychiatry, Diagnostic Sciences, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Allied Health Professions, Pharmacy & Pharmacology, Economic & Social Environment, Compulsive Behavior

Contact Details
----------------------------------------------
Division of Epidemiology, Services and Prevention Research
NIDA
6001 Executive Boulevard, Room 5193
Bethesda, MD 20892-9589
Tel: 1 301 594 4371
Email: deniscor@nida.nih.gov

FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related functional genetics, epigenetics and non-coding RNAs in drug addiction (R21) programme. This Aids-related R21 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction. This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-014, which encourages applications under the R01 research project grant mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.
Ref: PA-14-013 (reissue of PA-11-034).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 06 Dec 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-013

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biological Markers & Sensor Mechanisms, Addiction, Electrophysiology, Disease Models, Psychology, Epigenetics, Molecular Genetics, Biological Sciences, Neuroimaging, Ribonucleic Acid, RNA, Primary Care, Genomics, Immunological & Bioassay Methods, Drug & Substance Abuse, Behavioral Medicine, Proteomics & Molecular Interactions, HIV/AIDS, Biochemical Markers, Physiology, Pharmacokinetics, Neurotransmitters, Public Health, Health Services & Primary Care, Diagnostic Sciences

Contact Details
-----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 435 1020
Email: satterleej@nida.nih.gov

Extended Deadline: International Research Collaboration on Drug Abuse and Addiction Research (R21): AIDS-Related

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse has extended the closing date for its Aids-related international research collaboration on drug abuse and addiction research (R21) grants. The previous expiration date of 8 January has now been extended to 8 May 2015, making the last application deadline 7 May 2015. All other call details remain the same.***

This Aids-related R21 funding opportunity announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/AIDS and drug abuse, and prevention, initiation and treatment of nicotine and tobacco use. Applications are welcome from domestic and foreign for-profit or non-profit organizations and public or private institutions.

This FOA will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-12-040 and PA-12-042, that solicit applications under the research project grant (R01) and small research grant (R03) mechanisms, respectively.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-12-041 (replaces PA-09-021).

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2012 and are due by 5 pm local time of applicant organization every 7 January, 7 May and 7 September until 8 May 2015.

Posted date: 08 Jan 15
Award type: Directed grants to institutions, research groups etc., Networking/collaboration
Award amount max: $275,000
Website:
http://grants.nih.gov/grants/guide/pa-files/PA-12-041.html
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-041
EXTENDED DEADLINE: INTERNATIONAL RESEARCH COLLABORATION ON DRUG ABUSE AND ADDICTION RESEARCH (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse has extended the closing date for its Aids-related international research collaboration on drug abuse and addiction research (R03) grants. The previous expiration date of 8 January has now been extended to 8 May 2015, making the last application deadline 7 May 2015. All other call details remain the same. ***

This Aids-related R03 funding opportunity announcement encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the US. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects must have relevance to the mission of NIDA and where feasible should address NIDA’s scientific priority areas. Priority areas include: linkages between HIV/Aids and drug abuse, and prevention, initiation and treatment of nicotine and tobacco use.

Applications are welcome from domestic and foreign for-profit or non-profit organizations and public or private institutions. This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-040 and PA-12-041, that solicit applications under the research project grant (R01) and exploratory/developmental (R21) award mechanisms, respectively. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period.

Ref: PA-12-042 (replaces PA-09-022).

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2012 and are due by 5 pm local time of applicant organization every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 08 Jan 15
Award type: Directed grants to institutions, research groups etc., Networking/collaboration
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-042.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-042

Eligibility profile

Contact Details
Office of the Director
National Institute on Drug Abuse
9000 Rockville Pike, Room 1B59
Bethesda, MD 20892-9581
Tel: 1 301 443 6480
Email: ipdirector@nida.nih.gov
Country of applicant institution: Any

Disciplines

----------------------------------------------
Alcoholism, HIV/Aids, Smoking & Tobacco, Drug & Substance Abuse

Contact Details

----------------------------------------------
Office of the Director
National Institute on Drug Abuse
9000 Rockville Pike, Room 1B59
Bethesda, MD 20892-9581
Tel: 1 301 443 6480
Email: ipdirector@nida.nih.gov

SUBSTANCE USE AND ABUSE, RISKY DECISION MAKING AND HIV/AIDS (R21)
NIH: National Institute on Drug Abuse

Description:
The NIH's National Institute on Drug Abuse invites applications for its drug abuse, risky decision making and HIV/Aids funding opportunity announcement. This R21 call encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk Behaviors or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modeling are encouraged.
The total project period for an application submitted in response to this funding opportunity announcement may not exceed two years. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 and PA-14-063,that encourages applications under the R03 mechanism.

PA-14-062 (reissue of PA-11-007).

Closing date: 07 May 15
Deadline information: Aids-related applications due every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-062.html

Eligibility profile

----------------------------------------------
Country of applicant institution: Any

Disciplines

----------------------------------------------
Gender Roles & Sexuality, Economic & Social Environment, Neuropsychology, Toxicology, Medical Sociology, Neurobiology, Decision Science, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, Pharmacy & Pharmacology, Clinical Psychology, Neuropharmacology, Psychology, Physiology, Chemistry, Political Risk Factors & Analysis, Social Work & Social Policy, Pharmacokinetics, HIV/Aids, Addiction, Sociology, Built Environment &
Description:
The NIH's National Institute on Drug Abuse invites applications for its substance use and abuse, risky decision making and HIV/AIDS funding opportunity announcement. This R03 program is intended to stimulate research that will increase understanding of the way people make decisions about engaging in behaviors that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use/abuse and other HIV acquisition or transmission risks.

This FOA encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk Behaviors or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modeling are encouraged.

The NIH's National Institute on Drug Abuse invites applications for its substance use and abuse, risky decision making and HIV/AIDS funding opportunity announcement. This R03 program is intended to stimulate research that will increase understanding of the way people make decisions about engaging in behaviors that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use/abuse and other HIV acquisition or transmission risks.

This FOA for R03 applications is intended to support pilot and feasibility studies, small, self-contained research projects, development of research methodology, and development of new research technology that can be carried out in a short period of time with limited resources.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested for a maximum of US$100,000 direct costs over a two-year project period.

This FOA will utilize the NIH small research grant (R03) mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-061, that encourages applications under the R01 mechanism and PA-14-062 that encourages applications under the R21 mechanism. PA-14-063 (reissue of PA-11-008)

Closing date: 07 May 15
Deadline information: Standard applications due every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-063

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
NEUROSCIENCE RESEARCH ON DRUG ABUSE (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites Aids-related applications for its neuroscience research on drug abuse (R01) grants. This Aids-related R01 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate.

This FOA will use the R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21 exploratory/developmental grants mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Public and private, non-profit and for-profit, and domestic and foreign organizations are eligible. PA-13-338 (replaces PA-10-268).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-338

Eligibility profile
Country of applicant institution: Any
Disciplines
Drug & Substance Abuse, Neuroscience, Social Work & Social Policy, Cognitive & Behavioral Therapies, Psychology, Neuropsychology, Toxicology, Economic & Social Environment
EUROSCIENCE RESEARCH ON DRUG ABUSE (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its neuroscience research on drug abuse (R21) grants. This Aids-related R21 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate. This FOA will use the NIH exploratory/developmental (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-338, which encourages applications under the R01 research project grant mechanism, and PA-13-336, which encourages applications under the R03 small grant programme mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organizations are eligible. PA-13-337 (replaces PA-10-269).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFro mFedgrants?opportunity=PA-13-337

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Behavioral Medicine, Primary Care, Neurobiology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Biological Sciences, Allied Health Professions, Pharmacy & Pharmacology, Cognitive & Behavioral Therapies, Social Work & Social Policy, Psychology, Physiology, Addiction, HIV/AIDS, Drug & Substance Abuse, Neuroscience

Contact Details
---------------------------------------------------------------
Division of Basic Neuroscience and Behavioral Research
NIDA Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: 1 301 435 1317
Email: npilotte@nih.gov
EUROSCIENCE RESEARCH ON DRUG ABUSE (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites Aids-related applications for its neuroscience research on drug abuse (R03) grants. This Aids-related R03 funding opportunity announcement aims to understand the neurobiological mechanisms underlying drug abuse and addiction, with emphasis on changes that occur during chronic drug use, withdrawal and relapse. In vivo and in vitro model systems, as well as human studies, are appropriate. This FOA will use the NIH small research grant (R03) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-337, which encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-338, which encourages applications under the R01 research project grant mechanism. Direct costs are worth a maximum of US$100,000 over two years, with no more than US$50,000 in any year. Public and private, non-profit and for-profit, and domestic and foreign organizations are eligible. PA-13-336 (replaces PA-10-270).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 27 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000


Eligibility profile
Country of applicant institution: Any
Disciplines
Drug & Substance Abuse, Neuroscience, Psychology, Physiology, Cognitive & Behavioral Therapies, Social Work & Social Policy, HIV/Aids, Addiction, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, Pharmacy & Pharmacology, Allied Health Professions, Neurobiology, Primary Care, Behavioral Medicine

Contact Details
Division of Basic Neuroscience and Behavioral Research
NIDA
Neuroscience Center
6001 Executive Blvd, Rm 4282, MSC 9555
Bethesda, MD 20892-9555
Tel: 1 301 435 1317
Email: npilotte@nih.gov
DEVELOPMENT OF ASSAYS FOR HIGH-THROUGHPUT DRUG SCREENING FOR USE IN PROBE AND PRE-THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
Participating components of the National Institutes of Health invite applications for their AIDS-related development of assays for high-throughput drug screening for use in probe and pre-therapeutic discovery (R01). This AIDS-related R01 funding opportunity announcement aims to stimulate research in the following areas:

• developing assays for specific biological targets and disease mechanisms to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets or as pre-therapeutic leads;

• establishing collaboration with screening centers that have the requisite expertise and experience needed in implementation of HTS assays for the discovery and development of small molecule chemical probes.

Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years. Domestic and foreign for-profit and non-profit organizations and public and private institutions are eligible to apply. PAR-13-364 (replaces PA-10-213).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 30 Sep 13
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/AIDS, Diagnostic Sciences, Public Health, Health Services & Primary Care, Nursing, Primary Care, Blood Tests, Deoxyribonucleic Acid, DNA, Screening for Diseases, Immunological & Bioassay Methods, Pharmacotherapy, Clinical Medicine, Pharmacy & Pharmacology

Contact Details
NIDDK
6707 Democracy Boulevard
Bethesda MD 20892
Tel: 1 301 443 1421
Email: ili1@mail.nih.gov
DEVELOPMENT OF ANIMAL MODELS AND RELATED BIOLOGICAL MATERIALS FOR RESEARCH (R21): AIDS-RELATED
NIH: Office of the Director

Description:
The NIH Office of the Director invites AIDS-related applications for its development of animal models and related biological materials for research programme (R21). This AIDS-related R21 announcement solicits proposals to develop, characterize or improve animal models for human disease, or to improve diagnosis and control diseases of laboratory animals that may interfere with research. Topics include:

- disease models;
- genetically-modified animals and preservation of important disease models;
- fundamental biology of animal model systems;
- disease biomarkers;
- genetically encoded reporters;
- biological molecule interactive and functional networks;
- animal models for human rare disease conditions;
- complementary approaches to use of animal models;
- animal diseases.

Domestic and foreign for-profit and non-profit organizations and public or private institutions may apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

PA-13-145 (replaces PA-10-138).

Closing date: 07 May 15

Deadline information: Proposals due 5pm applicant’s local time, every 7 January, 7 May and 7 September until 8 May 2016.

Posted date: 20 Mar 13

Award type: Directed grants to institutions, research groups etc.

Award amount max: $275,000

Website:

Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Immunization Programmes & Vaccination, Bioinformatics, Laboratory Animals, Philosophy, Disease Models, Induced Pluripotent Stem Cells, Research Ethics & Misconduct, Clinical Medicine, Biological Sciences, Medical Genetics, Genetically Modified & Transgenic Animals, Gene Therapy, Ethical Use of Technology, Animal Parasites & Pathogens, Computer Science & Informatics, Stem Cell Genomics, Primary Care, Animal Breeding, Blood Tests, Animal Physiology, Veterinary Medicine, Ethology, Computer Simulation & Modeling, Regenerative Medicine, Stem Cell Therapy, HIV/AIDS, Stem Cell, Diagnostic Sciences, Genetics & Systems Biology, Public Health, Health Services & Primary Care, Embryonic Stem Cells

Contact Details
----------------------------------------------
DCM/ORIP/Division of Programme Coordination, Planning and Strategic Initiatives
Office of the Director
NIH
6701 Democracy Boulevard
Bethesda MD 20892-4874
Tel: 1 301 435 0744
Fax: 1 301 480 3819
Email: oleg.mirchnitchenko@nih.gov
BIOLGY OF MANUAL THERAPIES (R01): AIDS-RELATED
NIH: National Center for Complementary and Alternative Medicine

Description:
The National Center for Complementary and Alternative Medicine invites Aids-related applications for its call on biology of manual therapies (R01). This Aids-related R01 funding opportunity announcement supports studies of the basic science and mechanisms of action underlying the neurophysiological, immunological, endocrinological or biomechanical consequences of manual therapies such as spinal manipulation, mobilization and massage therapy.
This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-167, which solicits applications under the R21 mechanism.
Eligible institutions include domestic and foreign for-profit and non-profit organizations and public or private institutions.
Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.
Ref: PA-14-168 (replaces PA-10-209).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 31 Mar 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-168.html

Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-168

Eligibility profile
Country of applicant institution: Any

Disciplines

Contact Details
NCCAM
6707 Democracy Blvd, Suite 401
Bethesda, MD 20892
Tel: 1 301 594 3462
Fax: 1 301 401 1587
Email: patrap.khalsa@nih.gov
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R01) grants. This Aids-related R01 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-360 and PA-13-361, which use the R03 small grant programme and the R21 exploratory/developmental grant mechanisms, respectively. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-359 (replaces PA-10-239)

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc.

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-359

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Alcoholism, Allied Health Professions, Epidemiology, Psychology, Disease Models, Clinical Medicine, Addiction, Primary Care, Nutrition & Diets etics, Cognitive Processes, Pathophysiology, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, General Practice, HIV/Aids

Contact Details
-------------------------------------------------------------
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: 1 301 594 6231
Fax: 1 301 443 8614
Email: rbreslow@mail.nih.gov
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the Office of Dietary Supplements invite applications for their AIDS-related nutrition and alcohol-related health outcomes (R03) grants. This AIDS-related R03 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-361, which use the R01 research project grant and the R21 exploratory/developmental grant mechanisms, respectively. Budgets for direct costs of limited to US$50,000 per year over a maximum two year project period. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-360 (replaces PA-10-240)

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-360

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Foetal Health & Prenatal Development, Maternal Health, Allied Health Professions, Alcoholism, Epidemiology, Pathophysiology, Preventive Medicine, Public Health, Health Services & Primary Care, Clinical Medicine, Addiction, General Practice, HIV/Aids, Psychology, Disease Models, Primary Care, Nutrition & Dietetics, Cognitive Processes

Contact Details
----------------------------------------------
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: 1 301 594 6231
Fax: 1 301 443 8614
Email: rbreslow@mail.nih.gov
NUTRITION AND ALCOHOL-RELATED HEALTH OUTCOMES (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcholism and the Office of Dietary Supplements invite applications for their Aids-related nutrition and alcohol-related health outcomes (R21) grants. This Aids-related R21 funding opportunity announcement supports research to examine associations between nutrition and alcohol-related health outcomes in humans and animal models. The goal of this R01 funding opportunity announcement is to stimulate a broad range of research on the role of nutrition in the development, prevention, and treatment of a variety of alcohol-related health outcomes including alcohol use disorder and chronic disease.

This FOA will use the exploratory/developmental research grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-359 and PA-13-360, which use the R01 research project grant and the R03 small grant programme mechanisms, respectively. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-361 (replaces PA-10-241).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017
Posted date: 24 Sep 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Nutrition & Dietetics, Primary Care, Cognitive Processes, Addiction, Clinical Medicine, General Practice, HIV/AIDS, Disease Models, Psychology, Allied Health Professions, Alcoholism, Epidemiology, Pathophysiology, Preventive Medicine, Public Health, Health Services & Primary Care, Maternal Health, Foetal Health & Prenatal Development

Contact Details
Division of Epidemiology and Prevention Research
NIAAA
5635 Fishers Lane, Room 2081, MSC 9304
Bethesda, MD 20892-9304
Tel: 1 301 594 6231
Fax: 1 301 443 8614
Email: rbreslow@mail.nih.gov
RESEARCH ON THE HEALTH OF LGBTI POPULATIONS (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of 12 component organizations of the National Institutes of Health invite applications for their Aids-related research on the health of LGBTI populations (R01) grants. This Aids-related R01 funding opportunity announcement solicits grant applications for research that describes the biological, clinical, behavioral and social processes that affect the health and development among lesbian, gay, bisexual, transgender, intersex and related populations and among their families, and that leads to the development of effective supportive, preventive and treatment interventions and health service delivery methods to enhance the health and development of these populations. Research must focus on clearly defined health outcomes to be responsive to this FOA. Three types of research are included within this FOA:

• formative research that will design and pilot test new interventions;
• large-scale implementation and evaluation of preventive or treatment interventions that are evidence based;
• adaptations of current interventions that are based on strong rationales, including pilot data.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-112 that encourages applications under the NIH small grant program (R03) mechanism and PA-12-113 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-111 (replaces PA-07-409).

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 27 Feb 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-111.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-111

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Mental Illness, Drug & Substance Abuse, Health Disparities, HIV/AIDS, Sociology, Addiction, Psychology, Prejudice & Discrimination, Population Studies, Medical, Mental Health, Alcoholism, Allied Health Professions, Public Health, Health Services & Primary Care, Interpersonal Relationships, Diagnostic Sciences, Psychiatry, Medical Sociology, Lesbian, Gay, Bisexual & Transgender Studies, Economic & Social Environment, Behavioral Medicine, Gender Roles & Sexuality

Contact Details
----------------------------------------------
Demographic and Behavioral Sciences Branch
NICHD
6100 Executive Boulevard, Room 8B07
Rockville, MD 20852
Tel: 1 301 435 6981
Email: newcomes@nih.gov
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH SMALL GRANT PROGRAMME FOR NEW INVESTIGATORS (R03): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its small grant programme for new investigators (R03): Aids-related. This Aids-related R03 funding opportunity announcement supports pilot and developmental research with the intention of facilitating subsequent submission of an Individual research project grant (R01) application.

Budgets for direct costs of up to US$150,000 over a two-year period may be requested. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-348 (replaces PAR-10-275).

Closing date: 07 May 15
Deadline information: Submissions due by 5pm proposers’ local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 12 Sep 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $150,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Craniofacial Disorders, Dentistry, Oral Medicine, Oral & Maxillofacial Surgery, Dental Health & Hygiene, HIV/Aids, Diagnostic Sciences

Contact Details

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for health promotion among racial and ethnic minority males (R21): Aids-related. This Aids-related R21 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to:

- enhance understanding of the numerous factors influencing the health promoting Behaviors of racial and ethnic minority males and their sub populations across the life cycle;
- and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the exploratory/developmental (R21) grant
mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-328 that solicits applications under the R01 mechanism. Direct costs are limited to US$275,000 over a R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-331 (replaces PA-10-237).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-10-237

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Medical Sociology, Urology, Economic & Social Environment, Behavioral Medicine, HIV/Aids, Health Disparities, Medicine & Health, Sociology, Population Studies, Medical, Psychology, Disadvantaged & Minority Groups, Biomedical Engineering, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Diagnostic Sciences, Nursing, Health Promotion, Health Systems, Risk Management

Contact Details
----------------------------------------------
Office of Extramural Programs
NINR
6701 Democracy Blvd, Room 710, MSC 4870
Bethesda, MD 20892-4870
Tel: 1 301 402 6423
Email: cottonp@mail.nih.gov

HEALTH PROMOTION AMONG RACIAL AND ETHNIC MINORITY MALES (R01):
AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for health promotion among racial and ethnic minority males (R01): AIDS-related. This AIDS-related R01 funding opportunity announcement aims to stimulate and expand research in the health of minority men. Specifically, this initiative is intended to: enhance understanding of the numerous factors influencing the health promoting Behaviors of racial and ethnic minority males and their sub populations across the life cycle; and solicit applications focusing on the development and testing of culturally and linguistically appropriate health-promoting interventions designed to reduce health disparities among racially and ethnically diverse males and their sub populations aged 21 and older.

This FOA will use the R01 research project grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-331, which solicits applications under the R21 mechanism. Application budgets are not
limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-328 (replaces PA-10-236).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-328

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Behavioral Medicine, Urology, Economic & Social Environment, Medical Sociology, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Diagnostic Sciences, Disadvantaged & Minority Groups, Biomedical Engineering, Population Studies, Medical, Psychology, HIV/AIDS, Health Disparities, Medicine & Health, Sociology, Health Promotion, Nursing

Contact Details
----------------------------------------------
Office of Extramural Programs
NINR
6701 Democracy Blvd, Room 710, MSC 4870
Bethesda, MD  20892-4870
Tel: 1 301 402 6423
Email: cottonp@mail.nih.gov

EPIDEMIOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research programme. The goal of this R01 Aids-related funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders.
This funding opportunity announcement will utilizes the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-188, which solicits applications under the 21 exploratory of developmental grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.
Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
Ref: PA-14-190.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 May, 7 September and 7 January until 8 September 2017.
PIDEMOLOGY AND PREVENTION IN ALCOHOL RESEARCH (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epidemiology and prevention in alcohol research grants. The goal of this Aids-related R21 funding opportunity is to encourage the submission of investigator-initiated research grant applications to support research investigating the epidemiology of alcohol use, alcohol-related harms, and alcohol use disorders and the prevention of underage drinking, alcohol-related harms, and alcohol use disorders. This mechanism will support investigation of novel scientific ideas or new model systems, tools or technologies that have the potential for significant impact on biomedical or bio Behavioral research.

This funding opportunity announcement will utilize the NIH exploratory/developmental (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-190, which solicits applications under the R01 research project grant mechanism, and PA-14-189, which solicits applications under the R03 small grant programme mechanism.

Direct costs are limited to US$275,000 over a maximum period of two years, with no more than US$200,000 in direct costs allowed in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Ref: PA-14-188 (replaces PA-11-018).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 May, 7 September and 7 January until 8 September 2017.

Posted date: 28 Apr 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Medical Sociology, Economic & Social Environment, Behavioral Medicine, HIV/AIDS, Sociology, Addiction, Psychology, Population Studies, Medical, Epidemiology, Allied Health Professions, Alcoholism, Biomedical Engineering, Public Health, Health Services & Primary Care, Patient Care & Education, Preventive Medicine, Diagnostic Sciences

Contact Details
----------------------------------------------
NIAA
Building 5635FL, Room 2083
5635 Fishers Lane
Rockville MD 20852
Tel: 1 301 402 6328
Email: mscott@mail.nih.gov

INTERNATIONAL RESEARCH COLLABORATION ON ALCOHOL AND ALCOHOLISM (U01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related international research collaboration on alcohol and alcoholism (U01) grants. The purpose of this Aids-related U01 funding opportunity is to foster international collaborations between alcohol research investigators within the US and investigators located at non-US laboratories and performance sites, for the mutual advancement of the understanding of alcohol problems and of clinical and public health approaches to their solutions. The programme provides funds for research activities to be undertaken jointly between the US and a non-US laboratory that expands the research direction of both laboratories in a collaborative manner.

Grants are worth up to US$250,000 per year for direct costs. The maximum project period is five years.
Ref: PAR-14-268 (replaces PAR-11-282).

Closing date: 07 May 15
Deadline information: Applications are welcomed between 5 September 2014 and 5pm local time of applicant organization on every 7 September, 7 January and 7 May until 8 September 2017.
Posted date: 02 Jul 14
Award type: Directed grants to institutions, research groups etc., Networking/collaboration-Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-268.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
**Disciplines**

Alcoholism, Allied Health Professions, Molecular Genetics, Social Behavior & Attitudes, Epidemiology, Pathophysiology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Sociology, Public Health, Addiction, Behavioral Studies & Social Problems, HIV/AIDS, Psychology, Behavioral Medicine, Primary Care

**Contact Details**

NIAAA
5635 Fishers Lane, MSC 9304
Bethesda MD 20892-9304
Tel: 1 301 443 2594
Email: pmurray@mail.nih.gov

**ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R21): AIDS-RELATED**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute of Alcohol Abuse and Alcoholism invites applications for its AIDS-related alcohol use disorders: treatment, services and recovery research (R21) programme. This AIDS-related R21 funding opportunity announcement supports research on Behavioral and pharmacological treatment for alcohol use disorders; organizational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders.

Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. The total project period may not exceed two years. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. This programme will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with two programs of identical scientific scope: PA-13-160, which solicits applications under the R01 mechanism, and PA-13-161, which solicits applications under the R03 mechanism. PA-13-162 (replaces PA-10-102)

**Deadline information:** Deadlines every 7 January, 7 May and 7 September until 8 May 2016.

**Posted date:** 02 Apr 13

**Award type:** Directed grants to institutions, research groups etc.

**Award amount max:** $275,000


**Application form:** [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-161](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-161)

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Psychology, Pharmacy & Pharmacology, Allied Health Professions, Alcoholism, Health Systems, Administration, Primary Care, Experimental Psychology, Drug & Substance Abuse, Cognitive & Behavioral Therapies, HIV/AIDS, General Practice, Public Health, Health Services & Primary Care

**Closing date:** 07 May 15
PROGRAMME FOR EXTRAMURAL/INTRAMURAL ALCOHOL RESEARCH COLLABORATIONS (U01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its programme for extramural/intramural alcohol research collaborations (U01). The purpose of this Aids-related U01 funding opportunity is to bring together the research expertise that, as a functioning collaborative unit, will address key alcohol-based research questions that would not otherwise be possible by the same individuals working towards similar goals in isolation. The goal proposed by the collaborating investigators should address questions that advance alcohol research with respect to issues surrounding alcohol use disorders including dependence and the effects of alcohol on health.

The NIH U01 cooperative agreement award mechanism will be used. Applicants may request direct costs of up to US$250,000 per year. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-133 (replaces PAR-11-189).

Closing date: 07 May 15
Posted date: 07 Mar 13
Deadline information: Proposals due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2016

Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,250,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-133

Eligibility profile
Country of applicant institution: Any

Disciplines
Neuroscience, Human Metabolism, Epidemiology, Molecular Genetics, Alcoholism, Allied Health Professions, Diagnostic Sciences, HIV/AIDS, General Practice, Addiction, Electrophysiology, Physiology, Psychology, Behavioral Medicine

Contact Details
Intramural Programme
NIAAA
5635 Fishers Lane, Room 3001
Bethesda, MD 20892-9304
Tel: 1 301 402 6966
Email: psilverm@mail.nih.gov
Description:
The National Library of Medicine invites applications for its Aids-related express research grants in biomedical informatics (R01). This Aids-related R01 funding opportunity aims to advance the sciences of biomedical informatics. The scope of NLM's interest in the research domain of informatics is interdisciplinary, encompassing informatics problem areas in the application domains of health care, public health, basic biomedical research, bioinformatics, biological modeling, translational research and health information management in disasters. NLM defines biomedical informatics as the science of optimal organization, management, presentation and utilization of information relevant to human health and biology. Informatics research produces concepts, tools and approaches that advance what is known in the field and have the capacity to improve human health.

Applicants may request funding over up to US$250,000 per year for a period of four years. Eligible applicants include domestic public and private non-profit and for-profit organizations. PAR-13-300 (PAR-11-208).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,000,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-300

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids, Libraries & Information Science, Public Health, Public Health, Health Services & Primary Care, Translational Medicine, Health Systems, Health Informatics, Computer Science & Informatics, Business Big Data & Informatics, Informatics & Big Data, Bioinformatics, Clinical Medicine, Administrative Big Data & Informatics
Contact Details
NLM Extramural Programmes
6705 Rockledge Drive
Rockledge 1, Suite 301
Bethesda, MD 20892
Tel: 1 301 594 4882
Email: simh@mail.nih.gov
Epidemiology of Drug Abuse (R01): AIDS-Related
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related epidemiology of drug abuse grants. These R01 grants support AIDS-related projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including the following:

- individual, familial and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistence, recovery and relapse;
- co-occurring psychiatric conditions, behaviors and associated problems;
- indicators and mechanisms of risk, vulnerability and health disparities among and between subpopulations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to and utilization of drug abuse prevention and treatment services and the social, community and organizational factors that influence intervention development, availability and effectiveness.

Public health impacts of the attitudes, availability, behaviors and products, resulting from the shifting marijuana policy environment.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

This funding opportunity announcement utilize the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-15-001 that encourages applications under the NIH exploratory or developmental (R21) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.


Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc.

Eligibility profile

Country of applicant institution: Any

Disciplines

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related epidemiology of drug abuse grants. These AIDS-related R21 grants support research projects that enhance understanding of the nature, extent, distribution, etiology, comorbidities, and consequences of drug use, abuse, and addiction across individuals, families, age groups, gender, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to:

- individual, familial, and environmental factors associated with drug use;
- interplay of factors that exacerbate or mitigate risk for drug initiation, addiction, desistance, recovery, and relapse;
- co-occurring psychiatric conditions, Behaviors and associated problems;
- indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to, and utilization of drug abuse prevention and treatment services, and the social, community, and organizational factors that influence intervention development, availability, and effectiveness.

- public health impacts of the attitudes, availability, Behaviors, and products, resulting from the shifting marijuana policy environment. This funding opportunity announcement will utilise the NIH exploratory/developmental (R21) award mechanism and runs in parallel with funding opportunity announcements of identical scientific scope, PA-15-001 that encourages applications under the NIH research project mechanism (R01) and PA-15-002 that encourages applications under the NIH small research grant R03 mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible applicants include both domestic and foreign public or private institutions as well as non-profit and for-profit organizations. PA-15-001 (replaces PA-11-231)

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://grants.nih.gov/grants/guide/ApplyButton5Splash.cfm

Eligibility profile

Country of applicant institution: Any
Disciplines

Drug & Substance Abuse, Child Development, Psychopathology, Youth & Adolescents, Social Behavior & Attitudes, Epidemiology, Molecular Genetics, Diagnostic Sciences, Adolescent Paediatrics, Public Health, Health Services & Primary Care, Sociology, HIV/Aids, Health Disparities, Behavioral Studies & Social Problems, Population Studies, Medical, Psychology, Economic & Social Environment, Behavioral Medicine, Medical Sociology

Contact Details

DESPR
National Institute on Drug Abuse, NIH/DHHS
6001 Executive Boulevard, Room 5185, MSC 9589
Bethesda MD 20892-9589
Tel: 1 301 443 6504
Email: lopezmar@nida.nih.gov

Epidemiology of Drug Abuse (R03): AIDS-Related
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related epidemiology of drug abuse grants. This AIDS-related R03 funding opportunity announcement supports projects that enhance understanding of the nature, extent, distribution, aetiology, comorbidities and consequences of drug use, abuse and addiction across individuals, families, communities, and diverse population groups. Projects should aim to fill knowledge gaps related to changing patterns in drug use, associated factors and consequences in populations, including, but not limited to: individual, familial, and environmental factors associated with drug use;

- indicators and mechanisms of risk, vulnerability, and health disparities among and between sub-populations;
- developmental and life course trajectories related to the aetiology and natural history of drug use;
- need for, access to, and utilization of drug abuse prevention and treatment services, and the social, community, and organizational factors that influence intervention development, availability, and effectiveness.
- public health impacts of the attitudes, availability, Behaviors, and products, resulting from the shifting marijuana policy environment.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. This
funding opportunity announcement uses the NIH small research grant (R03) award mechanism and runs in parallel with opportunities of identical scientific scope: PA-15-001, which solicits applications under the NIH exploratory and developmental (R21) mechanism, and PA-15-003, which solicits applications under the NIH research project grant (R01) mechanism.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Eligibility profile

Country of applicant institution: Any

Disciplines


Contact Details

DESPR
National Institute on Drug Abuse, NIH/DHHS
6001 Executive Boulevard, Room 5185, MSC 9589
Bethesda, MD 20892-9589
Tel: 1 301 443 6504
Email: lpezmar@nida.nih.gov

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R03): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of existing alcohol epidemiology data (R03) grants. These R03 grants support AIDS-related, investigator-initiated research projects that either analyze previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.
This funding opportunity announcement uses the small grant programme (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Grants are worth up to US$50,000 per year for direct costs over a maximum period of two years.

Ref: PA-14-337 (replaces PA-11-309).

Closing date: 07 May 15

Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September 2015 until 8 September 2017.

Posted date: 10 Sep 14

Award type: Directed grants to institutions, research groups etc.

Award amount max: $100,000


S

ECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of existing alcohol epidemiology data (R01) grants. These R01 grants support AIDS-related, investigator-initiated research projects that either analyze previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-337.
that encourages applications under the small grant (R01) mechanism and PA-14-336 that encourages applications under the exploratory/developmental (R21) mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years. Ref: PAR-14-338 (replaces PA-11-308).

Closing date: 07 May 15
Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September 2015 until 8 September 2017.
Posted date: 10 Sep 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-338.html
Application form: http://www.grants.gov/web/grants/applicant/download-application-

EHAVIORAL OR SOCIAL INTERVENTION CLINICAL PLANNING GRANT (R34):
AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its Aids-related NIDCR Behavioral or social intervention clinical planning grant (R34). These R34 Aids-related grants support activities that include:
- the development of the Behavioral or social intervention manual and procedures for training interventionists;
- development of the clinical protocol that will guide a subsequent clinical trial;
- the tools for data management, participant safety and operational oversight;
- other activities to prepare for a subsequent clinical trial.
R34 applications preparing for a Behavioral or social intervention study may involve human subjects as part of small-scale testing of the feasibility and acceptability of the interventions, measures, methods and training approaches.
Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organizations. Grants are worth up to US$150,000 for a period of maximum of one year. PAR-14-342 (replaces PAR-11-338)

Closing date: 07 May 15
Deadline information: Applications open on 21 October 2014 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 22 Sep 14
Award type: Clinical trials, Directed grants to institutions, research groups etc., Innovation grants
Award amount max: $150,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-342.html
Application form: http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Any

Disciplines
Dentistry, Clinical Medicine, Biological Markers & Sensor Mechanisms, Clinical Chemistry, Oral Medicine, Drug Design, Diagnostic Sciences, Biochemical Markers, HIV/Aids, Dental Health & Hygiene

Contact Details
National Institute of Dental and Craniofacial Research
1DEM, Room 634, MSC 4878
6701 Democracy Boulevard
Bethesda, MD 20892-4878
1 301 594 4814
Email: dclark2@nidcr.nih.gov

EXTENDED DEADLINE: MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME – ETIOLOGY, DIAGNOSIS, PATHOPHYSIOLOGY AND TREATMENT (R21): AIDS-RELATED

NIH: Office of the Director

Description:
A total of six participating institutes and centers of the National Institutes of Health have announced an additional funding cycle for their Aids-related myalgic encephalomyelitis/chronic fatigue syndrome – etiology, diagnosis, pathophysiology and treatment (R21) grants. The expiration date has been extended from 25 October 2014 to 25 February 2015, making the last application deadline for this opportunity 7 January 2015.

This Aids-related R21 funding opportunity announcement encourages proposals to examine the etiology, diagnosis, pathophysiology, and treatment of chronic fatigue syndrome, or myalgic encephalomyelitis, in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among patient populations, and the common mechanisms influencing the multiple body systems that are affected in ME/CFS are encouraged.

This funding opportunity announcement uses the R21 exploratory and developmental research grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-032, which solicits applications under the R01 research project grant mechanism. Applications are open to foreign or domestic
for-profit and non-profit organizations and public or private institutions. Funding is worth up to US$275,000 over a two-year project period. Ref: PAR-12-033 (replaces PA-08-247).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 25 February 2015.
Posted date: 06 Nov 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-033](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-033)

---

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Automated Clinical Analysis, Prion Diseases, Pathophysiology, Diagnostic Sciences, Medical & Diagnostic Tests, Biological Markers & Sensor Mechanisms, General Practice, HIV/Aids, Clinical Medicine, Aetiology, Radiology & Medical Imaging, Chronic Fatigue Syndrome

**Contact Details**

ORWH
6707 Democracy Boulevard
Bethesda MD 20817
Tel: 1 301 435 1573
Email: maiers@od.nih.gov

---

**EXTENDED DEADLINE: RESEARCH TO ADVANCE VACCINE SAFETY (R21): AIDS-RELATED**

NIH: National Institute of Allergy and Infectious Diseases

**Description:**

The National Institute of Allergy and Infectious Diseases and the Centers for Disease Control’s National Center for Emerging and Zoonotic Infectious Diseases have extended the expiration date for their Aids-related research to advance vaccine safety (R21) funding opportunity announcement. The expiration date has been extended from 8 January to 8 May 2015, making the last application deadline for this opportunity 7 May 2015. All other call details remain unchanged. ***

This Aids-related R21 announcement supports research that will contribute to the overall understanding of vaccine safety. This FOA invites studies that address scientific areas potentially relevant to vaccine safety such as:

- physiological and immunological responses to vaccines and vaccine components;
- how genetic variations affect immune or physiological responses that may impact vaccine safety;
- identification of risk factors biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines;
- creation or evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems;
• the application of genomic or molecular technologies to improve knowledge of vaccine safety.
This funding opportunity will use the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-12-037 that encourages applications under the NIH research project grant (R01) grant mechanism. Direct costs are limited to $275,000 over an R21 two-year period, and no more than $200,000 may be requested in any year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-038 (replaces PA-08-257)

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 15 Dec 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-038.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-038

Eligibility profile
Country of applicant institution: Any
Disciplines
Immunization Programmes & Vaccination, Immunology, HIV/Aids

Contact Details
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases
Room Number 4103, MSC-6603
6610 Rockledge Drive
Bethesda, MD 20892-6603
1 301 496 1884
Email: bmulach@niaid.nih.gov

EXTENDED DEADLINE: PILOT AND FEASIBILITY CLINICAL RESEARCH GRANTS IN KIDNEY OR UROLOGIC DISEASES (R21): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases have extended the expiration date for applications for its Aids-related pilot and feasibility clinical research grants in kidney or urologic diseases (R21). The expiration date has been extended from 8 January to 8 May 2015, making the last application deadline for this opportunity 7 May 2015. All other call details remain unchanged.
This Aids-related award supports pilot and feasibility clinical and translational research studies, including clinical trials and epidemiological studies related to kidney or urologic disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies or randomized clinical trials of diagnosis, prevention, or treatment of kidney or urologic diseases.
This solicitation uses the NIH R21 exploratory and development research grant award mechanism. Applicants may request a project period of two years and a budget for direct costs of US$275,000 with no more than US$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May, 7 September until 8 May, 2015.
Posted date: 31 Oct 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/par-files/PAR-09-077.html

**SECONDARY ANALYSES IN OBESITY, DIABETES, DIGESTIVE AND KIDNEY DISEASES (R21): AIDS-RELATED**

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Alcohol and Alcoholism and the Office of Dietary Supplements invite AIDS-related grant applications to support secondary analyses in obesity, diabetes and digestive and kidney diseases. These AIDS-related R21 grants support the secondary analysis of existing data sets relevant to diabetes and endocrine and metabolic diseases; digestive diseases and nutrition, including obesity and eating disorders; and kidney, urological, and hematological diseases. The goal of this programme is to facilitate research that explores innovative hypotheses through the use of existing data sets. Research that employs analytic techniques demonstrating or promoting methodological advances in patient-oriented and epidemiological research is also of interest. Innovative and high-risk applications with likelihood for high impact are particularly encouraged.

This funding opportunity will use the exploratory/developmental (R21) grant mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-11-352

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Epidemiology, Clinical Medicine, Urology, Drug Design, Nephrology & Kidneys, Public Health, Health Services & Primary Care, Medical & Diagnostic Tests, Preventive Medicine, Diagnostic Sciences, HIV/Aids, General Practice

Contact Details
-------------------------------------------------------------
NIDDK
6707 Democracy Blvd
Bethesda, MD  20892-5458
Tel: 1 301 594 7717
Email: mm726k@nih.gov
PILOT AND FEASIBILITY STUDIES IN PREPARATION FOR DRUG ABUSE PREVENTION TRIALS (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for Aids-related pilot and feasibility studies in preparation for drug and alcohol abuse prevention trials. This Aids-related R34 funding opportunity announcement supports pilot or feasibility testing of new, revised or adapted preventive intervention approaches targeting the initiation of drug and alcohol use, the progression to abuse or dependence and the acquisition or transmission of HIV infection among diverse populations and settings. They also support pre-trial feasibility testing for prevention services and systems research. Applicants may request direct costs of up to US$450,000 for three years, and no more than US$225,000 in any one year. Eligible applicants include domestic and foreign for-profit and non-profit organizations, and public or private institutions. PA-12-171 (replaces PA-09-146).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 24 Apr 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-171.html
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-171](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-171)

Eligibility profile

Country of applicant institution: Any

Disciplines

Psychology, Behavioral Studies & Social Problems, Addiction, Alcoholism, Medical Sociology, Venereology & Sexually Transmitted Diseases, Drug & Substance Abuse, Behavioral Medicine, Economic & Social Environment, HIV/AIDS, Sociology, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Biomedical Engineering

Contact Details

Prevention Research Branch
Division of Epidemiology, Services and Prevention Research
National Institute on Drug Abuse
6001 Executive Blvd, Room 5166
Bethesda, MD 20892-9589
Tel: 1 301 443 8892
Fax: 1 301 443 2636
Email: lloydj2@nida.nih.gov

**Renal Function and Chronic Kidney Disease in Ageing (R01): AIDS-Related**

**NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

**Description:**

The National Institute on Aging and the National Institute of Diabetes and Digestive and Kidney Diseases invite grant applications for renal function and chronic kidney disease in ageing. This AIDS-related R01 funding opportunity announcement funds basic, clinical and translational AIDS-related research on chronic kidney disease and its consequences in ageing and in older persons. Applications should focus on:

- biology and pathophysiology of CKD in animal models;
- aetiology and pathophysiology of CKD in older adults;
- epidemiology and risk factors for the development of CKD with advancing age;
- diagnosis, medical management and clinical outcomes of CKD in this population.

This funding opportunity announcement will use the research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-210, which encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-211 (replaces PA-09-165).

Closing date: 07 May 15

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2015.

Posted date: 14 Jun 12

Award type: Directed grants to institutions, research groups etc.

Website: [http://grants.nih.gov/grants/guide/pa-files/PA-12-211.html](http://grants.nih.gov/grants/guide/pa-files/PA-12-211.html)

Eligibility profile

Country of applicant institution: Any

Disciplines

Translational Medicine, Biological Markers & Sensor Mechanisms, HIV/Aids, Geriatrics & Gerontology, Clinical Medicine, Aetiology, Blood Diseases, Epidemiology, Public Health, Health Services & Primary Care, Pathophysiology, Medical & Diagnostic Tests, Nephrology & Kidneys, Primary Care, Osteoporosis & Other Bone Diseases, Hormones & Endocrinology

Contact Details

Division of Geriatrics and Clinical Gerontology
National Institute on Aging
7201 Wisconsin Avenue
Gateway Building, Room 3C307
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: susan.zieman@nih.gov

**Renal Function and Chronic Kidney Disease in Ageing (R21): AIDS-Related**  
**NIH: National Institute on Aging**

**Description:**  
The National Institute on Aging invites grant applications for renal function and chronic kidney disease in ageing. This Aids-related R21 funding opportunity announcement funds basic, clinical and translational research on chronic kidney disease and its consequences in ageing and in older persons. Applications should focus on:

- biology and pathophysiology of CKD in animal models;
- aetiology and pathophysiology of CKD in older adults;
- epidemiology and risk factors for the development of CKD with advancing age;
- diagnosis, medical management and clinical outcomes of CKD in this population.

This funding opportunity announcement will use the exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-211, which encourages applications under the NIH research project grant (R01) mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-210 (replaces PA-09-166).

**Closing date:** 07 May 15  
**Deadline information:** Deadlines every 7 January, 7 May and 7 September until 8 January 2016.  
**Posted date:** 14 Jun 12  
**Award type:** Directed grants to institutions, research groups etc.  
**Award amount max:** $275,000  

**Application form:** [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-210](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-210)
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Translational Medicine, Epidemiology, Pathophysiology, Medical & Diagnostic Tests, Public Health, Health Services & Primary Care, Geriatrics & Gerontology, Clinical Medicine, Aetiology, Biological Markers & Sensor Mechanisms, HIV/AIDS, Blood Diseases, Hormones & Endocrinology, Primary Care, Nephrology & Kidneys, Osteoporosis & Other Bone Diseases

Contact Details
----------------------------------------------
Division of Geriatrics and Clinical Gerontology
National Institute on Aging
7201 Wisconsin Avenue
Gateway Building, Room 3C307
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: susan.zieman@nih.gov

PAIN IN AGEING (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This Aids-related funding opportunity announcement encourages exploratory and developmental research grant (R21) applications from institutions and organizations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:

• mechanisms and predictors of pain experience in ageing;
• development and evaluation of pain assessment tools for older adults or older model organisms;
• development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH exploratory/developmental research grant (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-058, that encourages applications under the research project grant (R01) grant mechanism, and PA-13-060, that encourages applications under the R03 small research grants mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PA-13-059 (replaces PA-09-194)

Closing date: 07 May 15
Deadline information: Applications are due every January 7, May 7 and September 7 until January 8, 2016.
Posted date: 27 Dec 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Pain in Ageing (R03): AIDS-Related
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This Aids-related funding opportunity announcement encourages small grant (R03) applications from institutions and organizations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:
• mechanisms and predictors of pain experience in ageing;
• development and evaluation of pain assessment tools for older adults or older model organisms;
• development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH R03 small research grants award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-058, that encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-059, that encourages applications under the research project grant (R01) mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to US$50,000 per year for a maximum of US$100,000 direct costs over a two-year project period. The maximum project period is two years. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PA-13-060 (replaces PA-09-195)

Closing date: 07 May 15
Deadline information: Applications are due every January 7, May 7 and September 7 until January 8, 2016.
Posted date: 27 Dec 12
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)


Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-060

Eligibility profile
Country of applicant institution: Any

Disciplines
Behavioral Medicine, Neurobiology, Primary Care, Biological Sciences, Public Health, Health Services & Primary Care, Diagnostic Sciences, Biochemistry & Molecular Biology, Psychology of Ageing, Psychology, Pain Management, Radiology & Medical Imaging, HIV/AIDS, Chronic Pain, Medical Effectiveness & Patient Outcomes, Geriatrics & Gerontology, Clinical Medicine, Biochemical Markers, Human Physiology

Contact Details
NIA
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: 1 301 496 9350
Email: chenw@nia.nih.gov

PAIN IN AGEING (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications under its pain in ageing programme. This Aids-related funding opportunity announcement encourages research project grant (R01) applications from institutions and organizations that propose to study pain from an ageing perspective, including studies of older populations, studies of age differences and age-related changes in pain processes and experiences, and studies of pain treatment and management in older adults. This FOA particularly encourages studies on:
• mechanisms and predictors of pain experience in ageing;
• development and evaluation of pain assessment tools for older adults or older model organisms;
• development and evaluation of pain management strategies in older adults, with particular attention to the challenges associated with treating pain in patients with multiple morbidities.

This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with FOAs of identical scientific scope, PA-13-059, that encourages applications under the R21 exploratory/developmental grant mechanism, and PA-13-060, that encourages applications under the R03 small research grants mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Eligible organizations include domestic and foreign public and private non-profit organizations.
Disciplines
---------------------------------------------
Chronic Pain, Medical Effectiveness & Patient Outcomes, Clinical Medicine, Psychology, Psychology of Ageing, Biological Sciences, Neurobiology, Primary Care, Behavioral Medicine, HIV/AIDS, Geriatrics & Gerontology, Biochemical Markers, Pain Management, Radiology & Medical Imaging, Public Health, Health Services & Primary Care, Diagnostic Sciences, Biochemistry & Molecular Biology

Contact Details
---------------------------------------------
NIA
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: 1 301 496 9350
Email: chenw@nia.nih.gov

Eligibility profile
---------------------------------------------
Country of applicant institution: Any

NCILLARY STUDIES OF ACUTE KIDNEY INJURY, CHRONIC KIDNEY DISEASE AND END STAGE RENAL DISEASE ACCESSING INFORMATION FROM CLINICAL TRIALS, EPIDEMIOLOGICAL STUDIES AND DATABASES (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute invite applications for their Aids-related ancillary studies of acute kidney injury, chronic kidney disease and end stage renal disease accessing information from clinical trials, epidemiological studies and databases (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigator-initiated ancillary studies to ongoing or completed clinical trials, existing epidemiological studies of kidney disease as well as clinical trials and epidemiological studies for other diseases or populations that lend themselves to the study of acute kidney injury and chronic kidney disease. The goal of these studies should be to extend understanding of risk factors for developing kidney disease and associated co-morbid illnesses, factors associated with rapid decline in kidney function among persons with chronic kidney disease, and the impact of these diseases on quality of life and mental and physical functioning. Investigations of acute kidney injury, including biomarkers, are also appropriate topics of investigation. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public and private institutions are eligible to apply. PA-12-299 (replaces PA-09-196).

Closing date: 07 May 15
Biomarkers for Early Detection of Haematopoietic Malignancies (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its AIDS-related biomarkers for early detection of haematopoietic malignancies (R01) grants. This AIDS-related R01 funding opportunity announcement encourages research projects for the development and validation of biomarkers for: early detection, prediction of progression, and recurrence of haematopoietic malignancies, especially in high-risk individuals; and for risk assessment of primary and secondary haematopoietic malignancies. This funding opportunity announcement also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with haematopoietic malignancies. This FOA uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-220 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-221 (replaces PA-09-197).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 29 Jun 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/ps-files/PA-12-221.html
IDENTIFYING NON-CODING RNA TARGETS FOR EARLY DETECTION OF CANCER (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its identifying non-coding RNA targets for early detection of cancer programme. This Aids-related R01 funding opportunity announcement encourages research on non-coding RNAs and their targets in preneoplastic lesions and early stage cancers. This FOA also encourages research projects to assess the usefulness of stable microRNAs and ncRNAs to predict progression to cancer and as biomarkers for early cancer detection and screening. Building on both basic and biomarker research no miRNA, this FOA will further promote research on all classes of ncRNAs and support the translation of stable miRNAs into cancer screening or diagnostic tests.

This funding opportunity announcement uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-214 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-12-213 (replaces PA-09-199).

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 20 Jun 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-213

Eligibility profile
Country of applicant institution: Any
NON-CODING RNA TARGETS FOR EARLY DETECTION OF CANCER (R21): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its identifying non-coding RNA targets for early detection of cancer programme. This Aids-related R21 funding opportunity announcement encourages research on non-coding RNAs and their targets in preneoplastic lesions and early stage cancers. This FOA also encourages research projects to assess the usefulness of stable microRNAs and ncRNAs to predict progression to cancer and as biomarkers for early cancer detection and screening. Building on both basic and biomarker research no miRNA, this FOA will further promote research on all classes of ncRNAs and support the translation of stable miRNAs into cancer screening or diagnostic tests.

This funding opportunity announcement uses the NIH R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-213 that encourages applications under the NIH research project R01 grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,00 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-214 (replaces PA-09-200).

Closing date: 07 May 15
Deadline information: Applications every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-214.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-214

Eligibility profile
Country of applicant institution: Any
Disciplines
------------------------------------------------
Clinical Medicine, Haematology, Biological
Markers & Sensor Mechanisms, Leukaemia &
Other Blood Cancers, Cancer Studies &
Oncology, Human Biological Sciences, Cancer
Cell Biology, Ovarian & Cervical Cancers,
Colorectal, Pancreatic & Stomach Cancers,
Carcinogenesis, Medical & Diagnostic Tests,
Diagnostic Sciences, Preventive Medicine,
Breast Cancer, Prostate & Testicular Cancers,
Biochemical Markers, HIV/Aids, Physiology

Contact Details
------------------------------------------------
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN 3138, MSC
7362
Rockville, MD 20852-7362
Tel: 1 301 594 7607
Fax: 1 301 402 8990
Email: wangw@mail.nih.gov

ATIGIBILITY, ACTIVITY LIMITATIONS AND BIOENERGETICS IN AGEING (R01):
AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the
Office of Research on Women’s health of the
National Institutes of Health invite
applications for their fatigability, activity
limitations and bioenergetics in ageing grants.
This Aids-related R01 funding opportunity
announcement invites applications proposing
to investigate the role of specific bioenergetic
factors in increased fatigability, reduced
activity, and diminished sense of well-being
in older persons; test the effects of
interventions targeted at such factors on
performance capabilities, functional status,
and other outcomes that relate to quality of
life; or develop and evaluate measures of
fatigability applicable for observational or
interventional studies.
This FOA uses the R01 research project grant
mechanism and runs in parallel with FOAs of
identical scientific scope, PA-12-225, that
encourages applications under the R21
exploratory/developmental research grant
award and PA-12-226, that encourages
applications under the R03 small research
grant mechanism.
Application budgets are not limited, but need
to reflect actual needs of the proposed project.
The maximum award period is 5 years;
exceptions to this period may be considered if
scientifically justified. The number of awards
is contingent upon NIH appropriations, and
the submission of a sufficient number of
meritorious applications. Eligible applicants
include domestic and foreign non-profit or
for-profit organizations and public or private
institutions. PA-12-227 (replaces PA-09-190)

Closing date: 07 May 15
Deadline information: Applications due
every 7 January, 7 May and 7 September
until 8 September 2015.
Posted date: 26 Apr 13
Award type: Directed grants to institutions,
research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-
files/PA-12-227.html
Application form: http://apply07.grants.gov/apply/GetGrantFro
mFedgrants?opportunity=PA-12-227

Eligibility profile
--------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Psychology, Epidemiology, Psychology of Ageing, Human Physiology, Exercise Physiology, Primary Care, Chronic Fatigue Syndrome, Physiology, Geriatrics & Gerontology, HIV/AIDS, Cell Physiology & Metabolism, Public Health, Health Services & Primary Care

Contact Details
----------------------------------------------
National Institute on Aging
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: eldadahb@nia.nih.gov

Fatigability, Activity Limitations and Bioenergetics in Ageing (R21): AIDS-Related

Description:
The National Institute on Aging and the Office of Research on Women’s health of the National Institutes of Health invite applications for their fatigability, activity limitations and bioenergetics in ageing aids-related grants. This AIDS-related R21 funding opportunity announcement invites applications proposing to investigate the role of specific bioenergetic factors in increased fatigability, reduced activity, and diminished sense of well-being in older persons; test the effects of interventions targeted at such factors on performance capabilities, functional status, and other outcomes that relate to quality of life; or develop and evaluate measures of fatigability applicable for observational or interventional studies. This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-12-226, that encourages applications under the R03 small research grant mechanism, and PA12-227, that encourages applications under the NIH research project grant (R01) grant mechanism. Direct costs are limited to US$275,000 over a two-year period. Applicants may request direct costs in US$25,000 modules, up to the total direct costs limitation. No more than US$200,000 may be requested in any single year. The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-225 (replaces PA-09-191)

Closing date: 07 May 15
Deadline information: Applications due every 7 September, 7 January and 7 May until 8 September 2015.
Posted date: 12 Jul 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-225.html

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-225

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
ATIGABILITY, ACTIVITY LIMITATIONS AND BIOENERGETICS IN AGEING (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the Office of Research on Women’s health of the National Institutes of Health invite applications for their fatigability, activity limitations and bioenergetics in ageing grants. This Aids-related R03 funding opportunity announcement invites applications proposing to investigate the role of specific bioenergetic factors in increased fatigability, reduced activity, and diminished sense of well-being in older persons; test the effects of interventions targeted at such factors on performance capabilities, functional status, and other outcomes that relate to quality of life; or develop and evaluate measures of fatigability applicable for observational or interventional studies.

This FOA uses the R03 small research grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-12-225, that encourages applications under the R21 exploratory/developmental research grant award and PA-12-227, that encourages applications under the R01 research project grant mechanism.

Direct costs are limited to US$100,000 over a two-year period. No more than US$50,000 may be requested in any single year. The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-226 (replaces PA-09-192)

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May, 7 September until 8 September, 2015.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-226.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-226

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology, Epidemiology, Psychology of Ageing, Exercise Physiology, Human Physiology, Primary Care, Chronic Fatigue Syndrome, Physiology, HIV/AIDS, Cell
Biomarkers for Early Detection of Haematopoietic Malignancies (R21): AIDS-Related
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its Aids-related biomarkers for early detection of haematopoietic malignancies (R01) grants. This Aids-related R01 funding opportunity announcement encourages research projects for the development and validation of biomarkers for: early detection, prediction of progression, and recurrence of haematopoietic malignancies, especially in high-risk individuals; and for risk assessment of primary and secondary haematopoietic malignancies. This funding opportunity announcement also encourages the development and improvement of specific technologies and methods for quantitative detection of novel biomarkers associated with haematopoietic malignancies.

This FOA uses the NIH exploratory/ developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-221 that encourages applications under the NIH research project R01 grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-220 (replaces PA-09-198).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 29 Jun 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/notice-files/PA-12-220.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-220

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids, Biological Markers & Sensor Mechanisms, Biochemical Markers, Haematology, Clinical Medicine, Chemotherapy, Diagnostic Sciences, Autoimmune Diseases

Contact Details
----------------------------------------------
Division of Cancer Prevention
National Cancer Institute
SECONDARY ANALYSES OF EXISTING DATA SETS AND STORED BIOSPECIMENS TO ADDRESS CLINICAL AGEING RESEARCH QUESTIONS (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute of Aging invites applications for its Aids-related secondary analyses of existing data sets and stored biospecimens to address clinical ageing research questions (R01) programme. This Aids-related R01 funding opportunity announcement will address clinically related issues on ageing changes influencing health across the life span or on diseases and disabilities in older persons.
This FOA will support activities addressing specific hypotheses in clinical ageing research, or informing the design and implementation of future epidemiologic or human intervention studies, or current geriatric practice in maintenance of health, management of disease, and prevention of disability.
Application budgets are not limited, but must reflect the actual needs of the project. Projects may not exceed five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-168 (replaces PA-09-265).

Closing date: 07 May 15
Deadline information: Deadlines every January 7, May 7 and September 7 until 8 May 2016.

Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc.
Website:

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids, Geriatrics & Gerontology, Public Health, Health Services & Primary Care, Preventive Medicine, Diagnostic Sciences, Biomedical Engineering, Nursing, Primary Care, Geriatric Nursing, Care for Disabled People, Epidemiology, Pharmacy & Pharmacology, Data Analysis

Contact Details
National Institute on Aging
7201 Wisconsin Ave, Suite 3C-307
Bethesda, MD 20892-9205
Tel: 1 301 435 3048
Email: duttac@mail.nih.gov
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R21): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders funding opportunity. This Aids-related R21 funding opportunity announcement encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. The goal is to advance new, innovative and effective therapies for the prevention and treatment of nervous system disorders. Studies aimed at the development and testing of compounds for novel targets are encouraged, however projects designed for target identification are not covered under this announcement. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations. This FOA will use the R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-13-048, that solicits applications under the R01 mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are limited to US$275,000 direct costs over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. PAR-13-049 (replaces PAR-10-002).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
Posted date: 19 Dec 12

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-049

Eligibility profile
Country of applicant institution: Any

Disciplines

Contact Details
NIMH
6001 Executive Boulevard, Room 7189
Rockville, MD 20852
DRUG DISCOVERY FOR NERVOUS SYSTEM DISORDERS (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Aging, the National Institute on Alcohol Abuse and Alcoholism, and the National Institute on Drug Abuse invite applications for their drug discovery for nervous system disorders funding opportunity. This AIDS-related R01 funding opportunity announcement encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders. The goal is to advance new, innovative and effective therapies for the prevention and treatment of nervous system disorders. Studies aimed at the development and testing of compounds for novel targets are encouraged, however projects designed for target identification are not covered under this announcement. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations. This FOA will use the R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-13-049, that solicits applications under the R21 mechanism. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PAR-13-048 (replaces PAR-10-001).

Closing date: 07 May 2015
Deadline information: Applications due by 5pm local time of applicant organization.

Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
Posted date: 19 Dec 12
Award type: Directed grants to institutions, research groups etc.
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-048

Eligibility profile
Country of applicant institution: Any
Disciplines
BEHAVIORAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAMME (R34): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the Office of Behavioral and Social Sciences Research invite applications for their AIDS-related Behavioral and integrative treatment development (R34) grants. The aim of this AIDS-related R34 programme is to develop and test Behavioral and integrative treatments for drug and alcohol abuse and dependence. Research will test efficacy, conduct clinical trials, examine mechanisms of Behavior change, determine dose-response, optimize combinations, or ascertain best sequencing of Behavioral, combined, sequential, or integrated Behavioral and pharmacological treatments in the following circumstances:

- drug abuse treatment interventions in diverse settings;
- drug abuse treatment and adherence interventions for use in primary care;
- drug abuse treatment and adherence interventions that use technologies to boost effects and increase implementability;
- interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment;
- interventions to promote adherence to drug abuse treatment, HIV and addiction medications;
- interventions to treat chronic pain.

Research of interest includes but is not limited to Stage II and Stage III efficacy research. This funding opportunity announcement will use the R34 award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-13-079, which solicits applications under the R03 small grant mechanism, and PA-13-077, that solicits applications under the R01 research project grant mechanism. Direct costs are limited to US$450,000 over three years, with no more than US$225,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. PA-13-078 (replaces PA-10-013).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
DEVELOPMENT AND CHARACTERISATION OF ANIMAL MODELS FOR AGEING RESEARCH (R01): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites AIDS-related R01 applications for its development and characterization of animal models for ageing research programme. The institute aims to promote AIDS-related research under the R01 mechanism that develops, characterizes, refines and enhances model systems for research on ageing. Studies that develop new model systems or refine existing models to maximize their value for ageing research will contribute to the understanding of normal changes in physiology and function with age and the onset, progression, therapeutics and prevention of age associated diseases. The objective of this programme is to enhance the biological resources and tools available to the research community for the study of biology of ageing.

This funding opportunity announcement will utilize the R01 award mechanism and runs in parallel with another FOA of identical scope, PA-13-156 that solicits applications under the R21 mechanism. Application budgets are not limited, and the maximum project period is five years. Eligible organizations include non-profit organizations and for-profit organizations. PA-13-155 (replaces PA-10-014).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization.
Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
Posted date: 25 Mar 13
Award type: Directed grants to institutions, research groups etc.
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-155

Eligibility profile
Country of applicant institution: Any

Disciplines
Human Physiology, Diagnostic Sciences, Biological Sciences, Physiology, Cell Lines,
NEI CLINICAL STUDY PLANNING GRANT PROGRAMME (R34): AIDS-RELATED

NIH: National Eye Institute

Description:
The National Eye Institute invites applications for its Aids-related clinical study planning grant programme (R34). This Aids-related R34 funding opportunity announcement will facilitate activities central to the refinement of a study protocol and procedures and the development of a detailed manual of procedures (MOP) for a large-scale clinical trial or epidemiologic study. Funding may support the development of an MOP, as well as to conduct preliminary studies to refine study procedures or document recruitment potential.

Direct costs are limited to US$150,000 per year and projects may not exceed two years. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PAR-13-073 (replaces PAR-10-017).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 07 Jan 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $300,000

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-073

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Vision Science, Diagnostic Sciences, HIV/Aids, Sensory Systems, Drug Design, Eye Diseases, Epidemiology

Contact Details
----------------------------------------------
Division Extramural Research
NEI
5635 Fishers Lane, Suite 1300, MSC 9300
Bethesda, MD 20892-9300
Tel: 1 301 451 2020
Fax: 1 301 402 0528
Email: everettd@mail.nih.gov
ACCELERATING THE PACE OF DRUG ABUSE RESEARCH USING EXISTING DATA (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Institute of Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism and the National Cancer Institute invite applications for their Aids-related accelerating the pace of drug abuse research using existing data programme. This Aids-related R01 funding opportunity announcement will support the innovative analysis of existing social science, Behavioral, administrative and neuroimaging data to study the aetiology and epidemiology of drug-using Behaviors and related disorders, associated HIV risk Behaviors, prevention of drug use and HIV, and health service use.

Direct costs are limited to US$450,000 direct costs over three years, with no more than US$150,000 in any year. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. PAR-13-080 (replaces PAR-10-018).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-080

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Behavioral Medicine, Diagnostic Sciences, Alcoholism, Epidemiology, Cognitive & Behavioral Therapies, Psychology, Aetiology, Smoking & Tobacco, HIV/AIDS, Behavioral Studies & Social Problems, Drug & Substance Abuse, Agriculture

Contact Details
-----------------------------------------------
Division of Epidemiology, Services, and Prevention Research
NIDA
6001 Executive Boulevard, Room 5144, MCS 9589
Bethesda, MD 20892-9589
Tel: 1 301 443 6504
Email: lopezmar@nida.nih.gov

OBESITY POLICY EVALUATION RESEARCH (R01): AIDS-RELATED
NIH: National Cancer Institute

Description:
Six organizations of the National Institutes of Health invite applications for their Aids-related obesity policy evaluation research (R01) grants. This Aids-related R01 funding opportunity announcement encourages evaluations of large scale policies or
programmes that are expected to influence obesity-related Behaviors or weight outcomes in an effort to prevent or reduce obesity. Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PA-13-110 (replaces PA-10-027).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 07 Feb 13
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-10-027.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-110

Eligibility profile

Country of applicant institution: Any

Disciplines

Dietary Guidelines, Food Consumption, Sports & Exercise Studies, Cancer Studies & Oncology, Nutrition & Dietetics, Primary Care, Obesity, Cancer Cell Biology, Exercise Physiology, Malnutrition, Physical & Sports Education, Carcinogenesis, Public Health, Health Services & Primary Care, Diagnostic Sciences, HIV/Aids, Education, Food Science

Contact Details

NIDDK
6707 Democracy Boulevard, Room 605
Bethesda, MD 20817
Tel: 1 301 594 4728
Email: ch514c@nih.gov

IDCR SMALL RESEARCH GRANTS FOR DATA ANALYSIS AND STATISTICAL METHODOLOGY APPLIED TO GENOME-WIDE DATA (R03): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites Aids-related proposals for its small research grants for data analysis and statistical methodology applied to genome-wide data. This Aids-related R03 funding opportunity announcement will support meritorious research projects that involve secondary data analyses or development of statistical methodology using existing genome-wide data, relevant to human dental or craniofacial conditions or traits. Development of statistical methodology appropriate for analyzing genome-wide data, relevant to human dental or craniofacial conditions or traits, may also be proposed. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations. Up to US$200,000 is available per year for direct costs, given that the total project budget does not exceed US$300,000 over a maximum project period of two years. PAR-13-044 (replaces PAR-10-041).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on deadline dates. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
TIMULATING HAEMATOLOGY INVESTIGATION: NEW ENDEAVOURS (SHINE) (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for its Aids-related stimulating haematology investigation: new endeavours (SHINE) programme. This Aids-related programme will support innovative, high-quality haematology research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases. Investigator-initiated research project grant applications are requested in specific areas of basic and translational haematology research where needs and opportunities for progress are particularly timely.

NIH intends to provide US$1 million to fund two to four awards in fiscal year 2013. Application budgets are not limited, but must reflect the actual needs of the project. Projects may request up to five years of support. Domestic and foreign public and private non-profit organizations and for-profit organizations are eligible to apply. PAS-13-031 (replaces PAS-10-046).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September 7 until 8 January 2016.
Posted date: 04 Dec 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa- files/PAS-10-046.html
Application form: http://apply07.grants.gov/apply/GetGrantFro mFedgrants?opportunity=PAS-13-031

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Nephrology & Kidneys, Gastroenterology, Hormones & Endocrinology, HIV/Aids,
TRUCTURAL INTERVENTIONS, ALCOHOL USE AND RISK OF HIV/AIDS (R01)
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites proposals for its structural interventions, alcohol use and risk of HIV/Aids (R01) programme. This R01 funding opportunity announcement solicits applications from institutions and organizations that propose to investigate the effectiveness of structural interventions that reduce the risk of HIV/Aids transmission by changing the environment of alcohol use. This FOA will use the research project grant R01 mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-192, which solicits applications under the R21 exploratory/developmental grant mechanism. Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-191 (replaces PA-10-242).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 12 Apr 13
Award type: Directed grants to institutions, research groups etc.

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-191

Eligibility profile
Country of applicant institution: Any

Disciplines
Mental Illness, Biomedical Engineering, Alcoholism, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Health Disparities, HIV/Aids, Education, Psychology, Social Work & Social Policy, Gender Roles & Sexuality, Behavioral Medicine, Primary Care, Health Systems Policy

Contact Details
NIAA
5635 Fishers Lane, Room 2073
Bethesda, MD 20892-9304
Tel: 1 301 443 8820
Email: rfreeman@mail.nih.gov
CALCIUM OXALATE STONE DISEASES (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases invites applications for research into calcium oxalate stone diseases. This Aids-related funding opportunity announcement R01 aims to increase investigator interest in research into oxalate metabolism, transport and homeostasis, and oxalate stone diseases. This initiative encourages basic, clinical or epidemiological studies that utilize new and innovative approaches to study the diagnosis, treatment and prevention of these disorders. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. PA-13-043 (replaces PA-09-213).

Closing date: 07 May 15
Posted date: 17 Dec 12
Award type: Directed grants to institutions, research groups etc.

Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-043.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-043

Eligibility profile
----------------------------------------------------------------------------------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------------------------------------------------------------------------------
Molecular Genetics, Aetiology, Clinical Medicine, Pathogenesis, Urology, Nephrology & Kidneys, Primary Care, Public Health, Health Services & Primary Care, Preventive Medicine, Diagnostic Sciences, Medical & Diagnostic Tests, HIV/Aids, General Practice

Contact Details
----------------------------------------------------------------------------------------------------------------------
Division of Kidney, Urologic, and Hematologic Diseases
NIDDK
6707 Democracy Blvd, Room 643
Bethesda, MD 20892-5458
Tel: 1 301 594 6007
Fax: 1 301 480 3510
Email: rebekah.rasooly@nih.gov

TECHNOLOGY-BASED INTERVENTIONS TO PROMOTE ENGAGEMENT IN CARE AND TREATMENT ADHERENCE FOR SUBSTANCE ABUSING POPULATIONS WITH HIV (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its technology-based interventions to promote engagement in care and treatment adherence for substance abusing populations with HIV (R01). This R01 funding opportunity announcement
encourages applications to test the utility and implementation of technological tools, including mobile devices, to promote engagement in HIV care among substance-abusing populations with HIV. Projects may focus on: the use of technology to directly improve patient-level outcomes; the capacity of HIV treatment providers and related service delivery organizations to adopt and integrate such technologies to promote HIV treatment outcomes; the use of technology to improve the organization and delivery of HIV treatment and services.

This funding opportunity announcement will use the R01 grant mechanism, and runs in parallel with an FOA of identical scope, PA-12-118, which encourages applications under the clinical trial planning grant (R34) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-12-117 (replaces PAS-10-097).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 26 Mar 12

Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-117

Eligibility profile
Country of applicant institution: Any

Disciplines
Medical Sociology, Innovation & Technology Management, Patient Compliance, Primary Care, Assistive Technology, HIV/AIDS, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Diagnostic Sciences, Biomedical Engineering

Contact Details
Division of Clinical Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Blvd
Bethesda, MD 20892-9593
Tel: 1 301 443 2261
Email: kahanas@mail.nih.gov

TECHNOLOGY-BASED INTERVENTIONS TO PROMOTE ENGAGEMENT IN CARE AND TREATMENT ADHERENCE FOR SUBSTANCE ABUSING POPULATIONS WITH HIV (R34)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its technology-based interventions to promote engagement in care and treatment adherence for substance abusing populations with HIV (R34). This R34 funding opportunity announcement encourages applications to test the utility and implementation of technological tools, including mobile devices, to promote engagement in HIV care among substance-abusing populations with HIV. Projects may focus on: the use of technology to directly improve patient-level outcomes; the capacity of HIV treatment providers and related
service delivery organizations to adopt and integrate such technologies to promote HIV treatment outcomes; the use of technology to improve the organization and delivery of HIV treatment and services.

This funding opportunity announcement will use the R34 grant mechanism, and runs in parallel with an FOA of identical scope, PA-12-118, which encourages applications under the research project grant (R01) mechanism. Applications for R34 grants may request up to US$450,000 in funding over three years, with no more than US$225,000 in any year. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-12-118 (replaces PAS-10-098).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000

Website:
http://grants.nih.gov/grants/guide/pa-files/PA-12-118.html
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-118

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Biomedical Engineering, Diagnostic Sciences, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, HIV/AIDS, Assistive Technology, Primary Care, Patient Compliance, Innovation & Technology Management, Medical Sociology

Contact Details
----------------------------------------------
Division of Clinical Neuroscience and Behavioral Research
National Institute on Drug Abuse
6001 Executive Blvd
Bethesda, MD 20892-9593
Tel: 1 301 443 2261
Email: kahanas@mail.nih.gov

UNDERSTANDING AND PROMOTING HEALTH LITERACY (R01): AIDS-RELATED
NIH: Office of the Director

Description:
A total of 11 institutes and offices of the National Institutes of Health invite proposals for the Aids-related understanding and promoting health literacy (R01) programme. The goal of this Aids-related R01 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.
This call will use the NIH R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-131, which uses the R03 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application
budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years. PAR-13-130 (replaces PAR-10-133).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until May 8, 2016.
Posted date: 04 Mar 13
Award type: Directed grants to institutions, research groups etc


Eligibility profile

Country of applicant institution: Any

Disciplines

Patient Care & Education, Health & Safety Education & Instruction, Clinical Medicine, Health Promotion, Health Education, Health Systems, Primary Care, Diagnostic Sciences, HIV/AIDS, Education, Public Health

Contact Details

OBSSR
NIH
31 Center Drive, Room B1C19
Bethesda, MD 20814
Tel: 1 301 401 0116
Email: elwoodwi@od.nih.gov

UNDERSTANDING AND PROMOTING HEALTH LITERACY (R03): AIDS-RELATED
NIH: Office of the Director

Description:
A total of eight institutes and offices of the National Institutes of Health invite proposals for the AIDS-related understanding and promoting health literacy (R03) programme. The goal of this AIDS-related R03 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions. This call will use the NIH R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-132, which uses the R21 grant mechanism.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Direct costs are limited to US$100,000 over two years with no more than US$50,000 in any year. PAR-13-132 (replaces PAR-10-134).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Mar 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
UNDERSTANDING AND PROMOTING HEALTH LITERACY (R21): AIDS-RELATED

NIH: Office of the Director

Description:
A total of nine institutes and offices of the National Institutes of Health invite proposals for the AIDS-related understanding and promoting health literacy (R21) programme. The goal of this AIDS-related R21 funding opportunity announcement is to encourage methodological, intervention and dissemination research for understanding and promoting health literacy. Health literacy is defined as the degree to which individuals have the capacity to obtain, process, and understand basic health information and services needed to make appropriate health decisions.

This call will use the NIH R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-130, which uses the R01 grant mechanism, and PAR-13-131, which uses the R03 grant mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Direct costs are limited to US$275,000 over two years with no more than US$200,000 available in any year. PAR-13-132 (replaces PAR-10-135).

Deadline information: Applications due by 5pm local time of applicant institution on every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Mar 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Patient Care & Education, Clinical Medicine, Health & Safety Education & Instruction, Patient Care & Education

Contact Details
OBSSR
NIH
31 Center Drive, Room B1C19
Bethesda, MD 20814
Tel: 1 301 401 0116
Email: elwoodwi@od.nih.gov

Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-131

Promotion, Clinical Medicine, Health & Safety Education & Instruction, Patient Care & Education

Closing date: 07 May 15
Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related alcohol use disorders: treatment, services and recovery research (R03) programme. This Aids-related R03 funding opportunity announcement supports research on Behavioral and pharmacological treatment for alcohol use disorders; organizational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. The total project period may not exceed two years. Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. This programme will use the NIH R03 grant mechanism and runs in parallel with two programmes of identical scientific scope: PA-13-160, which solicits applications under the R01 mechanism, and PA-13-162, which solicits applications under the R21 mechanism. PA-13-161 (replaces PA-10-101)

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
ALCOHOL USE DISORDERS: TREATMENT, SERVICES AND RECOVERY RESEARCH (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related alcohol use disorders: treatment, services and recovery research (R01) programme. This Aids-related R01 funding opportunity announcement supports research on Behavioral and pharmacological treatment for alcohol use disorders; organizational, financial and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; or the phenomenon of recovery from alcohol use disorders. Applications will be accepted from domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The total project period may not exceed five years. This programme will use the NIH R01 grant mechanism and runs in parallel with two programmes of identical scientific scope: PA-13-161, which solicits applications under the R21 mechanism, and PA-162, which solicits applications under the R03 mechanism. PA-13-160 (replaces PA-10-100).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.

Posted date: 02 Apr 13
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:

Eligibility profile
Country of applicant institution: Any
Disciplines
Health Systems, Administration, Allied Health Professions, Alcoholism, Pharmacy & Pharmacology, Psychology, Drug & Substance Abuse, Experimental Psychology, Primary Care, Public Health, Health Services & Primary Care, Cognitive & Behavioral Therapies, General Practice, HIV/Aids

Contact Details
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: 1 301 443 4715
Email: pchiapel@wilco.niaaa.nih.gov

INDS PHASE III INVESTIGATOR-INITIATED EFFICACY TRIALS (U01): AIDS-RELATED
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites U01 applications for its Aids-related NINDS phase III investigator-initiated efficacy clinical trials.
This Aids-related U01 funding opportunity will support investigator-initiated multi-site phase III randomized, controlled clinical trials which address research questions related to the mission and goals of NINDS. The clinical trials may evaluate an experimental intervention in comparison with a standard or control intervention, or compare two or more existing treatments. The programme supports drugs, biologics and devices, as well as surgical, Behavioral and rehabilitation therapies. Trials should recruit study subjects from two or more geographically distinct enrolment sites, or centers.

Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations and academic institutions. PAR-13-278 (previously PAR-11-173).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 23 Jul 13
Award type: Clinical trials

Website: http://grants.nih.gov/grants/guide/pa-files/PAR-13-278.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-278

Eligibility profile
---------------------------------
Country of applicant institution: Any
Disciplines
---------------------------------
Pharmacotherapy, Drug Design, Biological Sciences, Public Health, Health Services & Primary Care, General Surgery, Medical Devices, Diagnostic Sciences, Counseling & Therapy, Methods of Drug Delivery, Pharmacy & Pharmacology, Cognitive & Behavioral Therapies, HIV/Aids, Clinical Medicine, Ethology, Behavioral Medicine, Primary Care

Contact Details
---------------------------------
NINDS
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 496 9135
Email: phase3trial@ninds.nih.gov

INDS EXPLORATORY CLINICAL TRIALS (R01): AIDS-RELATED
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its NINDS exploratory clinical trials (R01). This R01 funding opportunity will support exploratory clinical trials that address research questions related to the mission and goals of NINDS. The clinical trials may evaluate drugs, biologics, devices, or surgical, Behavioral or rehabilitation therapies. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-281 (replaces PAR-10-199).

Closing date: 07 May 15
Deadline information: Application due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 24 Jul 13
OLLABORATIVE CLINICAL VISION RESEARCH PROJECT GRANT (U10): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its collaborative clinical vision research project grant (U10). This AIDS-related U10 funding opportunity announcement supports investigator-initiated clinical vision research projects, including multi-center clinical trials and other complex or high-risk clinical vision research studies. This funding opportunity announcement will use the U10 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-097, PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism. US and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-14-096 (replaces PAR-10-207).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 13 Feb 14
Award type: Research centers, Directed grants to institutions, research groups etc., Clinical trials
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-10-207.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Medicine & Health, HIV/AIDS, Cognitive & Behavioral Therapies, Stroke & Cerebrovascular Disorders, Diagnostic Sciences, Medical Devices, Counseling & Therapy, Public Health, Health Services & Primary Care, Primary Care, Neuroimaging, Neurobiology, Neurosurgery, Drug Design, Neuroscience, Behavioral Medicine, Muscle Diseases, Clinical Medicine, Neuropharmacology, Electrophysiology, Neurology, Pharmacy & Pharmacology, Biological Sciences
FUNCTIONAL GENETICS, EPIGENETICS AND NON-CODING RNAs IN DRUG ADDICTION (R01): AIDS-RELATED
 NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related functional genetics, epigenetics and non-coding RNAs in drug addiction (R01) programme. This Aids-related R01 funding opportunity announcement encourages basic functional genomic research in two areas: functional validation to determine which candidate genes or variants have an authentic role in addictive processes, and detailed elucidation of the molecular pathways and processes modulated by candidate genes or variants, particularly for those genes with an unanticipated role in addiction.

This FOA will use the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-013, which encourages applications under the R21 exploratory/developmental grant mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Applications budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.
Ref: PA-14-014 (reissue of PA-11-033).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 06 Dec 13
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-14-014

Eligibility profile
Country of applicant institution: Any

Disciplines
Immunological & Bioassay Methods, Behavioral Medicine, Proteomics & Molecular Interactions, Neuroimaging, Ribonucleic Acid, RNA, Primary Care, Molecular Genetics, Neurotransmitters, Biological Sciences, Public Health, Health Services & Primary Care, Diagnostic Sciences, HIV/Aids, Biological Markers & Sensor Mechanisms, Addiction, Biochemical Markers, Electrophysiology, Disease Models, Psychology, Physiology, Pharmacokinetics, Epigenetics, Drug & Substance Abuse, Genomics

Contact Details
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
GRAND OPPORTUNITY IN MEDICATIONS DEVELOPMENT FOR SUBSTANCE-USE DISORDERS (U01): AIDS RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its related grand opportunity in medications development for substance-use disorders (U01). This Aids-related U01 funding opportunity announcement will support a diverse array of preclinical and clinical projects to accelerate the development of medication for the treatment of substance-use disorders. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to approval by the US Food and Drug Administration. The aim is to enable critical medications development studies that would not be possible using traditional means.
Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.
The NIH intends to commit US$10 million to fund two to three awards in fiscal year 2013. Application budgets are limited to US$5m a year over a three-year period. PAR-13-270

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization.
Posted date: 12 Jul 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $15,000,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-270

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Human Biological Sciences, Primary Care, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Diagnostic Sciences, Clinical Pharmacy & Pharmacology, Pharmacy & Pharmacology, HIV/Aids, Clinical Medicine, Drug & Substance Abuse, Drug Design

Contact Details
----------------------------------------------
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
NIDA
NIH
9000 Rockville Pike
Bethesda, MD 20892
Tel: 1 301 443 8639
Email: imontoya@mail.nih.gov
FAMILY AND INTERPERSONAL RELATIONSHIPS IN AN AGEING CONTEXT (R01):
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its family and interpersonal relationships in an ageing context (R01) grants. This Aids-related R01 funding opportunity announcement encourages innovative, hypothesis-driven research that can expand understanding of the role and impact of families and interpersonal relationships on health and well-being in midlife and older age. This FOA encourages research that takes a life span perspective, including studies which focus on early life influences on later life outcomes and on processes in midlife that impact subsequent trajectories of health and function. NIA is particularly interested in research that can inform the design of interventions that target the maintenance and improvement of ageing-relevant outcomes for the following: satisfying, high quality intimate relationships, compliance and adherence to healthy Behaviors; adaptive caregiving relationships, shared decision-making and economic security.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must Contact Details NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Ref: PA-15-042 (reissue of PA-11-128).

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 21 Nov 14
Award type: Innovation grants, Directed grants to institutions, research groups etc.

Eligibility profile

Country of applicant institution: Any
Disciplines
Psychology of Ageing, HIV/Aids, Geriatrics & Gerontology

Contact Details

National Institute on Aging
NIH
GWY BG Room 533
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: 1 301 402 4156
Email: melissa.gerald@nih.gov
PREDICTIVE MULTISCALE MODELS FOR BIOMEDICAL, BIOLOGICAL, BEHAVIORAL, ENVIRONMENTAL AND CLINICAL RESEARCH (INTERAGENCY U01): AIDS-RELATED

NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
A total of 23 participating institutes and centers of the National Institutes of Health, the US Army Research Office, the Department of Energy, the US Food and Drug Administration, the National Aeronautics and Space Administration, the National Science Foundation and the Office of Naval Research invite applications for their predictive multi scale models for biomedical, biological, Behavioral, environmental and clinical research (interagency U01) grants. This AIDS-related funding opportunity aims to support the development of multi scale models to accelerate biological, biomedical, Behavioral, environmental and clinical research. This FOA supports the development of non-standard modeling methods and experimental approaches to facilitate multi scale modeling and active participation in community-driven activities through the Multiscale Modeling Consortium.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Direct costs are limited to US$500,000 per year and the maximum project period is five years.

Ref: PAR-15-085 (Reissue of PAR-11-203)

Closing date: 07 May 15
Deadline information: Applications open on 9 February 2015 and are due by 5 pm local applicant’s time every 7 January, 7 May and 7 September till 8 January 2018.

Posted date: 09 Jan 15

Award type: Innovation grants, Networking/collaboration, Directed grants to institutions, research groups etc.
Award amount max: $2,500,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Models, Mathematical, Bio molecular Modeling, Data Analysis, Computer Simulation & Modeling, Computational Biology, Disease Models, HIV/AIDS

Contact Details

NIBIB
BG 2 Dem Room 200
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 451 4778
Email: grace.peng@nih.gov
Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their AIDS-related spatial uncertainty: data, modeling and communication (R01) grants. This AIDS-related R01 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualize the nature and consequences of spatial uncertainty.

This FOA uses the NIH research project grant (R01) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-011, that solicit applications under the exploratory and developmental grant (R21) and the small grant award (R03) mechanisms, respectively. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-010 (replaces PA-11-238).

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization every, 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 13 Oct 14

Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-15-010

Eligibility profile

Country of applicant institution: Any

Disciplines

Preventive Medicine, Diagnostic Sciences, Disease Control, Public Health, Health Services & Primary Care, Social Work & Social Policy, Libraries & Information Science, HIV/AIDS, Demography, Health Systems, Risk Management, Informatics & Big Data, Prognosis & Natural History of Disease, Computer Science & Informatics, Primary Care, Health Informatics, Blood Tests, Epidemiology, Bioinformatics, Population Studies, Medical, Clinical Medicine

Contact Details

NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: 1 240 276 6851
Email: li.zhu@nih.gov
PATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R21) AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their AIDS-related spatial uncertainty: data, modeling and communication (R21) grants. This AIDS-related R21 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualize the nature and consequences of spatial uncertainty.

This FOA uses the NIH exploratory and developmental grant (R21) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-010 and PA-15-011, that solicit applications under the research project grant (R01) award and the small grant (R03) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Funding is worth up to US$275,000 over a maximum two-year project period.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2018.

Award type: Directed grants to institutions, research groups etc.

Award amount max: $275,000

Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Epidemiology, Clinical Medicine, Population Studies, Medical, Bioinformatics, Informatics & Big Data, Health Systems, Risk Management, Blood Tests, Computer Science & Informatics, Health Informatics, Primary Care, Prognosis & Natural History of Disease, Public Health, Health Services & Primary Care, Preventive Medicine, Diagnostic Sciences, Disease Control, Demography, HIV/Aids, Libraries & Information Science, Social Work & Social Policy

Contact Details

NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: 1 240 276 6851
Email: li.zhu@nih.gov
**SPATIAL UNCERTAINTY: DATA, MODELING AND COMMUNICATION (R03) AIDS-RELATED**

**NIH: National Cancer Institute**

**Description:**
The National Cancer Institute and the National Institute of Environmental Health Sciences invite applications for their AIDS-related spatial uncertainty: data, modeling and communication (R03) grants. This AIDS-related R03 funding opportunity announcement supports research that identifies sources of spatial uncertainty in public health data, incorporates the inaccuracy or instability into statistical methods and develops novel tools to visualize the nature and consequences of spatial uncertainty.

This FOA uses the NIH small grant (R03) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-009 and PA-15-010, that solicit applications under the exploratory and developmental grant (R21) and the research project grant (R01) award mechanisms, respectively. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Funding is worth up to US$50,000 per year over a maximum two-year project period.


**Closing date:** 07 May 15

**Deadline information:** Applications open on 16 January 2015 and are due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September annually until 8 January 2018.

**Posted date:** 13 Oct 14

**Award type:** Directed grants to institutions, research groups etc.

**Award amount max:** $100,000


**Application form:** http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-15-011

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Prognosis & Natural History of Disease, Computer Science & Informatics, Health Informatics, Health Systems, Risk Management, Informatics & Big Data, Social Work & Social Policy, Bioinformatics, Population Studies, Medical, Libraries & Information Science, Demography, HIV/AIDS, Preventive Medicine, Disease Control, Public Health, Health Services & Primary Care, Epidemiology, Primary Care

**Contact Details**

NCI
6116 Executive Boulevard, Room 504
Bethesda, MD 20852
Tel: 1 240 276 6851
Email: li.zhu@nih.gov
MACHANISTIC STUDIES OF PAIN AND ALCOHOL DEPENDENCE (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related mechanistic studies of pain and alcohol dependence (R01) research project grant. This Aids-related R01 funding opportunity announcement supports research in the mechanistic studies on the relationship between excessive alcohol drinking, alcohol dependence and pain with the aim of understanding genetic, pharmacological and learning mechanisms underlying the association between the propensity to drink alcohol excessively and pain responses. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Applicants requesting US$500,000 or more in direct costs in any year, excluding consortium facilities and administrative costs, must Contact Details NIH programme staff at least six weeks before submitting the application. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions.

Closing date: 07 May 15
Deadline information: Applications are invited between 5 January and 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 13 Nov 14
Award type: Directed grants to institutions, research groups etc.
Award budget total: -

Eligibility profile
Country of applicant institution: Any

Disciplines
Alcoholism, Chronic Pain, Pain Management, HIV/Aids

Contact Details
NIAAA
BG 5635FL RM 2052
5635 Fishers Ln
Rockville, MD 20852
Tel: 1 301 443 1192
Email: regunathans@mail.nih.gov

TARGETED BASIC BEHAVIORAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic Behavioral and social science and intervention development for HIV

ARXITECTED BASIC BEHAVIORAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic Behavioral and social science and intervention development for HIV
targeted basic Behavioral and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas. This FOA encourages research designed to:

- conduct basic Behavioral and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalize the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH research (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-128, that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The total project period may not exceed five years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. Ref: PA-14-127 (replaces PA-11-275).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-127.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Counseling, Health Systems, Biomedical Engineering, Preventive Medicine, Diagnostic Sciences, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Clinical Medicine, HIV/AIDS, Social Work & Social Policy, Psychology, Behavioral Medicine, Primary Care

Contact Details
NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: 1 301 433 6100
Email: ebrouwer@mail.nih.gov

TARGETED BASIC BEHAVIORAL AND SOCIAL SCIENCE AND INTERVENTION DEVELOPMENT FOR HIV PREVENTION AND CARE (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their targeted basic Behavioral and social...
science and intervention development for HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to provide a global outline of areas for innovative, targeted basic Behavioral and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.

This FOA encourages research designed to:

- conduct basic Behavioral and social science research that is needed to advance the development of HIV prevention and care interventions;
- translate and operationalize the findings from these basic studies to develop interventions and assess their feasibility;
- conduct tests of the efficacy of HIV prevention and care interventions.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-127, that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US$275,000 over a two year project period, with no more than US$200,000 allowed in any single year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. Ref: PA-14-128 (replaces PA-11-277).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-128.html
Application form: http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-128

Eligibility profile
---------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------
Psychology, Clinical Medicine, Health Systems, Primary Care, Health Counseling, Behavioral Medicine, Social Work & Social Policy, HIV/AIDS, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Biomedical Engineering

Contact Details
---------------------------------------------
NIMH
NSC BG
Room 6118
6001 Executive Boulevard
Rockville MD 20852
Tel: 1 301 433 6100
Email: ebrouwer@mail.nih.gov

SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIORAL AND SOCIAL SCIENCES (R01): AIDS-RELATED
NIH: Office of the Director

Description:
A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the Behavioral and social sciences
A compilation of the Research Services of the Office of Research, Innovation & Development (ORID)


SYSTEMS SCIENCE AND HEALTH IN THE BEHAVIORAL AND SOCIAL SCIENCES (R21): AIDS-RELATED
NIH: Office of the Director

Description:
A total of 11 participating institutes of the National Institutes for Health invite applications for their systems science and health in the Behavioral and social sciences (R21) grants. This Aids-related R21 funding opportunity announcement seeks to increase

(R01) grants. This Aids-related R01 funding opportunity announcement seeks to increase the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human Behavioral or social science focus and employ methodologies suited to addressing the complexity inherent in Behavioral and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modeling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

This funding opportunity announcement uses the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-047 that solicits applications under the exploratory/developmental research grant award (R21) mechanism. Application budgets are not limited but need to reflect actual needs of the proposed project. Applicants requesting US$500,000 or more in direct costs in any year must Contact Details NIH programme staff at least six weeks before submitting the application. The maximum project period is five years.

Closing date: 07 May 15
Deadline information: Applications are invited between 5 January and 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 24 Nov 14
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Social Sciences, Research Methods in Sociology, HIV/Aids, Behavioral Studies & Social Problems
Contact Details
----------------------------------------------
NCI
BG 9609 Room 3E602
9609 Medical Center DR
Rockville, MD 20850
Tel: 1 301 402 1146
Email: wireley@mail.nih.gov
the breadth and scope of topics that can be addressed with systems science methodologies. This FOA calls for research projects that are applied or basic in nature, including methodological and measurement development, have a human Behavioral or social science focus and employ methodologies suited to addressing the complexity inherent in Behavioral and social phenomena, referred to as systems science methodologies. Additionally, this FOA seeks to promote interdisciplinary collaboration among health researchers and experts in computational approaches to further the development of modeling- and simulation-based systems science methodologies and their application to important public health challenges. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. This funding opportunity announcement uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-15-048 that solicits applications under the research project grant award (R01) mechanism. Application budgets are limited to US$275,000 over the two-year R21 period, with no more than US$200,000 in any year. The maximum project period is two years.


Closing date: 07 May 15

Deadline information: Applications are invited between 16 January and 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 24 Nov 14

Award type: Directed grants to institutions, research groups etc.

Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Social Sciences, Behavioral Studies & Social Problems, HIV/Aids, Research Methods in Sociology

Contact Details

NCI
BG 9609 Room 3E602
9609 Medical Center DR
Rockville MD 20850
Tel: 1 301 402 1146
Email: wireley@mail.nih.gov

BUILDING GENETICS AND GENOMIC KNOWLEDGE ABOUT DENTAL, ORAL AND CRANIOFACIAL DISEASES AND DISORDERS (R01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its building a genetic and genomic knowledge base in dental, oral and craniofacial diseases and disorders (R01) grants. This Aids-related R01 funding opportunity announcement encourages research into dental, oral, and craniofacial diseases and disorders for which
there is evidence for genetic heritability but for which there is no strong understanding of the genetics or genomics of the disease or disorder. Research areas may include identification of promising areas of the genome, and characterization and elucidation of the functions of genetic variants that affect disease risk in humans. The goal is to drive development of effective diagnostic, therapeutic, and preventive approaches. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. The maximum project period is five years. Ref: PA-14-347 (replaces PA-11-317).

Closing date: 07 May 15
Deadline information: Applications open on 28 October 2014 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 23 Sep 14
Award type: Directed grants to institutions, research groups etc
Website: 
Application form: 
http://www.grants.gov/web/grants/applicants/download-application-

Eligibility profile
Country of applicant institution: Any
Disciplines
Quantitative Genetics, Special Needs Dentistry, Cancer Genetics, Genomics, Human Genome, Medical Genetics, Allied Health Professions, Dentistry, Biological Sciences, Public Health, Health Services & Primary Care, Preventive Medicine, Diagnostic Sciences, Genetics & Systems Biology, Population & Ecological Genetics, HIV/Aids, Medicine & Health, Clinical Medicine, Craniofacial Disorders, Preventive Dentistry, Genetic Diseases, Primary Care, Oral Medicine

Contact Details
NIDCR
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda, MD 20892-6400
Tel: 1 301 594 4846
Email: emily.harris@nih.gov

**HEALTHY HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIORS IN CHILDREN AND ADOLESCENTS (R01): AIDS-RELATED**

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their Aids-related healthy habits: timing for developing sustainable healthy Behaviors in children and adolescents (R01) grants. This R01 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of influence and promote positive sustainable health Behavior in children and youth up to the age of 21. Applications to promote positive health Behavior should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and
mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy Behavior choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health Behaviors;
- the role of technology and new media in promoting healthy Behavior;
- identification of factors that support healthy Behavior development in vulnerable populations, identification of barriers to healthy Behaviors;
- identification of mechanisms and mediators that are common to the development of a range of habitual health Behaviors.

Given the many factors involved in developing sustainable health Behaviors, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-177 (Reissue of PA-11-327).

Closing date: 07 May 15
Deadline information: Deadlines every 7 May, 7 September and 7 January until 8 May 2017.
Posted date: 22 Apr 14

Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-177.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------

Contact Details
----------------------------------------------
Tel: 1 301 594 6908
Email: mary.roary@nih.gov

H
E
A
L
T
H
Y
_HABITS: TIMING FOR DEVELOPING SUSTAINABLE HEALTHY BEHAVIORS IN CHILDREN AND ADOLESCENTS (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their Aids-related healthy habits: timing for developing sustainable healthy Behaviors in children and adolescents (R21) grants. This AIDS-related R21 funding opportunity announcement encourages applications that employ innovative research to identify mechanisms of
influence and promote positive sustainable health behavior in children and youth up to the age of 21. Applications to promote positive health behavior should target social and cultural factors, including schools, families, communities, population, food industry, age-appropriate learning tools and games, social media, social networking, technology and mass media. Topics to be addressed in this announcement include:

- effective, sustainable processes for influencing young people to make healthy behavior choices;
- identification of the appropriate stage of influence for learning sustainable lifelong health behaviors;
- the role of technology and new media in promoting healthy behavior;
- identification of factors that support healthy behavior development in vulnerable populations, identification of barriers to healthy behaviors;
- identification of mechanisms and mediators that are common to the development of a range of habitual health behaviors.

Given the many factors involved in developing sustainable health behaviors, applications from multidisciplinary teams are strongly encouraged. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-176 (Reissue of PA-11-329).

Closing date: 07 May 15

Deadline information: Deadlines every 16 February, 16 June and 16 October until 8 May 2017.
EFFECTS OF ADOLESCENT BINGE DRINKING ON BRAIN DEVELOPMENT (R21):
AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related effects of adolescent binge drinking on brain development (R21) grants. The objective of this AIDS-related R21 funding opportunity announcement is to promote research in animal models on the genetic, molecular and cellular mechanisms underlying the effects of excessive alcohol consumption on specific aspects of adolescent brain development. Researchers should conduct mechanistic studies on the effects of adolescent binge alcohol consumption on synaptic maturation and myelin formation in the developing brain. Studies examining the trajectory of ethanol-related effects from adolescence through adulthood are particularly encouraged.

This funding opportunity announcement utilizes the NIH exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-027, that solicits applications under the research project grant (R01) mechanism. Direct costs are limited to $275,000 over the two-year project period, and no more than $200,000 may be requested in any single year. The maximum project period is two years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-028

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.

Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-028](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-028)

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biological Sciences, Nucleus & Organelles, Molecular Genetics, Medical Genetics, Alcoholism, Psychology, Behavioral Studies & Social Problems, Central Nervous System, Diagnostic Sciences, Biochemistry & Molecular Biology, Genetics & Systems Biology, Youth & Adolescents, Physiology, Social Work & Social Policy, HIV/Aids, Animal Models, Sociology

Contact Details
----------------------------------------------
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane
Bethesda, MD 20892-9304
Tel: 1 301 443 9334
Email: baizerl@mail.nih.gov
HIGH THROUGHPUT SCREENING TO DISCOVER CHEMICAL PROBES (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
A total of 11 components of the National Institutes of Health invites applications for their solicitation of high throughput screening to discover chemical probes (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigators to form collaborations with an established academic, non-profit or commercial high throughput screening facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in:

• discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH institutes;
• discovery or validation of novel, biological targets that will inform studies of disease mechanisms.

Emphasis will be placed on assays that provide new insight into important disease targets and processes.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period may not exceed three years.
Ref: PAR-14-284 (replaces PAR-12-058).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 September, 7 January and 7 July until 8 September 2017.
Posted date: 18 Jul 14

Award type: Directed grants to institutions, research groups etc., Networking/collaboration
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-284.html
Application form: http://www.grants.gov/web/grants/applicant/package.html#download=true&oppNum=PAR-14-284

Eligibility profile
Country of applicant institution: Any

Disciplines
Physiology, Medicine & Health, HIV/Aids, Diagnostic Sciences, Medicinal Chemistry, Public Health, Health Services & Primary Care, Nursing, Translational Medicine, Molecular Probes, Primary Care, Human Biological Sciences, Screening for Diseases, Immunological & Bioassay Methods, Disease Models, Chemistry, Clinical Medicine, Dentistry, Allied Health Professions, Pharmacy & Pharmacology

Contact Details
National Institute of Mental Health
Division of Neuroscience and Basic Behavior Science
6001 Executive Boulevard, Room 7175, MSC 9641
Bethesda, MD 20892-9641
Tel: 1 301 443 6102
Email: yyao@mail.nih.gov
Biomechanisms of Peripheral Nerve Damage by Anti-Cancer Therapy (R01): AIDS-Related

NIH: National Cancer Institute

Description:
The National Cancer Institute and National Institute of Neurological Disorders and Stroke invite applications for their AIDS-related bio mechanisms of peripheral nerve damage by anti-cancer therapy (R01) grants. The purpose of this AIDS-related R01 funding opportunity announcement is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy. The majority of acquired peripheral research has focused on diabetic and inherited diseases and this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental CIPN initiation and maintenance. NCI and NINDS invites preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anaesthesias. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevent CIPN. This FOA will utilize the NIH research project grant (R01) award mechanism and runs in parallel with an FOAs of identical scientific scope, PA-12-083, which solicits applications under the exploratory/developmental grant (R21) research grant award mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-082.

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 18 Jan 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-082.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-082

Eligibility profile

Country of applicant institution: Any

Disciplines

Medicine & Health, HIV/Aids, General Practice, Carcinogenesis, Pharmaceutical Drugs, Chemotherapy, Biomechanics, Cancer Studies & Oncology, Central Nervous System, Pharmacy & Pharmacology

Contact Details

Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 2014, MSC 7340
Bethesda, MD 20892-7340
Tel: 1 301 496 8541
Email: breljm@mail.nih.gov
Description:
The National Cancer Institute and National Institute of Neurological Disorders and Stroke invite applications for their Aids-related biomechanisms of peripheral nerve damage by anti-cancer therapy (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to encourage basic biologic research on damage to the peripheral nervous system instigated by pharmacologic cancer treatments, known as chemotherapy-induced peripheral neuropathy. The majority of acquired peripheral research has focused on diabetic and inherited diseases and this FOA intends to stimulate neuroscience researchers to apply their expertise from studying these other neuropathies to the injuries incurred by cancer treatments. More data is necessary to understand the mechanisms of neuronal damage and to identify the targets instrumental CIPN initiation and maintenance. NCI and NINDS invites preclinical research that focuses not only on peripheral neuropathic pain but also on neurosensory symptoms such as paresthesias and peripheral anaesthesias. The ultimate goal of this FOA is to lead to a molecular understanding of CIPN that allows for the rational development of interventions that will treat or prevent CIPN.

This FOA will utilize the NIH exploratory/developmental (R21) research grant award mechanism and runs in parallel with an FOAs of identical scientific scope, PA-12-082, which solicits applications under the research project (R01) grant mechanism. Application budgets are limited to $275,000 over a two-year project period, and no more than $200,000 may be requested in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-083.

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 18 Jan 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-083.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-083

Eligibility profile
Country of applicant institution: Any

Disciplines
Cancer Studies & Oncology, Central Nervous System, HIV/AIDS, General Practice, Pharmacy & Pharmacology, Carcinogenesis, Pharmaceutical Drugs, Chemotherapy, Biomechanics

Contact Details
Division of Cancer Prevention
National Cancer Institute
6130 Executive Boulevard, EPN Room 2014, MSC 7340
Bethesda, MD 20892-7340
Tel: 1 301 496 8541
Email: breljm@mail.nih.gov
Research on the Health of LGBTI Populations (R03): AIDS-Related
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of 11 component organizations of the National Institutes of Health invite applications for their AIDS-related research on the health of LGBTI populations (R03) grants. This AIDS-related R03 funding opportunity announcement solicits grant applications for research that describes the biological, clinical, behavioral and social processes that affect the health and development among lesbian, gay, bisexual, transgender, intersex and related populations and among their families, and that leads to the development of effective supportive, preventive and treatment interventions and health service delivery methods to enhance the health and development of these populations. Research must focus on clearly defined health outcomes to be responsive to this FOA. Three types of research are included within this FOA:
- formative research that will design and pilot test new interventions;
- large-scale implementation and evaluation of preventive or treatment interventions that are evidence based;
- adaptations of current interventions that are based on strong rationales, including pilot data.

This FOA uses the NIH research project (R03) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-111 that encourages applications under the NIH research project grant (R01) mechanism and PA-12-113 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism.

Application budgets are limited to $50,000 in direct costs per year over a two-year project period. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-112 (replaces PA-07-409).

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 27 Feb 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-112.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-112

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Prejudice & Discrimination, Sociology, HIV/AIDS, Health Disparities, Psychiatry, Public Health, Health Services & Primary Care, Lesbian, Gay, Bisexual & Transgender Studies, Medical Sociology, Mental Illness, Behavioral Medicine, Drug & Substance Abuse, Gender Roles & Sexuality, Economic & Social Environment, Psychology, Population Studies, Medical, Addiction, Interpersonal Relationships, Mental Health, Alcoholism, Allied Health Professions

Contact Details
----------------------------------------------
Demographic and Behavioral Sciences Branch NICHD
6100 Executive Boulevard, Room 8B07
Rockville, MD 20852
Tel: 1 301 435 6981
Email: newcomes@nih.gov
Description:
A total of 11 component organizations of the National Institutes of Health invite applications for their Aids-related research on the health of LGBTI populations (R21) grants. This Aids-related R21 funding opportunity announcement solicits grant applications for research that describes the biological, clinical, behavioral and social processes that affect the health and development among lesbian, gay, bisexual, transgender, intersex and related populations and among their families, and that leads to the development of effective supportive, preventive and treatment interventions and health service delivery methods to enhance the health and development of these populations. Research must focus on clearly defined health outcomes to be responsive to this FOA. Three types of research are included within this FOA:

• formative research that will design and pilot test new interventions;
• large-scale implementation and evaluation of preventive or treatment interventions that are evidence based;
• adaptations of current interventions that are based on strong rationales, including pilot data.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-12-111 that encourages applications under the NIH research project grant (R01) mechanism and PA-12-112 that encourages applications under the NIH small grant program (R03) mechanism.

Application budgets are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-113 (replaces PA-07-409).

Closing date: 07 May 15
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-113.html
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-113

Eligibility profile
Country of applicant institution: Any

Disciplines
Behavioral Medicine, Gender Roles & Sexuality, Economic & Social Environment, Lesbian, Gay, Bisexual & Transgender Studies, Medical Sociology, Psychiatry, Public Health, Health Services & Primary Care, Interpersonal Relationships, Mental Health, Alcoholism, Allied Health Professions, Prejudice & Discrimination, Psychology, Population Studies, Medical, Addiction, Sociology, HIV/AIDS, Health Disparities, Drug & Substance Abuse, Mental Illness

Contact Details
Demographic and Behavioral Sciences Branch
NICHD
6100 Executive Boulevard, Room 8B07
Rockville, MD 20852
Tel: 1 301 435 6981
Email: newcomes@nih.gov
IDCR SMALL RESEARCH GRANTS FOR ORAL HEALTH DATA ANALYSIS AND
STATISTICAL METHODOLOGY DEVELOPMENT (R03): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its Aids-related small research grants for oral health data analysis and statistical methodology development (R03). The goal of this Aids-related R03 funding opportunity announcement is to support meritorious research projects that involve secondary data analyses using existing oral or craniofacial database resources or to develop needed statistical methodology for analyzing oral and craniofacial data using existing databases. This program announcement will use the NIH small research grant R03 award mechanism, and supports research specifically limited in time and amount for studies in categorical programme areas. A total project period of up to two years and a budget for direct costs of up to US$100,000 per year may be requested. Eligible organizations include domestic or foreign for-profit and non-profit organizations and public or private institutions. PAR-12-120 (replaces PAR-09-182).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 September 2015.

Posted date: 16 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $200,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-120.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-120

Eligibility profile
Country of applicant institution: Any
Disciplines
Data Analysis, Dentistry, Oral Medicine, HIV/AIDS

Contact Details
National Institute of Dental and Craniofacial Research
6701 Democracy Blvd, Room 640, MSC 4878
Bethesda, MD 20892-4878
Tel: 1 301 594 4876
Email: dena.fischer@nih.gov

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol and Tobacco Abuse (R34): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism invite applications for their Aids-related pilot health services and economic research on the treatment of drug, alcohol and tobacco abuse (R34). The purpose of this Aids-related R34 funding opportunity announcement is to encourage pilot or preliminary research on:
organizational or systems-level interventions that may optimize access, utilization, delivery, quality or cost of treatment services for drug, tobacco or alcohol abuse or dependence through the use of evidence-based practices;  
• organizational or systems-specific adaptations to existing evidence-based practices necessary to facilitate their implementation in these new contents;  
• novel service delivery models to be pilot-tested in preparation for larger-scale effectiveness trials. 
The ultimate goal is to facilitate the uptake of scientifically supported interventions.  
This FOA uses clinical trial planning grant funding mechanism. Applications budgets may not exceed US$450,000 in direct costs over a three year project period, and no more than US$225,000 is allowed in any year. Domestic and foreign for-profit and not-for-profit organizations and public or private institutions are eligible to apply. PA-12-130.

Closing date: 07 May 15  
Deadline information: Deadline: every January 7, May 7 and September 7 until May 8, 2015.  
Posted date: 20 Mar 12  
Award type: Directed grants to institutions, research groups etc.  
Award amount max: $450,000

Website:  
http://grants.nih.gov/grants/guide/pa-files/PA-12-130.html  
Application form:  
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-130

Eligibility profile  
----------------------------------------------  
Country of applicant institution: Any  
Disciplines  
----------------------------------------------  
Economics & Econometrics, Drug & Substance Abuse, Smoking & Tobacco, HIV/Aids, General Practice, Accounting & Finance, Psychology, Access to Health Care, Biomedical Engineering, Alcoholism, Health Systems, Administration, Public Health, Health Services & Primary Care, Primary Care, Human Biological Sciences, Health Economics  
Contact Details  
----------------------------------------------  
Services Research Branch  
Division of Epidemiology, Services & Prevention Research  
NIDA  
6001 Executive Boulevard  
Bethesda, MD 20892-9561  
Tel: 1 301 443 6504  
Email: lori.ducharme@nih.gov

TRANSLATIONAL RESEARCH AT THE AGEING/CANCER INTERFACE (R01): AIDS-RELATED  
NIH: National Institute on Aging

Description:  
The National Institute on Aging and the National Cancer Institute invite applications for their Aids-related translational research at the ageing/cancer interface (R01) grants. This Aids-related R01 funding opportunity announcement encourages translational research proposals in the overlapping areas of human ageing and cancer, linking basic and clinical research relevant to the care of older cancer patients. Ultimately, information from the research supported by this initiative should improve the health and well-being of
elderly patients at risk for, or diagnosed with, cancer and decrease the functional impairment and morbidity associated with cancer in this population. Highlighted areas for this FOA include:

- early detection and diagnosis;
- treatment efficacy and tolerance;
- comorbidity and cancer treatment;
- ageing and cancer pharmacology;
- cancer survivorship health issues.

This funding opportunity uses the research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-12-135, which encourages applications under the NIH exploratory/developmental (R21) mechanism. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign not-for-profit or for-profit organizations and public or private institutions. PA-12-136 (replaces PA-08-230).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 22 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-136

Eligibility profile
Country of applicant institution: Any

Disciplines
Ovarian & Cervical Cancers, Cancer Studies & Oncology, Leukaemia & Other Blood Cancers, Lung Cancer, Physiology, Geriatrics & Gerontology, Clinical Medicine, HIV/Aids, Diagnostic Sciences, Melanoma & Other Skin Cancers, Prostate & Testicular Cancers, Public Health, Health Services & Primary Care, Breast Cancer, Carcinogenesis, Colorectal, Pancreatic & Stomach Cancers, Primary Care

Contact Details
Division of Geriatrics and Clinical Gerontology
National Institute on Aging
Building 31, Room 5C27
31 Center Drive, MSC 2292
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: eldadahb@nia.nih.gov

TRANSLATIONAL RESEARCH AT THE AGEING/CANCER INTERFACE (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Cancer Institute invite applications for their Aids-related translational research at the ageing/cancer interface (R21) grants. This Aids-related R21 funding opportunity announcement encourages translational research proposals in the overlapping areas of human ageing and cancer, linking basic and clinical research relevant to the care of older cancer patients. Ultimately, information from the research supported by this initiative should improve the health and well-being of elderly patients at risk for, or diagnosed with, cancer and decrease the functional...
improvement and morbidity associated with cancer in this population. Highl

ted areas for this FOA include:
• early detection and diagnosis;
• treatment efficacy and tolerance;
• comorbidity and cancer treatment;
• ageing and cancer pharmacology;
• cancer survivorship health issues.

This funding opportunity uses the NIH exploratory/developmental (R21) mechanism and runs in parallel with one of identical scientific scope, PA-12-136, that encourages applications under the research project grant (R01) mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-135 (replaces PA-08-231).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 22 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

---

**ENVIRONMENTAL EXPOSURES AND HEALTH: EXPLORATION OF NON-TRADITIONAL SETTINGS (R01): AIDS-RELATED**

**NIH: National Institute of Nursing Research**

**Description:**
The National Institute of Nursing Research and the National Institute of Environmental Health Research invite applications for their Aids-related environmental exposures and health: exploration of non-traditional settings (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks,
symptoms and other health conditions including lower respiratory diseases, chronic obstructive pulmonary disease and cardiovascular diseases. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family and community which will advance nursing science.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope: PA-12-134 that solicits applications under the exploratory/developmental grant (R34) mechanism. Application budgets are not limited, but must reflect the actual needs of the project. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-133.

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Mar 12

Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-133.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-133

Eligibility profile
Country of applicant institution: Any
Disciplines
Respiratory Medicine, Environmental & Occupational Health & Safety, Clinical Medicine, Environmental Medicine, Chronic Care, Economic & Social Environment, Nursing, Primary Care, Public Health, Health Services & Primary Care, Preventive Medicine, Cardiovascular Diseases, Health Disparities, HIV/AIDS, Medicine & Health

Contact Details
Office of Extramural Activities
NINR
Tel: 1 301 594 5970
Email: hussk@mail.nih.gov

Environment exposure and health: exploration of non-traditional settings (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research and the National Institute of Environmental Health Research invite applications for their Aids-related environmental exposures and health: exploration of non-traditional settings (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to encourage interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms and other health conditions including lower respiratory diseases, chronic obstructive pulmonary disease and cardiovascular diseases. Risk identification and symptom management include prevention and behavior changes and actions.
to maintain health and prevent disease with an emphasis on the individual, family and community which will advance nursing science.

This funding opportunity announcement will use the NIH exploratory/developmental grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope: PA-12-133 that solicits applications under the research project grant (R01) mechanism. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-12-134.

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: [http://grants.nih.gov/grants/guide/pa-files/PA-12-134.html](http://grants.nih.gov/grants/guide/pa-files/PA-12-134.html)

**Application form:**
[http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-134](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-134)

Eligibility profile

Country of applicant institution: Any

**Disciplines**

Chronic Care, Nursing, Public Health, Health Services & Primary Care, Respiratory Medicine, Preventive Medicine, Environmental & Occupational Health & Safety, Cardiovascular Diseases, Health Disparities, HIV/Aids, Clinical Medicine, Medicine & Health, Environmental Medicine, Economic & Social Environment, Primary Care

**Contact Details**

Office of Extramural Activities
NINR
Tel: 1 301 594 5970
Email: hussk@mail.nih.gov

---

**PILOT AND FEASIBILITY CLINICAL RESEARCH STUDIES IN DIGESTIVE DISEASES AND NUTRITION (R21): AIDS-RELATED**

**NIH: National Cancer Institute**

**Description:**
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Cancer Institute and the Office of Dietary Supplements invite proposals for their Aids-related pilot and feasibility clinical research studies in digestive diseases and nutrition (R21) grants. The goal of this Aids-related R21 funding opportunity announcement is to encourage pilot and feasibility clinical and epidemiological research studies of new therapies or means of health promotion and prevention of digestive and liver diseases and nutritional disorders associated with digestive and liver diseases.

Domestic and foreign for-profit or non-profit organizations and public or private institutions are eligible to apply. A maximum of up US$275,000 is available over a R21 two-year period, with no more than US$200,00 in any year. PA-12-139 (replaces PA-09-151).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 26 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: [http://grants.nih.gov/grants/guide/pa-files/PA-12-139.html](http://grants.nih.gov/grants/guide/pa-files/PA-12-139.html)

Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-139](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-139)

Eligibility profile

Country of applicant institution: Any

Disciplines

Diagnostic Sciences, Preventive Medicine, Bowel Diseases, Public Health, Health Services & Primary Care, Gastroenterology, Primary Care, Nutrition & Dietetics, Hepatology, Allied Health Professions, Epidemiology, Clinical Medicine

Contact Details

Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases 6707 Democracy Boulevard, Room 681 Bethesda, MD 20892-5450 Tel: 1 301 594 4578 Fax: 1 301 480 8300 Email: evansmary@niddk.nih.gov

RESEARCH ON EMERGENCY MEDICAL SERVICES FOR CHILDREN (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development and the National Institute of Mental Health invite applications for their Aids-related research on emergency medical services for children (R01) grants. This Aids-related R01 funding opportunity announcement is designed to improve the quality and quantity of research related to EMSC, with the goal of reducing morbidity and mortality in children through improved care delivery. This FOA invites the submission of applications dealing with the following areas of research included under the term EMSC: Prevention research to reduce the need for emergency care;
• clinical research to ensure that children receive high-quality and appropriate medical, nursing and mental health care in an emergency;
• health systems research, from pre-hospital care, to the emergency department, to in-patient care and return to the community;
• models to improve service and cost efficiency in paediatric emergency care; and methodological studies to improve the quality of research conducted.

This funding opportunity announcement will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope: PA-12-142 that solicits applications under the exploratory/developmental grant (R21) mechanism. Applications may be submitted by domestic and foreign for-profit or non-profit organizations and public and private institutions. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is five years. PA-12-141 (replaces PAR-08-261).
Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May, and 7 September until 8 May 2015.
Posted date: 30 Mar 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-141.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-141

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Economic & Social Environment, Emergency Medicine, Behavioral Medicine, Primary Care, Traumatology, Accidents & Injury, Epidemiology, Access to Health Care, Health Systems, Administration, Mental Health, Public Health, Health Services & Primary Care, Preventive Medicine, Paediatrics, HIV/AIDS, Clinical Medicine, Psychology, Health Systems

Contact Details
----------------------------------------------
NICHD
6100 Executive Boulevard
Bethesda, MD  20892-7510
Tel: 1 301 435 6881
Email: lh179r@nih.gov

RESEARCH ON EMERGENCY MEDICAL SERVICES FOR CHILDREN (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development and the National Institute of Mental Health invite applications for their Aids-related research on emergency medical services for children (R21) grants. This Aids-related R21 funding opportunity announcement is designed to improve the quality and quantity of research related to EMSC, with the goal of reducing morbidity and mortality in children through improved care delivery. This FOA invites the submission of applications dealing with the following areas of research included under the term EMSC:
• prevention research to reduce the need for emergency care;
• clinical research to ensure that children receive high-quality and appropriate medical, nursing and mental health care in an emergency;
• health systems research, from pre-hospital care, to the emergency department, to in-patient care and return to the community;
• models to improve service and cost efficiency in paediatric emergency care; and methodological studies to improve the quality of research conducted.
This funding opportunity announcement will use the R21 exploratory/developmental grant mechanism, and runs in parallel with an FOA of identical scientific scope: PA-12-141 that solicits applications under the research project grant (R01) mechanism. Applications may be submitted by domestic and foreign for-profit or non-profit organizations and public and private institutions. Direct costs may not exceed US$275,000 over a two-year project
period, with no more than US$200,000 in any year. PA-12-142.

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 30 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-142.html

Disciplines
----------------------------------------------
Traumatology, Accidents & Injury, Primary Care, Behavioral Medicine, Economic & Social Environment, Emergency Medicine, Psychology, Paediatrics, HIV/AIDS, Clinical Medicine, Public Health, Health Services & Primary Care, Preventive Medicine, Epidemiology, Access to Health Care, Mental Health, Health Systems, Administration, Health Systems

Contact Details
----------------------------------------------
NICHD
6100 Executive Boulevard
Bethesda, MD  20892-7510
Tel: 1 301 435 6881
Email: lh179r@nih.gov

M ECHANISMS OF ALCOHOL-ASSOCIATED CANCERS (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Cancer Institute invite applications for their Aids-related mechanisms of alcohol-associated cancers (R01) grants. The goal of this Aids-related R01 funding opportunity announcement is to stimulate a broad range of research into the mechanisms by which alcohol increases cancer risk. Target sites for alcohol-related carcinogenesis include the oral cavity, pharynx, oesophagus, larynx, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption. This funding opportunity will use the R01 award mechanisms and runs in parallel with a funding opportunity of identical scientific scope, PA-12-147, which solicits proposals under the exploratory/developmental grant (R21) mechanism. Eligible organizations include domestic or foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-12-146 (replaces PA-07-069).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 30 Mar 12
Award type: Directed grants to institutions, research groups etc.
M ECHANISMS OF ALCOHOL-ASSOCIATED CANCERS (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Cancer Institute invite applications for their Aids-related mechanisms of alcohol-associated cancers (R01) grants. The goal of this Aids-related R21 funding opportunity announcement is to stimulate a broad range of research into the mechanisms by which alcohol increases cancer risk. Target sites for alcohol-related carcinogenesis include the oral cavity, pharynx, oesophagus, larynx, breast, liver, and colon. A better understanding of the molecular basis by which alcohol increases cancer risk could lead to improved therapeutic approaches and preventative strategies and would provide guidance on safe levels of alcohol consumption.

This funding opportunity will use the exploratory/developmental (R21) grant mechanism, and runs run in parallel with an FOA of identical scientific scope, PA-12-146, that will use the research project grant (R01) mechanism. Applicants may request direct costs of up to US$275,000 over a two-year, with no more than US$200,000 in any single year. Eligible organizations include domestic or foreign for-profit or non-profit organizations and public or private institutions. PA-12-147 (replaces PA-06-270).

Closing date: 07 May 15
Deadline information: Deadline: every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 30 Mar 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-147.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
FUNCTIONS OF SKELETAL MUSCLE BEYOND CONTRACTION (R01): AIDS-RELATED

NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Description:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases invite applications for their Aids-related function of skeleton muscle beyond contraction (R01) grants. This Aids-related R01 funding opportunity announcement will support innovative projects aimed at studying the spectrum of activities of skeletal muscle in health and disease that are beyond the role of contraction and locomotion. These activities include endocrine and paracrine functions of skeletal muscle, resting muscle thermogenesis, sensing of biomechanical stimuli, storing amino acids, regulating systemic metabolism and similar. Advancing understanding of these important functions of muscle may lead to novel strategies for the prevention or treatment of common conditions such as cachexia, obesity, diabetes and sarcopenia. This FOA will use the R01 research project grant and runs in parallel with an FOA of identical scope, PA-12-209, which uses the R21 exploratory/developmental research grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-208.

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc., Innovation grants
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-208.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-208

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Musculoskeletal System, Endocrine & Neuroendocrine Cancers, Diabetes, Human Metabolism, Diagnostic Sciences, Clinical
FUNCTIONS OF SKELETAL MUSCLE BEYOND CONTRACTION (R21): AIDS-RELATED
NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

Description:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases invites applications for its Aids-related function of skeleton muscle beyond contraction (R21) grants. This Aids-related R21 funding opportunity announcement will support innovative projects aimed at studying the spectrum of activities of skeletal muscle in health and disease that are beyond the role of contraction and locomotion. These activities include endocrine and paracrine functions of skeletal muscle, resting muscle thermogenesis, sensing of biomechanical stimuli, storing amino acids, regulating systemic metabolism and similar. Advancing understanding of these important functions of muscle may lead to novel strategies for the prevention or treatment of common conditions such as cachexia, obesity, diabetes and sarcopenia.

This FOA will use the R21 exploratory/developmental research grant award and runs in parallel with an FOA of identical scope, PA-12-208, which uses the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-209.

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 26 Apr 13
Award type: Directed grants to institutions, research groups etc., Innovation grants
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-209.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-209

Eligibility profile
Country of applicant institution: Any

Disciplines
Diabetes, Musculoskeletal System, Endocrine & Neuroendocrine Cancers, Human Metabolism, Diagnostic Sciences, Chemistry, Cell Physiology & Metabolism, HIV/Aids, Clinical Medicine, Muscle Diseases, Hormones & Endocrinology, Osteoporosis & Other Bone Diseases, Biomechanics, Obesity

Contact Details
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Tel: 1 301 594 5055
Email: boycea@mail.nih.gov
DEVELOPMENT AND TESTING OF NOVEL INTERVENTIONS TO IMPROVE HIV PREVENTION, CARE, AND PROGRAMME IMPLEMENTATION (R34)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its development and testing of novel interventions to improve HIV prevention, care and programme implementation funding opportunity announcement. This R34 funding opportunity announcement provides resources to support pilot or feasibility studies of new or adapted interventions to prevent HIV infection among populations where substance use may be a contributing factor; pilot or feasibility studies of new or adapted interventions to improve the care of HIV infection among populations where substance use is prevalent, including interventions that integrate treatment for substance use disorders and HIV infection; or pilot or feasibility studies to increase the scale, uptake, delivery, or quality of HIV prevention or care interventions with established evidence of efficacy. Both primary and secondary prevention will be supported. The full range of substance use will be considered including problematic episodic use and substance use disorders, as well as a full range of substances and modes of administration. The most important consideration is that substance use may affect transmission directly as in the case of injection drug use or may affect transmission risk Behavior. Domestic and overseas populations will be considered, with particular attention to populations with disproportionate burden of HIV infection and those where HIV infection or drug use are emergent.

Direct costs are limited to US$450,000 over a three-year period, with no more than US$225,000 direct costs allowed in any single year. The number of awards is contingent upon NIH appropriations, and the submission of a sufficient number of meritorious applications. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-231

Closing date: 07 May 15
Posted date: 09 Jul 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-231.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-231

Eligibility profile
--------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------
Biomedical Engineering, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, HIV/AIDS, Health Disparities, General Practice, Sociology, Education, Public Health,
PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its Aids-related physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R01) grants. This Aids-related R01 funding opportunity announcement encourages transdisciplinary and translational research that will identify specific biological or bioBehavioral pathways through which physical activity or weight control may affect cancer prognosis and survival. Applications must test these effects among cancer survivors identified by previous animal or observational research, including but not limited to: intervention-induced changes in sex hormones, insulin or insulin-like growth factors or their binding proteins; insulin resistance; glucose metabolism; leptin and other adipokines; immunologic or inflammatory factors; oxidative stress and DNA damage or repair capacity; angiogenesis; prostaglandins. This research will require approaches that bring together Behavioral intervention expertise, cancer biology and other relevant basic or clinical science disciplines.

This FOA will use the R01 award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-229, which solicits proposals under the exploratory/developmental grant (R21) mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-228.

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 12 Jul 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/par-files/PAR-12-228.html
Application form: 
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-228

Eligibility profile
------------------------------------------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
------------------------------------------------------------------------------------------------------------------
Biomedical Engineering, Carcinogenesis, Diagnostic Sciences, Melanoma & Other Skin Cancers, Prostate & Testicular Cancers, Breast Cancer, Inflammation, HIV/Aids, Physiology, Quantitative Genetics, Immunity & Immunogenetics, Chronic Care, Hormones & Endocrinology, Nucleic Acid Analogues, Cancer Studies & Oncology, Stress, Biological, Leukaemia & Other Blood Cancers, Obesity, Human Metabolism, Stress, Psychological, Ribonucleic Acid, RNA, Human Biological Sciences, Deoxyribonucleic Acid, DNA, Brain Cancer, Immunopathology, Colorectal, Pancreatic & Stomach Cancers, Ovarian & Cervical Cancers, Cancer Cell Biology, Biological Sciences, Clinical Medicine, Behavioral Studies & Social Problems, Pathology, Lung Cancer, Psychology, Non-cancerous Tumours

Contact Details
------------------------------------------------------------------------------------------------------------------
Division of Cancer Control and Population Sciences
NCI
6116 Executive Boulevard
Suite 404, MSC 8336
Bethesda, MD 20892-8336
Tel: 1 301 402 1450
Fax: 1 301 594 5070
Email: alfanoc@mail.nih.gov

PHYSICAL ACTIVITY AND WEIGHT CONTROL INTERVENTIONS AMONG CANCER SURVIVORS: EFFECTS ON BIOMARKERS OF PROGNOSIS AND SURVIVAL (R21): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its physical activity and weight control interventions among cancer survivors: effects on biomarkers of prognosis and survival (R21) grants. This R21 funding opportunity announcement encourages transdisciplinary and translational research that will identify specific biological or bioBehavioral pathways through which physical activity or weight control may affect cancer prognosis and survival. Applications must test these effects among cancer survivors identified by previous animal or observational research, including but not limited to: intervention-induced changes in sex hormones, insulin or insulin-like growth factors or their binding proteins; insulin resistance; glucose metabolism; leptin and other adipokines; immunologic or inflammatory factors; immunologic or inflammatory factors; oxidative stress and DNA damage or repair capacity; angiogenesis; prostaglandins. This research will require approaches that bring together Behavioral intervention expertise, cancer biology and other relevant basic or clinical science disciplines.

This FOA will use the exploratory/developmental (R21) grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-12-228, which solicits applications under the research project grant (R01) mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more
than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-229.

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 12 Jul 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-229.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-229

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Diagnostic Sciences, Breast Cancer, Melanoma & Other Skin Cancers, Prostate & Testicular Cancers, Biomedical Engineering, Carcinogenesis, Physiology, Inflammation, HIV/AIDS, Hormones & Endocrinology, Stress, Biological, Leukaemia & Other Blood Cancers, Nucleic Acid Analogues, Cancer Studies & Oncology, Immunity & Immunogenetics, Quantitative Genetics, Chronic Care, Cancer Cell Biology, Ovarian & Cervical Cancers, Colorectal, Pancreatic & Stomach Cancers, Stress, Psychological, Human Metabolism, Ribonucleic Acid, RNA, Obesity, Human Biological Sciences, Deoxyribonucleic Acid, DNA, Brain Cancer, Immunopathology, Biological Sciences, Lung Cancer, Non-cancerous Tumours, Psychology, Clinical Medicine, Pathology, Behavioral Studies & Social Problems

Contact Details
----------------------------------------------
Division of Cancer Control and Population Sciences
NCI
6116 Executive Boulevard
Suite 404, MSC 8336
Bethesda, MD 20892-8336
Tel: 1 301 402 1450
Fax: 1 301 594 5070
Email: alfanc@mail.nih.gov

STEM CELLS AND ALCOHOL-INDUCED TISSUE INJURIES (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related stem cells and alcohol-induced tissue injuries (R01) grants. This Aids-related R01 funding opportunity announcement encourages applications to study human and non-human stem cells involved in alcohol-induced tissue injuries. Alcohol abuse is known to cause pathology in a number of organ systems. Disorders most commonly associated with chronic alcohol consumption include alcoholic liver disease, pancreatitis, cardiovascular disease, neural damage, endocrine dysfunction, osteoporosis, cancer and immune dysfunction. The objective of this FOA is to understand the role of stem cells in alcohol-induced tissue damage and recovery, particularly how they are influenced by alcohol metabolism and their role in alcohol-related cancers.
Domestic and foreign for-profit or non-profit organizations and public or private institutions are eligible to apply. This FOA will use the R01 award mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-232, which solicits proposals under the exploratory/developmental grant (R21) mechanism. Application budgets are not limited, but need to reflect the actual needs of the project. The maximum project period is five years. PA-12-233.

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 12 Jul 12
Award type: Directed grants to institutions, research groups etc.
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-233](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-233)

---

STEM CELLS AND ALCOHOL-INDUCED TISSUE INJURIES (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related stem cells and alcohol-induced tissue injuries (R21) grants. This Aids-related R21 funding opportunity announcement encourages applications to study human and non-human stem cells involved in alcohol-induced tissue injuries. Alcohol abuse is known to cause pathology in a number of organ systems. Disorders most commonly associated with chronic alcohol consumption include alcoholic liver disease, pancreatitis, cardiovascular disease, neural damage, endocrine dysfunction, osteoporosis, cancer and immune dysfunction. The objective of this FOA is to understand the role of stem cells in alcohol-induced tissue damage and recovery, particularly how they are influenced by alcohol metabolism and their role in alcohol-related cancers.

Domestic and foreign for-profit or non-profit organizations and public or private institutions are eligible to apply. This FOA will use the exploratory/developmental (R21) grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-12-233, which solicits applications under the research project...
grant (R01) mechanism. Applicants may request direct costs of up to US$275,000 over a two-year project period, with no more than US$200,000 in any one year. Eligible organizations include domestic or foreign for-profit or non-profit organizations and public or private institutions. PA-12-232.

Closing date: 07 May 15  
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.  
Posted date: 12 Jul 12  
Award type: Directed grants to institutions, research groups etc.  
Award amount max: $275,000  
Website:  
http://grants.nih.gov/grants/guide/pa-  
files/PA-12-232.html  
Application form:  
http://grants.nih.gov/grants/guide/pa-  
files/PA-12-232.html

Eligibility profile
- Country of applicant institution: Any
- Disciplines
  Cardiology, Hormones & Endocrinology,  
  Cytopathology, Stem Cell Genomics,  
  Diagnostic Sciences, Stem Cell,  
  Pathophysiology, Hepatology, Neurology,  
  Embryonic Stem Cells, Cardiovascular  
  Diseases, Alcoholism, Psychology, Pathology,  
  HIV/AIDS, Stem Cell Therapy, Induced  
  Pluripotent Stem Cells, Addiction, Drug &  
  Substance Abuse, Health Systems, Risk  
  Management, Endocrine & Neuroendocrine  
  Cancers

Contact Details
- NIAAA  
  5635 Fishers Lane, Room 2035  
  Rockville, MD 20852  
  Tel: 1 301 443 6106  
  Email: gaozh@mail.nih.gov

**DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R21): AIDS-RELATED**  
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R21) grants. This Aids-related R21 funding opportunity announcement solicits proposals that seek to develop non-invasive or minimally invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. The announcement has two main aims:

- to encourage the development of devices or techniques that will improve estimations of a subject’s consumption of an abused drug during an outpatient clinical trial. Such a system would allow objective assessment of whether a medication reduces drug abuse, even if abstinence is not achieved. Proposed solutions should be able to assess systematic drug levels and be safe, portable, affordable and simple enough for subjects to take multiple samples at home and return them to the clinic for batch analysis;
- to develop new, improved markers to evaluate a subject’s adherence to the study medication. The goal is for investigators to be able to determine the level of
systematic medication exposure throughout a study. Assays should be applicable to one of the following situations – assessment of medication adherence in a manner suitable for use in a clinical setting; or the quantitative assessment of medication adherence throughout an outpatient clinical trial. This FOA will utilise the NIH exploratory/developmental grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-239, that solicits applications under the research project grant (R01) award mechanism. NIDA intends to commit up to US$2 million to fund both mechanisms in fiscal year 2013, and will fund up to seven R21 awards.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-12-238.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 17 Jul 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Website: [http://grants.nih.gov/grants/guide/pa-files/PAR-12-238.html](http://grants.nih.gov/grants/guide/pa-files/PAR-12-238.html)
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-238](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-238)

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, Pharmacotherapy, Nursing, Drug Design, Medical Devices, Public Health, Health Services & Primary Care, Community Health Services, Pharmacy & Pharmacology, Psychology, Biochemical Markers, Addiction, Clinical Medicine, HIV/AIDS, Biological Markers & Sensor Mechanisms, General Practice, Immunological & Bioassay Methods, Primary Care

Contact Details

Medications Research Grants Branch
NIDA
NIH
6001 Executive Boulevard
Rockville, MD 20852
Tel: 1 301 443 8039
Fax: 1 301 443 9649
Email: aidan.hampson@nih.gov

DEVELOPMENT OF MINIMALLY INVASIVE BIOASSAYS TO SUPPORT OUTPATIENT CLINICAL TRIALS OF THERAPEUTICS FOR SUBSTANCE USE DISORDERS (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related development of minimally invasive bioassays to support outpatient clinical trials of therapeutics for substance use disorders (R01) grants. This Aids-related R01 funding opportunity announcement solicits proposals that seek to develop non-invasive or minimally invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. The announcement has two main aims:

Announcement solicits proposals that seek to develop non-invasive or minimally invasive methods to support outpatient clinical trials of pharmacotherapies for substance use disorders. The announcement has two main aims:
• to encourage the development of devices or techniques that will improve estimations of a subject’s consumption of an abused drug during an outpatient clinical trial. Such a system would allow objective assessment of whether a medication reduces drug abuse, even if abstinence is not achieved. Proposed solutions should be able to assess systematic drug levels and be safe, portable, affordable and simple enough for subjects to take multiple samples at home and return them to the clinic for batch analysis;

• to develop new, improved markers to evaluate a subject’s adherence to the study medication. The goal is for investigators to be able to determine the level of systematic medication exposure throughout a study. Assays should be applicable to one of the following situations – assessment of medication adherence in a manner suitable for use in a clinical setting; or the quantitative assessment of medication adherence throughout an outpatient clinical trial.

This FOA will utilise the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope, PAR-12-238, that solicits applications under the exploratory/developmental grant (R01) mechanism. NIDA intends to commit up to US$2 million to fund both mechanisms in fiscal year 2013, and will fund up to four R01 awards.

Application budgets are limited to US$500,000 per year over a three-year period. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-12-239.

Closing date: 07 May 15
LYMPHATICS IN HEALTH AND DISEASE IN THE DIGESTIVE, URINARY, CARDIOVASCULAR AND PULMONARY SYSTEMS (R01): AIDS-RELATED

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Kidney Diseases and the National Heart, Lung and Blood Institute invite applications for their lymphatics in health and disease in the digestive, urinary, cardiovascular and pulmonary systems (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement supports research into aspects of lymphatic vessel physiology and pathophysiology related to health and disease of digestive system and urinary tract organs, and cardiovascular and pulmonary systems, in resolution of thromboembolic events and inflammation and immune responses as they relate to these diseases. Studies to understand the factors that control local lymphatic vessel functional anatomy and physiology during health or disease in these organs or systems, and the mechanisms by which alterations of lymphatic vessel function affect organ function are of interest. Studies with a major focus on immune mechanisms will not be considered responsive.

This FOA will use the R01 research project grant mechanism and runs in parallel with an FOA of identical scope, PAR-12-260, which uses the R21 exploratory/developmental research grant mechanism.

Application budgets are limited to US$250,000 in direct costs per year. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-12-259.

Closing date: 07 May 15
Deadline information: Applications due every 7 January, 7 May and 7 September until 8 September 2015.

Posted date: 09 Aug 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,250,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-259

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Dermatology, Cardiovascular Diseases, Humoural Immunity & Immunochemistry, Molecular Transport & Membranes, Diagnostic Sciences, HIV/ Aids, Inflammation, Physiology, Urology, Hypertension, Cardiology, Immunopathology, Human Biological Sciences, Immunology, Gastroenterology, Immunotherapy, Human Physiology, Allied Health Professions, Biological Sciences, Lymphatic System, Respiratory Medicine, Clinical Medicine, Lung Cancer

Contact Details
----------------------------------------------
Division of Digestive Diseases and Nutrition
NIDDK
6707 Democracy Boulevard, Room 661
Bethesda, MD 20817
Tel: 1 301 402 0671
Email: carringj@mail.nih.gov
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R21): AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R21): AIDS-related grants. The purpose of this AIDS-related R21 funding opportunity announcement is to evaluate the effect of care planning on cancer survivors’ health and psychosocial outcomes, self-management of late effects and adherence to cancer screening and health behavior guidelines, use of follow-up care, organizational-level factors influencing the implementation of care planning, and associated costs. The FOA aims to stimulate research that will:

- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors’ morbidity, self-management and adherence to care recommendations, use of follow-up care, and on systems outcomes;
- identify models and processes of care that promote effective survivorship care planning.

The ultimate goal is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors. This FOA will use the R21 exploratory/developmental research grant award and runs in parallel with an FOA of identical scope, PA-12-275, which uses the R01 research project grant.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-274.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 30 Aug 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: [http://grants.nih.gov/grants/guide/pa-files/PA-12-274.html](http://grants.nih.gov/grants/guide/pa-files/PA-12-274.html)
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-274](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-274)

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------------------------
Death & Mortality, Patient Care & Education, Social Psychology, Medical Effectiveness & Patient Outcomes, Clinical Medicine, Non-cancerous Tumours, Psychology, Lung Cancer, Emotional Rehabilitation, Accounting & Finance, Health Economics, Leukaemia & Other Blood Cancers, Cancer Studies & Oncology, Quality of Care, Health Systems, Risk Management, Blood Tests, Economics & Econometrics, Cancer Immunology, Brain Cancer, Human Biological Sciences, Primary Care, Oncology Nursing, Ovarian & Cervical Cancers, Cancer Cell Biology, Colorectal, Pancreatic & Stomach Cancers, Social Rehabilitation, Health Systems Policy, Nursing, Health Systems, Carcinogenesis, Breast Cancer, Chemotherapy, Public Health, Health Services & Primary Care, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Diagnostic Sciences, HIV/AIDS, Molecularly Targeted Therapy, Sociology, Physiology, Social Work & Social Policy
EXAMINATION OF SURVIVORSHIP CARE PLANNING EFFICACY AND IMPACT (R01):
AIDS-RELATED
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its examination of survivorship care planning efficacy and impact (R01): Aids-related grants. The purpose of this Aids-related R21 funding opportunity announcement is to evaluate the effect of care planning on cancer survivors’ health and psychosocial outcomes, self-management of late effects and adherence to cancer screening and health behavior guidelines, use of follow-up care, organizational-level factors influencing the implementation of care planning, and associated costs. The FOA aims to stimulate research that will:
- develop and test metrics for evaluating the impact of survivorship care planning;
- evaluate the impact of survivorship care planning on cancer survivors’ morbidity, self-management and adherence to care recommendations, use of follow-up care, and outcomes; and
- identify models and processes of care that promote effective survivorship care planning.

The ultimate goal is to generate a body of science that will inform the development and delivery of interventions and best practices in follow-up care for cancer survivors. This FOA will use the R01 research project grant and runs in parallel with an FOA of identical scope, PA-12-274, which uses the R21 exploratory/developmental research grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PA-12-275.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.
Posted date: 30 Aug 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-275.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-275

Eligibility profile
Country of applicant institution: Any
Disciplines
----------------------------------------------
Molecularly Targeted Therapy, HIV/Aids, Sociology, Physiology, Social Work & Social Policy, Carcinogenesis, Melanoma & Other Skin Cancers, Prostate & Testicular Cancers, Public Health, Health Services & Primary Care, Chemotherapy, Breast Cancer, Diagnostic Sciences, Human Biological Sciences, Brain Cancer, Cancer Immunology, Economics & Econometrics, Blood Tests, Oncology Nursing, Primary Care, Social Rehabilitation, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Ovarian & Cervical Cancers, Health Systems, Nursing, Health Systems Policy, Health Economics, Cancer Studies & Oncology, Leukaemia & Other Blood Cancers, Health Systems, Risk Management, Quality of Care, Social Psychology, Clinical Medicine, Medical Effectiveness & Patient Outcomes, Psychology, Non-cancerous Tumours, Accounting & Finance, Emotional Rehabilitation, Lung Cancer, Death & Mortality, Patient Care & Education

Contact Details
----------------------------------------------
Division of Cancer Control and Population Sciences
National Cancer Institute
6116 Executive Boulevard, Room 404
Bethesda, MD 20892
Tel: 1 301 435 4540
Fax: 1 301 480 6637
Email: carla.parry@nih.gov

PILOT INTERVENTION AND SERVICES RESEARCH GRANTS (R34): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol and Alcoholism solicits applications for its AIDS-related pilot interventions and services research grants (R34). The purpose of this AIDS-related R34 funding opportunity announcement is to encourage research on: the development or pilot testing of new or adapted interventions; the adaptation or pilot testing of interventions with demonstrated efficacy for use in broader scale effectiveness trials; or innovative services research directions that require preliminary testing or development. The award mechanism provides resources for evaluating the feasibility, tolerability, acceptability and safety of novel approaches to improving mental health and modifying health risk Behavior, and for obtaining the preliminary data needed as a prerequisite to a larger-scale intervention or services study.

The total project period may not exceed two years. Direct costs are limited to US$450,000, with no more than US$225,000 in direct costs allowed in any single year. Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organizations. PAR-12-279 (replaces PAR-09-173).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2015.
Posted date: 10 Sep 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-279.html
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-279](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-279)

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Psychology, HIV/AIDS, Psychiatry, Public Health, Health Services & Primary Care, Stress, Psychological, Primary Care, Mental Illness, Behavioral Medicine, Psychotherapy, Psychology, Psychopathology, Mental Health, Schizophrenia & Other Psychotic Disorders

Contact Details

Division of Services and Intervention Research
NIMH
6001 Executive Blvd, Room 7145, MSC 9633
Bethesda, MD 20892-9633
Tel: 1 301 443 2477
Email: jsherril@mail.nih.gov

**EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R21): AIDS-RELATED**

NIH: National Institute on Alcohol Abuse and Alcoholism

**Description:**
The National Institute on Alcohol Abuse and Alcoholism invites applications for its effects of in utero alcohol exposure on adult health and disease (R21): Aids-related grants. This Aids-related R21 funding opportunity announcement will support novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease concept which suggest that foetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to:

- leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process;
- identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring.

Studies supported by this FOA will provide fundamental insights into a possible foetal-basis to adult disease that is influenced by maternal alcohol use. This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-291, that solicits applications under the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-12-291.

**Closing date:** 07 May 15

**Deadline information:** Deadline every 7 January, 7 May and 7 September until 8 May 2016.

**Posted date:** 01 Oct 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-292.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-292

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Cognitive Processes, Reproductive Medicine, Growth & Growth Factors, Psychology,
Disease Models, HIV/Aids, Medicine & Health, Aetiology, Biological Sciences,
Diagnostic Sciences, Biochemistry & Molecular Biology, Cell & Developmental Biology, Alcoholism, Reproduction & Fertility, Child Development, Pregnancy & Birth, Foetal Health & Prenatal Development

Contact Details
----------------------------------------------
Division of Metabolism and Health Effects
NIAAA
5635 Fishers Lane, Room 2120
Bethesda, MD 20892-7003
Tel: 1 301 443 7351
Email: duntyw@mail.nih.gov

EFFECTS OF IN UTERO ALCOHOL EXPOSURE ON ADULT HEALTH AND DISEASE (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its effects of in utero alcohol exposure on adult health and disease (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement will support novel research on how prenatal alcohol exposure may contribute to the aetiology of chronic diseases and health conditions later in life. Central to this theme is the developmental origins of health and disease concept which suggest that foetal adaptations in response to adverse intrauterine conditions may increase the risk for childhood and adulthood disease. The goal of this FOA is to stimulate a broad range of research to:

- leverage existing prospective birth cohorts to define the role of maternal alcohol consumption in the DOHaD process;
- investigate the biological, cellular and molecular mechanisms by which prenatal alcohol exposure may impact disease outcomes later in life;
- identify biomarkers associated with gestational alcohol exposure that may predict adult disease susceptibility in exposed offspring.

Studies supported by this FOA will provide fundamental insights into a possible foetal-basis to adult disease that is influenced by maternal alcohol use. This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-12-292, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-
profit or for-profit organizations and public or private institutions. PA-12-291.

Closing date: 07 May 15
Deadline information: Deadline every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 01 Oct 12
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-12-291.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-12-291

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Growth & Growth Factors, Reproductive Medicine, Cognitive Processes, Reproduction & Fertility, Alcoholism, Cell & Developmental Biology, Biochemistry & Molecular Biology, Diagnostic Sciences, Biological Sciences, Aetiology, Medicine & Health, HIV/AIDS, Disease Models, Psychology, Foetal Health & Prenatal Development, Pregnancy & Birth, Child Development

Contact Details
----------------------------------------------
Division of Metabolism and Health Effects
NIAAA
5635 Flishers Lane, Room 2120
Bethesda, MD 20892-7003
Tel: 1 301 443 7351
Fax: 1 301 594 0673
Email: duntyw@mail.nih.gov

EPIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of Aids-related alcohol (R21) grants. This Aids-related R21 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects. This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-003, that solicits applications under the R01 research project grant mechanism. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-13-004.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Oct 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-004
EPGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL
(R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of Aids-related alcohol (R01) grants. This Aids-related R01 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-004, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-13-003.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Oct 12

Award type: Directed grants to institutions, research groups etc.

Eligibility profile

Country of applicant institution: Any
Disciplines

Biological Sciences, Reproduction & Fertility, Alcoholism, Epigenetics, Reproductive Medicine, Quantitative Genetics, Pharmaceutical Drugs, Diagnostic Sciences, HIV/Aids

Contact Details

Divison of Neuroscience and Behavior
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: 1 301 594 6228
Email: reillymt@mail.nih.gov

PIGENETIC INHERITANCE AND TRANSGENERATIONAL EFFECTS OF ALCOHOL
(R01): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its epigenetic inheritance and transgenerational effects of Aids-related alcohol (R01) grants. This Aids-related R01 funding opportunity announcement will support research proposing to conduct mechanistic studies in human and animal models on alcohol-induced transgenerational effects and the role of epigenetic inheritance in these effects.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-004, that solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PA-13-003.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Oct 12

Award type: Directed grants to institutions, research groups etc.

Eligibility profile

Country of applicant institution: Any
Disciplines

Biological Sciences, Reproduction & Fertility, Alcoholism, Epigenetics, Reproductive Medicine, Quantitative Genetics, Pharmaceutical Drugs, Diagnostic Sciences, HIV/Aids

Contact Details

Divison of Neuroscience and Behavior
NIAAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: 1 301 594 6228
Email: reillymt@mail.nih.gov
ELECTED TOPICS IN TRANSFUSION MEDICINE (R21): AIDS-RELATED
NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its Aids-related selected topics in transfusion medicine (R21) programme. This Aids-related R21 funding opportunity announcement will study topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Specifically, research focused on improving blood donor health, the safety and availability of blood products and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how to best minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing risks associated with the donation process and developing enhanced recruitment and retention programmes.

This FOA will use the NIH exploratory/developmental R21 grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-026, that encourages applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,00 in direct costs allowed in any single year. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PAR-13-025 (replaces PAR-10-033).

Deadline information: Applications due every 7 May and 7 January until 8 January 2017.

Closing date: 07 May 15
Posted date: 26 Nov 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
-------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------
Blood, Blood Products & Transfusions, Clinical Medicine, HIV/AIDS

Contact Details
-------------------------------
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Rockledge II, MSC 7950
6701 Rockledge Drive
Bethesda, MD 20892-7950
Tel: 1 301 435 0065
Fax: 1 301 480 0867
Email: zoussn@nhlbi.nih.gov
ELECTED TOPICS IN TRANSFUSION MEDICINE (R01): AIDS-RELATED
NIH: National Heart, Lung and Blood Institute

Description:
The National Heart, Lung and Blood Institute invites applications for its Aids-related selected topics in transfusion medicine (R01) programme. This Aids-related R01 funding opportunity announcement will study topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Specifically, research focused on improving blood donor health, the safety and availability of blood products and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how to best minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing risks associated with the donation process and developing enhanced recruitment and retention programmes. This FOA will use the NIH research project R01 grant mechanism and runs in parallel with an FOA of identical scope, PAR-13-025, that encourages applications under the R21 mechanism. Application budgets are not limited, but must reflect the actual needs of the project. Projects may not last longer than five years. Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PAR-13-023 (replaces PAR-10-034).

Closing date: 07 May 15
Deadline information: Applications due every 7 May and 7 January until 8 January 2017.
Posted date: 26 Nov 12
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-026

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/Aids, Blood, Blood Products & Transfusions, Clinical Medicine
Contact Details
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Rockledge II, MSC 7950
6701 Rockledge Drive
Bethesda, MD 20892-7950
Tel: 1 301 435 0065
Fax: 1 301 480 0867
Email: zouzn@nhlbi.nih.gov
ERYTHROPOIESIS: COMPONENTS AND MECHANISMS (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood, Institute invite applications for their AIDS-related erythropoiesis: components and mechanisms (R01) grants. This AIDS-related R01 funding opportunity announcement aims to support research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components contribute to erythropoiesis. Components include genes that are expressed in erythroid cells, either during development or during differentiation, and the proteins that are translated in erythroid cells, especially with post-translational modifications or subcellular localizations that are unique to erythroid cells. A long range goal of this program is to generate a concise description of erythropoiesis that unifies genetics, molecular processes and cytokine determinants in the erythroid lineages so that new therapeutics may be developed to measure and combat anaemia.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. PA-13-034 (replaces PA-09-255).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.

Posted date: 06 Dec 12
Award type: Directed grants to institutions, research groups etc.
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-034

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids, Diagnostic Sciences, Characteristics, Biological Macromolecules, Proteomics & Molecular Interactions, Haematology, Epigenetics, Protein Synthesis, Modification & Turnover, Cell & Developmental Biology, Molecular Genetics, Biological Sciences

Contact Details

Division of Kidney, Urologic, and Hematologic Diseases
NIDDK
6707 Democracy Boulevard
Room 619
Bethesda, MD 20817
Tel: 1 301 594 7726
Email: tb232j@nih.gov
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R01): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
A total of 15 participating institutes and centers of the National Institutes of Health invite applications for their Aids-related dissemination and implementation research in health (R01) grants. This Aids-related R01 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behavior change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.

This FOA will use the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-054, which encourages applications under the R21 exploratory/developmental award mechanism, and PAR-13-056, which encourages applications under the R03 small grant programme mechanism. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-055 (replaces PAR-10-038).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.

Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc.
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-055

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Promotion, Mental Illness, Health Systems, Biomedical Engineering, Mental Health, Health Systems, Administration, Medical & Diagnostic Tests, Preventive Medicine, Psychiatry, Public Health, Health Services & Primary Care, Sociology, Public Health, HIV/AIDS, General Practice, Psychology, Economic & Social Environment, Primary Care, Medical Sociology

Contact Details
Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: 1 301 443 3747
Fax: 1 301 443 4045
Email: dchamber@mail.nih.gov
DISSEMINATION AND IMPLEMENTATION RESEARCH IN HEALTH (R03): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
A total of nine participating institutes and centers of the National Institutes of Health invite applications for their AIDS-related dissemination and implementation research in health (R03) grants. This AIDS-related R03 funding opportunity announcement encourages investigators to submit applications that will identify, develop, evaluate and refine effective and efficient methods, systems, infrastructures, and strategies to disseminate and implement research-tested health behavior change interventions, evidence-based prevention, early detection, diagnostic, treatment and management, and quality of life improvement services, and data monitoring and surveillance reporting tools into public health and clinical practice settings that focus on patient outcomes.
This FOA will use the R03 small grant programme mechanism, and runs in parallel with two FOAs of identical scientific scope, PAR-13-055, which encourages applications under the research project grant mechanism, and PAR-13-054, which encourages applications under the R21 exploratory/developmental award mechanism.
Direct costs are limited to US$100,000 over a two-year period, with no more than US$50,000 in direct costs allowed in any single year. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. PAR-13-056 (replaces PAR-10-039).

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2016.

Posted date: 10 Jan 13
Award type: Directed grants to institutions, research groups etc
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-056

Eligibility profile
Country of applicant institution: Any
Disciplines
Economic & Social Environment, Primary Care, Medical Sociology, Biomedical Engineering, Health Systems, Administration, Mental Health, Medical & Diagnostic Tests, Preventive Medicine, Psychiatry, Public Health, Health Services & Primary Care, Sociology, Public Health, HIV/AIDS, General Practice, Psychology, Health Promotion, Mental Illness, Health Systems

Contact Details
Division of Services and Intervention Research
NIMH
6001 Executive Boulevard, Room 7133, MSC 9631
Bethesda, MD 20892-9631
Tel: 1 301 443 3747
Fax: 1 301 443 4045
Email: dchamber@mail.nih.gov
SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIORS AND WEIGHT OUTCOMES (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of four institutes and offices of the National Institutes of Health invites applications for their Aids-related school nutrition and physical activity policies, obesogenic Behaviors and weight outcomes (R21) grants. The objectives of this Aids-related R21 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity Behaviors and decrease childhood obesity. Applications should propose to:

• foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic Behaviors and weight outcomes;
• understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
• understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R21 exploratory/developmental research grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-099, which uses the R03 small grant programme mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US$275000 over a two-year project period, with no more than US$200,000 in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-13-098.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-098

Eligibility profile
--------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------------------------
Human Nutrient Requirements, Physical & Sports Education, Diagnostic Sciences, Public Health, Health Services & Primary Care, Education, HIV/AIDS, Social Work & Social Policy, Psychology, Sports & Exercise Studies, Behavioral Medicine, Nutrition & Dietetics, Primary Care, Obesity, Schools Policy & Politics, Health Education

Contact Details
--------------------------------------------------------------------------------
NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: 1 301 435 6888
Email: espositl@mail.nih.gov
School Nutrition and Physical Activity Policies, Obesogenic Behaviors and Weight Outcomes (R03): AIDS-Related

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of three institutes and offices of the National Institutes of Health invites applications for their Aids-related school nutrition and physical activity policies, obesogenic Behaviors and weight outcomes (R03) grants. The objectives of this Aids-related R03 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity Behaviors and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic Behaviors and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R03 small grant programme mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, which uses the R21 exploratory/developmental research grant mechanism, and PAR-13-100, which uses the R01 research project grant mechanism.

Application budgets are limited to US$50,000 per year over a two-year project period. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-13-099.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-099

Eligibility profile
Country of applicant institution: Any

Disciplines
Behavioral Medicine, Sports & Exercise Studies, Health Education, Nutrition & Dietetics, Primary Care, Obesity, Schools Policy & Politics, Diagnostic Sciences, Public Health, Health Services & Primary Care, Physical & Sports Education, Social Work & Social Policy, Psychology, Education, HIV/Aids, Human Nutrient Requirements

Contact Details
NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: 1 301 435 6888
Email: espositl@mail.nih.gov
SCHOOL NUTRITION AND PHYSICAL ACTIVITY POLICIES, OBESOGENIC BEHAVIORS AND WEIGHT OUTCOMES (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
A total of four institutes and offices of the National Institutes of Health invites applications for their AIDS-related school nutrition and physical activity policies, obesogenic Behaviors and weight outcomes (R01) grants. The objectives of this AIDS-related R01 funding opportunity announcement are to understand how school-related policies impact the school and home environment, promote positive nutrition and physical activity Behaviors and decrease childhood obesity. Applications should propose to:

- foster multidisciplinary research that will evaluate how policies can influence school physical activity and nutrition environments, youths’ obesogenic Behaviors and weight outcomes;
- understand how schools are implementing these policies and examine multi-level influences on adoption and implementation at various levels;
- understand the synergistic or counteractive effect of school nutrition and physical activity policies on the home and community environment and body weight.

This FOA will use the R01 research project grant mechanism and runs in parallel with two FOAs of identical scope, PAR-13-098, the R21 exploratory/developmental research grant mechanism, and PAR-13-099, which uses the R03 small grant programme mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-13-100.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 04 Feb 13
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-100.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-100

Eligibility profile
Country of applicant institution: Any

Disciplines
Psychology, Human Nutrient Requirements, Behavioral Medicine, Sports & Exercise Studies, Health Education, Schools Policy & Politics, Primary Care, Obesity, Nutrition & Dietetics, Public Health, Health Services & Primary Care, Diagnostic Sciences, Physical & Sports Education, Social Work & Social Policy, HIV/Aids, Education

Contact Details
NICHD
6100 Executive Boulevard, Room 4B05
Rockville, MD 20852
Tel: 1 301 435 6888
Email: espositl@mail.nih.gov
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R21 Aids-related applications for its regional and international differences in health and longevity at older ages grants. Aids-related applications are sought from organizations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialized nations and across geographical areas in the United States. This FOA will utilize the R21 award mechanism. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. The combined budget for direct costs may not exceed US$275,000 over two years, no more than US$200,000 per year may be requested. PA-13-124.

Closing date: 07 May 15
Deadline information: Applications due 5pm proposer's local time, 7 January, 7 May and 7 September annually until 8 September 2016.
Posted date: 22 Feb 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care, Social & Income Inequality, Life Expectancy & Quality of Life, Geriatrics & Gerontology, Health Disparities, HIV/AIDS, Social Work & Social Policy, Psychology, International Health, Population Studies, Medical, Psychology of Ageing, Public Health, Health Services & Primary Care

Contact Details
Tel: 1 301 496 3138
Email: patmiosg@nia.nih.gov

REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R03 Aids-related applications for its regional and international differences in health and longevity at older ages grants. Aids-related applications are sought from organizations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialized nations and across geographical areas in the United States. This FOA will utilize the R03 award mechanism. Domestic and foreign public and
REGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 Aids-related applications for its regional and international differences in health and longevity at older ages grants. Aids-related applications are sought from organizations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialized nations and across geographical areas in the United States. This FOA will utilize the R01 award mechanism. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.
PA-13-125.

Eligibility profile
---------------------------------------------------------------------------------
Country of applicant institution: Any
Disciplines
---------------------------------------------------------------------------------
Public Health, Health Services & Primary Care, Social Work & Social Policy, Health Disparities, HIV/Aids, Geriatrics & Gerontology, Social & Income Inequality, Primary Care, Psychology of Ageing, International Health, Population Studies, Medical, Psychology, Life Expectancy & Quality of Life

Contact Details
---------------------------------------------------------------------------------
Tel: 1 301 496 3138
Email: patmiosg@nia.nih.gov


Closing date: 07 May 15
Deadline information: Applications due 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 September 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

EGIONAL AND INTERNATIONAL DIFFERENCES IN HEALTH AND LONGEVITY AT OLDER AGES (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 Aids-related applications for its regional and international differences in health and longevity at older ages grants. Aids-related applications are sought from organizations proposing to advance knowledge on the reasons behind the divergent trends that have been observed in health and longevity at older ages, both across industrialized nations and across geographical areas in the United States. This FOA will utilize the R01 award mechanism. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years.
PA-13-123.

Eligibility profile
---------------------------------------------------------------------------------
Country of applicant institution: Any
Disciplines
---------------------------------------------------------------------------------
Public Health, Health Services & Primary Care, Social Work & Social Policy, Health Disparities, HIV/Aids, Geriatrics & Gerontology, Social & Income Inequality, Primary Care, Psychology of Ageing, International Health, Population Studies, Medical, Psychology, Life Expectancy & Quality of Life

Contact Details
---------------------------------------------------------------------------------
Tel: 1 301 496 3138
Email: patmiosg@nia.nih.gov

Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-123.html

Closing date: 07 May 15
Deadline information: Applications due 5pm proposer’s local time, 7 January, 7 May and 7 September annually until 8 September 2016.
Posted date: 22 Feb 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-123.html#_Section_IV._Application_1
CUTE KIDNEY INJURY IN OLDER ADULTS (R03) AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R03 Aid-related applications for its acute kidney injury in older adults' grants. Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This Aids-related programme announcement will utilize the R03 award mechanism. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Funding for direct costs may not exceed US$100,000 over two years, and no more than US$50,000 may be requested in any single year. PA-13-142.

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2016.

Posted date: 15 Mar 13

Award type: Directed grants to institutions, research groups etc.

Award amount max: $100,000

Website: http://grants.nih.gov/grants/guide/notice-files/PA-13-142.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Geriatrics & Gerontology, HIV/AIDS, Diagnostic Sciences, Public Health, Health Services & Primary Care, Traumatology, Accidents & Injury, Primary Care, Nephrology & Kidneys, Blood Tests, Prosthetic & Orthotic Devices, Diabetes, Clinical Medicine

Contact Details
Tel: 1 301 496 6761
Email: susan.zieman@nih.gov
CUTE KIDNEY INJURY IN OLDER ADULTS (R21) AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R21 AIDS-related applications for its acute kidney injury in older adults' grants. Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This AIDS-related programme announcement will utilize the R21 award mechanism. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Funding for direct costs may not exceed US$275,000 over two years, and no more than US$200,000 may be requested in any single year.

PA-13-143.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2016.
Posted date: 15 Mar 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-13-143.html

Eligibility profile
--------------------------------------------------
Country of applicant institution: Any
Disciplines
--------------------------------------------------
Clinical Medicine, Diabetes, Prosthetic & Orthotic Devices, Traumatology, Accidents & Injury, Primary Care, Blood Tests, Nephrology & Kidneys, Diagnostic Sciences, Public Health, Health Services & Primary Care, Geriatrics & Gerontology, HIV/Aids

Contact Details
--------------------------------------------------
Tel: 1 301 496 6761
Email: susan.zieman@nih.gov

CUTE KIDNEY INJURY IN OLDER ADULTS (R01) AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites R01 AIDS-related applications for its acute kidney injury in older adults' grants. Applications should propose basic, clinical, translational and outcomes research on kidney injury in older adults. Applications may focus on: the epidemiology, etiology and
risk factors for AKI in older adults; pathophysiology of AKI in the ageing kidney and its impact on chronic kidney disease (CKD) and other organ disease; early detection, diagnosis and monitoring of AKI; prevention, treatment and management strategies of AKI in older patients with the goal of improving short- and long-term outcomes, including morbidity, mortality, progression of CKD, functional independence and quality of life.

This Aids-related programme announcement will utilize the R01 award mechanism. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years. PA-13-141.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2016.

THE ROLE OF EXTRACELLULAR RNA IN MEDIATING THE HEALTH EFFECTS OF ALCOHOL (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for the Aids-related role of extracellular RNA in mediating the health effects of alcohol grant. This Aids-related R21 funding opportunity announcement supports innovative research into the role of extracellular RNA in the development of alcohol-related diseases and end-organ injuries. It is anticipated that this announcement will generate data that may lead to breakthroughs in the understanding of the role of eRNA communication in the initiation, progression and maintenance of diverse medical disorders caused by excessive, long-term alcohol consumption. Supported research may also provide information on the mechanistic basis of the health benefits of moderate alcohol consumption. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Foreign components are also allowed. Grants may not exceed US$275,000 in direct costs over a two-year period. PA-13-197.
HE EFFECTS OF MODULATING CHRONIC LOW GRADE INFLAMMATION ON GERIATRIC CONDITIONS - SECONDARY DATA OR BIOSPECIMEN ANALYSES AND ANCILLARY STUDIES IN ONGOING OR COMPLETED CLINICAL TRIALS (R01) AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites Aids-related R01 proposals on the effects of modulating chronic low grade inflammation on geriatric conditions - secondary data or biospecimen analyses and ancillary studies in ongoing or completed clinical trials. This Aids-related R01 opportunity supports ancillary studies and secondary analyses of data or biospecimens from ongoing or completed studies of the effects of inflammation or anti-inflammatory agents on geriatric conditions, such as functional decline, mobility disability, fatigue, falls, cognitive decline and dementia, and chronic pain.

Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Funding is available for up to five years. PA-13-221.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 08 May 13
Award type: Directed grants to institutions, research groups etc.
Research Grants Using the Resources from the Osteoarthritis Initiative (R21): AIDS-Related
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Center for Complementary and Alternative Medicine and the National Institute on Aging invite applications for their AIDS-related research grants using the resources from the osteoarthritis initiative (R21). This R21 funding opportunity announcement encourages research focused on the use of the Osteoarthritis Initiative (OAI) database, clinical data and images. This FOA seeks to expand the use of these resources by investigators in the broader research community. Domestic and foreign public and private non-profit organizations and for-profit organizations may apply. Direct costs may not exceed US$275,000 over a two-year project period, with no more than US$200,000 in any year. PA-13-237.

Closing date: 07 May 15
Posted date: 03 Jun 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Osteoporosis & Other Bone Diseases, Clinical Medicine, HIV/Aids, Bone Cancers, Rheumatology & Arthritis, Diagnostic Sciences

Contact Details
NIAMS
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 594 3511
Email: lester1@mail.nih.gov
Research to Characterize and Reduce Stigma to Improve Health (R03): AIDS-Related

NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterize and reduce stigma to improve health. This AIDS-related R03 funding opportunity announcement encourages research grant applications to characterize the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health behaviors and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.

This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-248, which uses the R03 research project grant mechanism.

The combined budget for direct costs over the two-year maximum period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year. PA-13-247.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September, 2016.

Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc.

Award amount max: $50,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care, Health Education, Medical Sociology, Economic & Social Environment, Behavioral Medicine, Geriatrics & Gerontology, Sociology, Education, Social Services Delivery, Health Disparities, HIV/Aids, Social Work & Social Policy, Psychology, Health Systems, Administration, Mental Health, Allied Health Professions, Psychology of Ageing, Public Health, Health Services & Primary Care

Contact Details

NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD  20892-9205
Tel: 1 301 402 4156
Email: nielsenli@nia.nih.gov
RESEARCH TO CHARACTERIZE AND REDUCE STIGMA TO IMPROVE HEALTH (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterize and reduce stigma to improve health. This Aids-related R21 funding opportunity announcement encourages research grant applications to characterize the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health Behaviors and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.
Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.
This funding opportunity uses the R21 exploratory/developmental research grant mechanism, and runs in parallel with two of identical scope, PA-13-248, which solicits applications under the R01 research project grant mechanism, and PA-13-247, which uses the R03 small grant mechanism.
The combined budget for direct costs over the two-year maximum period may not exceed US$275,000. No more than US$200,000 in direct costs may be requested in any single year. PA-13-246.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
HIV/Aids, Health Disparities, Social Services Delivery, Education, Geriatrics & Gerontology, Sociology, Psychology, Social Work & Social Policy, Psychology of Ageing, Allied Health Professions, Mental Health, Health Systems, Administration, Public Health, Health Services & Primary Care, Primary Care, Medical Sociology, Health Education, Economic & Social Environment, Behavioral Medicine

Contact Details
---------------------------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: 1 301 402 4156
Email: nielsenli@nia.nih.gov
RESEARCH TO CHARACTERIZE AND REDUCE STIGMA TO IMPROVE HEALTH (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
A total of six institutes of the NIH invite applications for grants for research to characterize and reduce stigma to improve health. This Aids-related R01 funding opportunity announcement encourages research grant applications to characterize the role of stigma in health, life course development, and ageing, both in the US and globally, and to test interventions to prevent or reduce the impact of stigma at the individual, community, healthcare system, and policy levels. The goal is to promote research addressing the health-related aspects of stigma, including the aetiology and perpetuation of it; its impact on physical and mental health, well-being, life course development, and ageing; its influence on health Behaviors and on use, access to, and quality of received healthcare services; its contribution to health disparities affecting vulnerable demographic groups; and intervention strategies to reduce health-related stigma or the negative health and life course developmental impacts of stigma.

Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.

This funding opportunity uses the NIH exploratory/developmental (R01) research project grant mechanism and runs in parallel with two of identical scientific scope, PA-13-246, which solicits applications under the NIH exploratory/developmental grant mechanism, and PA-13-247, which utilize the R03 small grant programme mechanism.

Application budgets are not limited, but need to reflect the actual needs of the proposed project. The scope of the project should determine the project period; the maximum period is five years. PA-13-248.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September, 2016.
Posted date: 17 Jun 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Allied Health Professions, Health Systems, Administration, Mental Health, Psychology of Ageing, Social Services Delivery, Psychology, Economic & Social Environment, Behavioral Medicine, Primary Care, Health Education, Medical Sociology, Public Health, Health Services & Primary Care, Education, Geriatrics & Gerontology, Sociology, HIV/AIDS, Health Disparities, Social Work & Social Policy

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: 1 301 402 4156
Email: nielsenli@nia.nih.gov
SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R21) grants. This Aids-related R21 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate cost-effective exploratory or novel studies that break new ground or extend previous discoveries towards new directions or applications.

This funding opportunity announcement will use the NIH exploratory/development research grant (R21) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism, and PA-13-260, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and nonprofit organizations and public or private institutions may apply. PA-13-251

Closing date: 07 May 15
Deadline information: Applications due by 5pm every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-251

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care, HIV/Aids, Clinical Medicine, Aetiology, Public Health, Health Services & Primary Care, Epidemiology, Alcoholism, Chronic Care

Contact Details
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: 1 301 594 6231
Email: rbreslow@mail.nih.gov
SECONARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R03): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of alcohol and chronic disease (R03) grants. This AIDS-related R03 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data. This funding opportunity announcement will use the NIH small grant programme (R03) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-260, which solicits applications under the R01 research project grant mechanism, and PA-13-251, which solicits applications under the R21 exploratory/developmental research grant mechanism.

Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year. Domestic and foreign for-profit and nonprofit organizations and public or private institutions may apply. PA-13-261.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.

Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-261

Eligibility profile
Country of applicant institution: Any

Disciplines
Clinical Medicine, Aetiology, Alcoholism, Epidemiology, Primary Care, Chronic Care, HIV/Aids, Public Health, Health Services & Primary Care

Contact Details
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: 1 301 594 6231
Email: rbreslow@mail.nih.gov

IMPLICATIONS OF NEW DIGITAL MEDIA USE FOR UNDERAGE DRINKING, DRINKING-RELATED BEHAVIORS AND PREVENTION RESEARCH (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related implications of new digital media use for underage drinking, drinking-related Behaviors and prevention research (R21) grants. This AIDS-related R21 funding
opportunity announcement aims to investigate whether, and how, having involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be used as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH exploratorydevelopment research grant (R21) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-262, which solicits applications under the R01 research project grant mechanism.

Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Domestic and foreign for-profit and non-profit organizations and public or private institutions may apply. PA-13-263.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
----------------------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------------------
HIV/Aids, Sociology, Social Behavior & Attitudes, Public Health, Health Services & Primary Care, Media Studies, Communication & Media Studies, Communication Studies, Primary Care, Business & Management Studies, Social Networks, Networking Protocols, Alcoholism

Contact Details
----------------------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: 1 301 443 8820
Email: rfreeman@mail.nih.gov

SECONDARY ANALYSES OF ALCOHOL AND CHRONIC DISEASE (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute of Alcohol Abuse and Alcoholism invites applications for its Aids-related secondary analyses of alcohol and chronic disease (R01) grants. This Aids-related R01 funding opportunity announcement aims to support secondary analyses of alcohol related to chronic disease aetiology and epidemiology. The goal of this programme is to facilitate innovative yet cost-effective research using previously collected data.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOA of identical scientific scope, PA-13-261, which solicits applications under the R03 small grant programme mechanism and PA-13-251, which solicits applications under the
R21 exploratory/developmental research grant mechanism.
Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organizations and public or private institutions may apply. PA-13-260.

Closing date: 07 May 15
Deadline information: Applications due by 5pm every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Chronic Care, HIV/AIDS, Aetiology, Clinical Medicine, Epidemiology, Alcoholism, Public Health, Health Services & Primary Care, Primary Care

Contact Details
----------------------------------------------
NIAAA
5635 Fishers Lane
Rockville, MD 20852
Tel: 1 301 594 6231
Email: rbreslow@mail.nih.gov

Implications of New Digital Media Use for Underage Drinking, Drinking-Related Behaviors and Prevention Research (R01): AIDS-Related
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related implications of new digital media use for underage drinking, drinking-related Behaviors and prevention research (R01) grants. This Aids-related R01 funding opportunity announcement aims to investigate whether, and how, having involvement in new digital media use, particularly social media and social networking sites, may influence adolescent alcohol use and drinking patterns, as well as drinking-related problems. The FOA also encourages studies exploring the ways new digital media may be used as platforms for preventative interventions aimed at underage drinking and related problems.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with an FOA of identical scientific scope, PA-13-263, which solicits applications under the R21 exploratory/developmental research grant mechanism.
Direct costs are not limited, but must reflect the needs of the project. The maximum project period is five years. Domestic and foreign for-profit and nonprofit organizations and public or private institutions may apply. PA-13-262.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 09 Jul 13
SYNERGISING OMIC AND SYMPTOM SCIENCE (R01): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites applications for its Aids-related synergising omic and symptom science (R01) grants. This Aids-related R01 funding opportunity announcement aims to promote integration of diverse information from molecular and biological processes with patient-reported outcomes.
Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-264.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 10 Jul 13
Award type: Directed grants to institutions, research groups etc.

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-264

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids, Diagnostic Sciences, Genomics, Carbohydrates, Proteomics & Molecular Interactions, Pharmacogenomics, Epigenetics, Medical Effectiveness & Patient Outcomes, Biological Sciences, Pharmacy & Pharmacology

Contact Details
NIHR
6701 Democracy Boulevard
Bethesda, MD 20817
SYSTEMIC AMYLOIDOSIS: BASIC, TRANSLATIONAL AND CLINICAL RESEARCH (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Disease, the National Cancer Institute and the National Institute on Aging invite applications for their AIDS-related systemic amyloidosis: basic, translational and clinical research (R01) grants. This AIDS-related R01 funding opportunity announcement will support basic and clinical research projects that advance understanding of pathogenic mechanisms underlying systemic amyloidosis, develop improved techniques for the clinical detection and diagnosis of systemic amyloid diseases, develop novel cellular and in vivo models to identify candidate therapeutic agents with, and evaluate the clinical efficacy of novel therapies designed to prevent, arrest and reverse the morbid and lethal progression of these diseases.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PA-13-286.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 29 Jul 13

Award type: Directed grants to institutions, research groups etc.

Eligibility profile
--------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------
Pathogenesis, Pharmacotherapy, Nursing, Public Health, Health Services & Primary Care, Medical & Diagnostic Tests, Diagnostic Sciences, Pharmacy & Pharmacology, Structural Biology, Protein Synthesis, Modification & Turnover, Chemistry, Protein Trafficking, Cell Physiology & Metabolism, HIV/AIDS, Clinical Medicine, Characteristics, Biological Macromolecules, Non-Communicable Diseases, Primary Care, Biological Sciences

Contact Details
--------------------------------------------------
NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 594 6007
Email: rasoolyr@mail.nih.gov
BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for AIDS-related its biomarkers: bridging paediatric and adult therapeutics (R21) grants. This Aids-related R21 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH exploratory/developmental research grant award (R21) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under the small grants programme (R03) mechanism and PAR-13-296, which solicits applications under the research project grant (R01) mechanism. Direct costs are limited to US$275,000 over two years, with no more than US$200,000 in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-295 (replaces PAR-11-324).

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Contact Details
----------------------------------------------
Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20892
Tel: 1 301 496 5589
Email: gg65m@nih.gov

Disciplines
----------------------------------------------
Clinical Medicine, Biological Markers & Sensor Mechanisms, Drug Design, Medical Instrumentation, Biochemical Markers, HIV/Aids, Paediatrics, Medical & Diagnostic Tests, Diagnostic Sciences
Biomarkers: Bridging Paediatric and Adult Therapeutics (R03): AIDS-Related

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its AIDS-related biomarkers: bridging paediatric and adult therapeutics (R03) grants. This AIDS-related R03 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH small grants programme (R03) mechanism and runs in parallel with two FOAs of identical scientific scope: PA-13-296, which solicits applications under the research project grants (R01) mechanism and PA-13-295, which solicits applications under the exploratory/developmental grant (R21) mechanism. Applicants may request up to US$50,000 per year in direct costs for a maximum of two years.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-299 (replaces PAR-11-323).

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 02 Aug 13

Award type: Directed grants to institutions, research groups etc.

Award amount max: $100,000

Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-299

Eligibility profile

Country of applicant institution: Any

Disciplines

Biological Markers & Sensor Mechanisms, Clinical Medicine, Drug Design, Paediatrics, HIV/AIDS, Biochemical Markers, Medical Instrumentation, Diagnostic Sciences, Medical & Diagnostic Tests

Contact Details

Obstetric and Paediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20892
Tel: 1 301 496 5589
Email: gg65m@nih.gov
THE ROLE OF THE CYTOSKELETON IN CELLULAR AGEING (R21/R33): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its Aids-related role of the cytoskeleton in cellular ageing (R21/R33) grants. This Aids-related R21/R33 funding opportunity announcement aims to stimulate the development of innovative research strategies to increase understanding of the molecular and cellular changes in the cytoskeleton that occur during the ageing process. Applications considering the effect of age on factors such as cytoskeleton structure and function, the impact of the cytoskeleton on intracellular organelle interactions, and the signaling or regulatory molecules controlling cellular architecture are encouraged. There is also interest in studying the role of the cytoskeleton in nuclear-cytoplasmic communications and in spatio-temporal relationships during the ageing process and in age-related diseases.
The total project period for the combined R21/R33 application submitted in response to this FOA may not exceed five years and total direct costs are limited to $1.18 million. The R21 phase may not exceed two years or $275,000 in direct costs. The R33 phase may not exceed three years or $900,000 in direct costs.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-301.

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 02 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,175,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-301

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Geriatrics & Gerontology, HIV/AIDS, Cell Physiology & Metabolism, Diagnostic Sciences, Biochemistry & Molecular Biology, Cell & Developmental Biology, Biological Sciences

Contact Details
---------------------------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: 1 301 496 6428
Email: jvelazqu@mail.nih.gov

BIOMARKERS: BRIDGING PAEDIATRIC AND ADULT THERAPEUTICS (R01): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its Aids-related biomarkers: bridging paediatric and adult therapeutics (R01) grants. This Aids-related R01 funding opportunity announcement invites applications that propose adapting adult biomarkers to children. This would include the application and validation of biomarkers developed in adults to paediatric diagnosis, prognosis, and estimation of disease progression, toxicity and response to therapy. Projects supported will be confined to those biomarkers that correlate with a clinical observation, have been extensively studied in adults, and for which there is solid evidence that they have paediatric applications. Discovery of new biomarkers for use in new drug development or in preclinical studies are not part of this FOA.

This funding opportunity announcement will use the NIH research project grant (R01) mechanism and runs in parallel with two FOAs of identical scientific scope: PAR-13-299, which solicits applications under small grants programme (R03) mechanism and PAR-13-295, which solicits applications under the exploratory/developmental grant (R21) programme. Application budgets are not limited, but must reflect actual needs of the project. The project period is a maximum of five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-296 (replaces PAR-11-322).

**Closing date:** 07 May 15

**Deadline information:** Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.

**Posted date:** 02 Aug 13

**Award type:** Directed grants to institutions, research groups etc.


**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

- HIV/Aids
- Paediatrics
- Medical Instrumentation
- Biochemical Markers
- Medical & Diagnostic Tests
- Diagnostic Sciences
- Drug Design
- Biological Markers & Sensor Mechanisms
- Clinical Medicine

**Contact Details**

Obstetric and Paediatric Pharmacology and Therapeutics Branch  
NICHD  
6100 Executive Boulevard, Room 4A01C, MSC 7510  
Bethesda, MD 20892  
Tel: 1 301 496 5589  
Email: gg65m@nih.gov

**Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R21): AIDS-RELATED**

**NIH: Office of the Director**

**Description:**

Participating institutes and centers of the National Institutes of Health invite applications for Aids-related Behavioral and social science research on understanding and reducing health disparities (R21) grants. This R21 funding opportunity announcement supports Behavioral and social science research on the causes and solutions to health
and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged.

This FOA will utilize the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR13-292, which solicits applications under the R01 mechanism. Direct costs are limited to US$275,000 over an R21 two year period, with no more than US$200,000 in direct costs allowed in any single year.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-288 (replaces PAR-10-137).

**Closing date: 07 May 15**

**Deadline information:** Deadlines by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

**Posted date: 05 Aug 13**

---

**Behavioral and Social Science Research on Understanding and Reducing Health Disparities (R01): AIDS-RELATED**

**NIH: Office of the Director**

**Description:**

Participating institutes and centers of the National Institutes of Health invite applications for Aids-related Behavioral and social science research on understanding and reducing health disparities (R01) grants. This Aids-related R01 funding opportunity announcement supports Behavioral and social science research on the causes and solutions to health and disabilities disparities in the US population. Emphasis is placed on research in and among three broad areas of action:

- public policy;
- healthcare;
- disease and disability prevention.

Particular attention is given to reducing health gaps among groups. Proposals that use an interdisciplinary approach, investigate
multiple levels of analysis, incorporate a life-course perspective, or employ innovative methods such as system science or community-based participatory research are particularly encouraged. This FOA will use the NIH research project grant (R01) award mechanism and runs in parallel with a FOA of identical scientific scope, PA-13-288, which solicits applications under the R21 mechanism. Projects may last up to five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-292 (replaces PAR-10-136).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-292

Eligibility profile
Country of applicant institution: Any

Disciplines
Behavioral Medicine, Economic & Social Environment, Health Systems Policy, Medical Sociology, Primary Care, Public Health, Health Services & Primary Care, Allied Health Professions, Disadvantaged & Minority Groups, Social Work & Social Policy, Population Studies, Medical, Psychology, Public Health, Clinical Medicine, Sociology, HIV/AIDS, Health Disparities, Rural Health, Care for Disabled People, Health Systems, Preventive Medicine

Contact Details
OBSSR
31 Center Drive
Building 31, Room B1C19
Bethesda, MD 20892-2027
Tel: 1 301 451 4286
Email: michael.spittel@mail.nih.gov

GUT MICROBIOITA- DERIVED FACTORS IN THE INTEGRATED PHYSIOLOGY AND PATHOPHYSIOLOGY OF DISEASES WITHIN NIDDK’S MISSION (R01): AIDS-RELATED
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Kidney Diseases invites applications for its AIDS-related gut microbiota-derived factors in the integrated physiology and pathophysiology of diseases within NIDDK’s mission (R01) grants. This AIDS-related R01 funding opportunity announcement supports research to define interactions between the host and the gut microbiota that regulate normal physiology and pathophysiology of diseases within NIDDK’s mission. The goal is to discover specific human gut microbiota-derived factors that affect or are affected by host physiology, homeostasis and disease pathophysiology. Projects will also define the specific factors and pathway microbiota-derived factors use to affect host processes within the gut or distant organ sites. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.
Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years. PAR-13-293.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 05 Aug 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile

UDACIOUS GOALS INITIATIVE HIGH PRIORITY RESEARCH AREA – INTERSECTION OF AGEING AND BIOLOGICAL MECHANISMS OF EYE DISEASE (R01): AIDS-RELATED

NIH: National Eye Institute

Description:
The National Eye Institute and the National Institute on Aging invites applications for its audacious goals initiative high priority research area: intersection of ageing and biological mechanisms of eye disease (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement aims to improve understanding of the intersection between ageing and the biological mechanism of eye disease. The following research areas are of interest:

- understanding how the biology of ageing contributes to disease;
- valuating how the failure of homeostatic processes causes or allows the transition from aging to early disease;
- defining the biological staging of disease to understand pathophysiology, identify biomarkers and explore therapy;
- distinguishing normal ocular changes associated with aging from pathophysiologic changes;
- investigate the diverse cellular, molecular, genetic, and neural circuitry mechanisms underlying age-related changes in the eye;
- ascertain the impact of age-related changes in the eye on the progression of visual function as well as associated brain or behavioral functions for the aged and the utility of such changes as early biomarkers for pathological processes for the aged;
- identify and evaluate interventions that will modify age-related changes to alter the course of pathological development.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

Country of applicant institution: Any

Disciplines

HIV/Aids, Diagnostic Sciences, Gastroenterology, Waste Recycling, Reduction & Recovery, Biological Sciences, Microbial Ecology

Contact Details

Division of Digestive Diseases and Nutrition
NIDDK
6707 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 451 3759
Email: greymj@mail.nih.gov
Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PA-13-332.

Closing date: 07 May 15
Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 15 Aug 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile

Country of applicant institution: Any

Disciplines

Pathophysiology, Diagnostic Sciences, Geriatrics & Gerontology, Biochemical Markers, HIV/Aids, Eye Diseases, Clinical Medicine, Biological Markers & Sensor Mechanisms

Contact Details

NEI
5635 Fishers Lane
Rockville MD, 20852
Tel: 1 301 451 2020
Email: mckiegeo@nei.nih.gov

STRATEGIC ALLIANCES FOR MEDICATIONS DEVELOPMENT TO TREAT SUBSTANCE USE DISORDERS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its strategic alliances for medications development to treat substance use disorders (R01). The purpose of this AIDS-related R01 funding opportunity announcement is to support research that advances compounds towards US Food and Drug Administration approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.

Application budgets for direct costs may be up to $3 million per year, but need to reflect the actual needs of the proposed project. The maximum period of support is three years. PAR-13-334 (Reissue of PAS-12-122).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization.
Posted date: 20 Aug 13
Award type: Directed grants to institutions, research groups etc., Academic-Industry links, Clinical trials, Networking/collaboration
Award amount max: $6,000,000
MECHANISMS OF ALCOHOL AND STIMULANT CO-ADDITION (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related mechanisms of alcohol and stimulant co-addiction (R21) grants. This Aids-related R21 funding opportunity announcement promotes research on neurobiological and Behavioral mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and Behavioral levels to promote co-addiction.
This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-339, which solicits applications under the R01 research project grant mechanism. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PA-13-340.

Closing date: 07 May 15

Deadline information: Deadlines every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 29 Aug 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Drug & Substance Abuse, Psychology, Addiction, HIV/Aids, Diagnostic Sciences, Biological Sciences, Public Health, Health Services & Primary Care, Alcoholism, Primary Care, Neurobiology, Behavioral Medicine
**Mechanisms of Alcohol and Stimulant Co-addiction (R01): AIDS-related**

**NIH: National Institute on Alcohol Abuse and Alcoholism**

**Description:**
The National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their AIDS-related mechanisms of alcohol and stimulant co-addiction (R01) grants. This AIDS-related R01 funding opportunity announcement promotes research on neurobiological and Behavioral mechanisms that might explain how alcohol and stimulants interact at genetic, epigenetic, cellular, neurocircuitry and Behavioral levels to promote co-addiction. This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PAR-13-340, which solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-339.

**Closing date: 07 May 15**

**Deadline information:** Deadlines every 7 January, 7 May and 7 September until 8 January 2017.

**Posted date: 29 Aug 13**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Behavioral Medicine, Neurobiology, Primary Care, Alcoholism, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, HIV/AIDS, Addiction, Psychology, Drug & Substance Abuse

**Contact Details**

NIAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: 1 301 443 7600
Email: igrakalic@mail.nih.gov

---

**Exploratory/Developmental Clinical Research Grants in Obesity (R21): AIDS-related**

**NIH: National Institute of Diabetes and Digestive and Kidney Diseases**

---

**Award type:** Directed grants to institutions, research groups etc.

**Website:**

**Application form:**

---

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Behavioral Medicine, Neurobiology, Primary Care, Alcoholism, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, HIV/AIDS, Addiction, Psychology, Drug & Substance Abuse

**Contact Details**

NIAA
6000 Executive Boulevard
Bethesda, MD 20892-7003
Tel: 1 301 443 7600
Email: igrakalic@mail.nih.gov
A total of six components of the National Institutes of Health invite applications for Aids-related exploratory/developmental clinical research grants in obesity. The goal of this Aids-related R21 funding opportunity announcement is to encourage exploratory and developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults or children. Exploratory epidemiological research with a goal of informing translation or clinical research will also be supported within this programme.

Direct costs are limited to US$275,000 over an R21 two year period, with no more than US$200,000 in direct costs allowed in any single year. Eligible institutions include domestic and foreign for-profit and not-for-profit organizations and public or private institutions. PA-12-179 (replaces PA-09-124).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time, every 7 January, 7 May and 7 September until 8 May 2015.
Posted date: 29 Aug 13
Award type: Directed grants to institutions, research groups etc.

Development of Appropriate Paediatric Formulations and Paediatric Drug Delivery Systems (R03): Aids-related

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the Office of Rare Diseases invite applications for the development of appropriate formulations and paediatric drug delivery systems (R03): Aids-related grants. This Aids-related R03 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative. This FOA also encourages development of novel drug delivery systems in the paediatric population. Investigators are encouraged to explore approaches and concepts new to the area of paediatric formulation development, testing and use of newly developed techniques.
superior to the ones currently used in the field.
This funding opportunity announcement will use the NIH research project R03 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-326, which solicits applications under the exploratory-development research grant award (R21) mechanism.
Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs per year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-344 (replaces PAR-11-302).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

**Development of Appropriate Paediatric Formulations and Paediatric Drug Delivery Systems (R21): AIDS-Related**

**NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development**

**Description:**
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R21): Aids-related grants. This Aids-related R21 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.
This funding opportunity announcement will use the NIH research project R21 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-325, which solicits applications under the research project grant (R01) mechanism and PAR-13-344, which solicits applications under the small grant award (R03) mechanism.
Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs per year.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-326 (replaces PAR-11-303)

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
Posted date: 05 Sep 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Drug Design, Allied Health Professions, Pharmacy & Pharmacology, Methods of Drug Delivery, Diagnostic Sciences, Clinical Medicine, Paediatrics

Contact Details

NICHD
Obstetric and Paediatric Pharmacology and Therapeutics Branch
6100 Executive Boulevard, Room 4A01C, MSC 7510
Bethesda, MD 20852
Tel: 1 301 496 5589
Email: gg65m@nih.gov

DEVELOPMENT OF APPROPRIATE PAEDIATRIC FORMULATIONS AND PAEDIATRIC DRUG DELIVERY SYSTEMS (R01): AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and the National Institute on Deafness and Other Communication Disorders invite applications for the development of appropriate formulations and paediatric drug delivery systems (R01): Aids-related grants. This Aids-related R01 funding opportunity announcement addresses different and complementary research needs for the development and acceptability of paediatric drug formulations in different age groups. Development and testing of novel paediatric drug delivery systems is also part of this initiative.

This funding opportunity announcement will use the NIH research project R01 grant mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-344, which solicits applications under the small grant (R03) mechanism and PAR-13-326, which solicits applications under the exploratory/developmental research grant award (R21) mechanism.

Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-325 (replaces PAR-11-301).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.
EARLY-CAREER AWARD IN CHEMISTRY OF DRUG ABUSE AND ADDICTION
(R21/R33): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related early-career award in chemistry of drug abuse and addiction (R21/R33). This AIDS-related R21/R33 funding opportunity announcement seeks to facilitate the entry of new-to-NIH investigators into basic chemistry research applied to drug abuse and addiction. Direct costs are limited to US$250,000 over a R21 two-year period, with a maximum of US$200,000 allowed in any single year. The R33 award phase will be limited to US$250,000 in direct costs per year. The total project period for an application submitted in response to this funding opportunity may not exceed four years. Awards will support milestone driven exploratory/feasibility proof of concept studies (R21 phase, up to two years), with possible rapid transition to expedited development (R33 phase, up to three years, depending upon the requested period for the R21 phase). Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PAR-13-350 (replaces PAS-10-274).

Closing date: 07 May 15
Deadline information: Submissions due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 September 2016.

Posted date: 12 Sep 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,000,000

Eligibility profile
Country of applicant institution: Any

Disciplines

Methods of Drug Delivery, Diagnostic Sciences, Paediatrics, Drug Design, Allied Health Professions, Pharmacy & Pharmacology, Clinical Medicine
ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R03 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged. This FOA uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope: PA-13-354, which solicits applications under the R01 research project grant mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; direct costs are limited to US$50,000 per year. PA-13-356.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Eligibility profile
Country of applicant institution: Any
**Disciplines**

Palliative Nursing, Primary Care, Pharmacy & Pharmacology, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Clinical Pharmacy & Pharmacology, HIV/Aids, Chronic Pain, Hospitalization, Clinical Medicine, Geriatrics & Gerontology, Social Work & Social Policy, Pain Management, Geriatric Nursing, Health Counseling, Blood Tests, Hospice & Palliative Care, Nursing, Health Systems

**Contact Details**

NIA  
7201 Wisconsin Avenue  
Suite 2C231 MSC 9205  
Bethesda, MD  20892-9205  
Tel: 1 301 496 6761  
Email: basil.eldadah@nih.gov

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R21): AIDS-RELATED

NIH: National Institute on Aging

**Description:**

The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This Aids-related R21 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasises studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. Types of studies may include observational, quasi-experimental, or interventional studies using primary data collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two of identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-354, which solicits applications under the R01 research project grant mechanism. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The total project period may not exceed two years; the combined budget for direct costs over this period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. PA-13-355.

**Closing date:** 07 May 15  
**Deadline information:** Applications due by 5pm local time of applicant organization.  
**Deadlines on:** 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.  
**Posted date:** 20 Sep 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Pain Management, Social Work & Social Policy, HIV/Aids, Geriatrics & Gerontology, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Clinical Pharmacy & Pharmacology, Health Systems, Nursing, Palliative Nursing, Blood Tests, Primary Care, Hospice & Palliative Care, Health Counseling, Geriatric Nursing, Hospitalization, Chronic Pain, Clinical Medicine, Pharmacy & Pharmacology

Contact Details
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: 1 301 496 6761
Email: basil.eldadah@nih.gov

ADVANCING THE SCIENCE OF GERIATRIC PALLIATIVE CARE (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Center for Complementary and Alternative Medicine invite applications for their grants for advancing the science of geriatric palliative care. This AIDS-related R01 funding opportunity announcement encourages research grant applications focused on palliative care in geriatric populations. This FOA emphasizes studies in a variety of settings including ambulatory care, hospitals, assisted living facilities, and short- and long-term care facilities; however, hospice and end-of-life settings are not included within the scope of this FOA, as they are the subject of other NIH programmes. Rather, this FOA highlights research on palliative care in settings and at time points earlier in geriatric patients' disease or disability trajectories. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited, but need to reflect the actual needs of the proposed collection or secondary analyses. Leveraging on-going cohorts, intervention studies, networks, data and specimen repositories, and other existing resources and infrastructure are encouraged. This FOA uses the R01 research project grant mechanism and runs in parallel with two of identical scientific scope: PA-13-356, which solicits applications under the R03 small grant programme mechanism, and PA-13-355, which solicits applications under the R21 exploratory/developmental grant mechanism. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.
project. The maximum project period is five years. PA-13-354.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization.
Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
Posted date: 20 Sep 13
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Pain Management, Social Work & Social Policy, Geriatrics & Gerontology, HIV/AIDS, Clinical Pharmacy & Pharmacology, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Nursing, Health Systems, Hospice & Palliative Care, Primary Care, Blood Tests, Palliative Nursing, Health Counseling, Geriatric Nursing, Clinical Medicine, Chronic Pain, Hospitalization, Pharmacy & Pharmacology

Contact Details
----------------------------------------------
NIA
7201 Wisconsin Avenue
Suite 2C231 MSC 9205
Bethesda, MD 20892-9205
Tel: 1 301 496 6761
Email: basil.eldadah@nih.gov

MODELING SOCIAL BEHAVIOR (R01): AIDS-RELATED
NIH: National Institute of General Medical Sciences

Description:
A total of 10 institutes and offices of the National Institutes of Health invites applications for their AIDS-related modeling social behavior (R01) call. This AIDS-related engineering approaches to deepen understanding of complex social behavior. This research will examine phenomena at multiple scales to address the emergence of collective behaviors that arise from individual elements or parts of a system working together.

Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. Transdisciplinary teams are encouraged, including at minimum researchers with expertise in the Behavioral or social sciences as well as those in computational and systems modeling. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years for new and early-stage investigators, and four years for established investigators.
Ref: PAR-13-374.

Closing date: 07 May 15
Deadline information: Applications due by 5pm, local time of applicant organization,
NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (COLLABORATIVE R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (collaborative R01): Aids-related grants. The aim of this collaborative R01 funding opportunity announcement is to support Aids-related development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness, This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

This FOA is suitable when two or more sites are needed to complete the study. Each site must have its own programme director or principal investigator. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply.

MIMH will invest US$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-391.

Closing date: 07 May 15
Deadline information: Deadlines 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2017.

Award type: Directed grants to institutions, research groups etc., Networking/collaboration

Website:

Application form:
**NEW COMPUTATIONAL METHODS FOR UNDERSTANDING THE FUNCTIONAL ROLE OF DNA VARIANTS THAT ARE ASSOCIATED WITH MENTAL DISORDERS (R01): AIDS-RELATED**

NIMH: National Institute of Mental Health

**Description:**
The National Institute of Mental Health invites applications for its new computational methods for understanding the functional role of DNA variants that are associated with mental disorders (R01): AIDS-related grants. The aim of this R01 funding opportunity announcement is to support AIDS-related development of advanced computational, bioinformatic and statistical tools to determine the functional relevance of genetic variants associated with mental disorders of complex aetiologies identified through genome-wide association or sequencing studies. The overarching goal of this initiative is to support the development of innovative computational methods that facilitate the elucidation of the functionality of genetic variants associated with mental illness. This should take into account the added complexities and nuances of brain diseases, and ultimately inform the identification and validation of potential targets for novel treatment development.

Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply.

MIMH will invest US$3 million in fiscal year 2015 to fund this and a companion FOA. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is three years.

Ref: PAR-13-391.

**Closing date:** 07 May 15

**Deadline information:** Deadlines 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2017.

**Posted date:** 14 Nov 13

**Award type:** Directed grants to institutions, research groups etc., Networking/collaboration

**Website:**

**Application form:**

**Eligibility profile**

Country of applicant institution: Any

Disciplines

Aetiology, Medical Informatics & Telemedicine, Bioinformatics, Psychology, Mental Health, Systematics, Health Informatics, Mental Illness, Deoxyribonucleic Acid, DNA, Biostatistics, Structural Biology, Human Genome, Diagnostic Sciences, Computer Science & Informatics

**Contact Details**

NIMH
6001 Executive Boulevard
Rockville MD 20852
Tel: 1 301 443 6653
Email: anjene.addington@nih.gov
PUBLIC HEALTH IMPACT OF THE CHANGING POLICY/LEGAL ENVIRONMENT FOR MARIJUANA (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related public health impact of the changing policy/legal environment for marijuana (R01) grants. This Aids-related R01 funding opportunity announcement encourages research on the impact of changing marijuana policies and laws on public health outcomes. This includes:
- marijuana exposure among children, adolescents and adults;
- other licit and illicit drug use;
- education and professional achievement;
- social development;
- risky Behaviors;
- mental health;
- HIV.
Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply.
NIH will invites US$3 million in fiscal year 2014 to fund six to ten awards. Application budgets are not limited but must reflect the actual needs of the project. The maximum project period is three years.
Ref: PAS-14-020.

Closing date: 07 May 15

Deadline information: Submissions due by 5pm proposers’ local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 09 Dec 13
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PAS-14-020.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Behavioral Medicine, Health Systems Policy, Primary Care, Educational Evaluation & Assessment, Diagnostic Sciences, Public Health, Health Services & Primary Care, Mental Health, Social Behavior & Attitudes, Pharmacokinetics, Cognitive & Behavioral Therapies, Social Work & Social Policy, Psychology, Medical Effectiveness & Patient Outcomes, Clinical Medicine, Sociology, Addiction, Education, Public Health, HIV/Aids, Drug & Substance Abuse, Child Development, Blood Tests
**EUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED**

**NIH: National Institute on Drug Abuse**

**Description:**
The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R21). This Aids-related R21 funding opportunity announcement aims to examine the molecular, cellular, circuit and Behavioral responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R21 exploratory/developmental research grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-084, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit or non-profit organizations and public or private institutions may apply. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-083.

**Closing date: 07 May 15**

**Deadline information:** Applications due by 5pm proposers’ local time, every 7 January, 7 May and 7 September until 8 May 2017.

**Posted date: 05 Feb 14**

**Award type:** Directed grants to institutions, research groups etc.

**Award amount max:** $275,000


**Application form:** [http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-083](http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-083)

**Eligibility profile**

**Country of applicant institution:** Any

**Disciplines**

Behavioral Medicine, Ethology, Primary Care, Cytopathology, Cell & Developmental Biology, Diagnostic Sciences, Biochemistry & Molecular Biology, Public Health, Health Services & Primary Care, Biological Sciences, HIV/Aids, Pathology, Psychology, Neuroscience, Drug & Substance Abuse

**Contact Details**

NIDA
6001 Executive Boulevard

Rockville, MD 20852
Tel: 1 301 443 6504
Email: lopezmar@mail.nih.gov

**EUROIMMUNE SIGNALLING AND FUNCTION IN SUBSTANCE ABUSE DISORDERS (R21): AIDS-RELATED**

**NIH: National Institute on Drug Abuse**

**Description:**
The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R21). This Aids-related R21 funding opportunity announcement aims to examine the molecular, cellular, circuit and Behavioral responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R21 exploratory/developmental research grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-084, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit or non-profit organizations and public or private institutions may apply. Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-083.

**Closing date: 07 May 15**

**Deadline information:** Applications due by 5pm proposers’ local time, every 7 January, 7 May and 7 September until 8 May 2017.

**Posted date: 05 Feb 14**

**Award type:** Directed grants to institutions, research groups etc.

**Award amount max:** $275,000


**Application form:** [http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-083](http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-083)

**Eligibility profile**

**Country of applicant institution:** Any

**Disciplines**

Behavioral Medicine, Ethology, Primary Care, Cytopathology, Cell & Developmental Biology, Diagnostic Sciences, Biochemistry & Molecular Biology, Public Health, Health Services & Primary Care, Biological Sciences, HIV/Aids, Pathology, Psychology, Neuroscience, Drug & Substance Abuse

**Contact Details**

NIDA
6001 Executive Boulevard

Rockville, MD 20852
Tel: 1 301 443 6504
Email: lopezmar@mail.nih.gov
**Description:**
The National Institute on Drug Abuse invites Aids-related applications for its grants on neuroimmune signalling and function in substance abuse disorders (R01). This Aids-related R01 funding opportunity announcement aims to examine the molecular, cellular, circuit and Behavioral responses to neuroimmune signalling within the central nervous system. Research should pertain to the initiation, escalation and maintenance of the neurological consequences resulting from substance use disorders and to abstinence, withdrawal and relapse. The goal is to determine the extent to which neuroimmune responses contribute to or protect against the risk and consequences of SUDs.

This FOA will use the R01 research project grant mechanism, and runs in parallel with an FOA of identical scientific scope, PA-14-083, which encourages applications under the R21 exploratory/developmental research grant mechanism.

US and foreign for-profit or non-profit organizations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-084.

**Closing date:** 07 May 15

**Deadline information:** Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

**Posted date:** 05 Feb 14

**Award type:** Directed grants to institutions, research groups etc.

**Website:**

**Application form:**

**Eligibility profile**
----------------------------------------------

Country of applicant institution: Any

**Disciplines**
----------------------------------------------
Public Health, Health Services & Primary Care, Diagnostic Sciences, Biochemistry & Molecular Biology, HIV/Aids, Ethology, Drug & Substance Abuse, Behavioral Medicine, Neuroscience, Cytopathology, Primary Care, Biological Sciences, Cell & Developmental Biology, Psychology, Pathology

**Contact Details**
----------------------------------------------

NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9561
Tel: 1 301 443 3205
Email: rsorense@mail.nih.gov
Description:
The NIH's National Institute on Drug Abuse invites applications for its drug abuse, risky decision making and HIV/AIDS funding opportunity announcement. This AIDS-related R01 funding opportunity announcement intends to stimulate model driven research that will increase understanding of the way people make decisions about engaging in behaviors that impact the risk of acquiring or transmitting HIV, or to adhere to treatments for HIV. Decision making processes may contribute to both substance use and abuse and other HIV acquisition or transmission risks.

This announcement encourages applications to study cognitive, motivational or emotional mechanisms and brain neuroendocrine and reinforcement systems that relate to HIV-risk behaviors or treatment non-compliance. Interdisciplinary studies that incorporate approaches from psychology, economics, anthropology, sociology, decision sciences, neuroscience and computational modeling are encouraged.

The total project period for an application submitted in response to this funding opportunity announcement may not exceed five years. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. This FOA utilize the NIH R01 research project grant award mechanism and runs in parallel with FOAs of identical scientific scope, PA-14-062, that solicits applications under the R21 mechanism and PA-14-063 that solicits applications under the R03 mechanism.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum funding period is five years.

Ref: PA-14-061 (reissue of PA-11-006)

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 19 Feb 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-061.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-061

Eligibility profile
---------------------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------------------

Contact Details
---------------------------------------------------------------------------------
Division of Clinical Neurosciences and Behavior Research
NIDA
6001 Executive Boulevard, Rm 3173
Rockville, MD 20852-9555
Tel: 1 301 435 1318
ERADICATION OF HIV-1 FROM CENTRAL NERVOUS SYSTEM RESERVOIRS (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute of Allergy and Infectious Disease, the National Institute on Drug Abuse and the National Institute of Neurological Disorders and Stroke invite research applications for their eradication of HIV infection of central nervous system reservoirs (R01) grants. This R01 programme announcement aims to address the problem of HIV-1 persistence focused solely on the CNS of persons treated with highly active anti-retroviral therapy. This FOA will support research in the following areas:

- basic research to identify and characterize persistent HIV-1 in CNS derived cells such as macrophages, microglia or astrocytes in the setting of suppressive anti-retroviral therapy, with or without substance use;
- basic research to determine the mechanisms involved in the temporal establishment, maintenance and resurgence of persistent HIV-1 in the CNS in relationship to the timing of antiretroviral therapy;
- development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART including effects of chronic substance use;
- assessment of current and emerging eradication approaches on whether or how well they have successfully reactivated persistent HIV from CNS-derived cells such as macrophages, microglia and astrocytes;
- assessment of CNS toxicity and adverse impacts of current and emerging eradication strategies.

Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.

Ref: PA-14-095.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 12 Feb 14
Award type: Directed grants to institutions, research groups etc.,
Networking/collaboration
Website: http://grants.nih.gov/grants/guide/photfiles/PA-14-095.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
C LINICAL VISION RESEARCH: RESOURCE CENTER GRANT (UG1): AIDS-RELATED

NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its clinical vision research: resource center grant (UG1). This AIDS-related UG1 funding opportunity announcement supports single component resource centers to provide imaging, laboratory or other requisite services for a multi-center clinical trial or other complex or high-risk clinical vision research study. This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-098, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism. US and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-14-097.

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 13 Feb 14
Award type: Research centers, Directed grants to institutions, research groups etc., Clinical trials
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-097.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Optometry, Sensory Systems, Eye Diseases, Drug Design, Vision Science, Epidemiology, Diagnostic Sciences, HIV/Aids

Contact Details
NEI
5635 Fishers Lane

Closing date: 07 May 15
CLINICAL VISION RESEARCH: CHAIR’S GRANT (UG1): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its clinical vision research: chair’s grant (UG1). This AIDS-related UG1 funding opportunity announcement supports the scientific rationale, study aims and significance of the research project.
This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-099 and PAR-14-100, each of which invites applications under the UG1 mechanism.
US and foreign public and private non-profit organizations and for-profit organizations may apply.
Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.
Ref: PAR-14-098.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 13 Feb 14

Award type: Clinical trials, Directed grants to institutions, research groups etc., Research centers
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-098.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Optometry, Drug Design, Eye Diseases, Sensory Systems, Diagnostic Sciences, Epidemiology, Vision Science, HIV/AIDS

Contact Details
NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: 1 301 451 2020
Email: everettd@mail.nih.gov
INICAL VISION RESEARCH: CLINICAL CENTER GRANT (UG1): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its clinical vision research: clinical center grant (UG1). This AIDS-related UG1 funding opportunity announcement supports the organization and operations of the clinical center responsible for recruitment and retention of study participants and implementation of the study protocol.

This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-100, each of which invites applications under the UG1 mechanism.

US and foreign public and private non-profit organizations and for-profit organizations may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-099.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 13 Feb 14
Award type: Research centers, Directed grants to institutions, research groups etc., Clinical trials
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-099.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Diagnostic Sciences, Vision Science, Epidemiology, HIV/AIDS, Optometry, Eye Diseases, Drug Design, Sensory Systems

Contact Details
NEI
5635 Fishers Lane
Bethesda, MD 20892-9300
Tel: 1 301 451 2020
Email: everettd@mail.nih.gov

CLINICAL VISION RESEARCH: COORDINATING CENTER GRANT (UG1): AIDS-RELATED
NIH: National Eye Institute

Description:
The National Eye Institute invites AIDS-related applications for its clinical vision research: coordinating center grant (UG1). This AIDS-related UG1 funding opportunity announcement supports the provision of details of the coordinating center's responsibilities and operations.
This funding opportunity announcement will use the UG1 grant mechanism, and run in parallel with FOAs of similar scientific scope, PAR-14-096, which invites applications under the U10 mechanism, and PAR-14-097, PAR-14-098 and PAR-14-099, each of which invites applications under the UG1 mechanism. US and foreign public and private non-profit organizations and for-profit organizations may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-14-100.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 13 Feb 14
Award type: Directed grants to institutions, research groups etc., Clinical trials, Research centers

**SYNTHEtic PSIcoactive DRUGs AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R03): AIDS-RELATED**

**NIH: National Institute on Drug Abuse**

**Description:**
The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R03). This Aids-related R03 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R03 small grant programme grant mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-105 and PAR-14-106 which use the R21 exploratory/developmental and R01 research project grant mechanisms respectively. The combined budget for direct costs for the maximum two year project period may not exceed US$100,000. No more than US$50,000 in direct costs may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organizations and public and private organizations. Ref: PAR-14-014.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Feb 14
SYNTHETIC PSYCHOACTIVE DRUGS AND STRATEGIC APPROACHES TO COUNTERACT THEIR DELETERIOUS EFFECTS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R21). This Aids-related R21 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-104 and PA-14-106 which use the R03 small grant and R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year.

Applications may be submitted by foreign or US for-profit and non-profit organizations and public and private organizations.

Ref: PA-14-105.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 21 Feb 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants-guide/pa-files/PA-14-105.html
Application form: http://www.grants.gov/web/grants/applicant/download-application-package.html#download=true&oppNum=PA-14-105
SYNTHEtic psychoACtive drugs and Strategic Approaches to counterAct their deleterious effects (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on synthetic psychoactive drugs and strategic approaches to counteract their deleterious effects (R01). This Aids-related R01 funding opportunity announcement aims to deepen knowledge of the use of synthetic psychoactive drugs, their mechanisms of action and their health effects, as well as develop prevention strategies and treatment strategies.

This FOA uses the R01 research project grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-105 and PA-14-106 which use the R21 exploratory/developmental and R03 small grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Applications may be submitted by foreign or US for-profit and non-profit organizations and public and private organizations.

Ref: PA-14-106.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Feb 14

Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://www.grants.gov/web/grants/applicant.s/download-application-package.html#download=true&oppNum=PA-14-106

Eligibility profile
Country of applicant institution: Any
Disciplines
General Practice, HIV/Aids, Pharmacokinetics, Methods of Drug Delivery, Diagnostic Sciences, Public Health, Health Services & Primary Care, Primary Care, Drug Design, Behavioral Medicine, Drug & Substance Abuse, Clinical Medicine, Chemistry, Psychology

Contact Details
Tel: 1 301 435 1304
Email: rrapaka@nida.nih.gov
Description:
The National Institute of Nursing Research invites applications for its Aids-related call on family-centered self-management of chronic conditions (R01). This Aids-related R01 funding opportunity announcement seeks to build on the science of family-centered self-management in chronic conditions. This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-113, which uses the R21 exploratory/developmental research grant mechanism. Foreign or US for-profit and non-profit organizations and public and private organizations may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PA-14-112.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 25 Feb 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-112.html
Eligibility profile
Country of applicant institution: Any
Disciplines
Social Programmes, Chronic Care, HIV/AIDS, Social Work & Social Policy, Community Health Services, Public Health, Health Services & Primary Care, Primary Care

Contact Details
Tel: 1 301 594 5970
Email: hussk@mail.nih.gov
Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-14-113.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 25 Feb 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-113.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Social Programmes, Chronic Care, HIV/AIDS, Social Work & Social Policy, Community Health Services, Public Health, Health Services & Primary Care, Primary Care

Contact Details

Tel: 1 301 594 5970
Email: hussk@mail.nih.gov

ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its alcohol-induced effects on tissue injury and repair (R21) grants. This Aids-related R21 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol’s effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-123, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-14-124.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://www.grants.gov/web/grants/applicant
ADVANCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R21)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Disease invite applications for their advancing structural level interventions through enhanced understanding of social determinants in HIV prevention and care (R21) grants. This R21 funding opportunity announcement aims to understand and address social determinants associated with the prevention and treatment of HIV. This FOA supports two research endeavors:

- characterizing the social determinants that are most relevant to HIV prevention and treatment outcomes, particularly in association with inequities in HIV risk or outcomes;
- developing and testing structural interventions aimed at reducing the negative impact or maximizing positive aspects of social determinants.

This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-133, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-134.

Closing date: 07 May 15
Deadline information: Applications due by 5pm, local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:
http://grants.nih.gov/grants/guide/announcements/PA-14-134.html

Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-134
Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Biomedical Engineering, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, Health Disparities, HIV/AIDS, Primary Care

Contact Details
----------------------------------------------
NIMH
NSC BG RM 6117
6001 Executive Blvd
Rockville MD 20852
Tel: 1 301 443 8962
Email: grossmanc@mail.nih.gov

I
MPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their improving delivery of HIV prevention and treatment through implementation science and translational research (R21) grant. This R21 funding opportunity announcement encourages research designed to increase the public health impact of efficacious HIV/AIDS-related interventions for prevention and treatment.
The goals of this scientific agenda are to learn how best to deliver interventions more efficiently and effectively in real-world communities and clinics, to more readily transfer interventions from one setting or population to another, and to make better informed choices for combination intervention packages.
This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-131, which solicits applications under the R01 research project grant mechanism.
Direct costs are limited to US$275,000 over a two year project period, with no more than US$200,000 allowed in any single year.
Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions.
Ref: PA-14-129.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-129

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Primary Care, Biomedical Engineering, Pharmaceutical Drugs, Public Health, Health

TRENGTHENING ADHERENCE TO ANTIRETROVIRAL-BASED HIV TREATMENT AND PREVENTION (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R21) grant. This R21 funding opportunity announcement supports research to understand and promote adherence to antiretroviral regimens for HIV treatment and prevention. Studies addressing pre-exposure prophylaxis and antiretroviral therapy are the foci of this FOA. The emphasis is on the development of feasible interventions to improve and sustain PrEP or ART adherence, which could be rapidly implemented to improve HIV treatment and prevention outcomes. This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-126, which solicits applications under the R01 research project grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-14-125.

Closing date: 07 May 15
Deadline information: Applications due by 5pm, local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-125.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-125

Eligibility profile
Country of applicant institution: Any
Disciplines
Clinical Medicine, Antivirals, Primary Care, Virology, HIV/Aids, General Practice,
ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R21)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R21) grant. This R21 funding opportunity announcement supports innovative studies to address gaps in HIV care continuum research. Research should focus on less-studied aspects of entering and remaining in HIV care.
This FOA will use the NIH R21 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-132, which solicits applications under the R01 research project grant mechanism.
US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year.
Ref: PA-14-130.

Closing date: 07 May 15
Deadline information: Applications due by 5pm, local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-130.html
Application form: http://www.grants.gov/web/grants/applicant/ download-application-package.html#download=true&oppNum=PA-14-130

Eligibility profile
Country of applicant institution: Any

Disciplines
Blood Tests, Quality of Care, HIV/Aids, Clinical Medicine, Standards of Care, Access to Health Care, Public Health, Health Services & Primary Care, Diagnostic Sciences, Primary Care, Health Systems, Consumer Choice

Contact Details
Tel: 1 301 443 1613
Email: cgordon1@mail.nih.gov
ALCOHOL-INDUCED EFFECTS ON TISSUE INJURY AND REPAIR (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its alcohol-induced effects on tissue injury and repair (R01) grants. This Aids-related R01 funding opportunity announcement supports the study of molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans. The NIAAA is especially interested in integrative research that elucidates alcohol’s effects on complex mechanisms of injury and repair that are either common or specific to each organ system. The call also encourages the study of alcohol’s effect on stem cells, embryonic development and regeneration, as well as the studies on molecular and cellular actions of moderate alcohol consumption.
This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-124, which solicits applications under the R21 exploratory/developmental grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years. Ref: PA-14-123.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-123.html
Application form: http://www.grants.gov/web/grants/applicant/package.html#download=true&oppNum=PA-14-123

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Diagnostic Sciences, Stem Cell, Pathophysiology, Embryonic Stem Cells, Stem Cell Therapy, HIV/Aids, Cellular Interactions, Foetal Health & Prenatal Development, Regenerative Medicine, Traumatology, Accidents & Injury, Stem Cell Genomics, Cytopathology, Biological Sciences, Alcoholism, Induced Pluripotent Stem Cells, Pathology

Contact Details
----------------------------------------------
Tel: 1 301 443 7351
Email: duntyw@mail.nih.gov
ADVENCING STRUCTURAL LEVEL INTERVENTIONS THROUGH ENHANCED UNDERSTANDING OF SOCIAL DETERMINANTS IN HIV PREVENTION AND CARE (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Disease invite applications for their advancing structural level interventions through enhanced understanding of social determinants in HIV prevention and care (R01) grants. This R01 funding opportunity announcement aims to understand and address social determinants associated with the prevention and treatment of HIV. This FOA supports two research endeavors:

- characterizing the social determinants that are most relevant to HIV prevention and treatment outcomes, particularly in association with inequities in HIV risk or outcomes;
- Developing and testing structural interventions aimed at reducing the negative impact or maximizing positive aspects of social determinants.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-134, which solicits applications under the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-133.

Closing date: 07 May 15

Deadline information: Applications due by 5pm, local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14

Award type: Directed grants to institutions, research groups etc.


Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care, Preventive Medicine, Diagnostic Sciences, Public Health, Health Services & Primary Care, Biomedical Engineering, Health Disparities, HIV/AIDS

Contact Details

NIHM
NSC BG RM 6117
6001 Executive Blvd
Rockville MD 20852
Tel: 1 301 443 8962
Email: grossmanc@mail.nih.gov
IMPROVING DELIVERY OF HIV PREVENTION AND TREATMENT THROUGH IMPLEMENTATION SCIENCE AND TRANSLATIONAL RESEARCH (R01)

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their improving delivery of HIV prevention and treatment through implementation science and translational research (R01) grant. This R01 funding opportunity announcement encourages research designed to increase the public health impact of efficacious HIV/AIDS-related interventions for prevention and treatment.

The goals of this scientific agenda are to learn how best to deliver interventions more efficiently and effectively in real-world communities and clinics, to more readily transfer interventions from one setting or population to another, and to make better informed choices for combination intervention packages.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-129, which solicits applications under the R21 exploratory/developmental grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions.

Ref: PA-14-131.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-131

Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine, Psychology, Population Studies, Medical, Health Counseling, Primary Care, Biomedical Engineering, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Public Health, General Practice, HIV/Aids, Social Work & Social Policy

Contact Details

NIMH
NSC BG
Room 6106
6001 Executive Boulevard
Rockville MD 20852
Tel: 1 301 443 1613
Email: cgordon1@mail.nih.gov
Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R01) grant. This R01 funding opportunity announcement supports research to understand and promote adherence to antiretroviral regimens for HIV treatment and prevention. Studies addressing pre-exposure prophylaxis and antiretroviral therapy are the foci of this FOA. The emphasis is on the development of feasible interventions to improve and sustain PrEP or ART adherence, which could be rapidly implemented to improve HIV treatment and prevention outcomes.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-125, which solicits applications under the R21 exploratory/developmental grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-126.

Closing date: 07 May 15
Deadline information: Applications due by 5pm, local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.
Posted date: 03 Mar 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-126.html
Application form: http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-126

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Antivirals, Virology, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Clinical Medicine, HIV/Aids, General Practice, Primary Care

Contact Details
---------------------------------------------------------------
NIMH
NSC BG
Room 6116
6001 Executive Boulevard
Rockville MD 20852
Tel: 1 301 443 6802
Email: stirrattm@mail.nih.gov
ACCELERATING IMPROVEMENTS IN THE HIV CARE CONTINUUM (R01)
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases invite applications for their strengthening adherence to antiretroviral-based HIV treatment and prevention (R01) grant. This R01 funding opportunity announcement supports innovative studies to address gaps in HIV care continuum research. Research should focus on less-studies aspects of entering and remaining in HIV care.

This FOA will use the NIH R01 award mechanism and runs in parallel with a FOA of identical scientific scope, PA-14-130, which solicits applications under the R21 exploratory/developmental grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-132.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2017.

Prevention and Treatment of Substance Using Populations with or At Risk for Hepatitis C Virus (R34): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R34). This Aids-related R34 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new
infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV. This FOA uses the R34 planning grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-136 and PA-14-137, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanisms respectively.

The combined budget for direct costs for the maximum three year project period may not exceed US$450,000. No more than US$225,000 may be requested in any single year. Applications may be submitted by foreign or US for-profit and non-profit organizations and public and private organizations.

Ref: PA-14-135.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000

Website:
Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-135

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
HIV/Aids, General Practice, Diagnostic Sciences, Preventive Medicine, Public Health, Health Services & Primary Care, Drug Design, Infectious Diseases, Infection Agents & Pathogens, Primary Care, Drug & Substance Abuse, Hepatology

Contact Details
----------------------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 443 3207
Email: aklinwm@nida.nih.gov

PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R21). This Aids-related R21 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-
14-137, which use the R34 planning grant mechanism and the R01 research project grant mechanisms respectively. The combined budget for direct costs for the maximum two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. Applications may be submitted by foreign or US for-profit and non-profit organizations and public and private organizations. Ref: PA-14-136.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer's local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:  
Application form:  
http://www.grants.gov/web/grants/applicant

EUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R21): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:  
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R21). This Aids-related R21 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and Behavioral changes induced by alcohol.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-139 which uses the R01 research project grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Direct costs are limited to US$275,000 over a two-year period, with no more than US$200,000 in direct costs allowed in any single year. Ref: PA-14-138.

Closing date: 07 May 15
PREVENTION AND TREATMENT OF SUBSTANCE USING POPULATIONS WITH OR AT RISK FOR HEPATITIS C VIRUS (R01): AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related grants on the prevention and treatment of substance using populations with or at risk for hepatitis C virus (R01). This Aids-related R01 funding opportunity announcement encourages research focused on the prevention and treatment of hepatitis C virus to reduce new infections and identify and treat existing infections more effectively. This FOA supports the initial development of a clinical trial or research project focused on HCV for at-risk substance using populations, including those with or at risk for HIV.

This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-135 and PA-14-136, which use the R34 planning grant mechanism and the R21 exploratory/developmental grant mechanisms respectively.

Application budgets are not limited, but need to reflect actual needs of the proposed project.

The maximum project period is five years.

Applications may be submitted by foreign or US for-profit and non-profit organizations and public and private organizations.

Ref: PA-14-137.

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 04 Mar 14

Award type: Directed grants to institutions, research groups etc.

Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-137.html

EUROIMMUNE MECHANISMS OF ALCOHOL-RELATED DISORDERS (R01): AIDS-RELATED
NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites Aids-related applications for its grants on neuroimmune mechanisms of alcohol-related disorders (R01). This Aids-related R01 funding opportunity announcement seeks studies to address the role of neuroimmune modulation in response to and in the neuroadaptation of the brain to acute and chronic alcohol exposure, and alcohol dependence and withdrawal. The goal is to achieve fundamental insights of neuroimmune mechanisms underlying brain functional and Behavioral changes induced by alcohol.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-14-138, which uses the R21 exploratory/developmental grant mechanism.

US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but must reflect the needs of the project. Funding will last a maximum of five years.

Ref: PA-14-139 (re-issue of PA-11-064).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 04 Mar 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-139.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-139

Eligibility profile
Country of applicant institution: Any

Disciplines
HIV/Aids, Diagnostic Sciences, Neurobiology, Immunology, Ethology, Behavioral Medicine, Neuropsychology, Endocrine & Neuroendocrine Cancers, Neuroscience, Psychology, Clinical Medicine,
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites Aids-related applications for its community partnerships to advance research (R21). This Aids-related R21 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes.

This funding opportunity announcement will use the NIH R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-142, which solicits applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.

Ref: PAR-14-141.

Award amount max: $275,000
Website:

Application form:
http://www.grants.gov/web/grants/applicant/package.html#download=true&oppNum=PA-14-141

Eligibility profile

Country of applicant institution: Any

Disciplines

Medical Effectiveness & Patient Outcomes, Clinical Medicine, Medical Research of Selected Fields, Translational Medicine, Nursing, Primary Care, HIV/AIDS, Pharmaceutical Drugs, Public Health, Health Services & Primary Care, Biomedical Engineering

Contact Details

NINR
National Institutes of Health
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: 1 301 594 5971
Email: mccloskd@mail.nih.gov
COMMUNITY PARTNERSHIPS TO ADVANCE RESEARCH (R01): AIDS-RELATED
NINH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research invites AIDS-related applications for its community partnerships to advance research (R01). This AIDS-related R01 funding opportunity announcement encourages researchers to partner with communities using community engaged research methodologies that will enhance relationships leading to better interventions and positive health outcomes. This funding opportunity announcement will use the NIH R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-141, which solicits applications under the R21 exploratory/developmental research grant award mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect actual needs of the proposed project. The maximum project period is five years. Ref: PAR-14-142.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 05 Mar 14

Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-142.html
Application form: http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=PA-14-142

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
Clinical Medicine, Medical Effectiveness & Patient Outcomes, Medical Research of Selected Fields, Nursing, Translational Medicine, Primary Care, HIV/AIDS, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Biomedical Engineering

Contact Details
-----------------------------------------------
NINR
National Institutes of Health
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: 1 301 594 5971
Email: mccloskd@mail.nih.gov

ESTABLISHING BEHAVIORAL AND SOCIAL MEASURES FOR CAUSAL PATHWAY
NINH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites AIDS-related applications for its grants on establishing Behavioral and social measures for causal
pathway research in dental, oral and craniofacial health (R21). This Aids-related R21 funding opportunity announcement aims to establish measures of specific Behavioral or social phenomena to test causal hypotheses about Behavioral and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health Behaviors, social interactions, community characteristics, built environments, targeted by Behavioral or social interventions to improve oral health;
- measures of the hypothesized moderators and mediators of a Behavioral or social intervention's effect.

This FOA uses the R21 exploratory/developmental grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-143, which uses the R01 research project grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions may apply. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Ref: PAR-14-144.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 May 2017.

Establishing Behavioral and Social Measures for Causal Pathway Research in Dental, Oral and Craniofacial Health (R01): AIDS-Related

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites Aids-related applications for its grants on establishing Behavioral and social measures for causal pathway research in dental, oral and craniofacial health (R01). This Aids-related program
R01 funding opportunity announcement aims to establish measures of specific Behavioral or social phenomena to test causal hypotheses about Behavioral and social contributors to dental, oral or craniofacial diseases. This announcement encourages the development and testing of two types of measures:

- measures of the health Behaviors, social interactions, community characteristics, built environments, targeted by Behavioral or social interventions to improve oral health;
- measures of the hypothesized moderators and mediators of a Behavioral or social intervention's effect.

This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-144, which uses the R21 exploratory/developmental grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions may apply.

Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Ref: PAR-14-143.

Closing date: 07 May 15

Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 06 Mar 14

Award type: Directed grants to institutions, research groups etc.
Award budget total: -

Website:

Application form:
http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true&oppNum=PAR-14-144

Eligibility profile

Country of applicant institution: Any

Disciplines

Oral & Maxillofacial Surgery, Dental Health & Hygiene, Restorative Dentistry, HIV/AIDS, Public Health, Health Services & Primary Care, Primary Care, Paediatric Dentistry, Behavioral Medicine, Special Needs Dentistry, Preventive Dentistry, Craniofacial Disorders, Psychology, Medical Education, Dentistry, Oral Medicine

Contact Details

NIDCR
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 451 3888
Email: riddleme@mail.nih.gov

EARLY STAGE DEVELOPMENT OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED

NIH: National Institute of General Medical Sciences

Description:
A total of 12 institutes and offices of the National Institutes of Health invite applications for their Aids-related grants on early stage development of technologies in biomedical computing, informatics and big data science (R01). This Aids-related R01 funding opportunity announcement aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science
that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centers and range from basic biomedicine and including research to all relevant organ systems and diseases.

Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. Application budgets may not exceed US$300,000 direct costs per year, over a maximum project period of three years. Ref: PA-14-155.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 17 Mar 14
Award type: Directed grants to institutions, research groups etc., Prototypes and demonstrations
Award amount max: $900,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-155.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Health Informatics, Computer Science & Informatics, Biotechnology, Innovation & Technology Management, Informatics & Big Data, HIV/Aids, Bioinformatics, Therapy Evaluation, Engineering Standards & Specifications, Disease Control, Diagnostic Sciences, Biological Sciences, Biomolecular Modeling, Research Management

Contact Details
NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: 1 301 451 6446
Email: lysterp@mail.nih.gov

EXTENDED DEVELOPMENT, HARDENING AND DISSEMINATION OF TECHNOLOGIES IN BIOMEDICAL COMPUTING, INFORMATICS AND BIG DATA SCIENCE (R01): AIDS-RELATED
NIH: National Institute of General Medical Sciences

Description:
A total of 12 institutes and offices of the National Institutes of Health invite applications for their Aids-related grants on extended development, hardening and dissemination of technologies in biomedical computing, informatics and big data science (R01). This Aids-related R01 funding opportunity announcement supports the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. The scheme aims to promote a broad base of research and development of technologies in biomedical computing, informatics and big data science that will support rapid progress in areas of scientific opportunity in biomedical research. Applications should develop enabling technologies that could apply to the interests of most NIH institutes and centers and range from basic biomedicine and including
research to all relevant organ systems and diseases. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PA-14-156.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017. Posted date: 17 Mar 14
Award type: Technology innovation/development, Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/notice-files/PA-14-156.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-

Eligibility profile
Country of applicant institution: Any

Disciplines
Computer Science & Informatics, Biotechnology, Health Informatics, Innovation & Technology Management, Informatics & Big Data, HIV/AIDS, Therapy Evaluation, Bioinformatics, Engineering Standards & Specifications, Biological Sciences, Diagnostic Sciences, Disease Control, Biomolecular Modeling, Research Management

Contact Details
NIGMS
45 Center Drive
Bethesda, MD 20814
Tel: 1 301 451 6446
Email: lysterp@mail.nih.gov

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their Aids-related call on translational research to help older adults maintain their health and independence in the community (R21). This Aids-related R21 funding opportunity announcement supports translational research collaborations between academic research centers and community-based organizations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.

This FOA uses the R21 exploratory/developmental research grant award mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-161, which solicits applications under the R01 research project grant mechanism. US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year. Ref: PAR-14-159 (replaces PAR-11-124).
Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Mar 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
Award amount max: £275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-159.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Primary Care, Health Systems Policy, Geriatrics & Gerontology, Accessibility for Disabled People, HIV/Aids, Social Work & Social Policy, Psychology, Access to Health Care, Psychology of Ageing, Public Health, Health Services & Primary Care, Home Health Care Services, Social Programmes

Contact Details

NIA
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: 1 301 402 4156
Email: kingjo@nia.nih.gov

TRANSLATIONAL RESEARCH TO HELP OLDER ADULTS MAINTAIN THEIR HEALTH AND INDEPENDENCE IN THE COMMUNITY (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging and the National Institute of Biomedical Imaging and Bioengineering invite applications for their Aids-related call on translational research to help older adults maintain their health and independence in the community (R01). This Aids-related R01 funding opportunity announcement supports translational research collaborations between academic research centers and community-based organizations with expertise in serving or engaging older adults to develop tools, techniques, programmes or policies to respond to the needs of the ageing population.
This FOA uses the R01 research project grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-159, which solicits applications under the R21 exploratory/developmental research grant award mechanism.
US and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
Application budgets are not limited but need to reflect actual needs of the proposed project.
The maximum project period is five years.
Ref: PAR-14-161 (replaces PAR-11-123).

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 21 Mar 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R21): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related call on the effects of cannabis use and cannabinoids on the developing brain (R21). This AIDS-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans. This FOA uses the R21 exploratory/developmental grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-163 and PA-14-164, which use the R01 research project grant mechanism and the R03 small research grant mechanism respectively.
US and foreign for-profit or non-profit organizations and public or private institutions may apply.
Direct costs are limited to US$275,000 over a two-year project period, with no more than US$200,000 in any year.
Ref: PA-14-162.

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-162.html


Eligibility profile
Country of applicant institution: Any

Disciplines
Neuroscience, Drug & Substance Abuse, Central Nervous System, Neurology, Diagnostic Sciences, Public Health, Health Services & Primary Care, HIV/AIDS, Pharmacokinetics, Psychology, Primary Care, Cognitive Processes
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R03): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its AIDS-related call on the effects of cannabis use and cannabinoids on the developing brain (R03). This AIDS-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.

This FOA uses the R03 small research grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-163, which use the R21 exploratory/developmental grant mechanism and the R01 research project grant mechanism respectively.

US and foreign for-profit or non-profit organizations and public or private institutions may apply.

Direct costs are limited to US$100,000 over a two-year project period, with no more than US$50,000 in any year.

Ref: PA-14-164.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-164.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Neurology, Psychology, Neuroscience, Central Nervous System, Drug & Substance Abuse, Cognitive Processes, Primary Care, Public Health, Health Services & Primary Care, Diagnostic Sciences, HIV/AIDS, Pharmacokinetics

Details
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 435 4649
Email: wudy@mail.nih.gov
EFFECTS OF CANNABIS USE AND CANNABINOIDS ON THE DEVELOPING BRAIN (R01): AIDS-RELATED
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its Aids-related call on the effects of cannabis use and cannabinoids on the developing brain (R01). This Aids-related R21 funding opportunity announcement supports the study of effects and functional consequences of cannabis and cannabinoid exposures on the developing brain, from pre-, peri- and postnatal development through young adulthood in animal models and humans.
This FOA uses the R01 research project grant mechanism, and runs in parallel with two FOAs of identical scientific scope, PA-14-162 and PA-14-164, which use the R21 exploratory/developmental grant mechanism and the R03 small research grant mechanism respectively.
US and foreign for-profit or non-profit organizations and public or private institutions may apply.
Application budgets are not limited, but must reflect the needs of the project. The maximum project period is five years.
Ref: PA-14-163.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 27 Mar 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-ffiles/PA-14-163.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmacokinetics, HIV/Aids, Public Health, Health Services & Primary Care, Diagnostic Sciences, Cognitive Processes, Primary Care, Central Nervous System, Drug & Substance Abuse, Neuroscience, Psychology, Neurology

Contact Details
NIDA
6001 Executive Boulevard
Bethesda, MD 20892
Tel: 1 301 435 4649
Email: wudy@mail.nih.gov

CLINICAL TRIAL PLANNING GRANT FOR INTERVENTIONS AND SERVICES TO IMPROVE TREATMENT AND PREVENTION OF HIV/AIDS (R34)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their clinical trial planning grant for interventions
and services to improve treatment and prevention of HIV/Aids. This R34 funding opportunity supports efforts to prevent acquisition and transmission of HIV infection, or to improve treatment and care for persons who are HIV infected, or both. Priority areas and potential research topics include:

- research to develop and test the feasibility and acceptability of integrated prevention and/or treatment strategies to improve clinical outcomes within target populations;
- novel approaches to maximize HIV testing, linkage to care, retention, and durable viral suppression;
- Behavioral or service interventions that initiate, sustain, and restore adherence to recommended HIV care or regimens;
- studies that elucidate information about barriers and needs of populations who have difficulty engaging in and sustaining treatment and prevention care;
- interventions that promote effective utilization of health services;
- acceptability or feasibility studies that inform drug development or that complement an ongoing efficacy or effectiveness trial of an experimental strategy or intervention;
- challenges and the implementation of multiple prevention methods;
- approaches that sustain engagement in care among people living with HIV and other serious co-morbidities or co-infections.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Direct costs are limited to US$450,000 over the project period, with no more than US$225,000 available in any single year. The maximum project period is three years.

Ref: PA-14-179.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time every 7 May, 7 September and 7 January until 8 January 2017.

Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000

Eligibility profile

Country of applicant institution: Any

Disciplines

Biomedical Engineering, Patient Care & Education, Preventive Medicine, Diagnostic Sciences, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Public Health, Clinical Medicine, HIV/Aids, Blood Tests

Contact Details

NIH: National Institutes of Health
6701 Rockledge Drive, Room 1040 - MSC 7710
Bethesda, MD 20892-7710
Tel: 1 301 451 7324
Fax: 1 301 480 8443
Email: elizabeth.flanagan@nih.gov
HEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R21): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite Aids-related applications for their mHealth tools to promote effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations R21 grants. The purpose of this R21 Aids-related funding opportunity announcement is to stimulate research utilizing mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. This funding opportunity announcement will utilize the NIH research project grant R21 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-180 that solicits applications under the research project grant (R01) funding mechanism. The combined budget for direct costs for the two year project period may not exceed US$275,000 and no more than US$200,000 may be requested in any single year. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Ref: PA-14-181 (Reissue of PA-11-332).

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
Country of applicant institution: Any

Disciplines
5G, Wireless & Mobile Networks, Clinical Medicine, Patient Care & Education, Social Programmes, Primary Care, Computer Science & Informatics, Assistive Technology, Chronic Care, Health Economics, Social Work & Social Policy, Rural Health, HIV/Aids, Medical & Diagnostic Tests, Public Health, Health Services & Primary Care, Pharmaceutical Drugs

Contact Details
Tel: 1 301 594 5971
Email: mccloskd@mail.nih.gov

HEALTH TOOLS FOR INDIVIDUALS WITH CHRONIC CONDITIONS TO PROMOTE EFFECTIVE PATIENT-PROVIDER COMMUNICATION, ADHERENCE TO TREATMENT AND SELF-MANAGEMENT (R01) AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
A total of two institutes and offices of the NIH invite applications for their Aids-related mHealth tools for individuals with chronic conditions to promote effective patient-
provider communication, adherence to treatment and self-management (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to stimulate research utilising mobile health (mHealth) tools aimed at the improvement of effective patient-provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. This funding opportunity announcement will utilise the NIH research project grant R01 mechanism and runs in parallel with another FOA of identical scientific scope: PA-14-181 that solicits applications under the exploratory/developmental grant (R21) funding mechanism. Application budgets are not limited, but need to reflect actual needs of the proposed project. The total project period is a maximum of five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Ref: PA-14-180 (Reissue of PA-11-330).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

XPLORATORY CLINICAL TRIALS OF MIND AND BODY INTERVENTIONS FOR NCCAM HIGH PRIORITY RESEARCH TOPICS (R34) AIDS-RELATED
NIH: National Center for Complementary and Alternative Medicine

Description:
The National Center for Complementary and Alternative Medicine (NCCAM) invites Aids-related applications for its exploratory clinical trials of mind and body interventions for NCCAM high priority research topics (R34). The goal of this R34 Aids-related funding opportunity is to support early phase clinical trials of mind and body approaches for conditions that have been identified by NCCAM as high priority research topics. Priority areas include:

- the mind and body or integrated approach, including spinal manipulation, mobilization, massage, tai chi, qi gong, yoga, acupuncture, hypnosis, guided imagery, light therapy, breathing activity, progressive relaxation, meditation, biofeedback, or mindfulness techniques;
- symptom management for chronic pain syndromes, reduction of prescription drug use or abuse in patients with chronic pain, medication adherence, post-traumatic
stress, traumatic brain injury, sleep disorders or disturbances, anxiety, depression, promotion of psychological resilience, weight loss and weight loss maintenance, smoking cessation and promotion of healthy eating and physical activity.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Proposals may request up to $450,000 over a maximum of three years.

Ref: PA-14-182.

Closing date: 07 May 15
Deadline information: Applications due by 5pm applicant’s local time. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.
Posted date: 23 Apr 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $450,000

Eligibility profile

Disciplines

Mental Health, Allied Health Professions, Pharmacy & Pharmacology, Sports Psychology, Clinical Medicine, Addiction, Chronic Pain, Sleep & Sleep Disorders, Psychology, Chronic Care, Sports & Exercise Studies, Drug & Substance Abuse, Depression & Other Mood Disorders, Health Counseling, Psychobiology, Health Promotion, Stress, Biological, Nutrition & Dietetics, Experimental Psychology, Stress, Psychological, Post Traumatic Stress Disorder, Exercise Physiology, Traumatology, Accidents & Injury, Folk, Complementary & Alternative Medicine, Clinical Pharmacy & Pharmacology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Pharmaceutical Drugs, Smoking & Tobacco, HIV/Aids, Anxiety Disorders, Cognitive & Behavioral Therapies, Pain Management, Social Work & Social Policy

Contact Details

Tel: 1 301 402 1272
Email: weberwj@mail.nih.gov

---

**UNCONVENTIONAL ROLES OF ETHANOL METABOLIZING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R01): AIDS-RELATED**

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its Aids-related unconventional roles of ethanol metabolizing enzymes, metabolites and cofactors in health and disease (R01) funding opportunity announcement. This Aids-related announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolizing pathways, their metabolites, cofactors and interactions with synergizing biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol
consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health. Research areas include the following: ethanol and NAD+; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolizing pathways – regulation of growth, development and disease. This announcement uses the R01 research project grant mechanism and runs in parallel with one of identical scientific scope, PA-15-057, which encourages applications under the R21 exploratory or developmental grant mechanism.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. Application budgets are not limited, but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-15-058 (reissue of PA-14-198).

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 09 Dec 14
Award type: Networking/collaboration, Innovation grants, Directed grants to institutions, research groups etc.
responses to HIV-1, applications that leverage multidisciplinary collaborations in synergistic basic discovery research in immunology, virology and host genetics are encouraged. These collaborations may comprise the translation of existing critical knowledge and technologies from other fields for the benefit of HIV-1 vaccine design. Translation of the proposed hypothesis into immunogen design or immunization strategies for evaluation in animal models is encouraged. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Ref: PA-14-216.

Closing date: 07 May 15
Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 13 May 14

Award type: Directed grants to institutions, research groups etc.

Eligibility profile
---------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------------
Diagnostic Sciences, Genetics & Systems Biology, HIV/Aids, Immunology, Virology, Medical Genetics, Clinical Medicine, Immunization Programmes & Vaccination

Contact Details
---------------------------------------------------------------------
Tel: 1 240 292 6130
Email: amalaspina@niaid.nih.gov

NK CELLS TO INDUCE IMMUNOLOGICAL MEMORY TO PREVENT HIV INFECTION (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its natural killer cells to induce immunological memory to prevent HIV infection (R01) grants. The purpose of this R01 funding opportunity is to support multidisciplinary, hypothesis-driven research on NK cells, leading to the discovery of pathways relevant for early immune responses and immune regulation impacting the potential protective immunity to be induced by HIV vaccination. Secondary objectives include the development of novel technologies to allow for more definitive studies of human immune monitoring in the context of vaccine clinical trials and the recruitment of innate immunologists to the HIV vaccine field. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years. Ref: PA-14-217

Closing date: 07 May 15
Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 13 May 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-217.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
------------------------------------------------------------------
Country of applicant institution: Any

Disciplines
------------------------------------------------------------------
Virology, Clinical Medicine, HIV/Aids, Immunization Programmes & Vaccination, Diagnostic Sciences, Immunology

Contact Details
------------------------------------------------------------------
Tel: 1 240 627 3038
Email: cesar.boggiano@nih.gov

FC RECEPTOR AND ANTIBODY EFFECTOR FUNCTION IN HIV VACCINE DISCOVERY (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its Fc Receptor and antibody effector function in HIV vaccine discovery (R01) grants. The purpose of this R01 funding opportunity is to stimulate and support investigator driven collaborative research to probe how vaccine elicited antibodies protect against viral acquisition via Fc receptor mediated mechanisms and also benchmark functional profiles of vaccines that protect against viral infections to inform advancement of HIV vaccine candidates. Areas of interest include, but are not limited to:

• identification of Fc receptor binding profiles that correlate with protective antibody responses;
• use of animal models to understand mechanisms of antibody dependent protective immune responses to broadly neutralizing antibodies and or candidate vaccines in vivo;
• examination of adjuvants in both modulating Fc receptor binding profiles and in their influence on immune effector function and/or antibody effector function;
• investigations of antibody glycosylation and Fc receptor-mediated activity and function;
• passive administration studies of BNAbs and or non-neutralizing antibodies in preclinical animal models to understand Fc-related mechanisms of immune protection;
• examination of Fc Receptor binding and effector function of vaccine-elicited IgA antibodies.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum project period is five years.
Ref: PA-14-218.

Closing date: 07 May 15
Deadline information: Deadlines every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 13 May 14
Award type: Directed grants to institutions, research groups etc.
IV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R21)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its HIV vaccine vector-host interactions: understanding the biology and immunology (R21) grants. The purpose of this R21 funding opportunity is to support increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors. This initiative is intended to advance understanding of the following:

- the biology and immune response to live attenuated or replication-defective viral vectors developed from adenoviridae, poxviridae, adeno-associated viruses and herpesviridae families in humans and non-human primates;
- the development of animal models that could better evaluate the potential for increased HIV acquisition following vaccination.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-14-214.

Closing date: 07 May 15
Deadline information: Applications due by 5pm, local time of applicant organization, on every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 14 May 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Immunology, Medical Genetics, Genetics & Systems Biology, Diagnostic Sciences,
HIV VACCINE VECTOR-HOST INTERACTIONS: UNDERSTANDING THE BIOLOGY AND IMMUNOLOGY (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites application for its HIV vaccine vector-host interactions: understanding the biology and immunology (R21) grants. The purpose of this R01 funding opportunity is to support increased understanding of the biology and immunology of natural viral infections and HIV vaccine vectors. This initiative is intended to advance understanding of the following:

- the biology and immune response to live attenuated or replication-defective viral vectors developed from adenoviridae, poxviridae, adeno-associated viruses and herpesviridae families in humans and non-human primates;
- the development of animal models that could better evaluate the potential for increased HIV acquisition following vaccination.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.
Ref: PA-14-215

Closing date: 07 May 15

Deadline information: Applications due by 5pm, local time of applicant institution, on every 7 September, 7 January and 7 May until 8 January 2017.
Posted date: 14 May 14
Award type: Directed grants to institutions, research groups etc.
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Virology, Immunization Programmes & Vaccination, HIV/Aids, Clinical Medicine, Genetics & Systems Biology, Diagnostic Sciences, Medical Genetics, Immunology

Contact Details
NIAID
Office of Communications and Public Liaison
Building 31, Room 7A-50
31 Center Drive MSC 2520
Bethesda, MD 20892-2520
Tel: 1 301 435 3749
Fax: 1 301 402 0120
Email: mpensiero@niaid.nih.gov
CLINICAL EVALUATION OF ADJUNCTS TO OPIOID THERAPIES FOR THE TREATMENT OF CHRONIC PAIN (R01) AIDS-RELATED

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse and the National Center for Complementary and Alternative Medicine invite applications for their clinical evaluation of adjuncts to opioid therapies for the treatment of chronic pain (R01) AIDS-related grants. The purpose of this R01 AIDS-related funding opportunity is to support meritorious clinical studies that seek to characterize opioid and pharmaceutical adjunct combinations that safely improve analgesia in chronic pain patients. As a secondary objective, this opportunity aims to disseminate the results of these studies as widely as possible to the healthcare providers who regularly prescribe opioids to the patient population. This will ensure that standard clinical practices are influenced by the findings of the proposed studies. In the population proposed to be studied, the subjects should be etiologically homogenous and symptomatically well-defined. Examples of such chronic pain populations in which opioids are often prescribed include patients with radicular cervical pain, metastatic bone pain or peripheral neuropathies. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is three years.

Ref: PAR-14-225

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017
Posted date: 16 May 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-225.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacy & Pharmacology, Molecular Genetics, Epidemiology, Mental Health, Biological Sciences, Chronic Pain, Opiates, Neuroscience, Drug & Substance Abuse, Neurobiology, Primary Care, Public Health, Health Services & Primary Care, Diagnostic Sciences, Preventive Medicine, HIV/AIDS, General Practice, Physiology, Cognitive & Behavioral Therapies, Pain Management

Contact Details

NIDA
6001 Executive Boulevard
Room 5213
Bethesda, MD 20892-9561
Tel: 1 301 443 8039
Email: aidan.hampson@nih.gov
ADVANCING RESEARCH IN VOICE DISORDERS (R21) AIDS-RELATED
NIH: National Institute on Deafness and other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R21) Aids-related grants. The purpose of this R21 Aids-related funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. This is to support the development of novel ideas, technologies, or methodologies at an early stage of development which have the potential to break new ground or extend toward new directions or applications. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. The combined budget for direct costs for the two year project period may not exceed US$275,000. No more than US$200,000 may be requested in any single year. The total project period may not exceed two years.
Ref: PA-14-235.

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 22 May 14

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/ra-files/PA-14-235.html
Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Allied Health Professions, Clinical Medicine, Speech & Language Therapy, Prosthetic & Orthotic Devices, Primary Care, Public Health, Health Services & Primary Care, Speech Pathology & Disorders, Physiology, HIV/AIDS

Contact Details
NIDCD
Division of Extramural Research
Executive Plaza South, Room 400C
6120 Executive Boulevard, MSC 7180
Rockville, MD 20892-7180
Tel: 1 301 496 5061
Email: shekiml@nidcd.nih.gov

ADVANCING RESEARCH IN VOICE DISORDERS (R01) AIDS-RELATED
NIH: National Institute on Deafness and other Communication Disorders

Description:
The National Institute on Deafness and Other Communication Disorders invites applications for its advancing research in voice disorders (R01) Aids-related grants. The
The purpose of this R01 Aids-related funding opportunity is to focus on advancing the scientific knowledge of the human larynx and human voice production in health and disease and optimal ways to prevent, evaluate, diagnose and clinically manage voice disorders. Furthermore, it encourages a range of research inclusive of basic, clinical, and translational. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PA-14-236

Closing date: 07 May 15
Deadline information: Applications due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 22 May 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-236.html

ASIC RESEARCH ON HIV PERSISTENCE (R21): AIDS-RELATED
NIH: National Institutes of Health

Description:
The National Institute of Mental Health invites applications for its basic research on HIV persistence (R21) Aids-related. This Aids-related R21 announcement will support basic research in aspects of the persistence of HIV or Simian immunodeficiency virus infection in individuals or animals receiving highly active anti-retroviral therapy. It is expected that applications will involve at least one of the following areas of study: cellular, structural or systems biology, host or viral genetics, immunology, or virology. The emphasis of this initiative is on the development of new ideas and approaches in HIV-1 persistence including model and assay development that may directly inform future studies on the design of therapeutic strategies to achieve long term remission without treatment or a complete eradication of residual virus and complete cure for HIV infection and AIDS.

Higher education institutions, non-profits other than institutions of higher education,
for-profit organizations, governments and foreign institutions are eligible to apply. Approximately eight awards are available, worth up to US$275,000 each for two years. Ref: PAR-14-428.

Closing date: 07 May 15

Deadline information: Application are due by 5pm local time of applicant organization, every 7 September, 7 January and 7 May until 8 January 2017.

Posted date: 05 Jun 14

Award type: Networking/collaboration, Innovation grants, Directed grants to institutions, research groups etc.

Award amount max: $275,000
Award budget total: $2,000,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Immunology, Cytopathology, Infection Agents & Pathogens, Primary Care, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, Pathology, Animal Models, HIV/Aids, Clinical Medicine, Virology, Blood Tests, Infectious Diseases

Contact Details

National Institute of Allergy and Infectious Diseases (NIAID)
Tel: 1 301 496 5332
Email: salzwedelk@niaid.nih.gov

MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION
(R21)

NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its multidisciplinary studies of HIV and viral hepatitis co-infection (R21) grant. The purpose of this R21 funding opportunity is to fill gaps in our understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV/hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV and HCV co-infection.

Research should focus on HIV-infected adults, pregnant or postpartum women, adolescents, children, infants and sub-populations at highest risk for HBV or HCV co-infection.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. The combined budget for direct costs for the two year project period may not exceed $275,000. No more than US$200,000 may be requested in any single year.

Ref: PAR-14-254.

Closing date: 07 May 15

Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.

Posted date: 11 Jun 14
MULTIDISCIPLINARY STUDIES OF HIV AND VIRAL HEPATITIS CO-INFECTION (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its multidisciplinary studies of HIV and viral hepatitis co-infection (R01) grant. The purpose of this R01 funding opportunity is to fill gaps in our understanding of the pathogenic interactions between HIV and hepatitis viruses, co-morbidities associated with HIV and hepatitis virus co-infection, and the effectiveness of interferon-free direct-acting antiviral drug regimens to treat HIV or HCV co-infection. Research should focus on HIV-infected adults, pregnant or postpartum women, adolescents, children, infants and sub-populations at highest risk for HBV or HCV co-infection. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAR-14-255.

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time, every 7 January, 7 May and 7 September until 8 May 2017.
Posted date: 11 Jun 14
Award type: Directed grants to institutions, research groups etc.
Website:

Eligibility profile
Country of applicant institution: Any
Disciplines
Infection Agents & Pathogens, Primary Care, Clinical Medicine, Public Health, Health Services & Primary Care, Diagnostic Sciences,
2020-TWINN-2015 CALL FOR TWINNING
Horizon 2020: Spreading Excellence and Widening Participation

Description:
The European Commission Horizon 2020: Spreading Excellence and Widening Participation invites proposals for its H2020-TWINN-2015 call for twinning. This aims to strengthen a defined field of research in a particular knowledge institution by creating a link between this institution and at least two internationally leading research institutions in other EU member states. Twinning will enhance the science and technology capacity of the linked institutions and help raise staff’s research profiles as well as the one of the institutions involved. Supported measures include: short term staff exchanges; expert visits and short-term on site or virtual training; workshops; conference attendance; organization of joint summer school activities; dissemination and outreach activities. Proposals may take the form of coordination and support actions and must involve a minimum of three participants. Applicant institutions from the following countries are eligible: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Slovenia, Albania, Bosnia and Herzegovina, Faroe Islands, Macedonia, Liechtenstein, Moldavia, Montenegro, Serbia and Turkey. Proposals must involve at least two internationally leading research intensive counterparts established in at least two different member states or associated countries other than that of the applicant institution.

The indicative budget for this call in 2015 is €65.27 million. Each successful proposal is expected to receive around €1m, although proposals for other amounts will also be considered.
Ref: OJ 2013/C 361/06.

Closing date: 07 May 15
Deadline information: Proposals due by 5pm Brussels local time.
Posted date: 03 Jul 14
Award type: Publish, edit, translate, disseminate, Networking/collaboration, Directed grants to institutions, research groups etc., Hosting visits, Travel to conferences, meetings etc., Institutional development, Hosting conferences
Award budget total: €65,270,000
Website:

Eligibility profile

Country of applicant institution: Any

Disciplines

Any
NIH CREATE BIO DISCOVERY TRACK: OPTIMISATION IN PREPARATION FOR DEVELOPMENT OF BIOTECHNOLOGY PRODUCTS AND BIOLIGICS (U01): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its cooperative research to enable and advance translational enterprises for biotechnology products and biologics discovery track: optimization in preparation for development of biotechnology products and biologics (U01) grants. The purpose of this Aids-related U01 funding opportunity announcement is the discovery of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. This FOA supports the optimization of therapeutic leads showing convincing proof-of-concept. At the end of the funding period, projects that successfully advance through support from this programme will have identified an optimized candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favorable properties that are consistent with the desired clinical application, and will be ready for entry into the CREATE bio development track for further development to enable filing for an investigational new drug. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics- based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets will normally remain under US$500,000 in direct costs in any given year. The project period is typically three years and may not exceed four years.

Closing date: 07 May 15

Deadline information: Applications open on 21 September and are due by 5pm local time of applicant organization on 7 January 2015 and every 7 May and 7 September until 8 May 2017.

Posted date: 21 Jul 14

Award type: Directed grants to institutions, research groups etc.


Eligibility profile

Country of applicant institution: Any

Disciplines

Pharmacotherapy, Drug Design, Blood Tests, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, Clinical Pharmacy & Pharmacology, Neurology, Methods of Drug Delivery, Pharmacy & Pharmacology, Neuropharmacology, Protein Synthesis, Modification & Turnover, Chemistry, Pharmacokinetics, Cell Physiology & Metabolism, HIV/AIDS, Clinical Medicine, Toxicology, Gene Therapy, Neurobiology, Primary Care

Contact Details

NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: 1 301 496 1779
Email: createnquiries@mail.nih.gov
INDS CREATE BIO DEVELOPMENT TRACK: PRECLINICAL AND EARLY-PHASE CLINICAL DEVELOPMENT FOR BIOTECHNOLOGY PRODUCTS AND BIOLOGICS (UH2/UH3): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its NINDS operative research to enable and advance translational enterprises for biotechnology products and biologics development track: preclinical and early-phase clinical development for biotechnology products and biologics (UH2/UH3) grants. The purpose of this Aids-related UH2/UH3 funding opportunity announcement is the development of therapeutic biotechnology products and biologics for disorders that fall under the NINDS mission. An identified candidate, which has sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy or target engagement, and other favorable properties that are consistent with the desired clinical application, is required for entry to the CREATE bio development track. The FOA supports investigational new drug-enabling studies for the candidate and early-phase clinical trials. At the end of the funding period, a successful project should have an IND application submitted to the US Food and Drug Administration, at a minimum. The NINDS CREATE bio programme is dedicated to biotechnology product and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies and cell therapies. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Applications should rarely exceed US$1million in direct costs per year during the UH2 phase and US$1.5million in direct costs per year during the UH3 phase. The proposed project period for the UH2 phase may not exceed two years and the UH3 phase may not exceed four and a half years. The total duration of UH2 and UH3 phases may not exceed five years. Ref: PAR-14-288.

Closing date: 07 May 15
Deadline information: Applications open on 21 September and are due by 5pm local time of applicant organization on 7 January 2015 and every 7 May and 7 September until 8 May 2017.
Posted date: 21 Jul 14
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Pharmacokinetics, HIV/Aids, Cell Physiology & Metabolism, Clinical Pharmacy & Pharmacology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Methods of Drug Delivery, Drug Design, Primary Care, Blood Tests, Neurobiology, Pharmacotherapy, Toxicology, Protein Synthesis, Modification & Turnover, Chemistry, Neuropharmacology, Clinical Medicine, Biological Sciences, Pharmacy & Pharmacology, Neurology, Gene Therapy

Contact Details
----------------------------------------------
NIH/NINDS
Neuroscience Center, Room 2106
6001 Executive Blvd MSC
Bethesda MD 20892
Tel: 1 301 496 1779
BLU EPRI NT NEUROTHERAPEUTICS NETWORK: SMALL MOLECULE DRUG DISCOVERY AND DEVELOPMENT FOR DISORDERS OF THE NERVOUS SYSTEM (UH2/UH3): AIDS-RELATED
NIH: National Institute of Neurological Disorders and Stroke

Description:
A total of nine participating institutes and centers of the National Institutes of Health invite applications for their Blueprint neurotherapeutics network: small molecule drug discovery and development for disorders of the nervous system (UH2/UH3) grants. The purpose of this Aids-related UH2/UH3 funding opportunity announcement is to help neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under good manufacturing practices, and phase I clinical testing. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. The combined duration of the UH2 and UH3 award cannot exceed five years. Ref: PAR-14-293.

Closing date: 07 May 15
Deadline information: Applications open on 21 September and are due by 5pm local time of applicant organization on 7 January 2015 and every 7 May and 7 September until 8 May 2017.
Posted date: 23 Jul 14

Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-293.html

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Clinical Pharmacy & Pharmacology, Diagnostic Sciences, Public Health, Health Services & Primary Care, Methods of Drug Delivery, Pharmacokinetics, HIV/AIDS, Cell Physiology & Metabolism, Central Nervous System, Pharmacotherapy, Toxicology, Gene Therapy, Drug Design, Primary Care, Neurobiology, Biological Sciences, Pharmacy & Pharmacology, Neurology, Protein Synthesis, Modification & Turnover, Chemistry, Neuropharmacology, Clinical Medicine

Contact Details
----------------------------------------------
NIH: NINDS
Division of Extramural Research
6001 Executive Boulevard Suite 3309
Bethesda, MD 20892-9531
Tel: 1 301 496 1779
Email: farkasr@ninds.nih.gov
ARTS-BASED APPROACHES IN PALLIATIVE CARE FOR SYMPTOM MANAGEMENT (R01): AIDS-RELATED
NIH: National Center for Complementary and Alternative Medicine

Description:
A total of four participating institutes and centers of the National Institutes of Health invite applications for their arts-based approaches in palliative care for symptom management (R01) grants. The purpose of this Aids-related R01 funding opportunity announcement is to foster research on the potential for arts-based approaches to enhance palliative care for individuals living with multiple symptoms related to serious chronic or terminal illness. This FOA is intended to support mechanistic clinical studies to provide an evidence base for the use of the arts in palliative care for symptom management. The objective is to understand the biological, physiological, neurological, psychological, or sociological mechanisms by which the arts exert their effects on symptom management during and throughout the palliative care continuum. The term “arts” refers not only to artistic activities, but also to creative activities, such as literature, rituals, oral histories and storytelling.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Applicants may request up to US$300,000 in direct costs per year. The maximum project period is three years.

Closing date: 07 May 15
Deadline information: Applications open on 5 September and are due by 5pm local time of applicant organization every 7 September, 7 January and 7 May until 8 September 2017.
Posted date: 25 Jul 14

Award type: Directed grants to institutions, research groups etc.
Award amount max: $900,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Allied Health Professions, Health Systems, Administration, Death & Mortality, Art Therapies, Art & Design: History, Practice & Theory, Literature, Drama, Psychology, Clinical Medicine, Music Therapy, Customs & Traditions, Theatre Studies, Nursing, Oral History, Hospice & Palliative Care, Primary Care, Palliative Nursing, Public Health, Health Services & Primary Care, Performing Arts, Visual Arts, Social Work & Social Policy, Paediatrics, HIV/Aids

Contact Details
----------------------------------------------
NIH: National Center for Complementary and Alternative Medicine
31 Center Drive, MSC 2182
Bethesda, MD 20892-2182
Tel: 1 301 443 8374
Email: lee.alekel@nih.gov
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R03) AIDS-RELATED

NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and pediatric care programme. This Aids-related R03 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and pediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH small grant (R03) mechanism and runs in parallel with one of identical scientific scope, PA-14-312, which solicits applications under the NIH research project grant (R01) mechanism.

Funding is worth up to US$50,000 per year for a maximum project period of two years.

Ref: PA-14-313 (replaces PAR-11-226).

Closing date: 07 May 15
Deadline information: Applications open on 16 September 2014 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
Award amount max: $100,000

Website:

Application form:
http://www.grants.gov/web/grants/applicant-package.html#download=true&oppNum=PA-14-313

Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/AIDS, Paediatrics, Public Health, Health Services & Primary Care, Health Professions, Medical & Diagnostic Tests, Diagnostic Sciences, Law, Safety & Accident Investigation, Blood Tests, Maternal Health, Primary Care, Health Informatics, Business & Management Studies, Nursing, Pregnancy & Birth, Clinical Decision-making & Analysis, Health Psychology, Quality of Care, Health Systems, Risk Management, Hospitalization, Paediatric Nursing, Medical Effectiveness & Patient Outcomes, Clinical Medicine, Medical Informatics & Telemedicine, Public Health & Medical Law, Psychology, Neonatal Disorders, Standards of Care, Medical Research of Selected Fields, Allied Health Professions, Patient Care & Education

Contact Details

NIH
Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: 1 301 435 6873
Fax: 1 301 496 3790
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL, AND PAEDIATRIC CARE (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its patient safety in the context of perinatal, neonatal, and paediatric care (R21) grants. The purpose of this Aids-related R21 funding opportunity announcement is to encourage a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and paediatric care both in routine hospital settings and in the intensive care units. The FOA welcomes applications related to the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional levels to help reduce and eliminate medical errors.

It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.

This FOA will utilize the R21 mechanism and runs in parallel with two FOAs of identical scientific scope, PAR-14-312 that encourages applications under the R01 research grant programme mechanism and PAR-14-313 that encourages applications under the R03 small grant programme mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Application budgets are limited to direct costs of up $275,000 over a two-year project period and no more than $200,000 may be requested in any one year.

Ref: PA-14-311 (replaces PAR-11-227).

Closing date: 07 May 15
Deadline information: Applications open on 16 September and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/par- files/PA-14-311.html
Application form: http://www.grants.gov/web/grants/applicant s/download-application-package.html#download=true&oppNum=PA-14-311

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Women’s Health, Primary Care, Epidemiology, Family Health, Public Health, Health Services & Primary Care, Patient Care & Education, Midwifery, General Practice, HIV/Aids, Pediatrics, Clinical Medicine, Pediatric Nursing, Neonatal Disorders, Obstetrics & Gynaecology, Quality of Care, Maternal Health, Pregnancy & Birth, Nursing

Contact Details
----------------------------------------------
NIH: National Institute of Child Health and Human Development
MOL ecular AND CELLULAR SUBSTRATES OF COMPLEX BRAIN DISORDERS (R21): AIDS-RELATED
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R21) grants. This Aids-related funding opportunity announcement uses the R21 mechanism to encourage new research activities directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. By using the R21 activity code, this funding opportunity seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to advance research at the interface between cellular and molecular mechanisms and that address gaps in understanding the biological mechanisms behind putative disease associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders.

This FOA uses the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-309 that encourages applications under the NIH research project (R01) grant mechanism. Direct costs are limited to US$275,000 over a two year period, with no more than US$200,000 in direct costs in any one year. The total project period may not exceed two years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Ref: PAR-14-310 (replaces PAR-11-300).

Closing date: 07 May 15 (Forecast)
Deadline information: Call has not yet been announced by funder, but this is the approximate deadline we expect. Applications open on 16 September and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000

Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
HIV/AIDS, Public Health, Health Services & Primary Care, Neuroanatomy, Biochemistry & Molecular Biology, Diagnostic Sciences, Intellectual Disabilities, Cognitive Processes, Mental Illness, Primary Care, Endocrine & Neuroendocrine Cancers, Neuroscience, Central Nervous System, Muscle Diseases,
Molecular and Cellular Substrates of Complex Brain Disorders (R01): AIDS-Related
NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health invites applications for its molecular and cellular substrates of complex brain disorders (R01) grants. This AIDS-related R01 funding opportunity announcement encourages research grant applications directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function. This FOA seeks to encourage innovative leads at the interface between cellular and molecular mechanisms, and that address gaps in understanding the biological mechanisms behind putative disease and associated processes with the goal of accelerating progress in emerging research areas relevant to complex brain disorders. Proposals should be hypothesis-driven and propose discovery-based studies with an emphasis on exploring neurobiological mechanisms at the molecular, cellular and circuit levels.

This FOA uses the NIH research project (R01) grant mechanism and runs in parallel with an FOA of identical scientific scope, PAR-14-310 that encourages applications under the NIH exploratory/developmental (R21) grant mechanism. Application budgets are not limited but must reflect the actual needs of the proposed project. The total project period may not exceed five years. Applicants that request US$500,000 or more in direct costs in any year must Contact Details the NIH six weeks prior to applying.

US and foreign for-profit and non-profit organizations, higher education institutions and public and private organizations may apply.

Ref: PAR-14-309 (replaces PAR-11-299).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 07 Aug 14
Award type: Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-14-309.html

Eligibility profile

Country of applicant institution: Any
PATIENT SAFETY IN THE CONTEXT OF PERINATAL, NEONATAL AND PAEDIATRIC CARE (R01) AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institutes of Health invites applications for their patient safety in the context of perinatal, neonatal and pediatric care programme. This Aids-related R01 funding opportunity announcement encourages collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. Proposals may address:

- the epidemiology of errors and adverse events in neonatal and pediatric care hospital units;
- medication errors;
- diagnostic errors;
- procedure-related errors;
- human factor and fatigue;
- promotion of a safety culture;
- other working conditions and systems issues;
- risk reduction and disclosure practices.

Eligibility is unrestricted. This funding opportunity uses the NIH research project grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-313, which solicits applications under the NIH small grant (R03) mechanism.

Applicants requesting US$500,000 or more in direct costs in any year must contact NIH programme staff at least six weeks before submitting the application. The total project period may not exceed five years.

Ref: NIH PA-14-312 (replaces PAR-11-225).

Closing date: 07 May 15
Deadline information: Applications due by 5pm proposer’s local time every 7 January, 7 May and 7 September until 8 September 2017.
Posted date: 07 Aug 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-312.html
Application form: http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-312
Eligibility profile

Country of applicant institution: Any

Disciplines

Health Psychology, Clinical Decision-making & Analysis, Quality of Care, Health Systems, Risk Management, Health Informatics, Blood Tests, Maternal Health, Nursing, Pregnancy & Birth, Allied Health Professions, Medical Research of Selected Fields, Standards of Care, Law, Diagnostic Sciences, Medical & Diagnostic Tests, Health Professions, Safety & Accident Investigation, Patient Care & Education, Public Health, Health Services & Primary Care, Paediatric Nursing, Medical Effectiveness & Patient Outcomes, Medical Informatics & Telemedicine, Clinical Medicine, pediatrics, HIV/AIDS, Hospitalization, Neonatal Disorders, Public Health & Medical Law, Psychology, Primary Care, Business & Management Studies

Contact Details

NIH
Pregnancy and Perinatology Branch
Eunice Kennedy Shriver National Institute of Child and Human Development
6100 Executive Blvd, 4B03D
Bethesda MD 20892
Tel: 1 301 435 6873
Fax: 1 301 496 3790
Email: kosomari@mail.nih.gov

SECONDARY ANALYSES OF EXISTING ALCOHOL EPIDEMIOLOGY DATA (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related secondary analyses of existing alcohol epidemiology data (R21) grants. These R21 grants support AIDS-related, investigator-initiated research projects that either analyze previously collected data in order to address key issues that have emerged from recent findings in alcohol epidemiology and prevention research, or develop new analytic techniques for conducting studies in alcohol epidemiology and prevention research. The goal is to enhance understanding of patterns of alcohol consumption and the epidemiology of alcohol-related problems.

This funding opportunity announcement uses the NIH exploratory/developmental research grant (R21) award mechanism and PA-14-338 that encourages applications under the research project grant (R01) mechanism and PA-14-337 that encourages applications under the small grant programme (R03) mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Grants are worth up to US$275,000 in direct costs over a maximum period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-14-336.

Closing date: 07 May 15
Deadline information: Applications open on 24 September 2014 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September 2015 until 8 September 2017. Deadlines on: 7 May 2015, 7
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R21): AIDS-RELATED
NIH: National Institute of Nursing Research

Description:
A total of three participating institutes and centers of the National Institutes of Health invite applications for their AIDS-related self-management for health in chronic conditions (R21) grants. These AIDS-related R21 grants support research in self-management focused across conditions. Projects should address the Institute of Medicine’s recommendation for crosscutting, coordinated public health actions for living well with chronic illness, by describing an initiative that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses or conditions.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

This FOA will use the NIH exploratory and developmental grant (R21) award mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-344 that encourages applications under the research project grant(R01) mechanism and PA-14-345 that encourages applications under the academic research enhancement award (R15) mechanism.

The combined budget for direct costs for the two-year project period may not exceed US$275,000. No more than US$200,000 in direct costs may be requested in any single year. The maximum project period is two years.

Ref: PA-14-343.

Closing date: 07 May 15

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 May 2015, 7
IDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY PLANNING GRANT (R34): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its NIDCR clinical trial or biomarker clinical validation study planning grant (R34) Aids-related call. This R34 Aids-related call for funding supports activities to develop a draft clinical protocol, the clinical investigators brochure, tools for data and quality management, safety and operational oversight plans, recruitment and retention strategies, a study team and other essential documents. US and foreign for-profit and non-profit organizations and public and private organizations may apply. This funding opportunity uses the NIH planning grant (R34) mechanism and runs in parallel with two opportunities of identical scientific scope, PAR-14-342, which solicits applications under the same mechanism (R34) and PAR-11-339, which solicits applications under the NIH research project cooperative agreement (U01) mechanism.

Direct costs may not exceed US$150,000 over a period of one year.

Ref: PAR-14-346 (replaces PAR-11-338).

Closing date: 07 May 15
Deadline information: Applications due by 5pm applicant’s local time. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.

Posted date: 22 Sep 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $150,000

Contact Details
----------------------------------------------
NINR
NIH
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: 1 301 594 5970
Email: hussk@mail.nih.gov
SELF-MANAGEMENT FOR HEALTH IN CHRONIC CONDITIONS (R01): AIDS-RELATED

NIH: National Institute of Nursing Research

Description:
The National Institute of Nursing Research, the National Institute on Ageing and the National Institute on Deafness and Other Communication Disorders invites applications for its Aids-related self-management for health in chronic conditions grants. These R01 AIDS-related grants support activities that focuses on self-management as a mainstream science in order to reduce the burden of chronic illnesses and conditions. Eligible applicants include domestic and foreign public or private institutions and non-profit or for-profit organizations. The maximum project period is five years.

PA-14-344

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May, 7 September until 8 January 2018.
Posted date: 22 Sep 14
Award type: Directed grants to institutions, research groups etc., Clinical trials

Website:
Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
------------------------------------------------------------
Country of applicant institution: Any
Disciplines
------------------------------------------------------------
Clinical Medicine, Allied Health Professions, Primary Care, Avionics, Employment & Unemployment Studies, Business & Management Studies, Chronic Care, Assistive Technology, Health Counseling, Combustion & Fuel Engineering, Chronic Fatigue Syndrome, Sociology, Public Health, HIV/Aids, Social Work & Social Policy, Public Health, Health Services & Primary Care

Contact Details
------------------------------------------------------------
NIH NIDCR
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: 1 301 435 7908
Email: jatkinso@mail.nih.gov
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R21): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its Aids-related studies in neonatal resuscitation (R21) grants. These Aids-related R21 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.
Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
This Aids-related funding opportunity uses the R21 exploratory and developmental grant mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-351, which solicits applications under the R03 small grant programme mechanism, and PA-14-350, which solicits applications under the R01 research project grant mechanism.
Application budgets are limited to US$275,000 over a maximum of two years, and no more than US$200,000 may be requested in a single year.

Ref: PA-14-349 (replaces PAR-11-224).
Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant institution on every 7 May, 7 September and 7 January until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc., Networking/collaboration
Award amount max: $275,000
Website:
Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Any

Disciplines
Foetal Health & Prenatal Development, Obstetrics & Gynaecology, Paediatrics, HIV/Aids, Clinical Medicine, Neonatal Disorders, Allied Health Professions, Respiratory Medicine, Cardiology

Contact Details
National Institute of Nursing Research
31 Center Drive, Room 5B10
Bethesda MD 20892-2178
Tel: 1 301 594 5970
Email: hussk@mail.nih.gov
STUDIES IN NEONATAL AND PAEDIATRIC RESUSCITATION (R03): AIDS-RELATED
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its AIDS-related studies in neonatal resuscitation (R03) grants. These AIDS-related R03 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation.
Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.
Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.
This AIDS-related funding opportunity utilize the R03 mechanism and runs in parallel with two FOAs of identical scientific scope, PA-14-350 that encourages applications under the R01 research project grant mechanism and PA-14-349 that encourages applications under the R21 exploratory or developmental grant mechanism.
Application budgets are limited to US$50,000 in direct costs per year over a maximum period of two years.
Ref: PA-14-351 (replaces PAR-11-223).
Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website:
Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-351

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Neonatal Disorders, Clinical Medicine, Respiratory Medicine, Allied Health Professions, Cardiology, Obstetrics & Gynaecology, Foetal Health & Prenatal Development, Paediatrics, HIV/AIDS

Contact Details
----------------------------------------------
NICHHD
Building 31, Room 2A32
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The Eunice Kennedy Shriver National Institute of Child Health and Human Development invites applications for its Aids-related studies in neonatal resuscitation (R01) grants. These Aids-related R01 grants support collaborative research projects on a wide range of topics related to neonatal resuscitation. Projects should help develop strategies to deliver highest quality of healthcare to newborn infants and children with utmost safety and effectiveness. Projects may relate to the epidemiology of various domains of medical errors and consequent patient harm, assessing the factors at various levels that contribute to such errors, and intervention strategies at individual, systems and institutional-levels to help reduce and eliminate medical errors.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. This Aids-related funding opportunity uses the R01 research project mechanism, and runs in parallel with two opportunities of identical scientific scope: PA-14-35, which solicits applications under the R03 small grant programme mechanism, and PA-14-349, which solicits applications under the R21 exploratory and developmental grant mechanism.

Application budgets are not limited, but must reflect the actual needs of the project. The total project period may not exceed five years. Ref: PA-14-350 (replaces PAR-11-222).

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 29 Sep 14
Award type: Directed grants to institutions, research groups etc.
Website:
Application form:
http://www.grants.gov/web/grants/applicants/download-application-package.html#download=true&oppNum=PA-14-350

Eligibility profile
Country of applicant institution: Any
Disciplines
Foetal Health & Prenatal Development, Obstetrics & Gynaecology, Clinical Medicine, HIV/Aids, Paediatrics, Neonatal Disorders, Allied Health Professions, Respiratory Medicine, Cardiology

Contact Details
NIH: National Institute of Child Health and Human Development
Building 31, Room 2A32
MSC 2425
31 Center Drive
Bethesda, MD 20892-2425
BIOLOGY OF THE TEMPOROMANDIBULAR JOINT IN HEALTH AND DISEASE (R21): AIDS-RELATED
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R21): Aids-related grants. This R21 Aids-related funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:
• bone;
• muscle;
• cartilaginous and ligamentous tissues;
• vascularisation and innervation;
• models;
• measurement of joint health, disease and functions.

This Aids-related funding opportunity uses the NIH research project (R21) grant mechanism and runs in parallel with one of identical scientific scope, PA-14-358, which solicits applications under the NIH exploratory and developmental grant (R01) mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Funding is worth up to US$275,000 over two years, and projects may request no more than US$200,000 per year.

Ref: PA-14-359.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization, every 7

January, 7 May and 7 September until 8 September 2017.
Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-359.html
Application form: http://www.grants.gov/web/grants/applicant-package.html#download=true?oppNum=PA-14-359

Eligibility profile

Country of applicant institution: Any

Disciplines

Movement Disorders, Clinical Medicine, Orthopaedic Surgery, Disease Models, Musculoskeletal System, Muscle Diseases, Cardiology, Human Biological Sciences, Primary Care, Osteoporosis & Other Bone Diseases, Human Physiology, Public Health, Health Services & Primary Care, Diagnostic Sciences, HIV/Aids, Physiology, Connective Tissue, Bone Cancers

Contact Details

NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
Bethesda MD 20892-6400
Tel: 1 301 594 9898
Biology of the Temporomandibular Joint in Health and Disease (R01): AIDS-Related

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research and the National Institute of Biomedical Imaging and Bioengineering invite applications for their biology of the temporomandibular joint in health and disease (R01): AIDS-related grants. This AIDS-related R01 funding opportunity encourages research that advances understanding of the temporomandibular joint in health and disease, and aims to stimulate research focused on the biology of joint function and the tissues that make up the joint. Focus areas include:

- bone;
- muscle;
- cartilaginous and ligamentous tissues;
- vascularization and innervation;
- models;
- measurement of joint health, disease and functions.

This AIDS-related funding opportunity uses the NIH exploratory and developmental grant (R01) mechanism and runs in parallel with one of identical scientific scope, PA-14-359, which solicits applications under the NIH research project (R21) grant mechanism. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Budgets are not limited but must reflect the actual needs of the proposed project. The scope of the project should define its duration. Ref: PA-14-358.

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 September 2017.

Posted date: 06 Oct 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PA-14-358.html
Application form: http://www.grants.gov/web/grants/applicant
donload-application-package.html#download=true?oppNum=PA
-14-358

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Diagnostic Sciences, Public Health, Health Services & Primary Care, HIV/AIDS, Bone Cancers, Physiology, Connective Tissue, Musculoskeletal System, Cardiology, Muscle Diseases, Primary Care, Human Biological Sciences, Human Physiology, Osteoporosis & Other Bone Diseases, Movement Disorders, Orthopedic Surgery, Clinical Medicine, Disease Models

Contact Details
----------------------------------------------
NIH: National Institute of Dental and Craniofacial Research
Public Information and Liaison Branch
45 Center Drive, MSC 6400
BIOBEHAVIORAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R21): AIDS-RELATED
NIH: National Institutes of Health

Description:
The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their Aids-related bioBehavioral and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These Aids-related R21 grants aim to stimulate clinical research focused on bioBehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R21 exploratory or developmental grant mechanism that seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets and technologies that have the potential to substantially advance biomedical research. The opportunity runs in parallel with two opportunities of identical scientific scope; PA-15-017, which solicits applications under the R01 research project grant mechanism, and PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged.

Grants cover direct costs up to a maximum of US$275,000 over a period of up to two years. Ref: PA-15-015.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 15 Oct 14
Award type: Directed grants to institutions, research groups etc., Networking/collaboration
Award amount max: $275,000

Eligibility profile
-----------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------
Neurology, Medical Effectiveness & Patient Outcomes, Clinical Medicine, Psychology, Neuroscience, Alzheimer’s Disease & Senile Dementia, Health Economics, Primary Care,
BIOBEHAVIORAL AND TECHNOLOGICAL INTERVENTIONS TO ATTENUATE COGNITIVE DECLINE IN INDIVIDUALS WITH COGNITIVE IMPAIRMENT OR DEMENTIA (R01): AIDS-RELATED

NIH: National Institutes of Health

Description:
The National Institutes of Health, under the National Institute of Nursing Research and the National Institute on Aging, invite applications for their AIDS-related bioBehavioral and technological interventions to attenuate cognitive decline in individuals with cognitive impairment or dementia grants. These AIDS-related R01 grants aim to stimulate clinical research focused on bioBehavioral or technological interventions to attenuate cognitive decline in individuals with dementia, mild cognitive impairment, or disease or age-related cognitive decline. Particular interest is on the following:

- interventions that can be implemented in community settings by the affected individual, informal caregivers or others in the community;
- research to inform the development of the type of interventions identified above;
- research that examines underlying mechanisms and biomarkers associated with response to interventions.

This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two opportunities of identical scientific scope; PA-15-016, which solicits applications under the R15 academic research enhancement award mechanism, and PA-15-015, which solicits applications under the R21 exploratory or developmental award mechanism.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. Interdisciplinary collaborations that include nurse scientists in the project team are strongly encouraged. Grants are awarded for a maximum project period of five years. Ref: PA-15-017.

Closing date: 07 May 15
Deadline information: Applications requesting US$500,000 or more in direct costs per year should Contact Details NIH staff at least six weeks before applying. Applications open on 5 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.

Posted date: 15 Oct 14
Award type: Directed grants to institutions, research groups etc., Networking/collaboration


Application form: http://grants.nih.gov/grants/guide/ApplyButonSplash.cfm
Eligibility profile

Country of applicant institution: Any

Disciplines

General Practice, HIV/Aids, Diagnostic Sciences, Public Health, Health Services & Primary Care, Primary Care, Cognitive Processes, Alzheimer’s Disease & Senile Dementia, Neuroscience, Health Economics, Clinical Medicine, Medical Effectiveness & Patient Outcomes, Psychology, Neurology

Contact Details

NINR
Building 1DEM
Suite 713A
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 594 5968
Email: tullyla@mail.nih.gov

PROMOTING RESEARCH IN BASIC NEUROSCIENCE (R01): AIDS-RELATED
NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke, the National Institute on Aging, the National Institute on Drug Abuse and the National Institute of Mental Health invite applications for their AIDS-related promoting research in basic neuroscience (R01) grants. These AIDS-related R01 grants aim to stimulate research addressing fundamental questions in basic neuroscience.

Projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the structure and/or function of the normal nervous system. Grants are not intended to stimulate research that is explicitly disease-related.

Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply.

Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Ref: PAS-15-029.

Closing date: 07 May 15

Deadline information: Applications requesting US$500,000 or more in direct costs per year should Contact Details NIH staff at least six weeks before applying. Applications are invited between 5 January and 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018. Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.

Posted date: 05 Nov 14

Award type: Directed grants to institutions, research groups etc., Networking/collaboration


Eligibility profile

Country of applicant institution: Any

Disciplines

Clinical Medicine, Electrophysiology, Neuropharmacology, Psychology, Neurology, Pharmacy & Pharmacology, Neuroendocrinology, Biological Sciences, Neurobiology, Neuroimaging, Primary Care,
**Diabetes and Cardiovascular Disease in Older Adults (R21): AIDS-Related**

*NIH: National Institute on Aging*

**Description:**
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R21) grants. These Aids-related R21 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons.

This funding opportunity uses the R21 exploratory and developmental research grant mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

Application budgets are limited to US$275,000 for direct costs over a maximum project period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-038.

**Closing date: 07 May 15**

**Deadline information:** Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.

**Posted date: 20 Nov 14**

**Award type:** Innovation grants, Directed grants to institutions, research groups etc.

**Award amount max:** $275,000

**Website:**

**Application form:**

**Eligibility profile**

Country of applicant institution: Any

**Disciplines**

Diabetes, HIV/Aids, Geriatrics & Gerontology, Cardiovascular Diseases
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R03): AIDS-RELATED

NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R03) grants. These Aids-related R03 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons. This funding opportunity uses the R03 small grant programme mechanism and runs in parallel with two of identical scientific scope, PA-15-037, which solicits applications under the R01 research project grant mechanism and PA-15-038, which solicits applications under the R21 exploratory and developmental research grant mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are limited to US$100,000 for direct costs over a maximum project period of two years. No more than US$50,000 may be requested in any single year.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 20 Nov 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant-
s/download-application-
package.html#download=true&oppNum=P A-15-039

Eligibility profile
Country of applicant institution: Any

Disciplines
Cardiovascular Diseases, HIV/AIDS, Geriatrics & Gerontology, Diabetes

Contact Details
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: 1 301 496 6761
Email: susan.zieman@nih.gov
DIABETES AND CARDIOVASCULAR DISEASE IN OLDER ADULTS (R01): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its diabetes and cardiovascular disease in older adults (R01) grants. These Aids-related R01 grants encourage basic, clinical and epidemiological outcomes research on the impact of age on the development of, diagnosis and management of diabetes and cardiovascular disease complications in older persons or animal models. Research supported by this initiative is expected to elucidate the role of ageing mechanisms that underlie the increased vulnerability of older adults to DM and its CVD complications and to provide evidence-based guidance to improve more appropriate diagnostic criteria, risk stratification and intervention recommendations to prevent the onset, or improve short- and long-term outcomes, of DM and CVD in older persons. This funding opportunity uses the R01 research project grant mechanism and runs in parallel with two of identical scientific scope, PA-15-038, which solicits applications under the R21 exploratory and developmental grant mechanism and PA-15-039, which solicits applications under the R03 small grant programme mechanism. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 05 Jan 15
Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -
Website:
Application form:

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Diabetes, Geriatrics & Gerontology, HIV/AIDS, Cardiovascular Diseases

Contact Details
----------------------------------------------
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: 1 301 496 6761
Email: susan.zieman@nih.gov
UNDERACTIVE BLADDER IN AGEING (R03): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its underactive bladder in ageing (R03) grants. This Aids-related R03 funding opportunity announcement invites applications that propose basic, clinical or translational research on underactive bladder and its consequences in ageing and in older persons. Applications should focus on the:
- biology, aetiology and pathophysiology of UAB in animal models and older adults;
- translation of basic or clinical research into clinical practice and health decision-making;
- diagnosis, prevention, management and clinical outcomes of UAB in older adults;
- epidemiology and risk factors for the development of UAB with advancing age.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. This FOA uses the NIH small grant (R03) mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-049 that solicits applications under the research project grant award (R01) mechanism and PA-15-051 that solicits applications under the exploratory/developmental (R21) mechanism. Application budgets are limited to US$100,000 over the two-year R03 period, with no more than US$50,000 in any year. The maximum project period is two years.
Ref: PA-15-050.

Closing date: 07 May 15

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 25 Nov 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000

Eligibility profile
----------------------------------------------
Country of applicant institution: Any
Disciplines
----------------------------------------------
Incontinence, Geriatrics & Gerontology, HIV/Aids, Urology
Contact Details
----------------------------------------------
NIA
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: 1 301 496 6761
Email: saliveme@mail.nih.gov
UNDERACTIVE BLADDER IN AGEING (R21): AIDS-RELATED
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its underactive bladder in ageing (R21) grants. This Aids-related funding opportunity announcement invites applications that propose basic, clinical or translational research on underactive bladder and its consequences in ageing and in older persons. Applications should focus on the:
- biology, aetiology and pathophysiology of UAB in animal models and older adults;
- translation of basic or clinical research into clinical practice and health decision-making;
- diagnosis, prevention, management and clinical outcomes of UAB in older adults;
- epidemiology and risk factors for the development of UAB with advancing age.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. This FOA uses the NIH exploratory/developmental R21 grant mechanism and runs in parallel with two FOAs of identical scientific scope, PA-15-049 that solicits applications under the research project grant award (R01) mechanism and PA-15-050 that solicits applications under the small grant programme (R03) mechanism. Application budgets are limited to US$275,000 over the two-year R21 period, with no more than US$200,000 in any year.

Ref: PA-15-051.

Closing date: 07 May 15

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 25 Nov 14

Award type: Directed grants to institutions, research groups etc., Innovation grants

Award amount max: $275,000


Eligibility profile
-----------------------------------------------
Country of applicant institution: Any

Disciplines
-----------------------------------------------
HIV/Aids, Geriatrics & Gerontology, Incontinence, Urology

Contact Details
-----------------------------------------------
NIA
GWY BG Room 3C307
7201 Wisconsin Avenue
Bethesda MD 20814
Tel: 1 301 496 6761
Email: saliveme@mail.nih.gov
UNCONVENTIONAL ROLES OF ETHANOL METABOLIZING ENZYMES, METABOLITES AND COFACTORS IN HEALTH AND DISEASE (R21): AIDS-RELATED

NIH: National Institute on Alcohol Abuse and Alcoholism

Description:
The National Institute on Alcohol Abuse and Alcoholism invites applications for its AIDS-related unconventional roles of ethanol metabolizing enzymes, metabolites and cofactors in health and disease (R21) funding opportunity announcement. This AIDS-related announcement provides support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolizing pathways, their metabolites, cofactors and interactions with synergizing biological pathways in the development of alcohol-induced diseases and end organ injuries.

The aim is to generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption. The generated knowledge should enable clinicians to improve disease outcomes and consequently, public health.

Research areas include the following: ethanol and NAD⁺; ethanol and acetate; ethanol and SAM; ethanol and zinc; endogenous substrates and functions of alcohol metabolizing pathways – regulation of growth, development and disease.

This announcement uses the R21 exploratory or developmental research grant mechanism and runs in parallel with one of identical scientific scope, PA-15-058, which encourages applications under the R01 research project grant mechanism.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply.

Grants cover direct costs up to a maximum of US$275,000 over a maximum period of two years. No more than US$200,000 may be requested in any single year.

Ref: PA-15-057 (reissue of PA-12-234).

Closing date: 07 May 15

Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization, every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 09 Dec 14

Award type: Innovation grants, Directed grants to institutions, research groups etc., Networking/collaboration

Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

HIV/Aids, Cell Physiology & Metabolism, Alcoholic Beverages, Alcoholism, Hepatology, Addiction

Contact Details

NIAAA
Building 5635FL, Room 2119
5635 Fishers Lane
Rockville, MD 20852
Tel: 1 301 443 2193
Email: orosza@mail.nih.gov
UDCR CLINICAL TRIAL OR BIOMARKER CLINICAL VALIDATION STUDY  
COOPERATIVE AGREEMENT (U01): AIDS-RELATED

NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its Aids-related clinical trial or biomarker validation study cooperative agreement (U01) funding opportunity announcement. This Aids-related announcement supports investigator-initiated phase I, II, III or IV clinical trials, stage one to four Behavioral or social intervention trials or biomarker validation studies that require prospective collection of clinical outcomes and clinical specimens through the funding mechanism. Eligible clinical trials may focus on the following:

- chemotherapeutic, pharmacologic or other interventions to prevent or treat periodontal diseases and various types of dental caries;
- testing new dental materials for restoration of carious lesions;
- testing non-opiate methods of reducing postoperative pain and swelling after dental surgery;
- preventing or treatment of HIV/Aids, its associated oral complications, confections or malignancies, and dental diseases caused by bacteria, fungi or viruses;
- testing therapies to prevent or treat oral candidiasis, oral herpes virus infections and other pathogens with oral targets that commonly occur in those with congenital or acquired immune dysfunction;
- testing treatments for oral mucositis and other oral manifestations of systemic diseases;
- comparing therapies for oral diseases in medically complex patients;
- preventing or managing salivary dysfunction;
- testing treatments for temporomandibular dysfunction and other orofacial pain conditions;
- validation of biomarkers of oral or dental diseases through prospective collection of biospecimens and data on clinical outcomes;
- testing the efficacy or effectiveness and mechanisms of action of Behavioral or social interventions to improve dental, oral or craniofacial health;
- adapting Behavioral or social principles, methods or interventions from other areas of health to be applied and tested in dental, oral or craniofacial health, or in the dental setting;
- developing and testing algorithms for tailoring or targeting Behavioral or social interventions for individuals, groups, communities or settings in which further testing is justified.

This announcement uses the NIH research (U01) grant mechanism and runs in parallel with two announcements of identical scientific scope, PAR-14-342 and PAR-14-346, both of which solicit applications under the NIH planning grant (R34) mechanism.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply.

Application budgets are not limited but must reflect the needs of the project. The maximum project period is five years.


Closing date: 07 May 15
Deadline information: Applications open on 5 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018.

Deadlines on: 7 May 2015, 7 September 2015, 7 January 2016, and repeated annually.

Posted date: 09 Dec 14

Award type: Directed grants to institutions, research groups etc., Networking/collaboration, Clinical trials
BUILDING ON HIGH IMPACT BASIC NEUROBIOLOGY THROUGH ASSAY DEVELOPMENT: ADVANCING TOOLS FOR THERAPEUTIC DISCOVERY (R01): AIDS-RELATED

NIH: National Institute of Mental Health

Description:
The National Institute of Mental Health, the National Institute on Alcohol Abuse and Alcoholism and the National Institute on Drug Abuse invite applications for their Aids-related building on high impact basic neurobiology through assay development: advancing tools for therapeutic discovery (R01) grants.

This Aids-related announcement encourages research to develop novel, robust assays to reveal changes in neuronal and glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms or perturbations in an unbiased and efficient manner.

US and foreign for-profit and non-profit organizations and public and private institutions are eligible to apply. Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants requesting US$500, 00 or more in direct costs in any year must

NIH programme staff at least six weeks before submitting the application. The maximum project period is four years.


Closing date: 07 May 15
Deadline information: Applications open on 23 January and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.

Posted date: 11 Dec 14
Award type: Directed grants to institutions, research groups etc., Innovation grants
Award amount max: -
Award amount min: -
Award budget total: -

Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Infection Agents & Pathogens, Biochemical Markers, HIV/Aids, Pain Management, Preventive Medicine, Dentistry

Contact Details

NIH
Building 1DEM, Room 634
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 435 7908
Email: jatkinso@mail.nih.gov
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): ASSAY DEVELOPMENT AND THERAPEUTIC AGENT IDENTIFICATION AND CHARACTERIZATION TO SUPPORT THERAPEUTIC DISCOVERY (R21/R33): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): assay development and therapeutic agent identification and characterization to support therapeutic discovery (R21/R33) funding opportunity announcement. This Aids-related announcement encourages research to develop in vitro or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

This funding opportunity uses the NIH phased innovation award (R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-071, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-070.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 15 Dec 14
Award type: Innovation grants, Directed grants to institutions, research groups etc.
Award amount max: $750,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Neurology, HIV/Aids
INNOVATION GRANTS TO NURTURE INITIAL TRANSLATIONAL EFFORTS (IGNITE): PHARMACODYNAMICS AND IN VIVO EFFICACY STUDIES FOR SMALL MOLECULES AND BIOLOGICS/BIOTECHNOLOGY PRODUCTS (R21/R33): AIDS-RELATED

NIH: National Institute of Neurological Disorders and Stroke

Description:
The National Institute of Neurological Disorders and Stroke invites applications for its innovation grants to nurture initial translational efforts (IGNITE): pharmacodynamics and in vivo efficacy studies for small molecules and biologics/biotechnology products (R21/R33) funding opportunity announcement. This Aids-related announcement provides funding to conduct pharmacodynamics, pharmacokinetics and in vivo efficacy studies to demonstrate that proposed therapeutic agents have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

This funding opportunity uses the NIH phased innovation award (R21/R33) grant mechanism and runs in parallel with one of identical scientific scope, PAR-15-070, which also solicits applications under the NIH phased innovation award (R21/R33) grant mechanism.

Application budgets are limited to US$750,000 over the maximum combined project period of three years, with a maximum of US$250,000 for the R21 phase and US$500,000 for the R33 phase. The R21 and R33 cannot be awarded in the same fiscal year.

Ref: PAR-15-071.

Closing date: 07 May 15
Deadline information: Applications open on 16 January 2015 and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2018.
Posted date: 15 Dec 14
Award type: Innovation grants, Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Neurology, HIV/Aids

Contact Details
----------------------------------------------
NSC BG Room 2106
6001 Executive Boulevard

Rockville MD 20852
Tel: 1 301 496 1779
Email: amir.tamiz@nih.gov
CADEMIC-INDUSTRIAL PARTNERSHIPS FOR TRANSLATION OF TECHNOLOGIES FOR CANCER DIAGNOSIS AND TREATMENT (R01): AIDS-RELATED

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its Aids-related academic-industrial partnerships for translation of technologies for cancer diagnosis and treatment (R01) funding opportunity announcement. This Aids-related announcement enables academic and industrial investigators to form research partnerships and work together to accelerate the translation of technologies, methods, assays or devices, systems for preclinical or clinical molecular diagnosis or in vitro imaging designed to solve a targeted cancer problem.

The proposed systems may include molecular diagnosis, molecular imaging or related research resources. Clinical trials that test functionality, and optimize and validate the performance of the proposed translational work may also be funded. US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. Application budgets are not limited but must reflect the needs of the project. The maximum funding period is five years.

Ref: PAR-15-075.

Closing date: 07 May 15

Deadline information: Applications open on 6 February and are due by 5pm local time of applicant organization on every 7 January, 7 May and 7 September until 8 January 2017.

Posted date: 17 Dec 14

Award type: Academic-Industry links, Directed grants to institutions, research groups etc., Clinical trials, Research calls for business, Networking/collaboration

Award amount max: -
Award amount min: -
Award budget total: -


Eligibility profile

Country of applicant institution: Any

Contact Details

NIH
Building 9609 Room 3W424
9609 Medical Center Drive
Rockville, MD 20850
Tel: 1 240 276 5714
Email: ossandom@mail.nih.gov

Disciplines

Oncology Nursing, Molecularly Targeted Therapy, Radiotherapy, Cancer Immunology, Chemotherapy, Cancer Diagnosis, HIV/AIDS
NIAID CLINICAL TRIAL PLANNING GRANTS (R34)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invite applications for its NIAID clinical trial planning grants. NIAID will support R34 applications that propose the complete planning, design and preparation of the documentation necessary for the implementation of investigator-initiated non-high-risk clinical trials. The trials must be hypothesis driven, milestone-driven, and related to the research mission of the NIAID and considered a high priority by the institute. Sufficient preclinical data to support the planning of the clinical trial should be available prior to submission of the R34 grant application.

This funding opportunity announcement will utilize the NIH R34 grant mechanism and runs in parallel with two related FOAs, PAR-13-151, which solicits applications under the U01 grant mechanism, and PAR-13-149, which solicits applications under the R01 grant mechanism. Eligible applicants include domestic and foreign for-profit or nonprofit organizations and public or private institutions. Application budgets are limited to US$150,000 direct costs and the maximum project period is one year. PAR-13-150 (replaces PAR-10-185).

Closing date: 13 May 15
Deadline information: Applications open 4 May 2013; applications due by 5pm local time of the applicant organization.

Posted date: 25 Mar 13
Award type: Clinical trials, Directed grants to institutions, research groups etc.
Award amount max: $150,000
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-150

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Infectious Diseases, Drug Design, General Practice, Pharmacy & Pharmacology, Diagnostic Sciences, Preventive Medicine, Clinical Pharmacy & Pharmacology, Medical & Diagnostic Tests, Pharmaceutical Drugs, Infection Agents & Pathogens, Immunology

Contact Details
----------------------------------------------
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892
Tel: 1 301 51 4414
Email: egoldmuntz@niaid.nih.gov
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its clinical trial implementation cooperative agreements. These U01 grants will support cooperative agreement applications for implementation of investigator initiated high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. The trials must be hypothesis driven, milestone-driven, and related to the research mission of the NIAID and considered a high priority by the institute.

This funding opportunity announcement will utilize the NIH U01 grant mechanism and runs in parallel with two related FOAs, PAR-13-149, which solicits applications under the R01 grant mechanism, and PAR-13-150, which solicits applications under the R34 grant mechanism. Eligible applicants include domestic and foreign for-profit or nonprofit organizations and public or private institutions. Application budgets are not limited, and the maximum project period is five years. PAR-13-151 (replaces PAR-11-234).

Closing date: 13 May 15

Country of applicant institution: Any

Disciplines
Pharmacy & Pharmacology, Drug Design, Infection Agents & Pathogens, Infectious Diseases, Immunology, Medical & Diagnostic Tests, Clinical Pharmacy & Pharmacology, Preventive Medicine, Diagnostic Sciences, Pharmaceutical Drugs, General Practice

Contact Details
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892
Tel: 1 301 51 4414
Email: egoldmuntz@niaid.nih.gov

Award type: Clinical trials, Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-151
NIH CLINICAL TRIAL IMPLEMENTATION GRANT (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for its NIAID clinical trial implementation grants. NIAID will support R01 applications that propose implementation of investigator-initiated non-high-risk clinical trials. The trials must be hypothesis driven, related to the research mission of the NIAID and considered a high priority by the institute. Applicants must propose a time-sensitive, milestone-driven clinical trial and describe the clinical trial stages, criteria for completion of the stages and contingency plans for each stage. The trial must have clear primary and secondary endpoints.

This funding opportunity announcement will utilize the NIH R01 grant mechanism and runs in parallel with two related FOAs, PAR-13-151, which solicits applications under the U01 grant mechanism, and PAR-13-150, which solicits applications under the R34 grant mechanism. Eligible applicants include domestic and foreign for-profit or nonprofit organizations and public or private institutions. Application budgets are not limited, and the maximum project period is five years. PAR-13-149 (replaces PAR-10-184).

Closing date: 13 May 15

Posted date: 25 Mar 13
Award type: Clinical trials, Directed grants to institutions, research groups etc.
Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-149

Eligibility profile
Country of applicant institution: Any

Disciplines
Pharmacy & Pharmacology, Infectious Diseases, Infection Agents & Pathogens, Immunology, Drug Design, General Practice, Preventive Medicine, Diagnostic Sciences, Medical & Diagnostic Tests, Clinical Pharmacy & Pharmacology, Pharmaceutical Drugs

Contact Details
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Room 3138, MSC-7616
6700-B Rockledge Drive
Bethesda, MD 20892
Tel: 1 301 51 4414
Email: egoldmuntz@niaid.nih.gov
BIOENGINEERING RESEARCH PARTNERSHIPS (R01)
NIH: National Institute of Biomedical Imaging and Bioengineering

Description:
10 participating institutes and centers of the National Institutes of Health invite applications for their bioengineering research partnerships (R01). This R01 funding opportunity announcement aims to accelerate the development and adoption of promising tools and technologies that can address important biomedical research problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing understanding of life science processes or the practice of medicine. Multidisciplinary teams should apply an integrative, quantitative bioengineering approach and engage biomedical researchers and clinicians throughout the project. This FOA will use the NIH R01 research project grant (R01) award mechanism and runs in parallel with two FOAs of similar scientific scope, PA-12-284, which solicits applications under the R21 exploratory/developmental research grant mechanism and PAR-13-137, which also solicits applications under the R01 mechanism.

US and foreign for-profit and non-profit organizations and public or private institutions may apply. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Ref: PAR-14-092 (replaces PAR-10-234).

Closing date: 20 May 15


Posted date: 07 Feb 14

Award type: Networking/collaboration, Directed grants to institutions, research groups etc.

Website: 

Application form: 

Eligibility profile

Country of applicant institution: Any

Disciplines

Health Informatics, Computer Science & Informatics, Translational Medicine, Metallurgy, Clinical Medicine, Medicine & Health, General Practice, Bioinformatics, Radiology & Medical Imaging, Bioengineering, Biomedical Engineering, Medical Research of Selected Fields, Medical & Diagnostic Tests, Medical Devices, Preventive Medicine, Public Health, Health Services & Primary Care, Primary Care, Biomaterials, Medical Physics, Behavioral Medicine, Materials Sciences
INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases invites applications for funding for international research in infectious diseases. This R01 funding opportunity announcement solicits applications from organizations and institutions in resource-constrained countries that propose research related to infectious diseases. The intent is to advance the development of local scientific expertise, build local research infrastructure and to increase collaborative research partnerships at NIAID international sites.

For-profit or non-profit organizations and public or private institutions in developing countries may apply. Principal investigators may not currently hold a NIH funded grant. Collaborative projects involving investigators and institutions from international sites and the US are particularly encouraged, but a US partner is not a requirement.

Grants are worth up to US$125,000 per year over a period of up to five years. PAR-14-080 (replaces PAR-11-145).

Closing date: 22 May 15
Deadline information: Applications due by 5pm local time of applicant organization.
Posted date: 31 Jan 14
Award type: Networking/collaboration, Directed grants to institutions, research groups etc.
Award amount max: $625,000
Website:

Application form:
http://grants.nih.gov/grants/guide/ApplyButtonSplash.cfm

Eligibility profile
Country of applicant institution: Lower-Middle-Income countries, Low Income countries, Upper-Middle-Income countries
Country of applicant institution: United States

Disciplines
Microbiology, Physiology, HIV/AIDS, Public Health, Health Services & Primary Care, Diagnostic Sciences, Tuberculosis, Influenza, Biostatistics, Human Biological Sciences, Venereology & Sexually Transmitted Diseases, Immunopathology, Virology, Immunology, Primary Care, Infectious Diseases, Gastroenterology, Parasitology, Infection Agents & Pathogens, Pathogenesis, Tropical & Neglected Diseases, Malaria, Drug Resistance, International Health, Pathology, Biological Sciences, Respiratory Medicine, Epidemiology, Allied Health Professions

Contact Details
Division of Microbiology and Infectious Diseases
NIAID
Room 3807, MSC-6603
6610 Rockledge Drive
Bethesda, MD 20892-6603
Tel: 1 301 496 1884
Fax: 1 301 480 4528
Email: ps31g@nih.gov
NIDIA RESEARCH EDUCATION PROGRAMME FOR CLINICAL RESEARCHERS AND CLINICIANS (R25)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its research education programme for clinical researchers and clinicians (R25) grants. This R25 funding opportunity announcement will support research education for those in clinically focused careers, in a topic area related to substance use, abuse or addiction. Participants should be training for careers as clinical researchers, clinicians or service providers, or optimally a combination of the two. This mechanism may not be used to support non-related-related clinical training. Direct costs are limited to US$350,000 in direct costs allowed in any single year. The maximum project period is five years. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. PAR-13-084 (replaces PAR-10-173).

Closing date: 22 May 15
Deadline information: Applications due by 5pm proposer's local time. Deadlines on: 22 May 2013, 22 May 2014, 22 May 2015.
Posted date: 11 Jan 13
Award type: Directed grants for individual investigators, Personal development
Award amount max: $1,750,000

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-084

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care, Clinical Medicine, Diagnostic Sciences, Public Health, Health Services & Primary Care, Drug & Substance Abuse

Contact Details
Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience and Behavioral Research
NIDA
6001 Executive Boulevard, Room 3157, MSC 9551
Bethesda, MD 20892-9551
Tel: 1 301 443 0107
Fax: 1 301 443 6814
Email: dg79a@nih.gov

LONG-TERM OUTCOMES OF BARIATRIC SURGERY USING LARGE DATASETS (R01)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute on Drug Abuse invite applications for their long-term outcomes of bariatric surgery using large datasets (R01) grants. The purpose of this R01 funding opportunity is to support applications that address the long-term clinical outcomes of

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-084

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care, Clinical Medicine, Diagnostic Sciences, Public Health, Health Services & Primary Care, Drug & Substance Abuse

Contact Details
Behavioral and Integrative Treatment Branch
Division of Clinical Neuroscience and Behavioral Research
NIDA
6001 Executive Boulevard, Room 3157, MSC 9551
Bethesda, MD 20892-9551
Tel: 1 301 443 0107
Fax: 1 301 443 6814
Email: dg79a@nih.gov
bariatric surgery using large datasets within healthcare delivery organizations. Clinical outcomes of interest to NIDDK include obesity, body composition and obesity-related complications within the NIDDK mission such as diabetes, metabolic liver disease, kidney and urological diseases. Studies should propose outcomes occurring at minimum five years post-surgery. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. Application budgets are limited to less than US$500,000 in direct costs per year. The maximum project period is five years. Ref: PAR-14-262.

Closing date: 03 Jun 15
Deadline information: Applications open on 3 September and are due by 5pm local time of applicant organization on 3 October 2014 and 3 June 2015.
Posted date: 19 Jun 14
Award type: Directed grants to institutions, research groups etc.
Award amount max: $500,000
Website:

LZHEIMER’S DISEASE SEQUENCING PROJECT REPLICATION PHASE ANALYSIS STUDIES (U01)
NIH: National Institute on Aging

Description:
The National Institute on Aging invites applications for its Alzheimer’s disease sequencing project replication phase analysis studies (U01) grants. These encourage research specific to targeted sequencing, genotyping and data analysis in the replication phase of the Alzheimer's disease sequencing project. The aim is to fund the following types of projects:

- genome wide association studies of subjects to be included in the replication phase of the study;
- targeted sequencing of signals in regions containing variants identified in the ADSP discovery phase;
- analysis of replication phase targeted sequence and genotype data that are provided by the large scale sequencing

Application form: http://www.grants.gov/applicants/apply-for-grants.html

Eligibility profile
Country of applicant institution: Any

Disciplines
Diabetes, Quality of Care, Clinical Decision-making & Analysis, Health Systems, Medical & Diagnostic Tests, General Surgery, Public Health, Health Services & Primary Care, Allied Health Professions, Access to Health Care, Standards of Care, Clinical Medicine, Medical Effectiveness & Patient Outcomes, General Practice, Health Systems, Consumer Choice, Urology, Primary Care, Obesity, Nutrition & Dietetics, Nephrology & Kidneys, Hepatology

Contact Details
NIHDK
Building 31, Room 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560
Tel: 1 301 594 8803
Email: teffk@mail.nih.gov
and analysis centers and those data provided under awards to the companion FOA, RFA-AG-16-001, NIA coordinating center for genetics and genomics of Alzheimer’s disease (U54), or those provided by other through related data sets.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

NIA intends to commit US$2.25 million in financial year 2016 to fund from one to four awards. The direct cost limit in the first year is US$600,000. Total costs across the remaining years are limited to US$1.3m with no more than US$500,000 in any single year. The maximum project period is five years.

Ref: RFA-AG-16-002.

Closing date: 03 Jun 15
Deadline information: Applications open on 3 May and are due by 5pm local time of applicant organization, 3 June 2015.
Posted date: 26 Nov 14
Award type: Directed grants to institutions, research groups etc.

Award amount max: $1,900,000

Eligibility profile
---------------------------------------------------------------
Country of applicant institution: Any

Disciplines
---------------------------------------------------------------
Alzheimer’s Disease & Senile Dementia

Contact Details
---------------------------------------------------------------
NIA
GWY Building, Room 350
7201 Wisconsin Avenue
Bethesda, MD 20814
Tel: 1 301 496 9350
Email: millerm@nia.nih.gov

DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R01)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R01) funding opportunity announcement. This announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan.

This FOA encourages investigations of cognitive, Behavioral, and social processes as they relate to:

• development of novel prevention approaches;
• efficacy and effectiveness of prevention interventions or programmes;
• processes that optimize the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
• methodologies appropriate for studying complex aspects of prevention science.
Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. This FOA uses the research project grant (R01) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-081 which respectively use the exploratory/developmental grant (R21) and the small grant programme (R03) funding mechanism. Application budgets are not limited, but should reflect the actual needs of the project. The maximum project period is five years.

Ref: PA-15-082 (reissue of PA-11-311)

Closing date: 05 Jun 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organization every 5 February, 5 June and 5 October until 8 September 2017.
Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc.

Eligibility profile
Country of applicant institution: Any
Disciplines
Drug & Substance Abuse, Alcoholism, Smoking & Tobacco

Contact Details
NIDA
NSC BG Room 5171
6001 Executive Boulevard
Rockville MD 20852
Tel: 1 301 443 6504
Email: hperl@mail.nih.gov

**BUILDING EVIDENCE: EFFECTIVE PALLIATIVE/END OF LIFE CARE INTERVENTIONS (R01)**

NIH: National Institute of Nursing Research

**Description:**
The National Institute of Nursing Research invites applications for its building evidence: effective palliative/end of life care interventions (R01) grants. This R01 funding opportunity announcement seeks to stimulate research that develops and tests optimal palliative and end-of-life care interventions based on measurable outcomes. It also aims to standardize such interventions across outcomes, programmes and settings in order to achieve synchrony and the ability to pool data as needed for further analyses that can substantiate the directions and domains of scientific growth in this area.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. PAR-13-289.

Closing date: 09 Jun 15
Deadline information: Applications due by 5pm proposer’s local time on every 8 October and 9 June until 10 June 2016.

Description:
The National Cancer Institute invites applications for its fundamental mechanisms of affective and decisional processes in cancer control (U01) grants. This R01 funding opportunity announcement aims to generate fundamental knowledge of affective processes. Basic affective sciences should have key downstream consequences for single and multiple event decisions and behaviors across the cancer prevention and control continuum. This FOA encourages scientific disciplines that have not traditionally conducted cancer research, such as affective and cognitive neuroscience, decision science and consumer science, to elucidate perplexing and understudied problems in basic affective and decision sciences with promise of having downstream implications for cancer prevention and control science. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. NCI anticipates most requests for direct costs to be in the range of US$250,000 and US$450,000 per year. Direct costs may not exceed US$700,000 per year. The maximum project period is five years. Ref: PAR-14-067.

Closing date: 10 Jun 15
Deadline information: Applications due by 5pm proposer’s local time. Deadlines on: 10 June 2014, 15 October 2014, 10 June 2015, 14 October 2015, 10 June 2016, 10 June 2016. Posted date: 10 Jan 14
Award type: Networking/collaboration, Innovation grants, Directed grants to institutions, research groups etc.
Award amount max: $3,500,000
Website: http://grants.nih.gov/grants/guide/par-files/PAR-14-067.html

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R21) funding opportunity announcement. This announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. This FOA encourages investigations of cognitive, behavioral, and social processes as they relate to:

- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimize the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

This FOA uses the exploratory/developmental grant (R21) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-081 and PA-15-082 which respectively use the small grant programme (R03) and the research project grant (R01) funding mechanism.

Direct costs are limited to US$275,000 over an R21 two-year period, with no more than US$200,000 in direct costs allowed in any single year.

Ref: PA-15-080 (reissue of PA-11-312).

Closing date: 16 Jun 15

Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organization every 16 February, 16 June and 16 October until 8 September 2017.

Posted date: 12 Jan 15

Award type: Directed grants to institutions, research groups etc., Innovation grants

Award amount max: $275,000


Application form: http://www.grants.gov/web/grants/applicant
DRUG ABUSE PREVENTION INTERVENTION RESEARCH (R03)
NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its drug abuse prevention intervention research (R03) funding opportunity announcement. This announcement aims to support research that will employ rigorous scientific methods to test theoretically derived hypotheses to increase understanding of the science of drug use prevention within diverse populations and settings and across the lifespan. This FOA encourages investigations of cognitive, behavioral, and social processes as they relate to:
- development of novel prevention approaches;
- efficacy and effectiveness of prevention interventions or programmes;
- processes that optimize the selection, integration, implementation and sustainability of science-based prevention, including systems-level and health economic factors;
- methodologies appropriate for studying complex aspects of prevention science.
Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

This FOA uses the small grant programme (R03) funding mechanism and runs in parallel with two opportunities of identical scientific scope, PA-15-080 and PA-15-082 which respectively use the exploratory/developmental grant (R21) and the research project grant (R01) funding mechanism.
Direct costs of up to US$50,000 per year and a project duration of up to two years may be requested.
Ref: PA-15-081 (reissue of PA-11-313).

Closing date: 16 Jun 15
Deadline information: Applications open on 16 May and are due by 5pm local time of applicant organization every 16 February, 16 June and 16 October until 8 September 2017.
Posted date: 12 Jan 15
Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://www.grants.gov/web/grants/applicant/s/download-application-
MALL GRANTS FOR NEW INVESTIGATORS TO PROMOTE DIVERSITY IN HEALTH-RELATED RESEARCH (R03)
NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Description:
The National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Mental Health and the Office of Dietary Supplements invite applications for small grants for new investigators to promote diversity in health-related research (R03). This R03 funding opportunity announcement will provide support for new investigators from underrepresented backgrounds to conduct small research projects in the areas of research relevant to the sponsoring institutes. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Direct costs are limited to US$125,000 per year for a maximum of three years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PAR-13-074 (replaces PAR-09-223).

Closing date: 16 Jun 15
Posted date: 08 Jan 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $375,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-074

Eligibility profile
Country of applicant institution: Any
Disciplines
Diabetes, Human Metabolism, Diagnostic Sciences, Haematology, Clinical Medicine, Hormones & Endocrinology, Urology, Gastroenterology, Nutrition & Dietetics, Obesity, Nephrology & Kidneys
NIH: NATIONAL CANCER INSTITUTE

Description:
The National Cancer Institute invites applications for its exploratory/developmental grants programme for basic cancer research in cancer health disparities (R21) funding opportunity announcement. This announcement encourages basic research studies into the biological and genetic causes and mechanisms of cancer health disparities. Awards support pilot and feasibility studies such as mechanistic studies of biological factors associated with cancer disparities, development and testing of new methodologies and models and secondary data analyses.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply.

This FOA uses the NIH exploratory/developmental (R21) research grant award mechanism and runs in parallel with one of identical scientific scope, PA-15-093, which solicits applications under the research project (R01) award mechanism. Application budgets are limited to US$275,000 over a two-year project period, and no more than US$200,000 may be requested in any single year.

Ref: PAR-15-092 (Reissue of PAR-12-094).

Closing date: 17 Jun 15

Deadline information: Applications open on 17 May and are due by 5pm local time of applicant organization on 17 June and 17 November 2015, 17 June and 17 November 2016 and 19 June and 17 November 2017.

Posted date: 19 Jan 15

Award type: Innovation grants, Directed grants to institutions, research groups etc.

Award amount max: $275,000

Website:

Application form:

Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology, Cancer Genetics, Health Disparities, Cancer Cell Biology

Contact Details

NCI
BG 9609 Room 6W416
9609 Medical Center Drive
Rockville MD 20850
Bridging the Gap Between Cancer Mechanism and Population Science (U01)

NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute on Alcohol Abuse and Alcoholism invites applications for their bridging the gap between cancer mechanism and population science (U01) grants. This U01 funding opportunity announcement will support projects that bridge biological mechanism to population level scales. By incorporating insights and data from one end of the cancer research spectrum into the framework of the other, projects should be able to cross-validate data gathered at different scales, and explore links between basic biology, population science and potential health applications in treatment, prevention, diagnosis and screening. Proposed projects should pose a challenging cancer research question that would be difficult to address through biological or epidemiological investigation alone. Only a single cohesive project integrating aspects from these two areas is allowed in each application.

Direct costs are limited to US$700,000 per year over a five-year project period. Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply.

PAR-13-081.

Closing date: 17 Jun 15
Posted date: 11 Jan 13
Award type: Directed grants to institutions, research groups etc.
Award amount max: $3,500,000

Website:
Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-081

Eligibility profile
Country of applicant institution: Any

Disciplines
Biological Sciences, Clinical Medicine, Population Studies, Medical, Non-cancerous Tumors, Lung Cancer, Cancer Studies & Oncology, Leukemia & Other Blood Cancers, Screening for Diseases, Brain Cancer, Human Biological Sciences, Cancer Immunology, Oncology Nursing, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Ovarian & Cervical Cancers, Nursing, Carcinogenesis, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Chemotherapy, Breast Cancer, Medical & Diagnostic Tests, Diagnostic Sciences, Preventive Medicine, General Practice, Molecularly Targeted Therapy, Physiology

Contact Details
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, EPN Room 5000
Rockville, MD 20892
Tel: 1 301 435 5226
Email: couchj@mail.nih.gov
BASIC CANCER RESEARCH IN CANCER HEALTH DISPARITIES (R01)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its basic cancer research in cancer health disparities (R01) funding opportunity announcement. This announcement encourages basic research studies into the biological and genetic causes and mechanisms of cancer health disparities. Awards support pilot and feasibility studies such as mechanistic studies of biological factors associated with cancer disparities, development and testing of new methodologies and models and secondary data analyses.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. This FOA uses the NIH research project (R01) award mechanism and runs in parallel with one of identical scientific scope, PA-15-092, which solicits applications under the exploratory/developmental (R21) research grant award mechanism.

Application budgets are limited to US$250,000 per year in direct costs. The maximum project period is five years.
Ref: PAR-15-093.

Closing date: 17 Jun 15
Deadline information: Applications open on 17 May and are due by 5pm local time of applicant organization on 17 June and 17 November 2015, 17 June and 17 November 2016 and 19 June and 17 November 2017.

Award type: Directed grants to institutions, research groups etc.
Award amount max: $1,250,000

Eligibility profile
Country of applicant institution: Any

Disciplines
Health Disparities, Cancer Cell Biology, Cancer Genetics, Cancer Studies & Oncology

Contact Details
NCI
BG 9609 Room 6W416
9609 Medical Center Drive
Rockville MD 20850
Tel: 1 240 276 6205
Email: woodhousee@mail.nih.gov

ADVANCED DEVELOPMENT OF INFORMATICS TECHNOLOGY (U24)
NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its advanced development of informatics technology grants. This U24 funding opportunity announcement is aimed
at funding advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis and dissemination of data and knowledge in cancer research. The grants form a component of the institute’s informatics technology for cancer research initiative whose central mission is to promote research-driven informatics technology development. This funding opportunity will utilize the cooperative agreement (U24) resource grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public and private organizations.

Direct costs may not exceed US$500,000 per year and applicants may request support for up to five years. PAR-12-287.

Closing date: 18 Jun 15
Posted date: 21 Sep 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $2,500,000

**EARLY-STAGE DEVELOPMENT OF INFORMATICS TECHNOLOGY (U01)**

**NIH: National Cancer Institute**

**Description:**
The National Cancer Institute invites applications for its early-stage development of informatics technology grants. This R01 funding opportunity announcement is aimed at funding the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge in cancer research. The grants form a component of the institute’s informatics technology for cancer research initiative and are focused on early-stage development from prototyping to hardening and adaptation.

This FOA will use the cooperative agreement (U01) resource grant mechanism.

Applications may be submitted by foreign or domestic for-profit and non-profit
organizations and public and private organizations. Direct costs may not exceed US$250,000 per year and applicants may request support for up to three years. A number of awards may be awarded. PAR-12-288.

Closing date: 18 Jun 15
Posted date: 21 Sep 12
Award type: Directed grants to institutions, research groups etc.
Award amount max: $750,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-288.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-288

NIH: National Cancer Institute

Description:
The National Cancer Institute invites proposals for its collaborative research in integrative cancer biology (U01) grants. This U01 funding opportunity announcement encourages new research into integrative cancer biology by fostering collaboration between investigators currently affiliated with and those unaffiliated with the Integrative Cancer Biology Programme. Projects should leverage existing expertise and resources from within the ICBP research community and combine those with new approaches, technologies or methods. Application budgets are not limited, but must reflect actual needs of the project. Projects may last for up to five years. Domestic and foreign for-profit and non-profit organizations and public or private institutions are eligible to apply. PAR-13-184.

Closing date: 18 Jun 15
Posted date: 10 Apr 13
Award type: Directed grants to institutions, research groups etc.
MAGE-GUIDED DRUG DELIVERY IN CANCER (R01)

NIH: National Cancer Institute

Description:
The National Cancer Institute and the National Institute of Biomedical Imaging and Bioengineering invite applications for their image-guided drug delivery in cancer (R01) programme. This R01 funding opportunity announcement encourages innovative research in image-guided drug delivery in cancer. It will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer and other diseases, quantitative imaging assays of drug delivery and early intervention.

Applications budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years.

Eligible organizations include domestic and foreign public and private non-profit organizations and for-profit organizations. PAR-13-185 (replaces PA-09-253).

Closing date: 19 Jun 15
Deadline information: Applications due 19 June and 19 November annually until 20 November 2015.
Posted date: 11 Apr 13
Award type: Directed grants to institutions, research groups etc.
Website:

Application form:
http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PA-13-185

Eligibility profile
Country of applicant institution: Any

Country of applicant institution: Any

Disciplines
Ovarian & Cervical Cancers, Nursing, Brain Cancer, Oncology Nursing, Cancer Studies & Oncology, Leukemia & Other Blood Cancers, Physiology, Non-cancerous Tumours, Lung Cancer, Molecularly Targeted Therapy, Clinical Medicine, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Breast Cancer, Chemotherapy, Diagnostic Sciences, Carcinogenesis, Colorectal, Pancreatic & Stomach Cancers, Cancer Cell Biology, Human Biological Sciences, Cancer Immunology

Contact Details
Structural Biology and Molecular Applications Branch
Division of Cancer Biology
National Cancer Institute
9609 Medical Center Drive
Rockville, MD 20850
Tel: 1 301 435 5226
Email: couchj@mail.nih.gov
Disciplines

Pharmacy & Pharmacology, Non-cancerous Tumors, Clinical Medicine, Cancer Studies & Oncology, Toxicology, Pharmacotherapy, Nursing, Cancer Cell Biology, Primary Care, Brain Cancer, Diagnostic Sciences, Public Health, Health Services & Primary Care, Carcinogenesis, Methods of Drug Delivery, Radiology & Medical Imaging, Pharmacokinetics, Molecularly Targeted Therapy

Contact Details

NCI
6130 Executive Boulevard
Bethesda, MD 20852-7412
Tel: 1 301 276 5921
Email: farahank@mail.nih.gov

EXPLORATORY GRANT AWARD TO PROMOTE WORKFORCE DIVERSITY IN BASIC CANCER RESEARCH (R21)

NIH: National Cancer Institute

Description:
The National Cancer Institute invites applications for its exploratory grant award to promote workforce diversity in basic cancer research (R21) grants. These aim to enhance the diversity of the NCI-funded research workforce by supporting and recruiting eligible investigators from groups that have been shown to be underrepresented in the biomedical, clinical, Behavioral and social sciences workforce. Grants also provide a bridge to investigators who have completed their research training and may need extra time to develop a larger grant application. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

Application budgets are limited to US$275,000 over the two-year period, with no more than US$200,000 available in any year. The maximum project period is two years.

Ref: PAR-15-053 (reissue of PAR-12-096).

Deadlines on: 22 June 2015, 30 November 2015, and repeated annually.

Posted date: 26 Nov 14

Award type: Directed grants to institutions, research groups etc., Innovation grants

Award amount max: $275,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Cancer Studies & Oncology

Contact Details

NCI
BG 9609 Room 6W240
9609 Medical Center DR
PHARMACOGENOMICS OF OROFACIAL PAIN MANAGEMENT (R01)
NIH: National Institute of Dental and Craniofacial Research

Description:
The National Institute of Dental and Craniofacial Research invites applications for its pharmacogenomics of orofacial pain management (R01) funding opportunity announcement. This announcement aims to encourage research on the genetic basis of variability in therapeutic drug responses and adverse events in individuals with painful conditions of the dental, and orofacial region. The objectives include the following:

• determining the role of genetic variability in pharmacokinetics, pharmacodynamics and drug toxicities that contribute to, and predict the clinical outcomes of analgesic treatment of individuals with acute and chronic pain conditions;
• identifying key molecular signatures that are predictive of a therapeutic response is a second objective.

US and foreign for-profit and non-profit organizations and public and private organizations are eligible to apply. Clinical and basic science researchers are encouraged to form multidisciplinary teams.
The total budget of approximately US$2 million will fund four to six awards over a maximum period of four years.
Ref: RFA-DE-16-001.

Closing date: 24 Jun 15
Deadline information: Applications are invited between 24 May and 5pm local time of applicant organization on 24 June 2015. This call is repeated once a year.
Posted date: 09 Jan 15

Award type: Directed grants to institutions, research groups etc., Directed grants for individual investigators
Award amount max: -
Award amount min: -
Award budget total: $2,000,000
Website:
Application form:
http://www.grants.gov/web/grants/applicant-s/download-application-package.html#download=true&oppNum=RFA-DE-16-001

Eligibility profile
----------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Proteomics & Molecular Interactions, Molecular Genetics, Pain Management, Pharmacogenomics, Pharmacotherapy, Pharmacokinetics, Pharmaceutical Drugs, Dentistry

Contact Details
----------------------------------------------
NIDCR
Building 1, Room 627
6701 Democracy Boulevard
Bethesda, MD 20817
Tel: 1 301 594 9898
Email: mjasonwan@mail.nih.gov
IDENTIFICATION OF GENE VARIANTS FOR ADDICTION-RELATED TRAITS BY NEXT-GEN SEQUENCING IN MODEL ORGANISMS SELECTIVELY BRED FOR ADDICTION TRAITS (UH2/UH3)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its identification of gene variants for addiction-related traits by next-gen sequencing in model organisms selectively bred for addiction traits grants. This UH2/UH3 funding opportunity announcement will support projects aimed at discovery of gene variants in selectively bred animal models through the use of next-gen sequencing technologies. The initiative has two goals:

• to develop strategies and methodologies for the sequencing, mapping and genomic analyzing of established phenotypes of selectively bred animal models with addiction traits;
• to identify, from new or existing selectively bred animal models, genetic variants with implications for addiction-related traits.

Domestic and foreign for-profit or non-profit organizations and public or private institutions may apply. Direct costs are limited to US$125,000 per year over a three-year project period.

Ref: PAR-14-010.

Closing date: 30 Jun 15
Deadline information:
Posted date: 26 Nov 13
Award type: Directed grants to institutions, research groups etc.

Award amount max: $375,000
Website:

Application form:
http://www.grants.gov/web/grants/applicant
s/download-application-package.html#download=true&oppNum=P AR-14-010

Eligibility profile
----------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------
Psychology, Addiction, Clinical Medicine, Population & Ecological Genetics, Biological Sciences, Medical Genetics, Genomics, Cancer Genetics, Genetic Diseases, Quantitative Genetics, Physiology, Animal Models, Diagnostic Sciences, Genetics & Systems Biology

Contact Details
----------------------------------
NIDA
6001 Executive Boulevard
Bethesda, MD 20892-9550
Tel: 1 301 435 4649
Email: wudy@nida.nih.gov
TARGETING PERSISTENT HIV RESERVOIRS (R21/R33)
NIH: National Institute of Allergy and Infectious Diseases

Description:
The National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health invite applications for their targeting persistent HIV reservoirs (R21/R33) grants. This R21/R33 funding opportunity announcement aims to stimulate the development of innovative tools and strategies for curing HIV infection. This FOA provides funding for high-risk, technology-driven research to address the following three critical gaps in efforts to develop and test viable strategies for eradicating HIV from the individual:

- development of methods for isolating, quantifying and characterizing rare reservoir cells;
- identification of markers of latency or specific re-activators of HIV gene expression that would permit targeting of reservoir cells;
- testing of strategies to eliminate or inactive reservoir cells.

This funding opportunity uses the R21/R33 phased innovation award mechanism. Applications for R21 support alone will not be considered. Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions.

Direct costs are limited to US$275,000 for the R21 phase, with a maximum of US$200,000 in any single year, and US$300,000 per year for the R33 phase. The total project period cannot exceed five years, with no more than two years in the R21 phase and no more than three years in the R33 phase.

Ref: PAR-15-041 (reissue of PAR-12-109).

Closing date: 07 Apr 15
Deadline information: Applications open on 7 March 2015 and are due by 5pm local time of applicant organization every 7 April until 8 April 2017.
Posted date: 21 Nov 14
Award type: Directed grants to institutions, research groups etc., Innovation grants
Award amount max: $1,175,000

Eligibility profile
Country of applicant institution: Any
Disciplines
HIV/AIDS

Contact Details
NIAID
BG 5601FL Room 9G31
5601 Fishers Lane
Rockville MD 20852
Tel: 1 301 496 5332
Email: salzwedelkd@mail.nih.gov
STUDIES OF HIV/AIDS AND AGEING (R21)
NIH: National Institute on Aging

Description:
A total of nine institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/AIDS and ageing (R21) programme. This R21 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or biobehavioral or social factors associated with HIV/AIDS research in the context of ageing or in older adults. Research approaches of interest include clinical translational, observational and intervention studies in domestic and international settings.

This FOA will use the R21 exploratory/developmental research grant award and runs in parallel with two FOAs of identical scope, PAR-12-175, which uses the R01 research project grant mechanism and PAR-12-176, which uses the R03 small grant mechanism.

Application budgets are limited to US$275,000 over a two-year project period, with no more than US$200,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-12-174.

Closing date: 07 Apr 15
Posted date: 25 Apr 12

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Application form: [http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-174](http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-174)

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
-------------------------------------------------------------
Lung Cancer, Clinical Medicine, Cancer Studies & Oncology, Leukemia & Other Blood Cancers, Colorectal, Pancreatic & Stomach Cancers, Ovarian & Cervical Cancers, Human Biological Sciences, Primary Care, Public Health, Health Services & Primary Care, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Breast Cancer, Diagnostic Sciences, Carcinogenesis, Biomedical Engineering, Physiology, General Practice, HIV/AIDS, Geriatrics & Gerontology, Medicine & Health

Contact Details
-------------------------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: basil.eldadah@nih.gov
MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R01)
NIH: National Institute on Aging

Description:
A total of eleven institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/Aids and ageing (R01) programme. This R01 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or bioBehavioral or social factors associated with HIV/Aids research in the context of ageing or in older adults. Research approaches of interest include clinical translational, observational and intervention studies in domestic and international settings. This FOA will use the R01 research project grant and runs in parallel with two FOAs of identical scope, PAR-12-174, which uses the R21 exploratory/developmental research grant mechanism and PAR-12-176, which uses the R03 small grant mechanism. Application budgets are not limited, but must reflect the actual needs of the project. The maximum project period is five years. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-12-175.

Closing date: 07 Apr 15
Posted date: 25 Apr 12
Award type: Directed grants to institutions, research groups etc.

Award amount max: -
Award amount min: -
Award budget total: -
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-175.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-175

Eligibility profile
Country of applicant institution: Any

Disciplines
Human Biological Sciences, Primary Care, Colorectal, Pancreatic & Stomach Cancers, Carcinogenesis, Biomedical Engineering, Public Health, Health Services & Primary Care, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Breast Cancer, Diagnostic Sciences, General Practice, HIV/Aids, Clinical Medicine, Geriatrics & Gerontology, Medicine & Health, Physiology, Lung Cancer, Cancer Studies & Oncology, Leukemia & Other Blood Cancers, Ovarian & Cervical Cancers

Contact Details
NIACentral
7201 Wisconsin Avenue
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: basil.eldadah@nih.gov
MULTIDISCIPLINARY STUDIES OF HIV/AIDS AND AGEING (R03)
NIH: National Institute on Aging

Description:
A total of six institutes of the National Institutes of Health invite applications for their multidisciplinary studies of HIV/AIDS and ageing (R03) programme. This R03 funding opportunity announcement will support studies of HIV infection, HIV-associated conditions, HIV treatment or bioBehavioral or social factors associated with HIV/AIDS research in the context of ageing or in older adults. Research approaches of interest include clinical translational, observational and intervention studies in domestic and international settings. This FOA will use the R03 small grant mechanism and runs in parallel with two FOAs of identical scope, PAR-12-174, which uses the R21 exploratory/developmental research grant mechanism and PAR-12-175, which uses the R03 research project grant. Application budgets are limited to US$100,000 over a two-year project period, with no more than US$50,000 in direct costs allowed in any year. Applications may be submitted by foreign or domestic for-profit and non-profit organizations and public or private institutions. PAR-12-176.

Closing date: 07 Apr 15
Posted date: 25 Apr 12

Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Website: http://grants.nih.gov/grants/guide/pa-files/PAR-12-176.html
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-12-176

Eligibility profile
--------------------------------------------------------------
Country of applicant institution: Any

Disciplines
--------------------------------------------------------------
Clinical Medicine, Lung Cancer, Human Biological Sciences, Primary Care, Colorectal, Pancreatic & Stomach Cancers, Ovarian & Cervical Cancers, Cancer Studies & Oncology, Leukemia & Other Blood Cancers, General Practice, HIV/AIDS, Geriatrics & Gerontology, Medicine & Health, Physiology, Carcinogenesis, Biomedical Engineering, Public Health, Health Services & Primary Care, Prostate & Testicular Cancers, Melanoma & Other Skin Cancers, Breast Cancer, Diagnostic Sciences

Contact Details
--------------------------------------------------------------
NIA
7201 Wisconsin Avenue
Bethesda, MD 20892
Tel: 1 301 496 6761
Email: basil.eldadah@nih.gov
INTEGRATION OF INFECTIOUS DISEASES AND SUBSTANCE ABUSE INTERVENTION SERVICES FOR INDIVIDUALS LIVING WITH HIV (R01)

NIH: National Institute on Drug Abuse

Description:
The National Institute on Drug Abuse invites applications for its integration of infectious diseases and substance abuse intervention services for individuals living with HIV funding (R01) funding opportunity announcement. This announcement aims to develop and test organizational and systems level interventions to determine how best to provide comprehensive, high quality, integrated, sustainable, cost-effective interventions to improve the health outcomes of people living with HIV/Aids with substance use disorders and other comorbid conditions. This FOA will support multidisciplinary research to:

- enhance the adoption and integration of evidence-based screening and treatment of substance abuse in HIV centers;
- increase the adoption and integration of HIV testing and linkage to HIV care in addiction treatment settings.

Eligible applicants include domestic and foreign for-profit or non-profit organizations and public or private institutions. The total amount of funds available is $3 million in fiscal year 2015 for an anticipated four to six awards. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years.


Closing date: 14 Apr 15

Deadline information: Applications open on 14 March and are due by 5pm local time of applicant organization on 14 April 2015.

Posted date: 09 Jan 15

Award type: Directed grants to institutions, research groups etc.

Award budget total: $3,000,000


Eligibility profile

Country of applicant institution: Any

Disciplines

Drug & Substance Abuse, HIV/Aids

Contact Details

NIDA
NSC Building, Room 5177
6001 Executive Blvd
Rockville MD 20852
Tel: 1 301 443 6504
Email: rchandle@nida.nih.gov
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R03)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for translational research in pediatric and obstetric pharmacology (R03) grants. This R03 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:

• to improve the safety and effectiveness of current drugs for pediatric or obstetric patients;
• to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R03 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-309 that encourages applications under the R01 grant mechanism and PAR-13-311 that encourages applications under the R21 grant mechanism. Budgets for direct costs of up to US$50,000 per year and a project duration of up to two years may be requested. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PAR-13-310 (replaces PAR-11-247).

Closing date: 15 Apr 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $100,000
Application form: http://apply07.grants.gov/apply/GetGrantFromFedgrants?opportunity=PAR-13-310

Eligibility profile
Country of applicant institution: Any

Disciplines
Primary Care, Epigenetics, Neonatal Disorders, Biological Markers & Sensor Mechanisms, Paediatrics, Clinical Medicine, Public Health, Health Services & Primary Care, Biological Sciences, Diagnostic Sciences, Pharmacy & Pharmacology, Medical Genetics, Translational Medicine, Genomics, Pregnancy & Birth, Maternal Health, Cancer Genetics, Obstetrics & Gynaecology, Foetal Health & Prenatal Development

Contact Details
Obstetric and Pediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: 1 301 402 9340
Email: zren@mail.nih.gov
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY  
(R01) 
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for its translational research in pediatric and obstetric pharmacology (R01) grants. This R01 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for pediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R01 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-311 that encourages applications under the R21 grant mechanism. Application budgets are not limited but need to reflect the actual needs of the project. The maximum project period is five years. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PAR-13-309 (replaces PAR-11-246).

Closing date: 15 Apr 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: -
Award amount min: -
Award budget total: -

Eligibility profile
-------------------------------------------------------------
Country of applicant institution: Any

Disciplines
----------------------------------------------
Paediatrics, Diagnostic Sciences, Public Health, Health Services & Primary Care, Primary Care, Maternal Health, Pregnancy & Birth, Translational Medicine, Genomics, Foetal Health & Prenatal Development, Cancer Genetics, Obstetrics & Gynaecology, Clinical Medicine, Biological Markers & Sensor Mechanisms, Neonatal Disorders, Epigenetics, Medical Genetics, Pharmacy & Pharmacology, Biological Sciences

Contact Details
-------------------------------------------------------------
Obstetric and Pediatric Pharmacology and Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: 1 301 402 9340
Email: zren@mail.nih.gov
TRANSLATIONAL RESEARCH IN PAEDIATRIC AND OBSTETRIC PHARMACOLOGY (R21)
NIH: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Description:
The National Institute of Child Health and Human Development invites applications for translational research in pediatric and obstetric pharmacology (R21) grants. This R21 funding opportunity announcement funds translational and clinical research and clinical trials to advance knowledge about the underlying mechanisms of drug action, response and safety in children and developing foetuses. The overall goals of this funding opportunity announcement are:

- to improve the safety and effectiveness of current drugs for pediatric or obstetric patients;
- to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

This FOA will use the R21 award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-13-310 that encourages applications under the R03 grant mechanism and PAR-13-309 that encourages applications under the R01 grant mechanism. Direct costs are limited to US$275,000 over an R21 two-year period. Eligible applicants include domestic and foreign non-profit or for-profit organizations and public or private institutions. PAR-13-311 (replaces PAR-11-248).

Closing date: 15 Apr 15
Deadline information: Applications due by 5pm proposer’s local time.
Posted date: 06 Aug 13

Award type: Directed grants to institutions, research groups etc.
Award amount max: $275,000
Website:
Application form:

Eligibility profile
Country of applicant institution: Any

Disciplines
Maternal Health, Pregnancy & Birth,
Translational Medicine, Genomics, Foetal
Health & Prenatal Development, Cancer
Genetics, Obstetrics & Gynaecology, Clinical
Medicine, Biological Markers & Sensor
Mechanisms, Paediatrics, Neonatal Disorders,
Epigenetics, Medical Genetics, Pharmacy &
Pharmacology, Diagnostic Sciences, Public
Health, Health Services & Primary Care,
Biological Sciences, Primary Care

Contact Details
Obstetric and Pediatric Pharmacology and
Therapeutics Branch
NICHD
6100 Executive Boulevard
Room 4A01D MSC 7510
Bethesda, MD 20892-7510
Tel: 1 301 402 9340
Email: zren@mail.nih.gov